# ::tok We next examined the mechanisms accounting for the increase in HER3 by MAPK pathway inhibitors in BRAF mutant thyroid cell lines .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 1-1.3 2-1 4-1.2 5-1.2.1 6-1.2.1.1.r 8-1.2.1.1 9-1.2.1.1.2.r 10-1.2.1.1.2.1.1 11-1.2.1.1.1.r 12-1.2.1.1.1.1.1.1.1 13-1.2.1.1.1.1.1 14-1.2.1.1.1 14-1.2.1.1.1.1 14-1.2.1.1.1.1.r 15-1.2.1.1.1.1.2.r 16-1.2.1.1.1.1.2.2.1.1.1.1 17-1.2.1.1.1.1.2.2.1.1 17-1.2.1.1.1.1.2.2.1.1.2 17-1.2.1.1.1.1.2.2.1.1.2.r 18-1.2.1.1.1.1.2.1 19-1.2.1.1.1.1.2 20-1.2.1.1.1.1.2
# ::id bio-exp_0001.1
# ::preferred 
(e / examine-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (m / mechanism~e.4
            :ARG0-of (a / account-01~e.5
                  :ARG1~e.6 (i / increase-01~e.8
                        :ARG0~e.11 (m2 / molecular-physical-entity~e.14
                              :ARG0-of~e.14 (i2 / inhibit-01~e.14
                                    :ARG1 (p / pathway~e.13
                                          :name (n3 / name :op1 "MAPK"~e.12))
                                    :location~e.15 (c / cell-line~e.19,20
                                          :source (t / thyroid~e.18)
                                          :ARG1-of (e3 / encode-01
                                                :ARG0 (d / DNA
                                                      :part (g / gene~e.17
                                                            :name (n4 / name :op1 "BRAF"~e.16)
                                                            :ARG1-of~e.17 (m3 / mutate-01~e.17)))))))
                        :ARG1~e.9 (e2 / enzyme
                              :name (n2 / name :op1 "HER3"~e.10)))))
      :time (n / next~e.1))

# ::tok Upregulation of HER3 has been found to mediate resistance to PI3K @/@ AKT ( 26 ) or HER2 ( 27 ) inhibitors in HER2 @-@ amplified breast cancer cell lines , which is caused in part through a FoxO3A @-@ dependent induction of HER3 gene transcription .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 5-1 6-1.1.3 7-1.1 8-1.1.2 9-1.1.2.1.r 10-1.1.2.1.1.1.1.1.1 12-1.1.2.1.1.1.1.1.1 14-1.1.2.1.1.1.1.2.1.1.1 16-1.1.2.1.1.1 17-1.1.2.1.1.1.2.1.1 19-1.1.2.1.1.1.2.2.1.1.1 21-1.1.2.1 21-1.1.2.1.1 21-1.1.2.1.1.r 22-1.1.2.2.r 23-1.1.2.2.2.1 25-1.1.2.2.2 26-1.1.2.2.1.1 27-1.1.2.2.1 28-1.1.2.2 29-1.1.2.2 33-1.1.3 34-1.1.3.2.r 35-1.1.3.2 38-1.1.3.1.2.1.1.1 40-1.1.3.1.2 41-1.1.3.1 42-1.1.3.1.1.r 43-1.1.3.1.1.1.1.1 44-1.1.3.1.1.1 45-1.1.3.1.1
# ::id bio-exp_0001.2
# ::preferred 
(f / find-01~e.5
      :ARG1 (m / mediate-01~e.7
            :ARG0 (u / upregulate-01~e.0
                  :ARG1~e.1 (e / enzyme
                        :name (n / name :op1 "HER3"~e.2)))
            :ARG1 (r / resist-01~e.8
                  :ARG1~e.9 (m2 / molecular-physical-entity~e.21
                        :ARG0-of~e.21 (i / inhibit-01~e.21
                              :ARG1 (o / or~e.16
                                    :op1 (p / pathway
                                          :name (n2 / name :op1 "PI3K/AKT"~e.10,12)
                                          :ARG1-of (d2 / describe-01
                                                :ARG0 (p5 / publication
                                                      :ARG1-of (c4 / cite-01 :ARG2 "26"~e.14))))
                                    :op2 (p2 / protein
                                          :name (n3 / name :op1 "HER2"~e.17)
                                          :ARG1-of (d3 / describe-01
                                                :ARG0 (p6 / publication
                                                      :ARG1-of (c5 / cite-01 :ARG2 "27"~e.19)))))))
                  :location~e.22 (c / cell-line~e.28,29
                        :source (c2 / cancer~e.27
                              :mod (b / breast~e.26))
                        :ARG0-of (a / amplify-01~e.25
                              :ARG1 p2~e.23)))
            :ARG1-of (c3 / cause-01~e.6,33
                  :ARG0 (i2 / induce-01~e.41
                        :ARG1~e.42 (t / transcribe-01~e.45
                              :ARG1 (g / gene~e.44
                                    :ARG0-of (e2 / encode-01
                                          :ARG1 e~e.43)))
                        :ARG0-of (d / depend-01~e.40
                              :ARG1 (p4 / protein
                                    :name (n4 / name :op1 "FoxO3A"~e.38))))
                  :mod~e.34 (p3 / part~e.35))))

# ::tok As shown in Fig. 5A , PLX4032 treatment increased HER3 and HER2 mRNAs in all six BRAF @-@ mutant thyroid cancer cell lines tested .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.3 4-1.3.1.1 6-1.1.1.1.1 7-1.1 8-1 9-1.2.1.1.1.1.1 10-1.2.1.1 11-1.2.1.1.2.1.1 12-1.2 13-1.4.r 14-1.4.3.2 15-1.4.3.1.1 16-1.4.2.1.1.1.1 18-1.4.2.1.1 18-1.4.2.1.1.2 18-1.4.2.1.1.2.r 19-1.4.1.1 20-1.4.1 21-1.4 22-1.4.3.1 23-1.4.3.1.2
# ::id bio-exp_0001.3
# ::preferred 
(i / increase-01~e.8
      :ARG0 (t / treat-03~e.7
            :ARG3 (s2 / small-molecule
                  :name (n / name :op1 "PLX4032"~e.6)))
      :ARG1 (m3 / mRNA~e.12
            :ARG0-of (e / encode-01
                  :ARG1 (a / and~e.10
                        :op1 (p / protein
                              :name (n2 / name :op1 "HER3"~e.9))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "HER2"~e.11)))))
      :ARG1-of (s / show-01~e.1
            :location (f / figure :mod "5A"~e.4))
      :location~e.13 (c / cell-line~e.21
            :source (c2 / cancer~e.20
                  :mod (t2 / thyroid~e.19))
            :ARG1-of (e2 / encode-01
                  :ARG0 (d / DNA
                        :part (g / gene~e.18
                              :name (n4 / name :op1 "BRAF"~e.16)
                              :ARG1-of~e.18 (m2 / mutate-01~e.18))))
            :ARG1-of (i2 / include-91
                  :ARG2 (c3 / cell-line~e.22
                        :quant "6"~e.15
                        :ARG1-of (t3 / test-01~e.23))
                  :ARG3 (a2 / all~e.14))))

# ::tok Similar results were found following treatment with the MEK inhibitor AZD6244 ( not shown ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2 5-1.2.1 6-1.2.1.1.r 8-1.2.1.1.2.1.1.1 9-1.2.1.1 9-1.2.1.1.2 9-1.2.1.1.2.r 10-1.2.1.1.1.1 12-1.1.3.1 12-1.1.3.1.r 13-1.1.3
# ::id bio-exp_0001.4
# ::preferred 
(f / find-01~e.3
      :ARG1 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :ARG1-of (r2 / resemble-01~e.0)
            :ARG1-of (s / show-01~e.13 :polarity~e.12 "-"~e.12))
      :ARG1-of (f2 / follow-01~e.4
            :ARG2 (t2 / treat-04~e.5
                  :ARG2~e.6 (m / molecular-physical-entity~e.9
                        :name (n2 / name :op1 "AZD6244"~e.10)
                        :ARG0-of~e.9 (i / inhibit-01~e.9
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "MEK"~e.8)))))))

# ::tok The effects of the MEK inhibitor on total HER2 , HER3 protein and on pHER3 were dose dependent , and inversely associated with the degree of inhibition of pERK ( Fig. 5B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1.1.1.r 4-1.1.1.1.1.1.1.1 5-1.1.1.1 5-1.1.1.1.1 5-1.1.1.1.1.r 6-1.1.1.2.r 7-1.1.1.2.1.2 8-1.1.1.2.1.1.1 10-1.1.1.2.2.1.1 10-1.1.1.2.3.1.1 12-1.1.1.2 16-1.1.2 17-1.1 19-1 20-1.2.3 20-1.2.3.r 21-1.2 22-1.2.2.r 24-1.2.2.1.r 26-1.2.2.1 31-1.3.1.1
# ::id bio-exp_0001.5
# ::preferred 
(a / and~e.19
      :op1 (d / depend-01~e.17
            :ARG0 (a2 / affect-01~e.1
                  :ARG0~e.2 (m / molecular-physical-entity~e.5
                        :ARG0-of~e.5 (i / inhibit-01~e.5
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "MEK"~e.4))))
                  :ARG1~e.6 (a3 / and~e.12
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "HER2"~e.8)
                              :mod (t / total~e.7))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "HER3"~e.10))
                        :op3 (e4 / enzyme
                              :name (n4 / name :op1 "HER3"~e.10)
                              :ARG3-of (p / phosphorylate-01))))
            :ARG1 (d2 / dose-01~e.16))
      :op2 (a4 / associate-01~e.21
            :ARG1 a2
            :ARG2~e.22 (t2 / thing
                  :degree-of~e.24 (i2 / inhibit-01~e.26
                        :ARG1 (e5 / enzyme
                              :name (n5 / name :op1 "ERK")
                              :ARG3-of p)))
            :manner~e.20 (i3 / inverse~e.20))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "5B"~e.31)))

# ::tok RAF or MEK inhibitors induced luciferase activity of a HER3 promoter construct spanning ~ 1 kb upstream of the transcriptional start site in 8505C cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1.1 1-1.1 2-1.1.2.1.1.1.1 3-1.1.1 3-1.1.1.1 3-1.1.1.1.r 3-1.1.2 3-1.1.2.1 3-1.1.2.1.r 4-1 5-1.2.2 9-1.2.1.1.1.1.1 11-1.2.1 12-1.2.1.2 14-1.2.1.2.3.1.1 16-1.2.1.2.1.2 20-1.2.1.2.1.1.1 21-1.2.1.2.1.1 24-1.2.1.2.2
# ::id bio-exp_0001.6
# ::preferred 
(i / induce-01~e.4
      :ARG0 (o / or~e.1
            :op1 (m / molecular-physical-entity~e.3
                  :ARG0-of~e.3 (i2 / inhibit-01~e.3
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "RAF"~e.0))))
            :op2 (m2 / molecular-physical-entity~e.3
                  :ARG0-of~e.3 (i3 / inhibit-01~e.3
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "MEK"~e.2)))))
      :ARG1 (a / act-01
            :ARG0 (c / construct-01~e.11
                  :ARG0-of (p / promote-01
                        :ARG1 (e3 / enzyme
                              :name (n3 / name :op1 "HER3"~e.9)))
                  :ARG0-of (s / span-01~e.12
                        :ARG1 (r / relative-position
                              :op1 (p2 / protein-segment~e.21
                                    :location-of (s3 / start-01~e.20
                                          :ARG1 (t / transcribe-01)))
                              :direction (u / upstream~e.16))
                        :location (c2 / cell~e.24
                              :name (n4 / name :op1 "8505S"))
                        :quant (a2 / approximately
                              :op1 (d / distance-quantity
                                    :quant "1"~e.14
                                    :unit (k / kilo-base-pair)))))
            :ARG1 (l / luciferase~e.5)))

# ::tok Serial deletions identified a minimal HER3 promoter retaining transcriptional response to vemurafenib and AZD6244 , which was located between -@ 401 and -@ 42 bp ( Fig. 5C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2.2 5-1.2.1.1.1.1 7-1.2.3 9-1.2.3.1 9-1.2.3.1.1 9-1.2.3.1.1.r 10-1.2.3.1.1.1.r 11-1.2.3.1.1.1.1.1.1 12-1.2.3.1.1.1 13-1.2.3.1.1.1.2.1.1 17-1.2.4.r 18-1.2.4 20-1.2.4.1.1 21-1.2.4 23-1.2.4.2.1 27-1.3.1.1
# ::id bio-exp_0001.7
# ::preferred 
(i / identify-01~e.2
      :ARG0 (d / delete-01~e.1
            :manner (s2 / serial~e.0))
      :ARG1 (m / molecular-physical-entity
            :ARG0-of (p / promote-01
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "HER3"~e.5)))
            :mod (m2 / minimal~e.4)
            :ARG0-of (r / retain-01~e.7
                  :ARG1 (t / thing~e.9
                        :ARG2-of~e.9 (r2 / respond-01~e.9
                              :ARG1~e.10 (a / and~e.12
                                    :op1 (s3 / small-molecule
                                          :name (n3 / name :op1 "vemurafenib"~e.11))
                                    :op2 (s / small-molecule
                                          :name (n2 / name :op1 "AZD6244"~e.13)))))
                  :mod (t2 / transcribe-01))
            :location~e.17 (b / between~e.18,21
                  :op1 (d2 / distance-quantity
                        :quant "-401"~e.20
                        :unit (b2 / base-pair))
                  :op2 (d3 / distance-quantity
                        :quant "-42"~e.23
                        :unit (b3 / base-pair))))
      :ARG1-of (d4 / describe-01
            :ARG0 (f / figure :mod "5C"~e.27)))

# ::tok This region does not contain any predicted FoxO binding sites .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2 3-1.1 3-1.1.r 4-1 5-1.3.1 6-1.3.2 7-1.3.3.1.1.1 8-1.3.3 9-1.3
# ::id bio-exp_0001.8
# ::preferred 
(c / contain-01~e.4
      :polarity~e.3 "-"~e.3
      :ARG0 (r / region~e.1
            :mod (t / this~e.0))
      :ARG1 (p3 / protein-segment~e.9
            :mod (a / any~e.5)
            :ARG1-of (p / predict-01~e.6)
            :ARG1-of (b / bind-01~e.8
                  :ARG2 (p2 / protein
                        :name (n / name :op1 "FoxO"~e.7)))))

# ::tok Moreover , PLX4032 led to an increase in phosphorylation of FoxO1 @/@ 3A between 4 – 10 h after addition of compound ( not shown ) , which is known to promote its dissociation from DNA , and likely discards involvement of these factors as transcriptional regulators of HER3 in response to MAPK pathway inhibition .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1 3-1.1 6-1.1.2 7-1.1.2.1.r 8-1.1.2.1 9-1.1.2.1.1.r 10-1.1.2.1.1.1.1 12-1.1.2.1.1.1.1 13-1.1.2.2.2 14-1.1.2.2.2.1.1 16-1.1.2.2.2.2.1 18-1.1.2.2 19-1.1.2.2.1 20-1.1.2.2.1.1.r 21-1.1.2.2.1.1 23-1.1.2.3.1 23-1.1.2.3.1.r 24-1.1.2.3 29-1.1.2.4.2 31-1.1.2.4 32-1.1.2.4.1.1 32-1.1.2.4.1.1.r 33-1.1.2.4.1 34-1.1.2.4.1.2.r 35-1.1.2.4.1.2 37-1.1.2.2.2 38-1.1.2.5.2 39-1.1.2.5 40-1.1.2.5.1 41-1.1.2.5.1.1.r 42-1.1.2.5.1.1.1 43-1.1.2.5.1.1 44-1.1.2.2.r 46-1.1.2.5.1.2 46-1.1.2.5.1.2.1 46-1.1.2.5.1.2.1.r 47-1.1.2.5.1.2.1.1.r 48-1.1.2.5.1.2.1.1.1.1 49-1.1.2.5.3.r 50-1.1.2.5.3 51-1.1.2.5.3.1.r 52-1.1.2.5.3.1.1.1.1 53-1.1.2.5.3.1.1 54-1.1.2.5.3.1
# ::id bio-exp_0001.9
# ::preferred 
(a / and
      :op2 (l / lead-03~e.3
            :ARG0 (s / small-molecule
                  :name (n / name :op1 "PLX4032"~e.2))
            :ARG1 (i / increase-01~e.6
                  :ARG1~e.7 (p / phosphorylate-01~e.8
                        :ARG1~e.9 (p2 / protein
                              :name (n2 / name :op1 "FoxO1/3A"~e.10,12)))
                  :time~e.44 (a2 / after~e.18
                        :op1 (a3 / add-02~e.19
                              :ARG1~e.20 (c / compound~e.21))
                        :quant (b / between~e.13,37
                              :op1 (t / temporal-quantity
                                    :quant "4"~e.14
                                    :unit (h / hour))
                              :op2 (t2 / temporal-quantity
                                    :quant "10"~e.16
                                    :unit (h2 / hour))))
                  :ARG1-of (s2 / show-01~e.24 :polarity~e.23 "-"~e.23)
                  :ARG0-of (p3 / promote-01~e.31
                        :ARG1 (d / dissociate-01~e.33
                              :ARG1~e.32 p2~e.32
                              :ARG2~e.34 (d2 / DNA~e.35))
                        :ARG1-of (k / know-01~e.29))
                  :ARG0-of (d3 / discard-01~e.39
                        :ARG1 (i2 / involve-01~e.40
                              :ARG1~e.41 (f / factor~e.43
                                    :mod (t3 / this~e.42))
                              :mod (m / molecular-physical-entity~e.46
                                    :ARG0-of~e.46 (r / regulate-01~e.46
                                          :ARG1~e.47 (e / enzyme
                                                :name (n3 / name :op1 "HER3"~e.48)))
                                    :mod (t4 / transcribe-01)))
                        :mod (l2 / likely~e.38)
                        :ARG2-of~e.49 (r2 / respond-01~e.50
                              :ARG1~e.51 (i3 / inhibit-01~e.54
                                    :ARG1 (p4 / pathway~e.53
                                          :name (n4 / name :op1 "MAPK"~e.52))))))))

# ::tok The minimal HER3 promoter region regulated by MAPK inhibitors overlaps with sequences previously described to be immunoprecipitated using antibodies against the ZFN217 transcription factor and CtBP1 @/@ CtBP2 corepressors ( 28–30 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.2 2-1.1.1.1.1.1.1 4-1.1 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.1.1.1 8-1.1.2.1 8-1.1.2.1.1 8-1.1.2.1.1.r 9-1 10-1.2.r 11-1.2 12-1.2.1.2.1 13-1.2.1.2 13-1.3 17-1.2.1.1 18-1.2.1.1.1 19-1.2.1.1.1.1 21-1.2.1.1.1.1.1.1.1.1.1.1 22-1.2.1.1.1.1.1.1.1 23-1.2.1.1.1.1.1.1 24-1.2.1.1.1.1.1 25-1.2.1.1.1.1.1.2.1.1.1 27-1.2.1.1.1.1.1.2.2.1.1
# ::id bio-exp_0001.10
# ::preferred 
(o / overlap-01~e.9
      :ARG0 (r / region~e.4
            :part (m / molecular-physical-entity
                  :ARG0-of (p2 / promote-01
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "HER3"~e.2)))
                  :mod (m2 / minimal~e.1))
            :ARG1-of (r2 / regulate-01~e.5
                  :ARG0~e.6 (m3 / molecular-physical-entity~e.8
                        :ARG0-of~e.8 (i / inhibit-01~e.8
                              :ARG1 (p / pathway
                                    :name (n2 / name :op1 "MAPK"~e.7))))))
      :ARG1~e.10 (s / sequence~e.11
            :ARG1-of (i2 / immunoprecipitate-00
                  :ARG2-of (u / use-01~e.17
                        :ARG1 (a / antibody~e.18
                              :ARG0-of (o2 / oppose-01~e.19
                                    :ARG1 (a2 / and~e.24
                                          :op1 (f / factor~e.23
                                                :ARG0-of (t / transcribe-01~e.22
                                                      :ARG1 (e2 / enzyme
                                                            :name (n3 / name :op1 "ZFN217"~e.21))))
                                          :op2 (o3 / or
                                                :op1 (c / corepressor
                                                      :name (n4 / name :op1 "CtBP1"~e.25))
                                                :op2 (c2 / corepressor
                                                      :name (n5 / name :op1 "CtBP2"~e.27)))))))
                  :ARG1-of (d / describe-01~e.13
                        :time (p3 / previous~e.12))))
      :ARG1-of (d2 / describe-01~e.13
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (v / value-interval :op1 "28" :op2 "30")))))

# ::tok CtBPs have also been described to negatively regulate transcriptional activity of the HER3 promoter in breast carcinoma cell lines ( 30 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.4 4-1 4-1.5 4-1.5.r 12-1.2.1.1.1.1.1.1 14-1.3.r 15-1.3.1.1 16-1.3.1 17-1.3 18-1.3 20-1.5.1.1.1
# ::id bio-exp_0001.11
# ::preferred 
(d / describe-01~e.4
      :ARG1 (p / protein
            :name (n2 / name :op1 "CtBP"))
      :ARG2 (d2 / downregulate-01
            :ARG1 (a / act-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (p2 / promote-01
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "HER3"~e.12))))
                  :ARG1 (t / transcribe-01))
            :ARG2 p)
      :location~e.14 (c / cell-line~e.17,18
            :mod (c2 / carcinoma~e.16
                  :mod (b / breast~e.15)))
      :mod (a2 / also~e.2)
      :ARG1-of~e.4 (d3 / describe-01~e.4
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "30"~e.20))))

# ::tok Silencing of CtBP1 , and to a lesser extent CtBP2 , increased basal HER3 in 8505C cells , and markedly potentiated the effects of PLX4032 ( Fig. 5D and 5E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1.1 4-1.1.1.1 7-1.1.1.1.2.2 7-1.1.1.1.2.2.1 7-1.1.1.1.2.2.1.r 9-1.1.1.1.2.1.1 11-1.1 12-1.1.2.2 13-1.1.2.1.1 14-1.1.3.r 15-1.1.3.1.1 16-1.1.3 18-1 18-1.3.1 19-1.2.3 19-1.2.3.r 22-1.2.2 23-1.2.2.1.r 24-1.2.2.1.1.1 27-1.3.1.1.1 28-1.3.1 29-1.3.1.2.1
# ::id bio-exp_0001.12
# ::preferred 
(a / and~e.18
      :op1 (i / increase-01~e.11
            :ARG0 (s / silence-01~e.0
                  :ARG1~e.1 (a2 / and~e.4
                        :op1 (p / protein
                              :name (n2 / name :op1 "CtBP1"~e.2))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "CtBP2"~e.9)
                              :degree (l / less~e.7
                                    :degree~e.7 (m / more~e.7)))))
            :ARG1 (e / enzyme
                  :name (n / name :op1 "HER3"~e.13)
                  :mod (b / basal~e.12))
            :location~e.14 (c / cell~e.16
                  :name (n4 / name :op1 "8505C"~e.15)))
      :op2 (p3 / potentiate-00
            :ARG0 s
            :ARG1 (a3 / affect-01~e.22
                  :ARG0~e.23 (s2 / small-molecule
                        :name (n5 / name :op1 "PLX4032"~e.24)))
            :manner~e.19 (m2 / marked~e.19))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and~e.18,28
                  :op1 (f / figure :mod "5D"~e.27)
                  :op2 (f2 / figure :mod "5E"~e.29))))

# ::tok Knockdown of these factors modestly increased basal and PLX4032 - induced HER2 levels , which likely contributes to the remarkable increase in pHER3 we observed ( Fig. 5D and 5E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1 3-1.1.1 4-1.3 5-1 6-1.2.1.1.2 7-1.2 8-1.2.2.1.2.1.1.1 10-1.2.2.1.2 11-1.2.1.1.1.1 11-1.2.2.1.1.1 12-1.2.1 12-1.2.2 15-1.4.2 16-1.4 19-1.4.1.3 20-1.4.1 23-1.4.1.2.1 24-1.4.1.2 27-1.5.1.1.1 28-1.5.1 29-1.5.1.2.1
# ::id bio-exp_0001.13
# ::preferred 
(i / increase-01~e.5
      :ARG0 (k / knock-02
            :ARG1 (f / factor~e.3
                  :mod (t / this~e.2)))
      :ARG1 (a / and~e.7
            :op1 (l / level~e.12
                  :quant-of (e / enzyme
                        :name (n / name :op1 "HER2"~e.11)
                        :mod (b / basal~e.6)))
            :op2 (l2 / level~e.12
                  :quant-of (e2 / enzyme
                        :name (n2 / name :op1 "HER2"~e.11)
                        :ARG1-of (i2 / induce-01~e.10
                              :ARG0 (s / small-molecule
                                    :name (n3 / name :op1 "PLX4032"~e.8))))))
      :degree (m / modest~e.4)
      :ARG0-of (c / contribute-01~e.16
            :ARG1 (i3 / increase-01~e.20
                  :ARG1 (e3 / enzyme
                        :name (n4 / name :op1 "HER3")
                        :ARG3-of (p / phosphorylate-01))
                  :ARG1-of (o / observe-01~e.24
                        :ARG0 (w / we~e.23))
                  :mod (r / remarkable~e.19))
            :mod (l3 / likely~e.15))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.28
                  :op1 (f2 / figure :mod "5D"~e.27)
                  :op2 (f3 / figure :mod "5E"~e.29))))

# ::tok Finally , CtBP1 and CtBP2 chromatin immunoprecipitation assays showed decreased binding to the HER3 promoter after treatment with PLX4032 ( Fig. 5F ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 2-1.1.1.1.1.1.1 3-1.1.1.1 4-1.1.1.1.2.1.1 5-1.1.1.2 7-1.1 8-1 9-1.2.2 10-1.2 11-1.2.1.r 13-1.2.1.1.1.1.1 15-1.2.2.1 16-1.2.2.1.1 17-1.2.2.1.1.1.r 18-1.2.2.1.1.1.1.1 21-1.3.1.1
# ::id bio-exp_0001.14
# ::preferred 
(s / show-01~e.8
      :ARG0 (a / assay-00~e.7
            :ARG1 (i / immunoprecipitate-00
                  :ARG1 (a2 / and~e.3
                        :op1 (p / protein
                              :name (n2 / name :op1 "CtBP1"~e.2))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "CtBP2"~e.4)))
                  :mod (c / chromatin~e.5)))
      :ARG1 (b / bind-01~e.10
            :ARG2~e.11 (m / molecular-physical-entity
                  :ARG0-of (p3 / promote-01
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "HER3"~e.13))))
            :ARG1-of (d / decrease-01~e.9
                  :time (a3 / after~e.15
                        :op1 (t / treat-04~e.16
                              :ARG2~e.17 (s2 / small-molecule
                                    :name (n4 / name :op1 "PLX4032"~e.18))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "5F"~e.21))
      :time (f2 / final~e.0))

# ::tok These findings were confirmed in a second cell line ( Supplementary Fig. S5A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2.r 6-1.2.1 6-1.2.1.1 6-1.2.1.1.r 7-1.2 8-1.2 12-1.3.1.1
# ::id bio-exp_0001.15
# ::preferred 
(c / confirm-01~e.3
      :ARG1 (t2 / thing~e.1
            :ARG1-of~e.1 (f / find-01~e.1)
            :mod (t / this~e.0))
      :location~e.4 (c2 / cell-line~e.7,8
            :ord (o / ordinal-entity~e.6 :value~e.6 "2"~e.6))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure
                  :mod "S5A"~e.12
                  :ARG2-of (s / supplement-01))))

# ::tok Activation of Raf occurs via a complex , yet incompletely understood mechanism requiring membrane translocation , regulatory phosphorylation / dephosphorylation events and , crucially , allosteric activation in the context of a side @-@ to @-@ side dimer comprising two Raf molecules or a Raf and a Ksr molecule .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1 1-1.1.r 2-1.1.1.1 4-1.2.3.1.1.1.r 6-1.2.1 9-1.2.2.1 9-1.2.2.1.1 9-1.2.2.1.1.r 10-1.2.2 11-1.2 12-1.2.3 13-1.2.3.1.1.1 14-1.2.3.1.1 16-1.2.3.1.2.1 16-1.2.3.1.3.1 17-1.2.3.1.2 19-1.2.3.1.3 21-1.2.3.1 23-1.2.3.1.4.2 25-1.2.3.1.4.1 26-1.2.3.1.4 32-1.2.3.1.4.3.1.1 34-1.2.3.1.4.3.1.1 36-1.2.3.1.4.3.1.1 37-1.2.3.1.4.3.1 38-1.2.3.1.4.3.1.2 39-1.2.3.1.4.3.1.2.1.1.1 40-1.2.3.1.4.3.1.2.1.1.2.1 40-1.2.3.1.4.3.1.2.1.2.1.1.1 42-1.2.3.1.4.3.1.2.1 44-1.2.3.1.4.3.1.2.1.1.2.1 44-1.2.3.1.4.3.1.2.1.2.1.1.1 45-1.2.3.1.4.3.1.2.1.2 47-1.2.3.1.4.3.1.2.1.2.2.1.1
# ::id bio-kappa_0001.1
# ::preferred 
(a / activate-01~e.0
      :ARG1~e.1 (e / enzyme
            :name (n / name :op1 "Raf"~e.2))
      :manner (m / mechanism~e.11
            :mod (c / complex~e.6)
            :ARG1-of (u / understand-01~e.10
                  :degree (c2 / complete~e.9 :polarity~e.9 "-"~e.9))
            :ARG0-of (r / require-01~e.12
                  :ARG1 (a2 / and~e.21
                        :op1 (t / translocate-00~e.14
                              :path~e.4 (m2 / membrane~e.13))
                        :op2 (p2 / phosphorylate-01~e.17
                              :ARG0-of (r2 / regulate-01~e.16))
                        :op3 (d / dephosphorylate-01~e.19
                              :ARG0-of (r3 / regulate-01~e.16))
                        :op4 (a3 / activate-01~e.26
                              :mod (a4 / allosteric~e.25)
                              :mod (c3 / crucial~e.23)
                              :condition (h / have-part-91
                                    :ARG1 (d2 / dimer~e.37
                                          :mod (s / side-to-side~e.32,34,36)
                                          :ARG1-of (c5 / comprise-01~e.38
                                                :ARG2 (o / or~e.42
                                                      :op1 (e2 / enzyme
                                                            :quant "2"~e.39
                                                            :name (n2 / name :op1 "Raf"~e.40,44))
                                                      :op2 (a5 / and~e.45
                                                            :op1 (e3 / enzyme
                                                                  :name (n3 / name :op1 "Raf"~e.40,44))
                                                            :op2 (e4 / enzyme
                                                                  :name (n4 / name :op1 "Ksr"~e.47))))))
                                    :ARG2 e))))))

# ::tok Of the three Raf kinases , only B @-@ Raf is able to function as an allosteric activator in the context of the Raf heterodimers , a role independent of B @-@ Raf kinase activity .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.1.1.2.1.1 3-1.1.1.2.1.2.1 4-1.1.1 4-1.1.1.2.1 6-1.1.1.3 7-1.1.1.1.1 9-1.1.1.2.1.2.1 9-1.1.3.1.1.1.1 10-1.1.r 11-1 16-1.1.2 17-1.1 23-1.1.1.2.1.2.1 23-1.1.3.1.1.1.1 24-1.1.3.1 28-1.1.4 28-1.1.4.1 28-1.1.4.1.r 29-1.1.4.2.r 30-1.1.4.2.1 31-1.1.4.2.1 32-1.1.4.2.1 33-1.1.4.2.1 34-1.1.4.2
# ::id bio-kappa_0001.2
# ::preferred 
(p / possible~e.11
      :domain~e.10 (a / activate-01~e.17
            :ARG0 (k2 / kinase~e.4
                  :name (n / name :op1 "B-Raf"~e.7)
                  :ARG1-of (i / include-91
                        :ARG2 (k / kinase~e.4
                              :quant "3"~e.2
                              :name (n2 / name :op1 "Raf"~e.3,9,23)))
                  :mod (o / only~e.6))
            :mod (a2 / allosteric~e.16)
            :condition (h2 / have-part-91
                  :ARG1 (h / heterodimer~e.24
                        :part (e / enzyme
                              :name (n3 / name :op1 "Raf"~e.9,23)))
                  :ARG2 k2)
            :ARG0-of (d / depend-01~e.28
                  :polarity~e.28 "-"~e.28
                  :ARG1~e.29 (a3 / act-02~e.34
                        :ARG0 k2~e.30,31,32,33))))

# ::tok The molecular basis for this has recently been elucidated by the Shaw lab , who has shown that the ability of acting as an activator depends on the presence of negative charges in the Raf N @-@ terminal acidic motif .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.2.1 2-1.2.2 3-1.2.2.1.r 4-1.2.2.1 6-1.3 8-1 9-1.1.r 11-1.1.1.1 12-1.1 16-1.1.2 22-1.1.2.1.r 22-1.3.r 24-1.1.2.1.1.1 25-1.1.2.1 26-1.1.2.1.2.r 28-1.1.2.1.2 29-1.1.2.1.2.1.r 30-1.1.2.1.2.1.1 31-1.1.2.1.2.1 32-1.1.2.1.2.1.2.r 34-1.1.2.1.2.1.2.2.2.1.1 35-1.1.2.1.2.1.2.2.1.1 37-1.1.2.1.2.1.2.2.1.1 38-1.1.2.1.2.1.2.1 39-1.1.2.1.2.1.2
# ::id bio-kappa_0001.3
# ::preferred 
(e / elucidate-01~e.8
      :ARG0~e.9 (l / lab~e.12
            :name (n / name :op1 "Shaw"~e.11)
            :ARG0-of (s / show-01~e.16
                  :ARG1~e.22 (d / depend-01~e.25
                        :ARG0 (p / possible
                              :domain (a / activate-01~e.24))
                        :ARG1~e.26 (p2 / present~e.28
                              :domain~e.29 (c / charge~e.31
                                    :mod (n2 / negative~e.30)
                                    :location~e.32 (m3 / motif~e.39
                                          :mod (a2 / acid~e.38)
                                          :part-of (p3 / protein-segment
                                                :name (n3 / name :op1 "N-terminus"~e.35,37)
                                                :part-of (e2 / enzyme
                                                      :name (n4 / name :op1 "Raf"~e.34)))))))))
      :ARG1 (m / mechanism
            :mod (m2 / molecule~e.1)
            :ARG2-of (b / base-02~e.2
                  :ARG1~e.3 (t / this~e.4)))
      :time~e.22 (r / recent~e.6))

# ::tok In B @-@ Raf , this motif is negatively charged due to the constitutive phosphorylation of Ser446 and @/@ or 447 , and to the presence of two aspartates at position 448 @/@ 9 ( Fig. 2A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.1 3-1.1.2.1.1 5-1.1.1 6-1.1 6-1.3.1.2.2.1 6-1.3.1.2.2.2 8-1.2 9-1 10-1.3 11-1.3 13-1.3.1.1.2 14-1.3.1.1 17-1.3.1.1.1 19-1.3.1.1.1 20-1.3.1.1.1.2.1 22-1.3.1 27-1.3.1.2.1.1 29-1.3.1.2 31-1.3.1.2.2.1.1 36-1.4.1.1
# ::id bio-kappa_0001.4
# ::preferred 
(c / charge-03~e.9
      :ARG1 (m / motif~e.6
            :mod (t / this~e.5)
            :part-of (e2 / enzyme
                  :name (n6 / name :op1 "B-Raf"~e.1,3)))
      :mod (n / negative~e.8)
      :ARG1-of (c2 / cause-01~e.10,11
            :ARG0 (a / and~e.22
                  :op1 (p / phosphorylate-01~e.14
                        :ARG1 (a6 / and-or~e.17,19
                              :op1 (a2 / amino-acid
                                    :mod "446"
                                    :name (n2 / name :op1 "serine"))
                              :op2 (a3 / amino-acid
                                    :mod "447"~e.20
                                    :name (n3 / name :op1 "serine")))
                        :mod (c3 / constitutive~e.13))
                  :op2 (b / be-located-at-91~e.29
                        :ARG1 (a4 / amino-acid
                              :quant "2"~e.27
                              :name (n4 / name :op1 "aspartate"))
                        :ARG2 (a5 / and
                              :op1 (p2 / protein-segment~e.6 :mod "448"~e.31)
                              :op2 (p3 / protein-segment~e.6 :mod "449")))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2A"~e.36)))

# ::tok Allosteric activation by B @-@ Raf induces cis @-@ autophosporylation in the activation loop of the receiver kinase , i.e. C @-@ Raf , and renders it able to phosphorylate Mek .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1 5-1.1.1.1.1.1 6-1.1 12-1.1.2.3.1 13-1.1.2.3 17-1.1.2.3.1.1 19-1.2.2.1.r 20-1.1.2.3.1.1.2.1.1.1 22-1.1.1.1.1.1 22-1.1.2.3.1.1.2.1.1.1 24-1 25-1.2 27-1.2.2 29-1.1.2 29-1.2.2.1 30-1.2.2.1.1.1.1
# ::id bio-kappa_0001.5
# ::preferred 
(a3 / and~e.24
      :op1 (i / induce-01~e.6
            :ARG0 (a / activate-01~e.1
                  :ARG0~e.2 (e / enzyme
                        :name (n / name :op1 "B-Raf"~e.3,5,22))
                  :mod (a2 / allosteric~e.0))
            :ARG1 (p / phosphorylate-01~e.29
                  :ARG1 (k / kinase~e.17
                        :ARG0-of (r2 / receive-01)
                        :ARG1-of (m / mean-01
                              :ARG2 (e2 / enzyme
                                    :name (n2 / name :op1 "C-Raf"~e.20,22))))
                  :ARG2 k
                  :subevent-of (l / loop~e.13
                        :ARG0-of (a4 / activate-01~e.12
                              :ARG1 k))))
      :op2 (r / render-01~e.25
            :ARG0 a
            :ARG1 (p2 / possible~e.27
                  :domain~e.19 (p3 / phosphorylate-01~e.29
                        :ARG1 (e3 / enzyme
                              :name (n3 / name :op1 "Mek"~e.30))
                        :ARG2 e2))))

# ::tok Mek , in turn , phosphorylates the N @-@ terminal acidic motif in C @-@ Raf , converting it to an allosteric activator of other Rafs ( Fig. 2B and C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 2-1.4 3-1.4 5-1 7-1.1.2.1.1 9-1.1.2.1.1 10-1.1.1 11-1.1 12-1.4 13-1.1.2.2.1.1 15-1.1.2.2.2.2.1.1.1.1 17-1.1.2.2.2 18-1.1.2.2.2.1 21-1.1.2.2.2.2.1.2 22-1.1.2.2.2.2 22-1.1.2.2.2.2.1 22-1.1.2.2.2.2.1.r 24-1.1.2.2.2.2.1.1.2 28-1.3.1.1.1 29-1.3.1 30-1.1.2.2.1.1
# ::id bio-kappa_0001.6
# ::preferred 
(p / phosphorylate-01~e.5
      :ARG1 (m / motif~e.11
            :mod (a / acid~e.10)
            :part-of (p2 / protein-segment
                  :name (n2 / name :op1 "N-terminus"~e.7,9)
                  :part-of (e2 / enzyme
                        :name (n3 / name :op1 "C-Raf"~e.13,30)
                        :ARG1-of (c2 / convert-01~e.17
                              :ARG0 e~e.18
                              :ARG2 (e3 / enzyme~e.22
                                    :ARG0-of~e.22 (a2 / activate-01~e.22
                                          :ARG1 (e4 / enzyme
                                                :name (n4 / name :op1 "Raf"~e.15)
                                                :mod (o / other~e.24))
                                          :mod (a3 / allosteric~e.21)))))))
      :ARG2 (e / enzyme
            :name (n / name :op1 "Mek"~e.0))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and~e.29
                  :op1 (f / figure :mod "2B"~e.28)
                  :op2 (f2 / figure :mod "2C")))
      :mod (i / in-turn~e.2,3,12))

# ::tok This model explains why C @-@ Raf mutants devoid of kinase activity cannot function as activators , and why B @-@ Raf can activate Mek directly as a homodimer .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2 3-1.2.1 3-1.2.1.r 4-1.2.1.1.1.2.1.1.1 6-1.2.1.1.1.2.1.1.1 7-1.2.1.1.1.2.1 7-1.2.1.1.1.2.1.2 7-1.2.1.1.1.2.1.2.r 10-1.2.1.1.1.2.1.3.2 12-1.2.1.1.1.1 12-1.2.1.1.1.2.1.3.1 12-1.2.1.1.1.2.1.3.1.r 15-1.2.1.1.1.2 17-1.2.1.1 18-1.2 18-1.2.1 18-1.2.1.r 19-1.2.1.1.2.1.1.1.1 21-1.2.1.1.2.1.1.1.1 22-1.2.1.1.1 22-1.2.1.1.2 23-1.2.1.1.2.1 24-1.2.1.1.2.1.2.1.1 25-1.2.1.1.2.1.3 25-1.2.1.1.2.1.3.r 28-1.2.1.1.2.1.1.2.1
# ::id bio-kappa_0001.7
# ::preferred 
(e / explain-01~e.2
      :ARG0 (m / model~e.1
            :mod (t3 / this~e.0))
      :ARG1 (t2 / thing~e.3,18
            :ARG0-of~e.3,18 (c2 / cause-01~e.3,18
                  :ARG1 (a6 / and~e.17
                        :op1 (p / possible~e.22
                              :polarity "-"~e.12
                              :domain (a2 / activate-01~e.15
                                    :ARG0 (e2 / enzyme~e.7
                                          :name (n / name :op1 "C-Raf"~e.4,6)
                                          :ARG2-of~e.7 (m2 / mutate-01~e.7)
                                          :ARG0-of (a3 / act-01
                                                :polarity~e.12 "-"~e.12
                                                :ARG1 (k / kinase~e.10)))))
                        :op2 (p2 / possible~e.22
                              :domain (a4 / activate-01~e.23
                                    :ARG0 (e3 / enzyme
                                          :name (n2 / name :op1 "B-Raf"~e.19,21)
                                          :ARG0-of (a5 / act-01
                                                :ARG1 (h / homodimer~e.28)))
                                    :ARG1 (e4 / enzyme
                                          :name (n3 / name :op1 "Mek"~e.24))
                                    :manner~e.25 (d / direct~e.25)))))))

# ::tok Phosphorylated Ksr can also function as a transactivator ; however , since Raf binding to Ksr induces limited kinase activity , in quiescent cells the constitutive association of Ksr with B @-@ Raf may serve to prevent C @-@ Raf binding to B @-@ Raf , safeguarding against undue activation of the pathway .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1.1.1 2-1.1.3 3-1.1.2 9-1.1.3.r 11-1.1.3.3 12-1.1.3.3.1.1.1.1.1 13-1.1.3.3.1.1 14-1.1.3.3 14-1.1.3.3.1.1.2.r 15-1.1.3.3.1.1.2 16-1.1.3.3.1 17-1.1.3.3.1.2.2 18-1.1.3.3.1.2.1 22-1.1.3.2.1 23-1.1.3.2 25-1.1.3.1.1.3 26-1.1.3.1.1 27-1.1.3.1.1.1.r 28-1.1.3.1.1.1 29-1.1.3.1.1.2.r 30-1.1.3.1.1.2.1.1 32-1.1.3.1.1.2.1.1 33-1 33-1.1.3 34-1.1.3.1 36-1.1.3.1.2 37-1.1.3.1.2.2.1.1.1 39-1.1.3.1.2.2.1.1.1 40-1.1.3.1.2.2 41-1.1.3.1.2.2.2.r 42-1.1.3.1.2.2.2 43-1.1.3.1.2.2.2 44-1.1.3.1.2.2.2 46-1.1.3.1.2.3 48-1.1.3.1.2.3.1.2 48-1.1.3.1.2.3.1.2.1 48-1.1.3.1.2.3.1.2.1.r 49-1.1.3.1.2.3.1 50-1.1.3.1.2.3.1.1.r 52-1.1.3.1.2.3.1.1
# ::id bio-kappa_0001.8
# ::preferred 
(p / possible~e.33
      :domain (t2 / transactivate-00
            :ARG0 (e / enzyme
                  :name (n / name :op1 "Ksr"~e.1)
                  :ARG3-of (p2 / phosphorylate-01~e.0))
            :mod (a / also~e.3)
            :concession-of~e.9 (p3 / possible~e.2,33
                  :domain (s / serve-01~e.34
                        :ARG0 (a3 / associate-01~e.26
                              :ARG1~e.27 e~e.28
                              :ARG2~e.29 (e3 / enzyme
                                    :name (n3 / name :op1 "B-Raf"~e.30,32))
                              :mod (c2 / constitutive~e.25))
                        :ARG1 (p4 / prevent-01~e.36
                              :ARG0 a3
                              :ARG1 (b / bind-01~e.40
                                    :ARG1 (e4 / enzyme
                                          :name (n4 / name :op1 "C-Raf"~e.37,39))
                                    :ARG2~e.41 e3~e.42,43,44)
                              :ARG0-of (s2 / safeguard-01~e.46
                                    :ARG2 (a4 / activate-01~e.49
                                          :ARG1~e.50 (p5 / pathway~e.52)
                                          :mod (d / due~e.48 :polarity~e.48 "-"~e.48)))))
                  :location (c / cell~e.23
                        :mod (q / quiescent~e.22))
                  :ARG1-of (c3 / cause-01~e.11,14
                        :ARG0 (i / induce-01~e.16
                              :ARG0 (b2 / bind-01~e.13
                                    :ARG1 (e6 / enzyme
                                          :name (n6 / name :op1 "Raf"~e.12))
                                    :ARG2~e.14 e~e.15)
                              :ARG1 (a2 / act-01
                                    :ARG1 (k / kinase~e.18)
                                    :ARG1-of (l / limit-01~e.17)))))))

# ::tok PSPs dephosphorylate phosphoserine and phosphothreonine residues .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1 5-1.1.1 5-1.1.2
# ::id bio-kappa_0001.9
# ::preferred 
(d / dephosphorylate-01~e.1
      :ARG1 (a / and~e.3
            :op1 (r / residue~e.5
                  :mod (a2 / amino-acid
                        :name (n / name :op1 "serine")
                        :ARG3-of (p2 / phosphorylate-01)))
            :op2 (r2 / residue~e.5
                  :mod (a3 / amino-acid
                        :name (n2 / name :op1 "threonine")
                        :ARG3-of (p4 / phosphorylate-01))))
      :ARG2 (s / small-molecule
            :name (n3 / name :op1 "PSP")))

# ::tok One of the most abundantly expressed PSPs , protein phosphatase 2A ( PP2A ) , can regulate the Raf / Mek / Erk pathway both positively and negatively .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.2.2.1.2.1.1 4-1.1.1.2.2.1.2.1 5-1.1.1.2.2.1.2 8-1.1.1.2.1.1 9-1.1.1.2.1.2 10-1.1.1.2.1.3 15-1 18-1.1.1.1.1.1 20-1.1.1.1.1.1 22-1.1.1.1.1.1 23-1.1.1.1 26-1.1
# ::id bio-kappa_0001.10
# ::preferred 
(p / possible~e.15
      :domain (a3 / and~e.26
            :op1 (u / upregulate-01
                  :ARG1 (p3 / pathway~e.23
                        :name (n3 / name :op1 "Raf/Mek/Erk"~e.18,20,22))
                  :ARG2 (e2 / enzyme
                        :name (n2 / name
                              :op1 "protein"~e.8
                              :op2 "phosphatase"~e.9
                              :op3 "2A"~e.10)
                        :ARG1-of (i / include-91
                              :ARG2 (s / small-molecule
                                    :name (n / name :op1 "PSP")
                                    :ARG2-of (e / express-03~e.5
                                          :degree (a / abundant~e.4
                                                :degree (m2 / most~e.3)))))))
            :op2 (d / downregulate-01
                  :ARG1 p3
                  :ARG2 e2)))

# ::tok As a positive regulator , PP2A associates with C @-@ Raf and Ksr1 and dephosphorylates negative regulatory sites on both proteins , allowing their recruitment to the membrane and leading to Mek and Erk activation .
# ::amr-annotator SDL-AMR-09
# ::alignments 5-1.1.1.1.1 6-1.1 7-1.1.2.r 8-1.1.2.1.1.1 10-1.1.2.1.1.1 12-1.1.2.2.1.1 13-1.2.1.2 17-1.2.1 20-1.2.1 22-1.3 23-1.3.1.1 23-1.3.1.1.r 24-1.3.1 25-1.3.1.2.r 27-1.3.1.2 28-1 28-1.1.2 29-1.4 30-1.4.1.r 31-1.4.1.1.1.1.1 32-1.4.1.1 33-1.4.1.1.2.1.1 34-1.4.1
# ::id bio-kappa_0001.11
# ::preferred 
(a / and~e.28
      :op1 (a7 / associate-01~e.6
            :ARG1 (e / enzyme
                  :name (n / name :op1 "PP2A"~e.5))
            :ARG2~e.7 (a2 / and~e.28
                  :op1 (e2 / enzyme
                        :name (n2 / name :op1 "C-Raf"~e.8,10))
                  :op2 (e3 / enzyme
                        :name (n3 / name :op1 "Ksr1"~e.12))))
      :op2 (d / dephosphorylate-01
            :ARG1 (p2 / protein-segment~e.17,20
                  :ARG0-of (d2 / downregulate-01)
                  :part-of (a3 / and~e.13
                        :op1 e2
                        :op2 e3))
            :ARG2 e)
      :ARG0-of (a4 / allow-01~e.22
            :ARG1 (r / recruit-01~e.24
                  :ARG1~e.23 a2~e.23
                  :destination~e.25 (m / membrane~e.27)))
      :ARG0-of (l / lead-03~e.29
            :ARG2~e.30 (a5 / activate-01~e.34
                  :ARG1 (a6 / and~e.32
                        :op1 (e4 / enzyme
                              :name (n5 / name :op1 "Mek"~e.31))
                        :op2 (e5 / enzyme
                              :name (n6 / name :op1 "Erk"~e.33)))))
      :condition (u / upregulate-01
            :ARG2 e))

# ::tok A similar role in C @-@ Raf activation has been described for the catalytic subunit of PP1C , which associates with C @-@ Raf in Ras @- and growth factor - stimulated cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1.1.2.r 4-1.1.2.1.1.1 6-1.1.2.1.1.1 7-1.1.2 10-1 11-1.2.r 13-1.2 13-1.2.1 13-1.2.1.r 15-1.2.2.r 16-1.2.2.1.1 21-1.2.3.1 22-1.2.3.1 23-1.2.3.1 25-1.2.3.2.1.1.1.1.1 27-1.2.3.2.1.1 28-1.2.3.2.1.1.2.1.1 29-1.2.3.2.1.1.2.1.2 31-1.2.3.2.1 32-1.2.3.2
# ::id bio-kappa_0001.12
# ::preferred 
(d / describe-01~e.10
      :ARG1 (r / role~e.2
            :ARG1-of (r2 / resemble-01~e.1)
            :purpose~e.3 (a / activate-01~e.7
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "C-Raf"~e.4,6))))
      :topic~e.11 (p / protein-segment~e.13
            :ARG0-of~e.13 (c / catalyze-01~e.13)
            :part-of~e.15 (e2 / enzyme
                  :name (n2 / name :op1 "PP1C"~e.16))
            :ARG1-of (b / bind-01
                  :ARG2 e~e.21,22,23
                  :location (c2 / cell~e.32
                        :ARG1-of (s / stimulate-01~e.31
                              :ARG0 (a2 / and~e.27
                                    :op1 (e3 / enzyme
                                          :name (n3 / name :op1 "Ras"~e.25))
                                    :op2 (s2 / small-molecule
                                          :name (n4 / name :op1 "growth"~e.28 :op2 "factor"~e.29))))))))

# ::tok In addition to promoting C @-@ Raf activation , PP2A is also able to dephosphorylate Erk - dependent sites on C @-@ Raf .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1 3-1.1 4-1.1.2.1 5-1.1.2.1 6-1.1.2.1 7-1.1.2 9-1.2.1.2.1.1 10-1.2.1.r 11-1.2.2 12-1.2 14-1.2.1 15-1.2.1.1.1.1.1.1 17-1.2.1.1.1 18-1.2.1.1 19-1.2.1.1.2.r 20-1.2.1.1.2.1.1 22-1.2.1.1.2.1.1
# ::id bio-kappa_0001.13
# ::preferred 
(a / and~e.0,1
      :op1 (p3 / promote-02~e.3
            :ARG0 (e / enzyme
                  :name (n / name :op1 "PP2A"~e.9))
            :ARG1 (a2 / activate-01~e.7
                  :ARG1 e3~e.4,5,6))
      :op2 (p / possible~e.12
            :domain~e.10 (d / dephosphorylate-01~e.14
                  :ARG1 (p2 / protein-segment~e.18
                        :ARG0-of (d2 / depend-01~e.17
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "Erk"~e.15)))
                        :part-of~e.19 (e3 / enzyme
                              :name (n3 / name :op1 "C-Raf"~e.20,22)))
                  :ARG2 e)
            :mod (a3 / also~e.11)))

# ::tok Since the sites have been described alternatively as negative regulatory or activating , the significance of these dephosphorylation events for Raf activation is unclear .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.3.1.1 5-1.3.1 6-1.3.1.3 6-1.3.1.3.r 10-1.3.1.2 11-1.3.1.2.2 14-1.2 15-1.2.2.r 16-1.2.2.1 17-1.2.2 19-1.2.1.r 20-1.2.1.1.1.1 21-1.2.1 22-1.2.r 23-1 23-1.1 23-1.1.r
# ::id bio-kappa_0001.14
# ::preferred 
(c / clear~e.23
      :polarity~e.23 "-"~e.23
      :domain~e.22 (s / significance~e.14
            :topic~e.19 (a3 / activate-01~e.21
                  :ARG1 (e2 / enzyme
                        :name (n2 / name :op1 "Raf"~e.20)))
            :mod~e.15 (d / dephosphorylate-01~e.17
                  :mod (t / this~e.16)))
      :ARG1-of (c2 / cause-01~e.0
            :ARG0 (d2 / describe-01~e.5
                  :ARG1 (p / protein-segment~e.2)
                  :ARG2 (o / or~e.10
                        :op1 (d3 / downregulate-01
                              :ARG2 p)
                        :op2 (a2 / activate-01~e.11
                              :ARG0 p))
                  :manner~e.6 (a / alternative~e.6))))

# ::tok As a negative regulator of the pathway , PP2A can dephosphorylate the adapter protein Shc , required downstream of some tyrosine kinase receptors for the activation of the Raf / Mek / Erk module ; and it can dephosphorylate Mek and Erk proteins , thus inhibiting the cascade directly .
# ::amr-annotator SDL-AMR-09
# ::alignments 6-1.1.1.3.1 8-1.1.1.2.1.1 9-1.1 10-1.1.1 12-1.1.1.1.2 13-1.1.1.1 13-1.1.1.1.3.1.2.1 14-1.1.1.1.1.1 16-1.1.1.1.3 17-1.1.1.1.3.1.2.2 18-1.1.1.1.3.1.2.1.2.r 19-1.1.1.1.3.1.2.1.2 20-1.1.1.1.3.1.2.1.1.1 21-1.1.1.1.3.1.2.1.1.2 22-1.1.1.1.3.1.2.1.1.3 25-1.1.1.1.3.1 26-1.1.1.1.3.1.1.r 28-1.1.1.1.3.1.1.1.1 30-1.1.1.1.3.1.1.1.1 32-1.1.1.1.3.1.1.1.1 33-1.1.1.1.3.1.1.1.2 35-1 37-1.2 38-1.2.1 39-1.2.1.1.1.1.1 40-1.2.1.1 41-1.2.1.1.2.1.1 42-1.1.1.1 45-1.2.1.3 47-1.2.1.3.1 48-1.2.1.3.2 48-1.2.1.3.2.r
# ::id bio-kappa_0001.15
# ::preferred 
(a / and~e.35
      :op1 (p6 / possible~e.9
            :domain (d / dephosphorylate-01~e.10
                  :ARG1 (p2 / protein~e.13,42
                        :name (n2 / name :op1 "Shc"~e.14)
                        :mod (a2 / adapter~e.12)
                        :ARG1-of (r / require-01~e.16
                              :ARG0 (a3 / activate-01~e.25
                                    :ARG1~e.26 (p3 / pathway
                                          :name (n3 / name :op1 "Raf/Mek/Erk"~e.28,30,32 :op2 "module"~e.33))
                                    :location (r3 / relative-position
                                          :op1 (p / protein~e.13
                                                :name (n7 / name
                                                      :op1 "tyrosine"~e.20
                                                      :op2 "kinase"~e.21
                                                      :op3 "receptor"~e.22)
                                                :quant~e.18 (s / some~e.19))
                                          :direction (d2 / downstream~e.17)))))
                  :ARG2 (e / enzyme
                        :name (n / name :op1 "PP2A"~e.8))
                  :condition (d5 / downregulate-01
                        :ARG1 (p4 / pathway~e.6)
                        :ARG2 e)))
      :op2 (p7 / possible~e.37
            :domain (d4 / dephosphorylate-01~e.38
                  :ARG1 (a4 / and~e.40
                        :op1 (e2 / enzyme
                              :name (n4 / name :op1 "Mek"~e.39))
                        :op2 (e3 / enzyme
                              :name (n5 / name :op1 "Erk"~e.41)))
                  :ARG2 e
                  :ARG0-of (i / inhibit-01~e.45
                        :ARG1 (c / cascade~e.47)
                        :manner~e.48 (d3 / direct~e.48)))))

# ::tok A further negative regulator of the cascade , at the level of C @-@ Raf , is Protein phosphatase 5 ( PP5 ) , which associates with C @-@ Raf via its N @-@ terminal tetratricopeptide ( TPR ) domain in growth factor stimulated cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 6-1.2 11-1.2.1.r 12-1.2.1 13-1.2.1 14-1.2.1 17-1.1.1.1 18-1.1.1.2 19-1.1.1.3 25-1.1 25-1.1.2 25-1.1.2.r 26-1.1.2.1.r 26-1.1.2.3.r 27-1.1.2.1.1.1 29-1.1.2.1.1.1 31-1.1.2.3.2.2 31-1.1.2.3.2.2.r 32-1.1.2.3.2.1.1 34-1.1.2.3.2.1.1 35-1.1.2.3.1.1 39-1.1.2.3.1.2 40-1.1.2.2.r 41-1.1.2.2.1.1.1.1 42-1.1.2.2.1.1.1.2 43-1.1.2.2.1 44-1.1.2.2
# ::id bio-kappa_0001.16
# ::preferred 
(d3 / downregulate-01
      :ARG0 (e3 / enzyme~e.25
            :name (n / name
                  :op1 "Protein"~e.17
                  :op2 "phosphatase"~e.18
                  :op3 "5"~e.19)
            :ARG1-of~e.25 (a / associate-01~e.25
                  :ARG2~e.26 (e2 / enzyme
                        :name (n2 / name :op1 "C-Raf"~e.27,29))
                  :location~e.40 (c / cell~e.44
                        :ARG1-of (s / stimulate-01~e.43
                              :ARG0 (s2 / small-molecule
                                    :name (n5 / name :op1 "growth"~e.41 :op2 "factor"~e.42))))
                  :instrument~e.26 (p2 / protein-segment
                        :name (n4 / name :op1 "tetratricopeptide"~e.35 :op2 "domain"~e.39)
                        :part-of (p / protein-segment
                              :name (n3 / name :op1 "N-terminal"~e.32,34)
                              :part-of~e.31 e2~e.31)))
            :mod (f / further~e.1))
      :ARG1 (c2 / cascade~e.6
            :location~e.11 e2~e.12,13,14))

# ::tok This interaction leads to the activation of PP5 catalytic activity and to the selective dephosphorylation of the activating serine residue at position 338 , terminating the signal .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 5-1.2.1 7-1.2.1.1.1.1.1 8-1.2.1.1.2 10-1.2 13-1.2.2.2 14-1.2.2 15-1.2.2.1.r 17-1.2.2.1.3 18-1.2.2.1.2.1.1 19-1.2.2.1 22-1.2.2.1.1 24-1.2.3 26-1.2.3.1
# ::id bio-kappa_0001.17
# ::preferred 
(l / lead-03~e.2
      :ARG0 (i2 / interact-01~e.1
            :mod (t / this~e.0))
      :ARG2~e.3 (a3 / and~e.10
            :op1 (a / activate-01~e.5
                  :ARG1 (a2 / act-01
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "PP5"~e.7))
                        :ARG1 (c2 / catalyze-01~e.8)))
            :op2 (d / dephosphorylate-01~e.14
                  :ARG1~e.15 (r / residue~e.19
                        :mod "338"~e.22
                        :mod (a4 / amino-acid
                              :name (n2 / name :op1 "serine"~e.18))
                        :ARG0-of (a5 / activate-01~e.17))
                  :mod (s / selective~e.13))
            :ARG0-of (t2 / terminate-01~e.24
                  :ARG1 (s3 / signal~e.26))))

# ::tok Following ligand binding , Sos is brought from the cytoplasm to the activated receptor in a phosphotyrosine - dependent manner through adapter proteins such as Grb2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.6 1-1.6.1.1 2-1.6.1 4-1.1.1.1 6-1 7-1.3.r 9-1.3 10-1.2.r 12-1.2.1 13-1.2 18-1.4 19-1.4.r 21-1.5.2 22-1.5 23-1.5.1.r 24-1.5.1.r 25-1.5.1.1.1
# ::id bio-kappa_0001.18
# ::preferred 
(b / bring-01~e.6
      :ARG1 (p3 / protein
            :name (n3 / name :op1 "Sos"~e.4))
      :ARG2~e.10 (r / receptor~e.13
            :ARG1-of (a / activate-01~e.12))
      :ARG4~e.7 (c / cytoplasm~e.9)
      :manner~e.19 (d / depend-01~e.18
            :ARG0 b
            :ARG1 (a2 / amino-acid
                  :name (n / name :op1 "tyrosine")
                  :ARG3-of (p4 / phosphorylate-01)))
      :instrument (p / protein~e.22
            :example~e.23,24 (p2 / protein
                  :name (n2 / name :op1 "Grb2"~e.25))
            :mod (a3 / adapter~e.21))
      :ARG1-of (f / follow-01~e.0
            :ARG2 (b2 / bind-01~e.2
                  :ARG1 (l / ligand~e.1))))

# ::tok Grb2 contains SH3 domains that are bound constitutively to a carboxy - terminal proline - rich region of Sos , and the Grb2 ' 96 Sos complex is recruited to activated receptors by interactions between the SH2 domain of Grb2 and phosphotyrosine residues on the receptor .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1.1 3-1.1.2.1.2 6-1.1.2 6-1.1.2.2 6-1.1.2.2.r 7-1.1.2.2.2 8-1.1.2.2.1.r 10-1.1.2.2.1.2.1.1 12-1.1.2.2.1.2.1.1 13-1.1.2.2.1.1.1.1.1 15-1.1.2.2.1.1 16-1.1.2.2.1 18-1.1.2.2.1.2.2.1.1 22-1.1.1.1.1 23-1.1.r 25-1.2.2.2 26-1.2.2 28-1.2 29-1.2.3.r 30-1.2.3.1 31-1.2.3 32-1.2.1.r 33-1.2.1 36-1.2.1.1.1.1 37-1.2.1.1.1.2 39-1.2.1.1.2 40-1 42-1.2.1.2 43-1.2.1.2.1.r 45-1.2.1.2.1
# ::id bio-kappa_0001.19
# ::preferred 
(a / and~e.40
      :op1~e.23 (c / contain-01~e.1
            :ARG0 (p / protein
                  :name (n / name :op1 "Grb2"~e.0,22))
            :ARG1 (p2 / protein-segment~e.6
                  :name (n2 / name :op1 "SH3"~e.2 :op2 "domain"~e.3)
                  :ARG1-of~e.6 (b / bind-01~e.6
                        :ARG2~e.8 (r4 / region~e.16
                              :mod (r6 / rich~e.15
                                    :topic (a3 / amino-acid
                                          :name (n3 / name :op1 "proline"~e.13)))
                              :part-of (p5 / protein-segment
                                    :name (n4 / name :op1 "carboxy-terminus"~e.10,12)
                                    :part-of (p6 / protein
                                          :name (n5 / name :op1 "Sos"~e.18))))
                        :mod (c2 / constitutive~e.7))))
      :op2 (r5 / recruit-01~e.28
            :ARG0~e.32 (i / interact-01~e.33
                  :ARG0 (p7 / protein-segment
                        :name (n7 / name :op1 "SH2"~e.36 :op2 "domain"~e.37)
                        :part-of p~e.39)
                  :ARG1 (r2 / residue~e.42
                        :location~e.43 (r3 / receptor~e.45)
                        :mod (a4 / amino-acid
                              :name (n6 / name :op1 "tyrosine")
                              :ARG3-of (p3 / phosphorylate-01))))
            :ARG1 (m2 / macro-molecular-complex~e.26
                  :part p
                  :part p6~e.25)
            :destination~e.29 (r / receptor~e.31
                  :ARG1-of (a2 / activate-01~e.30))))

# ::tok The guanine nucleotide @-@ binding switch in three dimensions .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 2-1.1.1.2 4-1.1.1.2 5-1 6-1.2.r 7-1.2.1 8-1.2
# ::id bio-kappa_0001.20
# ::preferred 
(s / switch~e.5
      :mod (p / protein
            :name (n / name :op1 "guanine"~e.1 :op2 "nucleotide-binding"~e.2,4))
      :prep-in~e.6 (d / dimension~e.8 :quant "3"~e.7))

# ::tok Activation requires dissociation of protein - bound GDP , an intrinsically slow process that is accelerated by guanine nucleotide ' 96 exchange factors ( GEFs ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2 3-1.2.1.r 4-1.2.1.2.1 6-1.2.1 6-1.2.1.2 6-1.2.1.2.r 7-1.2.1.1.1 10-1.2.2.1 11-1.2.2 15-1.2.3 16-1.2.3.1.r 17-1.2.3.1.1.1 18-1.2.3.1.1.2 21-1.2.3.1.1.3 22-1.2.3.1.1.4
# ::id bio-kappa_0001.21
# ::preferred 
(r / require-01~e.1
      :ARG0 (a / activate-01~e.0)
      :ARG1 (d / dissociate-01~e.2
            :ARG1~e.3 (s / small-molecule~e.6
                  :name (n / name :op1 "GDP"~e.7)
                  :ARG1-of~e.6 (b / bind-01~e.6
                        :ARG2 (p / protein~e.4)))
            :mod (s2 / slow~e.11
                  :mod (i / intrinsic~e.10))
            :ARG1-of (a2 / accelerate-01~e.15
                  :ARG0~e.16 (p2 / protein
                        :name (n2 / name
                              :op1 "guanine"~e.17
                              :op2 "nucleotide"~e.18
                              :op3 "exchange"~e.21
                              :op4 "factor"~e.22)))))

# ::tok This switch - ON process involves the exchange of GDP for GTP , and is , at least in principle , reversible .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 4-1.1.1 5-1.1 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1.1 10-1.1.2.2.r 11-1.1.2.2.1.1 13-1 14-1.2.1.r 16-1.2.2.1 17-1.2.2.1 18-1.2.2 19-1.2.2
# ::id bio-kappa_0001.22
# ::preferred 
(a / and~e.13
      :op1 (i2 / involve-01~e.5
            :ARG0 (p / process~e.4
                  :mod (t / this~e.0)
                  :mod (a3 / activate-01))
            :ARG1 (e / exchange-01~e.7
                  :ARG1~e.8 (s / small-molecule
                        :name (n / name :op1 "GDP"~e.9))
                  :ARG3~e.10 (s2 / small-molecule
                        :name (n2 / name :op1 "GTP"~e.11))))
      :op2 (p3 / possible
            :domain~e.14 (r / reverse-01
                  :ARG1 p)
            :mod (i / in-principle~e.18,19
                  :mod (a2 / at-least~e.16,17))))

# ::tok The switch - OFF process is entirely different and involves hydrolysis of GTP to GDP , the guanosine triphosphatase ( GTPase ) reaction , which is basically irreversible .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.1 6-1.1.2 7-1.1 8-1 9-1.2 10-1.2.1 11-1.2.1.1.r 12-1.2.1.1.1.1 13-1.2.1.2.r 14-1.2.1.2.1.1 17-1.2.1.3.1.1.1 18-1.2.1.3.1.1.2 22-1.2.1.3 26-1.2.1.3.2.1.2 27-1.2.1.3.2.1.1
# ::id bio-kappa_0001.23
# ::preferred 
(a / and~e.8
      :op1 (d2 / differ-02~e.7
            :ARG1 (p / process~e.4
                  :mod (d / deactivate-01))
            :degree (e / entire~e.6))
      :op2 (i / involve-01~e.9
            :ARG1 (h / hydrolyze-01~e.10
                  :ARG1~e.11 (s / small-molecule
                        :name (n / name :op1 "GTP"~e.12))
                  :ARG3~e.13 (s2 / small-molecule
                        :name (n2 / name :op1 "GDP"~e.14))
                  :ARG2-of (r / react-01~e.22
                        :ARG0 (e2 / enzyme
                              :name (n3 / name :op1 "guanosine"~e.17 :op2 "triphosphatase"~e.18))
                        :ARG1-of (r2 / reverse-01
                              :mod (p2 / possible
                                    :polarity "-"~e.27
                                    :mod (b / basic~e.26)))))
            :ARG2 p))

# ::tok It is also intrinsically very slow and thus has to be accelerated by GTPase - activating proteins ( GAPs ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.r 2-1.4 3-1.3 4-1.2 5-1 7-1.5 8-1.5.1 9-1.5.1 11-1.5.1.1 12-1.5.1.1.1.r 13-1.5.1.1.1.1.1.1.1 15-1.5.1.1.1.1 16-1.5.1.1.1
# ::id bio-kappa_0001.24
# ::preferred 
(s / slow~e.5
      :domain~e.1 (i / it~e.0)
      :degree (v / very~e.4)
      :mod (i2 / intrinsic~e.3)
      :mod (a4 / also~e.2)
      :ARG0-of (c / cause-01~e.7
            :ARG1 (o2 / obligate-01~e.8,9
                  :ARG2 (a / accelerate-01~e.11
                        :ARG0~e.12 (p / protein~e.16
                              :ARG0-of (a3 / activate-01~e.15
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "GTPase"~e.13))))
                        :ARG1 i))))

# ::tok The mechanism of GEF action involves a series of fast reaction steps , which lead from a binary protein - nucleotide complex via a trimeric GNBP - nucleotide - GEF complex to a binary nucleotide - free complex , which is stable in the absence of nucleotide .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1.2.1.r 3-1.2.1.1.1.1 4-1.2.1 5-1 7-1.1 8-1.1.1.r 9-1.1.1.1 10-1.1.1.2 11-1.1.1 17-1.1.1.3.2.3 18-1.1.1.3.2.1 20-1.1.1.3.1.1.1 21-1.1.1.3.2 21-1.1.1.3.3 22-1.1.1.3.3.r 24-1.1.1.3.3.1 25-1.1.1.3.3.2.1.1 27-1.1.1.3.3.3 29-1.1.1.3.3.4.1.1 30-1.1.1.3.2 33-1.1.1.3.2.3 34-1.1.1.3.1.1.1 36-1.1.1.3.1.1 37-1.1.1.3.1 40-1.1.1.3.1.2.1.1.r 41-1.1.1.3.1.2 42-1.1.1.3.1.2.1.r 44-1.1.1.3.1.2.1 46-1.1.1.3.1.2.1.1
# ::id bio-kappa_0001.25
# ::preferred 
(i / involve-01~e.5
      :ARG1 (s / series~e.7
            :consist-of~e.8 (s2 / step~e.11
                  :mod (f / fast~e.9)
                  :mod (r / react-01~e.10)
                  :ARG0-of (t3 / turn-02
                        :ARG2 (c2 / complex~e.37
                              :ARG1-of (f2 / free-04~e.36
                                    :ARG2 (n3 / nucleotide~e.20,34))
                              :mod (s3 / stable~e.41
                                    :condition~e.42 (a2 / absent~e.44
                                          :domain~e.40 n3~e.46)))
                        :ARG3 (m2 / macro-molecular-complex~e.21,30
                              :part (p2 / protein~e.18)
                              :part n3
                              :mod (b2 / binary~e.17,33))
                        :path~e.22 (m3 / macro-molecular-complex~e.21
                              :mod (t2 / trimeric~e.24)
                              :part (p3 / protein
                                    :name (n2 / name :op1 "GNBP"~e.25))
                              :part n3~e.27
                              :part (p4 / protein
                                    :name (n4 / name :op1 "GEF"~e.29))))))
      :ARG2 (m / mechanism~e.1
            :mod~e.2 (a / act-02~e.4
                  :ARG0 (p / protein
                        :name (n / name :op1 "GEF"~e.3)))))

# ::tok This series of reactions is reversed by rebinding of nucleotide , predominantly GTP , because of its higher concentration in the cell .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2 2-1.2.2.r 3-1.2.2 5-1 9-1.1.1 11-1.1.1.1.2 12-1.1.1.1.1.1.1 14-1.1.1.1.2.1 15-1.1.1.1.2.1.1.r 16-1.1.1.1.2.1.1.1 16-1.1.1.1.2.1.1.1.r 17-1.1.1.1.2.1.1.2 17-1.1.1.1.2.1.1.2.1 17-1.1.1.1.2.1.1.2.1.r 18-1.1.1.1.2.1.1 19-1.1.1.1.2.1.1.3.r 21-1.1.1.1.2.1.1.3
# ::id bio-kappa_0001.26
# ::preferred 
(r / reverse-01~e.5
      :ARG0 (b / bind-01
            :ARG1 (n / nucleotide~e.9
                  :ARG1-of (m2 / mean-01
                        :ARG2 (s2 / small-molecule
                              :name (n2 / name :op1 "GTP"~e.12))
                        :mod (p / predominant~e.11
                              :ARG1-of (c / cause-01~e.14
                                    :ARG0~e.15 (c2 / concentrate-02~e.18
                                          :ARG1~e.16 s2~e.16
                                          :mod (h / high~e.17
                                                :degree~e.17 (m / more~e.17))
                                          :location~e.19 (c3 / cell~e.21))))))
            :mod (a / again))
      :ARG1 (s / series~e.1
            :mod (t / this~e.0)
            :consist-of~e.2 (r2 / react-01~e.3)))

# ::tok In principle , these reactions are fast and fully reversible , so that the GEF merely acts as a catalyst to increase the rate at which equilibrium between the GDP @- and GTP - bound forms of the protein is reached .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3 3-1.1.1.1 4-1.1.1 5-1.1.1.r 6-1.1 7-1 8-1.2.1.2 11-1.4 12-1.4.1.4.r 14-1.4.1.1.1.1 15-1.4.1.3 16-1.4.1 21-1.4.1.4 23-1.4.1.4.2 29-1.4.1.4.2.1.1.1.1.1.1.1.1 31-1.4.1.4.2.1.1.1 32-1.4.1.4.2.1.1.1.2.1.1.1.1 34-1.4.1.4.2.1.1.1.1.1 34-1.4.1.4.2.1.1.1.2.1 38-1.4.1.4.2.1.1.1.1 38-1.4.1.4.2.1.1.1.2 40-1.4.1.4.2.1
# ::id bio-kappa_0001.27
# ::preferred 
(a / and~e.7
      :op1 (f / fast~e.6
            :domain~e.5 (r / react-01~e.4
                  :mod (t / this~e.3)))
      :op2 (p / possible
            :domain (r2 / reverse-01
                  :ARG1 r
                  :degree (f2 / full~e.8)))
      :mod (i2 / in-principle~e.0,1)
      :ARG0-of (c / cause-01~e.11
            :ARG1 (a2 / act-01~e.16
                  :ARG0 (p3 / protein
                        :name (n / name :op1 "GEF"~e.14))
                  :ARG1 (c2 / catalyze-01)
                  :degree (m / mere~e.15)
                  :purpose~e.12 (i / increase-01~e.21
                        :ARG0 p3
                        :ARG1 (r3 / rate~e.23
                              :degree-of (r4 / reach-01~e.40
                                    :ARG1 (e / equilibrate-01
                                          :ARG1 (a4 / and~e.31
                                                :op1 (p2 / protein~e.38
                                                      :ARG1-of (b / bind-01~e.34
                                                            :ARG2 (s / small-molecule
                                                                  :name (n2 / name :op1 "GDP"~e.29))))
                                                :op2 (p5 / protein~e.38
                                                      :ARG1-of (b2 / bind-01~e.34
                                                            :ARG2 (s2 / small-molecule
                                                                  :name (n3 / name :op1 "GTP"~e.32))))))))))))

# ::tok Protein kinase A @-@ dependent phosphorylation of serine 43 within the regulatory domain of Raf @-@ 1 reciprocally potentiates its interaction with Rheb and decreases its interaction with H @-@ Ras .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.2.1.1.1 1-1.1.1.2.1.1.2 2-1.1.1.2.1.1.3 4-1.1.1.2 5-1.1.1 6-1.1.1.1.r 7-1.1.1.1.2.1 8-1.1.1.1.1 11-1.1.1.1.3.1 12-1.1.1.1.3 13-1.1.1.1.3.2.r 14-1.1.1.1.3.2.1.1 16-1.1.1.1.3.2.1.1 17-1.1.3 18-1.1 19-1.1.2.1 19-1.1.2.1.r 20-1.1.2 21-1.1.2.2.r 22-1.1.2.2.1.1 23-1 24-1.2 26-1.2.2 27-1.2.2.2.r 28-1.2.2.2.1.1 30-1.2.2.2.1.1
# ::id bio.bel_0002.1
# ::preferred 
(a / and~e.23
      :op1 (p / potentiate-00~e.18
            :ARG0 (p3 / phosphorylate-01~e.5
                  :ARG1~e.6 (a2 / amino-acid
                        :mod "43"~e.8
                        :name (n5 / name :op1 "serine"~e.7)
                        :part-of (d2 / domain~e.12
                              :mod (r / regulate-01~e.11)
                              :part-of~e.13 (e2 / enzyme
                                    :name (n3 / name :op1 "Raf-1"~e.14,16))))
                  :ARG0-of (d3 / depend-01~e.4
                        :ARG1 (e3 / enzyme
                              :name (n4 / name
                                    :op1 "protein"~e.0
                                    :op2 "kinase"~e.1
                                    :op3 "A"~e.2))))
            :ARG1 (i / interact-01~e.20
                  :ARG0~e.19 e2~e.19
                  :ARG1~e.21 (p2 / protein
                        :name (n / name :op1 "Rheb"~e.22)))
            :mod (r2 / reciprocal~e.17))
      :op2 (d / decrease-01~e.24
            :ARG0 p3
            :ARG1 (i2 / interact-01~e.26
                  :ARG0 e2
                  :ARG1~e.27 (e / enzyme
                        :name (n2 / name :op1 "H-Ras"~e.28,30)))))

# ::tok We show that wild @-@ type B @-@ RAF forms a complex with C @-@ RAF in a RAS @-@ dependent manner , whereas the mutants bind independently of RAS .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.2 5-1.2.1.1.2 6-1.2.1.1.1.1 8-1.2.1.1.1.1 8-1.2.1.2.1.1 8-1.2.3.1.1.1.1 8-1.2.3.1.2.1.1 9-1.2 11-1.2.1 12-1.2.1.2.r 13-1.2.1.2.1.1 15-1.2.1.2.1.1 18-1.2.2.1.1.1 20-1.2.2 20-1.2.3.1.3 23-1.2.3 25-1.2.3.1.1 25-1.2.3.1.1.2 25-1.2.3.1.1.2.r 25-1.2.3.1.2 25-1.2.3.1.2.2 25-1.2.3.1.2.2.r 26-1.2.3.1 27-1.2.3.1.3.1 28-1.2.3.1.3.2.r 29-1.2.3.1.3.2
# ::id bio.bel_0002.2
# ::preferred 
(s / show-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (f / form-01~e.9
            :ARG1 (m / macro-molecular-complex~e.11
                  :part (e4 / enzyme
                        :name (n / name :op1 "B-RAF"~e.6,8)
                        :mod (w2 / wild-type~e.3,5))
                  :part~e.12 (e / enzyme
                        :name (n2 / name :op1 "C-RAF"~e.8,13,15)))
            :ARG0-of (d / depend-01~e.20
                  :ARG1 (e3 / enzyme
                        :name (n3 / name :op1 "RAS"~e.18)))
            :ARG1-of (c / contrast-01~e.23
                  :ARG2 (b / bind-01~e.26
                        :ARG1 (e5 / enzyme~e.25
                              :name (n4 / name :op1 "B-RAF"~e.8)
                              :ARG1-of~e.25 (m2 / mutate-01~e.25))
                        :ARG2 (e2 / enzyme~e.25
                              :name (n5 / name :op1 "C-RAF"~e.8)
                              :ARG1-of~e.25 (m3 / mutate-01~e.25))
                        :ARG0-of (d2 / depend-01~e.20
                              :polarity "-"~e.27
                              :ARG1~e.28 e3~e.29)))))

# ::tok Importantly , we show that wild @-@ type B @-@ RAF can also activate C @-@ RAF .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.r 5-1.2.1.1.2 7-1.2.1.1.2 8-1.2.1.1.1.1 10-1.2.1.1.1.1 10-1.2.1.2.1.1 11-1.2 12-1.2.1.3 13-1.2.1 14-1.2.1.2.1.1 16-1.2.1.1.1.1 16-1.2.1.2.1.1
# ::id bio.bel_0002.3
# ::preferred 
(s / show-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.4 (p / possible~e.11
            :domain (a / activate-01~e.13
                  :ARG0 (e2 / enzyme
                        :name (n / name :op1 "B-RAF"~e.8,10,16)
                        :mod (w2 / wild-type~e.5,7))
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "C-RAF"~e.10,14,16))
                  :mod (a2 / also~e.12)))
      :mod (i / important~e.0))

# ::tok The homologous site on B @-@ Raf , S445 , is constitutively phosphorylated , accounting for the higher basal activity of B @-@ Raf .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.3.1.1 6-1.1.3.1.1 11-1.2 12-1 14-1.3 15-1.3.1.r 17-1.3.1.3 17-1.3.1.3.1 17-1.3.1.3.1.r 18-1.3.1.2 19-1.3.1 20-1.3.1.1.r 21-1.3.1.1 22-1.3.1.1 23-1.3.1.1
# ::id bio.bel_0002.4
# ::preferred 
(p / phosphorylate-01~e.12
      :ARG1 (a3 / amino-acid
            :mod "445"
            :name (n3 / name :op1 "serine")
            :part-of (e / enzyme
                  :name (n4 / name :op1 "B-Raf"~e.4,6))
            :mod (h2 / homologue))
      :mod (c / constitutive~e.11)
      :ARG0-of (a / account-01~e.14
            :ARG1~e.15 (a2 / act-02~e.19
                  :ARG0~e.20 e~e.21,22,23
                  :mod (b / basal~e.18)
                  :mod (h / high~e.17
                        :degree~e.17 (m / more~e.17)))))

# ::tok In addition , introduction of B @-@ Raf enhances and sustains integrin @-@ mediated activation of ERK in wild @-@ type primary fibroblasts
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 0-1.1 0-1.1.r 1-1 1-1.1 1-1.1.r 3-1.1.1.1 4-1.1.1.1.1.r 5-1.1.1.1.1.1.1 7-1.1.1.1.1.1.1 8-1.1.1 9-1.1 10-1.1.2 11-1.1.1.2.3.1 13-1.1.1.2.3 14-1.1.1.2 15-1.1.1.2.1.r 16-1.1.1.2.1.1.1 17-1.1.1.2.2.r 18-1.1.1.2.2.1 20-1.1.1.2.2.1 21-1.1.1.2.2.2 22-1.1.1.2.2
# ::id bio.bel_0002.5
# ::preferred 
(a4 / and~e.0,1
      :op2~e.0,1 (a / and~e.0,1,9
            :op1 (e / enhance-01~e.8
                  :ARG0 (i / introduce-02~e.3
                        :ARG1~e.4 (e2 / enzyme
                              :name (n / name :op1 "B-Raf"~e.5,7)))
                  :ARG1 (a2 / activate-01~e.14
                        :ARG1~e.15 (e3 / enzyme
                              :name (n2 / name :op1 "ERK"~e.16))
                        :location~e.17 (f / fibroblast~e.22
                              :mod (w / wild-type~e.18,20)
                              :mod (p / primary~e.21))
                        :ARG1-of (m / mediate-01~e.13
                              :ARG0 (i2 / integrin~e.11))))
            :op2 (s / sustain-01~e.10
                  :ARG0 i
                  :ARG1 a2)))

# ::tok siRNA @-@ mediated depletion of B @-@ Raf reduced cell proliferation by up to 65 % through the inhibition of ERK1 @/@ 2 activation , irrespective of the mutational status of B @-@ Raf .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.1.1 2-1.1.2 3-1.1 4-1.1.1.r 5-1.1.1.1.1 7-1.1.1.1.1 8-1 9-1.2.1 10-1.2 11-1.3.r 12-1.3 13-1.3 14-1.3.1.1 15-1.3.1 18-1.4 19-1.4.1.r 20-1.4.1.1.1.1 22-1.4.1.1.1.1 23-1.4.1 26-1.5.r 28-1.5.2 29-1.5 30-1.5.1.r 31-1.5.1 32-1.5.1 33-1.5.1
# ::id bio.bel_0002.6
# ::preferred 
(r / reduce-01~e.8
      :ARG0 (d / deplete-01~e.3
            :ARG1~e.4 (e / enzyme
                  :name (n2 / name :op1 "B-Raf"~e.5,7))
            :ARG1-of (m / mediate-01~e.2
                  :ARG0 (r2 / rna-region
                        :name (n / name :op1 "siRNA"~e.0))))
      :ARG1 (p2 / proliferate-01~e.10
            :ARG0 (c / cell~e.9))
      :ARG2~e.11 (u / up-to~e.12,13
            :op1 (p / percentage-entity~e.15 :value "65"~e.14))
      :manner (i / inhibit-01~e.18
            :ARG1~e.19 (a / activate-01~e.23
                  :ARG1 (e2 / enzyme
                        :name (n3 / name :op1 "ERK1/2"~e.20,22))))
      :concession~e.26 (s / status~e.29
            :poss~e.30 e~e.31,32,33
            :mod (m2 / mutate-01~e.28)))

# ::tok Following expression of BRAFV600E in melanocytes , the majority of cells became senescent ( Figure 1D and data not shown ) , consistent with previous studies ( Michaloglou et al. , 2005 )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3.1 8-1.1.1 9-1.1.1.r 10-1.1 11-1 12-1.2 14-1.4.1.1 15-1.4.1.1.1 16-1.4.1 17-1.4.1.2 18-1.4.1.2.1.1 18-1.4.1.2.1.1.r 19-1.4.1.2.1 22-1.5 23-1.5.1.r 24-1.5.1.1 25-1.5.1 27-1.5.1.2.1.1.1.1.1 28-1.5.1.2.1.1 29-1.5.1.2.1.1.2.1 31-1.5.1.2.1.2.1
# ::id bio.bel_0002.7
# ::preferred 
(b / become-01~e.11
      :ARG1 (c / cell~e.10
            :quant~e.9 (m / majority~e.8))
      :ARG2 (s / senescent~e.12
            :domain c)
      :ARG1-of (f / follow-01~e.0
            :ARG2 (e / express-03~e.1
                  :ARG2 (e2 / enzyme
                        :name (n / name :op1 "B-Raf")
                        :ARG2-of (m2 / mutate-01 :value "V600E"))
                  :ARG3 (m3 / melanocyte)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a / and~e.16
                  :op1 (f2 / figure~e.14 :mod "1D"~e.15)
                  :op2 (d3 / data~e.17
                        :ARG1-of (s2 / show-01~e.19 :polarity~e.18 "-"~e.18))))
      :ARG1-of (c3 / consistent-01~e.22
            :ARG2~e.23 (s3 / study~e.25
                  :time (p / previous~e.24)
                  :ARG1-of (d4 / describe-01
                        :ARG0 (p2 / publication-91
                              :ARG0 (a2 / and~e.28
                                    :op1 (p3 / person
                                          :name (n2 / name :op1 "Michaloglou"~e.27))
                                    :op2 (p4 / person
                                          :mod (o / other~e.29)))
                              :time (d / date-entity :year "2005"~e.31))))))

# ::tok disruption of the KSR1 @/@ CK2 interaction or inhibition of CK2 activity significantly reduces the growth @-@ factor @-@ induced phosphorylation of C @-@ Raf and B @-@ Raf on the activating serine site in the negative @-@ charge regulatory region ( N @-@ region ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.r 3-1.1.1.1.1.1.1 5-1.1.1.1.2.1.1 6-1.1.1.1 7-1.1 8-1.1.2 9-1.1.2.1.r 10-1.1.2.1.1 11-1.1.2.1 12-1.3 13-1 15-1.2.2.1.1.1 17-1.2.2.1.1.2 19-1.2.2 20-1.2 21-1.2.1.r 22-1.2.1.3.3.1.1.1 24-1.2.1.3.3.1.1.1 24-1.2.1.3.3.2.1.1 25-1.2.1.3.3 26-1.2.1.3.3.2.1.1 28-1.2.1.3.3.1.1.1 28-1.2.1.3.3.2.1.1 31-1.2.1.1 32-1.2.1.2.1.1 33-1.2.1 36-1.2.1.3.2.1 38-1.2.1.3.2 39-1.2.1.3.1 40-1.2.1.3 44-1.2.1.3
# ::id bio.bel_0002.8
# ::preferred 
(r / reduce-01~e.13
      :ARG0 (o / or~e.7
            :op1 (d / disrupt-01~e.0
                  :ARG1~e.1 (i / interact-01~e.6
                        :ARG0 (e3 / enzyme
                              :name (n4 / name :op1 "KSR1"~e.3))
                        :ARG1 (e4 / enzyme
                              :name (n5 / name :op1 "CK2"~e.5))))
            :op2 (i2 / inhibit-01~e.8
                  :ARG1~e.9 (a3 / act-02~e.11
                        :ARG0 e4~e.10)))
      :ARG1 (p / phosphorylate-01~e.20
            :ARG1~e.21 (p2 / protein-segment~e.33
                  :ARG0-of (a2 / activate-01~e.31)
                  :mod (a4 / amino-acid
                        :name (n7 / name :op1 "serine"~e.32))
                  :part-of (r2 / region~e.40,44
                        :ARG0-of (r3 / regulate-01~e.39)
                        :ARG1-of (c / charge-03~e.38
                              :mod (n3 / negative~e.36))
                        :part-of (a / and~e.25
                              :op1 (e / enzyme
                                    :name (n / name :op1 "C-Raf"~e.22,24,28))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "B-Raf"~e.24,26,28)))))
            :ARG1-of (i3 / induce-01~e.19
                  :ARG0 (s4 / small-molecule
                        :name (n6 / name :op1 "growth"~e.15 :op2 "factor"~e.17))))
      :ARG2 (s / significant-02~e.12))

# ::tok Sorafenib is a potent TKI of VEGFR @-@ 2 , VEGFR @-@ 3 , B @-@ RAF , and PDGFR @-@ B
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 3-1.3 6-1.2.1.1.1 6-1.2.2.1.1 8-1.2.1.1.1 10-1.2.1.1.1 10-1.2.2.1.1 12-1.2.2.1.1 14-1.2.3.1.1 14-1.2.4.1.1 16-1.2.3.1.1 18-1.2 19-1.2.4.1.1 21-1.2.3.1.1 21-1.2.4.1.1
# ::id bio.bel_0002.9
# ::preferred 
(i / inhibit-01
      :ARG0 (s2 / small-molecule
            :name (n2 / name :op1 "Sorafenib"~e.0))
      :ARG1 (a / and~e.18
            :op1 (k / kinase
                  :name (n / name :op1 "VEGFR-2"~e.6,8,10))
            :op2 (k2 / kinase
                  :name (n3 / name :op1 "VEGFR-3"~e.6,10,12))
            :op3 (k3 / kinase
                  :name (n4 / name :op1 "B-RAF"~e.14,16,21))
            :op4 (k4 / kinase
                  :name (n5 / name :op1 "PDGFR-B"~e.14,19,21)))
      :mod (p / potent~e.3))

# ::tok In addition , we found that Rheb inhibits the association of B @-@ Raf with H @-@ Ras .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1 3-1.1.1 4-1.1 5-1.1.2.r 6-1.1.2.1.1.1 7-1.1.2 9-1.1.2.2 10-1.1.2.2.1.r 11-1.1.2.2.1.1.1 13-1.1.2.2.1.1.1 14-1.1.2.2.2.r 15-1.1.2.2.2.1.1 17-1.1.2.2.2.1.1
# ::id bio.bel_0002.10
# ::preferred 
(a3 / and~e.0,1
      :op2 (f / find-01~e.4
            :ARG0 (w / we~e.3)
            :ARG1~e.5 (i / inhibit-01~e.7
                  :ARG0 (p / protein
                        :name (n / name :op1 "Rheb"~e.6))
                  :ARG1 (a2 / associate-01~e.9
                        :ARG1~e.10 (e2 / enzyme
                              :name (n2 / name :op1 "B-Raf"~e.11,13))
                        :ARG2~e.14 (e3 / enzyme
                              :name (n3 / name :op1 "H-Ras"~e.15,17))))))

# ::tok hKSR @-@ 2 selectively inhibited the Cot @-@ mediated activation of MEK by 60 % .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1.3 3-1.3.r 4-1 6-1.2.2.1.1.1 8-1.2.2 9-1.2 10-1.2.1.r 11-1.2.1.1.1 12-1.4.r 13-1.4.1 14-1.4
# ::id bio.bel_0002.11
# ::preferred 
(i / inhibit-01~e.4
      :ARG0 (e / enzyme
            :name (n / name :op1 "hKSR-2"~e.0,2))
      :ARG1 (a / activate-01~e.9
            :ARG1~e.10 (e2 / enzyme
                  :name (n2 / name :op1 "MEK"~e.11))
            :ARG1-of (m / mediate-01~e.8
                  :ARG0 (e3 / enzyme
                        :name (n3 / name :op1 "Cot"~e.6))))
      :manner~e.3 (s / selective~e.3)
      :quant~e.12 (p / percentage-entity~e.14 :value "60"~e.13))

# ::tok In contrast , hKSR @-@ 2 up @-@ regulated the Rafmediated MEK activation by up to 70 % .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.2.1.1 5-1.1.2.1.1 6-1.1.3 11-1.1.1.1.1.1 12-1.1.1 14-1.1.3 15-1.1.3 15-1.1.3.1.r 16-1.1.3.1.1 17-1.1.3.1
# ::id bio.bel_0002.12
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (u / upregulate-01
            :ARG1 (a / activate-01~e.12
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "MEK"~e.11))
                  :ARG1-of (m / mediate-01
                        :ARG0 (e2 / enzyme
                              :name (n2 / name :op1 "Raf"))))
            :ARG2 (e3 / enzyme
                  :name (n3 / name :op1 "hKSR-2"~e.3,5))
            :quant (u2 / up-to~e.6,14,15
                  :op1~e.15 (p / percentage-entity~e.17 :value "70"~e.16))))

# ::tok GSK PI3K Phase 2 , part 1: List of non @-@ position specific phosphorylation effects on parent protein 's activity , derived from existing causal assertions of position @-@ specific phosphorylations on the parent protein activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.2.1.1 2-1.3 3-1.3.1 5-1.3.2 5-1.3.2.r 7-1.3.2.2 8-1.3.2.2.1.r 9-1.3.2.2.1.1.1.1 9-1.3.2.2.1.1.1.1.r 11-1.3.2.2.1.1.1 12-1.3.2.2.1.1.1.2 13-1.3.2.2.1.1 14-1.3.2.2.1 15-1.3.2.2.1.2.r 16-1.3.2.2.1.2.1.1 17-1.3.2.2.1.2.1 18-1.3.2.2.1.2.1.r 19-1.3.2.2.1.2 21-1.3.2.2.2 25-1.3.2.2.2.1 26-1.3.2.2.2.1.1.r 27-1.3.2.2.2.1.1.1 29-1.3.2.2.2.1.1.1.1 30-1.3.2.2.2.1.1 31-1.3.2.2.2.1.2.r 33-1.3.2.2.2.1.2 34-1.3.2.2.2.1.2 35-1.3.2.2.2.1.2
# ::id bio.bel_0002.13
# ::preferred 
(a4 / and
      :op1 (e / enzyme
            :name (n / name :op1 "GSK"~e.0))
      :op2 (e2 / enzyme
            :name (n2 / name :op1 "PI3K"~e.1))
      :mod (p8 / phase~e.2
            :mod "2"~e.3
            :part~e.5 (p9 / part~e.5
                  :mod "1"
                  :topic (l / list-01~e.7
                        :ARG1~e.8 (a / affect-01~e.14
                              :ARG0 (p / phosphorylate-01~e.13
                                    :mod (p2 / position~e.11
                                          :polarity~e.9 "-"~e.9
                                          :mod (s / specific~e.12)))
                              :ARG1~e.15 (a2 / act-02~e.19
                                    :ARG0~e.18 (p3 / protein~e.17
                                          :mod (p4 / parent~e.16))))
                        :ARG1-of (d / derive-01~e.21
                              :ARG2 (a3 / assert-03~e.25
                                    :ARG1~e.26 (p5 / phosphorylate-01~e.30
                                          :mod (p6 / position~e.27
                                                :mod s~e.29))
                                    :ARG3~e.31 a2~e.33,34,35
                                    :ARG0-of (c / cause-01)))))))

# ::tok Sasaki et al. , “ Ubiquitination of Ras enhances activation and facilitates binding to select downstream effectors ” ( PMC3437993 )
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.2.1.1.1 1-1.2 2-1.2.2.1 5-1.3.1.1 6-1.3.1.1.1.r 7-1.3.1.1.1.1.1 8-1.3.1 9-1.3.1.2 10-1.3 11-1.3.2 12-1.3.2.2 13-1.3.2.2.1.r 14-1.3.2.2.1.2 15-1.3.2.2.1.1 16-1.3.2.2.1 19-1.1
# ::id bio.bmtr_0001.1
# ::preferred 
(p / publication-91
      :ARG8 "PMC3437993"~e.19
      :ARG0 (a / and~e.1
            :op1 (p2 / person
                  :name (n / name :op1 "Sasaki"~e.0))
            :op2 (p3 / person
                  :mod (o / other~e.2)))
      :ARG1 (a2 / and~e.10
            :op1 (e / enhance-01~e.8
                  :ARG0 (u / ubiquitinate-01~e.5
                        :ARG1~e.6 (e3 / enzyme
                              :name (n2 / name :op1 "Ras"~e.7)))
                  :ARG1 (a3 / activate-01~e.9))
            :op2 (f / facilitate-01~e.11
                  :ARG0 u
                  :ARG1 (b / bind-01~e.12
                        :ARG2~e.13 (e2 / effector~e.16
                              :location (d / downstream~e.15)
                              :mod (s2 / select~e.14))))))

# ::tok We utilized an unbiased mass spectrometry @-@ based approach to identify ubiquitination sites of Ras .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 1-1 3-1.2.2 3-1.2.2.1 3-1.2.2.1.r 4-1.2.1.1.1 5-1.2.1.1 7-1.2.1 8-1.2 10-1.3 11-1.3.2.2 12-1.3.2 13-1.3.2.1.r 14-1.3.2.1.1.1
# ::id bio.bmtr_0001.2
# ::preferred 
(u / utilize-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (a / approach-02~e.8
            :ARG1-of (b / base-02~e.7
                  :ARG2 (s / spectrometry~e.5
                        :mod (m / mass~e.4)))
            :ARG1-of (b2 / bias-01~e.3 :polarity~e.3 "-"~e.3))
      :purpose (i / identify-01~e.10
            :ARG0 w
            :ARG1 (p / protein-segment~e.12
                  :part-of~e.13 (e / enzyme
                        :name (n / name :op1 "Ras"~e.14))
                  :ARG1-of (u2 / ubiquitinate-01~e.11))))

# ::tok His @-@ tagged ubiquitin and Flag @-@ tagged K @-@ Ras4B ( K @-@ Ras hereafter ) were expressed in HEK293T cells at levels similar to endogenous K @-@ Ras ( Fig . 1B ) and subjected to sequential affinity chromatography .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.1.1.1.2 2-1.1.1.2.3 3-1.1.1.1.1.1 5-1.1.1.2.3.1.1.1 7-1.1.1.2.3 8-1.1.1.2.1.1 8-1.1.1.2.2.1 10-1.1.1.2.1.1 12-1.1.1.2.1.1 12-1.1.1.2.2.1 14-1.1.1.2.2.1 18-1.1 18-1.1.3.1.1.1 19-1.1.2.r 20-1.1.2.1.1 21-1.1.2 22-1.1.3.r 23-1.1.3 23-1.1.3.1.1 24-1.1.3.1 25-1.1.3.1.1.1.1.r 26-1.1.3.1.1.1.1.2 27-1.1.1.2.1.1 27-1.1.1.2.2.1 27-1.1.3.1.1.1.1.1.1 29-1.1.1.2.2.1 29-1.1.3.1.1.1.1.1.1 33-1.1.4.1.1 35-1 36-1.2 37-1.2.2.r 38-1.2.2.2 39-1.2.2.1 40-1.2.2
# ::id bio.bmtr_0001.3
# ::preferred 
(a3 / and~e.35
      :op1 (e / express-03~e.18
            :ARG2 (a / and
                  :op1 (p / protein
                        :name (n2 / name :op1 "ubiquitin"~e.3)
                        :ARG1-of (t / tag-01~e.2
                              :ARG2 (p3 / protein-segment
                                    :part (a2 / amino-acid
                                          :name (n5 / name :op1 "histidine")))))
                  :op2 (e5 / enzyme
                        :name (n3 / name :op1 "K-Ras4B"~e.8,10,12,27)
                        :name (n4 / name :op1 "K-Ras"~e.8,12,14,27,29)
                        :ARG1-of (t2 / tag-01~e.2,7
                              :ARG2 (p4 / protein-segment
                                    :name (n6 / name :op1 "Flag"~e.5)))))
            :ARG3~e.19 (c / cell-line~e.21
                  :name (n / name :op1 "HEK293T"~e.20))
            :degree~e.22 (l / level~e.23
                  :ARG1-of (r / resemble-01~e.24
                        :ARG2 (l2 / level~e.23
                              :degree-of (e3 / express-03~e.18
                                    :ARG2~e.25 (e4 / enzyme
                                          :name (n7 / name :op1 "K-Ras"~e.27,29)
                                          :mod (e2 / endogenous~e.26))
                                    :ARG3 c))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "1B"~e.33)))
      :op2 (s2 / subject-01~e.36
            :ARG1 a
            :ARG2~e.37 (c2 / chromatography~e.40
                  :mod (a4 / affinity~e.39)
                  :mod (s3 / sequence~e.38))))

# ::tok His @-@ ubiquitinated proteins were purified by Co2+ metal affinity chromatography in 8M urea denaturing conditions .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.1.1 3-1.1 5-1 6-1.2.r 7-1.2.1.1.1.1 8-1.2.1.1 9-1.2.1 10-1.2 13-1.2.2.2.1.1 14-1.2.2
# ::id bio.bmtr_0001.4
# ::preferred 
(p / purify-01~e.5
      :ARG1 (p2 / protein~e.3
            :ARG3-of (u / ubiquitinate-01~e.2
                  :mod (a / amino-acid
                        :name (n / name :op1 "histidine"))))
      :manner~e.6 (c / chromatography~e.10
            :mod (a2 / affinity~e.9
                  :topic (m / metal~e.8
                        :name (n2 / name :op1 "Co2+"~e.7)))
            :mod (d / denature-00~e.14
                  :ARG1 p2
                  :instrument (s / small-molecule
                        :name (n3 / name :op1 "urea"~e.13)
                        :mod (c2 / concentration-quantity
                              :quant "8"
                              :unit (m2 / molar))))))

# ::tok His @-@ ubiquitinated K @-@ Ras was subsequently purified with anti @-@ Flag resin .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.1.2 3-1.1.1.1 5-1.1.1.1 7-1.2 7-1.2.r 8-1 9-1.3.r 10-1.3.1 12-1.3.1.1.1.1 13-1.3
# ::id bio.bmtr_0001.5
# ::preferred 
(p / purify-01~e.8
      :ARG1 (e / enzyme
            :name (n / name :op1 "K-Ras"~e.3,5)
            :ARG3-of (u / ubiquitinate-01~e.2
                  :mod (a / amino-acid
                        :name (n2 / name :op1 "histidine"))))
      :time~e.7 (s / subsequent~e.7)
      :instrument~e.9 (r / resin~e.13
            :ARG0-of (c / counter-01~e.10
                  :ARG1 (p2 / protein-segment
                        :name (n3 / name :op1 "Flag"~e.12)))))

# ::tok Following purification , mono @- and di @- ubiquitinated K @-@ Ras appeared to be the major ubiquitination forms , which is consistent with the endogenous K @-@ Ras ubiquitination pattern ( Fig . 1 , A and B ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.4 1-1.1.4.1 3-1.1.2.1 6-1.1.2.2 8-1.1.1 9-1.1.1.1.1.1 11-1.1.1.1.1.1 12-1 17-1.1.1 22-1.1.5 23-1.1.5.1.r 25-1.1.5.1.1.1.2 26-1.1.5.1.1.1.1.1 28-1.1.5.1.1.1.1.1 29-1.1.5.1.1 30-1.1.5.1 34-1.1.2.1 37-1.2.1
# ::id bio.bmtr_0001.6
# ::preferred 
(a / appear-02~e.12
      :ARG1 (h / have-quant-91
            :ARG1 (u / ubiquitinate-01~e.8,17
                  :ARG3 (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.9,11)))
            :ARG2 (o / or :op1 "1"~e.3,34 :op2 "2"~e.6)
            :degree (m / most)
            :ARG1-of (f / follow-01~e.0
                  :ARG2 (p / purify-01~e.1
                        :ARG1 e))
            :ARG1-of (c / consistent-01~e.22
                  :ARG2~e.23 (p2 / pattern~e.30
                        :topic (u2 / ubiquitinate-01~e.29
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "K-Ras"~e.26,28)
                                    :mod (e3 / endogenous~e.25))))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.37
                  :op1 (f2 / figure :mod "1A")
                  :op2 (f3 / figure :mod "1B"))))

# ::tok H @-@ Ras ubiquitination sites were also determined by the same approach .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2.1.1 2-1.1.2.1.1 3-1.1.1 4-1.1 6-1.3 7-1 8-1.2.r 10-1.2.1 11-1.2
# ::id bio.bmtr_0001.7
# ::preferred 
(d / determine-01~e.7
      :ARG1 (p / protein-segment~e.4
            :ARG1-of (u / ubiquitinate-01~e.3)
            :part-of (e / enzyme
                  :name (n / name :op1 "H-Ras"~e.0,2)))
      :manner~e.8 (a / approach-02~e.11
            :mod (s / same~e.10))
      :mod (a2 / also~e.6))

# ::tok Tandem mass spectrometric analysis of tryptic fragments from the bands migrating at the positions expected for mono @- and di @-@ ubiquitinated Ras revealed ubiquitination at Lys residues 104 and 147 of K @-@ Ras , and Lys residues 117 , 147 and 170 for H @-@ Ras ( fig . S1C ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2.2 1-1.1.2.1 2-1.1.2 3-1.1 4-1.1.1.r 5-1.1.1.1.1.1.1 7-1.1.1.2.r 9-1.1.1.2 10-1.1.1.2.1 11-1.1.1.2.1.1.1 13-1.1.1.2.1.1 14-1.1.1.2.1.1.1.2 16-1.1.1.2.1.1.1.1.2.1.1 16-1.1.1.2.1.1.1.1.2.1.r 19-1.1.1.2.1.1.1.1.2.1.2 19-1.1.1.2.1.1.1.1.2.1.r 21-1.1.1.2.1.1.1.1.2 21-1.2 22-1.1.1.2.1.1.1.1.1.1 23-1 24-1.1.1.2.1.1.1.1.2 24-1.2 25-1.1.1.2.1.1.1 25-1.2.1.r 26-1.2.1.1.1.1.2.1 26-1.2.1.1.2.1.2.1 26-1.2.1.2.1.1.2.1 26-1.2.1.2.2.1.2.1 27-1.2.1.1.1 27-1.2.1.1.2 27-1.2.1.2.1 27-1.2.1.2.2 28-1.2.1.1.1.1.1 29-1.2.1.1 30-1.2.1.1.2.1.1 32-1.2.1.1.3.1.1 34-1.2.1.1.3.1.1 36-1.2.1 36-1.2.1.1 36-1.2.1.1.r 36-1.2.1.2 37-1.2.1.1.2.1.2.1 37-1.2.1.2.1.1.2.1 37-1.2.1.2.2.1.2.1 37-1.2.1.2.3.1.2.1 38-1.2.1.1.2 38-1.2.1.2.1 38-1.2.1.2.2 38-1.2.1.2.3 39-1.2.1.2.1.1.1 41-1.2.1.2.2.1.1 43-1.2.1.2.3.1.1 44-1.2.1.2.r 45-1.2.1.2.4.1.1 47-1.2.1.2.4.1.1 51-1.3.1.1
# ::id bio.bmtr_0001.8
# ::preferred 
(r / reveal-01~e.23
      :ARG0 (a / analyze-01~e.3
            :ARG1~e.4 (p3 / protein-segment
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e2 / enzyme
                              :name (n2 / name :op1 "trypsin"~e.5)))
                  :source~e.7 (b / band~e.9
                        :ARG0-of (m / migrate-01~e.10
                              :ARG1 (p / position~e.13
                                    :ARG2-of (b2 / be-located-at-91~e.11,25
                                          :ARG1 (e5 / enzyme
                                                :name (n / name :op1 "Ras"~e.22)
                                                :ARG3-of (u / ubiquitinate-01~e.21,24
                                                      :quant~e.16,19 (o / or :op1 "1"~e.16 :op2 "2"~e.19)))
                                          :ARG1-of (e / expect-01~e.14))))))
            :manner (s / spectrometry~e.2
                  :mod (m2 / mass~e.1)
                  :mod (t / tandem~e.0)))
      :ARG1 (u2 / ubiquitinate-01~e.21,24
            :ARG1~e.25 (a2 / and~e.36
                  :op1~e.36 (a8 / and~e.29,36
                        :op1 (r2 / residue~e.27
                              :mod (a3 / amino-acid
                                    :mod "104"~e.28
                                    :name (n3 / name :op1 "lysine"~e.26)))
                        :op2 (r3 / residue~e.27,38
                              :mod (a4 / amino-acid
                                    :mod "147"~e.30
                                    :name (n4 / name :op1 "lysine"~e.26,37)))
                        :part-of (e4 / enzyme
                              :name (n5 / name :op1 "K-Ras"~e.32,34)))
                  :op2~e.44 (a9 / and~e.36
                        :op1 (r4 / residue~e.27,38
                              :mod (a5 / amino-acid
                                    :mod "117"~e.39
                                    :name (n6 / name :op1 "lysine"~e.26,37)))
                        :op2 (r5 / residue~e.27,38
                              :mod (a6 / amino-acid
                                    :mod "147"~e.41
                                    :name (n7 / name :op1 "lysine"~e.26,37)))
                        :op3 (r6 / residue~e.38
                              :mod (a7 / amino-acid
                                    :mod "170"~e.43
                                    :name (n8 / name :op1 "lysine"~e.37)))
                        :part-of (e3 / enzyme
                              :name (n9 / name :op1 "H-Ras"~e.45,47)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "S1C"~e.51)))

# ::tok The tryptic peptide with ubiquitination at Lys147 ( K147 ) was the most frequently observed peptide for both K @-@ Ras and H @-@ Ras , while Lys117 appeared as a secondary major ubiquitination site in H @-@ Ras .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.1.3.2.1.1.1 2-1.1 2-1.1.3 4-1.1.3.1.3 10-1.1.3.r 12-1.1.1.1.1 13-1.1.1.1 14-1.1.1 15-1.1 15-1.1.3 18-1.1.2.1.1.1.1 20-1.1.2.1.1.1.1 20-1.1.2.1.2.1.1 22-1.1.2.1.2.1.1 24-1.1.2.1.1.1.1 24-1.1.2.1.2.1.1 26-1 28-1.2 29-1.2.1.r 31-1.2.1.4 32-1.2.1.3 33-1.2.1.2 34-1.2.1 36-1.1.2.1.2.1.1 36-1.2.1.1.1.1 38-1.1.2.1.1.1.1 38-1.1.2.1.2.1.1 38-1.2.1.1.1.1
# ::id bio.bmtr_0001.9
# ::preferred 
(c / contrast-01~e.26
      :ARG1 (p / peptide~e.2,15
            :ARG1-of (o / observe-01~e.14
                  :frequency (f / frequent~e.13
                        :degree (m / most~e.12)))
            :part-of (e2 / enzyme
                  :mod (o2 / or
                        :op1 (e3 / enzyme
                              :name (n3 / name :op1 "K-Ras"~e.18,20,24,38))
                        :op2 (e4 / enzyme
                              :name (n4 / name :op1 "H-Ras"~e.20,22,24,36,38))))
            :domain~e.10 (p2 / peptide~e.2,15
                  :part (a / amino-acid
                        :mod "147"
                        :name (n / name :op1 "lysine")
                        :ARG3-of (u / ubiquitinate-01~e.4))
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e / enzyme
                              :name (n2 / name :op1 "trypsin"~e.1)))
                  :part-of e2))
      :ARG2 (a3 / appear-01~e.28
            :ARG1~e.29 (p3 / protein-segment~e.34
                  :part-of (e5 / enzyme
                        :name (n5 / name :op1 "H-Ras"~e.36,38))
                  :ARG1-of (u2 / ubiquitinate-01~e.33)
                  :mod (m2 / major~e.32)
                  :mod (s / secondary~e.31)
                  :domain (a2 / amino-acid
                        :mod "117"
                        :name (n6 / name :op1 "lysine")))))

# ::tok To examine the effect of ubiquitination on GTP loading , we purified wild @-@ type K @-@ Ras , oncogenic G12V @-@ K @-@ Ras mutant or the ubiquitinated subfraction of wild @-@ type K @-@ Ras from 32P @-@ orthophosphate labeled cells and utilized thin layer chromatography ( TLC ) and high performance liquid chromatography ( HPLC ) to assess the ratio of 32P @-@ GTP to 32P @-@ GDP that co @-@ purified with each form of K @-@ Ras .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.3 3-1.3.2 4-1.3.2.1.r 5-1.3.2.1 6-1.3.2.2.r 7-1.3.2.2.1.1.1 8-1.3.2.2 10-1.1.1 11-1.1 12-1.1.2.1.1.2 12-1.1.2.1.3.2 14-1.1.2.1.1.2 14-1.1.2.1.3.2 15-1.1.2.1.1.1.1 15-1.1.2.1.2.1.1 15-1.1.2.1.3.1.1 17-1.1.2.1.1.1.1 17-1.1.2.1.2.1.1 17-1.1.2.1.3.1.1 19-1.1.2.1.2 19-1.1.2.1.2.2 19-1.1.2.1.2.2.1 19-1.1.2.1.2.2.1.r 19-1.1.2.1.2.2.r 20-1.1.2.1.2.3.1 22-1.1.2.1.2.1.1 24-1.1.2.1.2.1.1 25-1.1.2.1.2.3 26-1.1.2.1 28-1.1.2.1.3.3 29-1.1.2.1.3.4 31-1.1.2.1.1.2 31-1.1.2.1.3.2 33-1.1.2.1.1.2 33-1.1.2.1.3.2 34-1.1.2.1.1.1.1 34-1.1.2.1.2.1.1 34-1.1.2.1.3.1.1 36-1.1.2.1.1.1.1 36-1.1.2.1.2.1.1 36-1.1.2.1.3.1.1 37-1.1.3.r 40-1.1.3.1.1.1.1 41-1.1.3.1 42-1.1.3 43-1 43-1.1.2 44-1.2 45-1.2.2.1.1.1 46-1.2.2.1.1 47-1.2.2.1 51-1.2.2 52-1.2.2.2.1.1.1 53-1.2.2.2.1.1 54-1.2.2.2.1 55-1.2.2.2 60-1.2.3 62-1.2.3.2 63-1.2.3.2 66-1.2.3.2.1.1.1 70-1.2.3.2.2.1.1 74-1.1 79-1.1.2.1.1.1.1 79-1.1.2.1.2.1.1 79-1.1.2.1.3.1.1 81-1.1.2.1.1.1.1 81-1.1.2.1.2.1.1 81-1.1.2.1.3.1.1
# ::id bio.bmtr_0001.10
# ::preferred 
(a2 / and~e.43
      :op1 (p / purify-01~e.11,74
            :ARG0 (w / we~e.10)
            :ARG1 (a / and~e.43
                  :op1 (o / or~e.26
                        :op1 (e / enzyme
                              :name (n2 / name :op1 "K-Ras"~e.15,17,34,36,79,81)
                              :mod (w2 / wild-type~e.12,14,31,33))
                        :op2 (e2 / enzyme~e.19
                              :name (n3 / name :op1 "K-Ras"~e.15,17,22,24,34,36,79,81)
                              :ARG0-of~e.19 (c / cause-01~e.19
                                    :ARG1~e.19 (c2 / cancer~e.19))
                              :ARG2-of (m / mutate-01~e.25 :value "G12V"~e.20))
                        :op3 (e3 / enzyme
                              :name (n4 / name :op1 "K-Ras"~e.15,17,34,36,79,81)
                              :mod (w3 / wild-type~e.12,14,31,33)
                              :ARG3-of (u / ubiquitinate-01~e.28)
                              :mod (s2 / subfraction~e.29)))
                  :op2 (s4 / small-molecule
                        :name (n6 / name :op1 "GTP"~e.66)
                        :part (p4 / phosphorus
                              :mod (m3 / molecular-mass :value "32")))
                  :op3 (s5 / small-molecule
                        :name (n7 / name :op1 "GDP"~e.70)
                        :part (p5 / phosphorus
                              :mod (m4 / molecular-mass :value "32"))))
            :source~e.37 (c3 / cell~e.42
                  :ARG1-of (l / label-01~e.41
                        :ARG2 (s3 / small-molecule
                              :name (n5 / name :op1 "orthophosphate"~e.40)
                              :part (p2 / phosphorus
                                    :mod (m2 / molecular-mass :value "32"))))))
      :op2 (u2 / utilize-01~e.44
            :ARG0 w
            :ARG1 (a5 / and~e.51
                  :op1 (c4 / chromatography~e.47
                        :mod (l3 / layer~e.46
                              :mod (t / thin~e.45)))
                  :op2 (c5 / chromatography~e.55
                        :mod (l4 / liquid~e.54
                              :ARG0-of (p3 / perform-01~e.53
                                    :degree (h / high~e.52)))))
            :purpose (a3 / assess-01~e.60
                  :ARG0 w
                  :ARG1 (r / ratio-of~e.62,63
                        :op1 s4
                        :op2 s5)))
      :purpose (e4 / examine-01~e.1
            :ARG0 w
            :ARG1 (a4 / affect-01~e.3
                  :ARG0~e.4 (u3 / ubiquitinate-01~e.5)
                  :ARG1~e.6 (l2 / load-01~e.8
                        :ARG2 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.7))))))

# ::tok As expected based on previous studies , wild @-@ type K @-@ Ras bound primarily 32P @-@ GDP , while G12V @-@ Ras bound 32P @-@ GTP ( Fig.2 , A and B ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.4.1.1.1.r 1-1.4 2-1.4.1 4-1.4.1.1.1 5-1.4.1.1 7-1.1.1.2 9-1.1.1.2 10-1.1.1.1.1 12-1.1.1.1.1 13-1.1 14-1.1.3 17-1.1.2.1.1 19-1 20-1.2.1.2.1 22-1.2.1.1.1 23-1.2 26-1.2.2.1.1 31-1.3.1
# ::id bio.bmtr_0001.11
# ::preferred 
(c / contrast-01~e.19
      :ARG1 (b / bind-01~e.13
            :ARG1 (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.10,12)
                  :mod (w / wild-type~e.7,9))
            :ARG2 (s / small-molecule
                  :name (n2 / name :op1 "GDP"~e.17)
                  :part (p / phosphorus
                        :mod (m / molecular-mass :value "32")))
            :mod (p2 / primary~e.14))
      :ARG2 (b2 / bind-01~e.23
            :ARG1 (e2 / enzyme
                  :name (n3 / name :op1 "Ras"~e.22)
                  :ARG2-of (m2 / mutate-01 :value "G12V"~e.20))
            :ARG2 (s2 / small-molecule
                  :name (n4 / name :op1 "GTP"~e.26)
                  :part (p3 / phosphorus
                        :mod (m3 / molecular-mass :value "32"))))
      :ARG1-of (d / describe-01
            :ARG0 (a / and~e.31
                  :op1 (f / figure :mod "2A")
                  :op2 (f2 / figure :mod "2B")))
      :ARG1-of (e3 / expect-01~e.1
            :ARG1-of (b3 / base-02~e.2
                  :ARG2 (s4 / study~e.5
                        :time~e.0 (p4 / previous~e.4)))))

# ::tok Interestingly , the ubiquitinated subfraction of wild @-@ type K @-@ Ras retained a significant amount of 32P @-@ GTP .
# ::amr-annotator ISI-AMR-01
# ::alignments 3-1.1.3 4-1.1.4 6-1.1.2 8-1.1.2 9-1.1.1.1 11-1.1.1.1 12-1 14-1.2.3.1 15-1.2.3 16-1.2.3.r 19-1.2.1.1
# ::id bio.bmtr_0001.12
# ::preferred 
(r / retain-01~e.12
      :ARG0 (e / enzyme
            :name (n / name :op1 "K-Ras"~e.9,11)
            :mod (w / wild-type~e.6,8)
            :ARG3-of (u / ubiquitinate-01~e.3)
            :mod (s2 / subfraction~e.4))
      :ARG1 (s / small-molecule
            :name (n2 / name :op1 "GTP"~e.19)
            :part (p / phosphorus
                  :mod (m / molecular-mass :value "32"))
            :quant~e.16 (a / amount~e.15
                  :ARG1-of (s3 / significant-02~e.14)))
      :ARG2-of (i / interest-01))

# ::tok These results are consistent with a model in which ubiquitination of Lys147 ( or Lys117 ) , destabilizes GDP binding , allowing spontaneous GDP @/@ GTP exchange .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2.r 6-1.2 9-1.2.1.1 13-1.2.1.1.1 17-1.2.1 18-1.2.1.2.1.1.1 19-1.2.1.2 21-1.2.1.3 22-1.2.1.3.1.3 23-1.2.1.3.1.1.1.1 25-1.2.1.3.1.2.1.1 26-1.2.1.3.1
# ::id bio.bmtr_0001.13
# ::preferred 
(c / consistent-01~e.3
      :ARG1 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG2~e.4 (m / model~e.6
            :topic (d / destabilize-01~e.17
                  :ARG0 (u / ubiquitinate-01~e.9
                        :ARG1 (o / or~e.13
                              :op1 (a / amino-acid
                                    :mod "147"
                                    :name (n2 / name :op1 "lysine"))
                              :op2 (a3 / amino-acid
                                    :mod "117"
                                    :name (n5 / name :op1 "lysine"))))
                  :ARG1 (b / bind-01~e.19
                        :ARG2 (s / small-molecule
                              :name (n / name :op1 "GDP"~e.18)))
                  :ARG0-of (a2 / allow-01~e.21
                        :ARG1 (e / exchange-01~e.26
                              :ARG1 (s3 / small-molecule
                                    :name (n3 / name :op1 "GDP"~e.23))
                              :ARG3 (s4 / small-molecule
                                    :name (n4 / name :op1 "GTP"~e.25))
                              :mod (s2 / spontaneous~e.22))))))

# ::tok It could be argued that GTP loading occurs prior to ubiquitination and that the GTP bound form of K @-@ Ras , via interaction with effectors , is preferentially mono @-@ ubiquitinated via a feedback mechanism .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1 2-1.1.r 3-1.1 4-1.1.1.r 5-1.1.1.1.1.1.1 5-1.1.1.2.2.2.1.1.1 6-1.1.1.1 8-1.1.1.1.2 10-1.1.1.1.2.1 10-1.1.1.2 11-1.1.1 14-1.1.1.1.1.1.1 14-1.1.1.2.2.2.1.1.1 15-1.1.1.2.2 15-1.1.1.2.2.2 15-1.1.1.2.2.2.r 18-1.1.1.2.2.1.1 20-1.1.1.2.2.1.1 23-1.1.1.2.4 24-1.1.1.2.4.2.r 25-1.1.1.2.4.2 28-1.1.1.2.3 29-1.1.1.2.1 29-1.1.1.2.1.r 31-1.1.1.2 34-1.1.1.2.5
# ::id bio.bmtr_0001.14
# ::preferred 
(p / possible~e.1
      :domain~e.2 (a / argue-01~e.3
            :ARG1~e.4 (a2 / and~e.11
                  :op1 (l / load-01~e.6
                        :ARG2 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.5,14))
                        :time (p2 / prior~e.8
                              :op1 (u / ubiquitinate-01~e.10)))
                  :op2 (u2 / ubiquitinate-01~e.10,31
                        :quant~e.29 "1"~e.29
                        :ARG1 (e / enzyme~e.15
                              :name (n2 / name :op1 "K-Ras"~e.18,20)
                              :ARG1-of~e.15 (b / bind-01~e.15
                                    :ARG2 (s2 / small-molecule
                                          :name (n3 / name :op1 "GTP"~e.5,14))))
                        :ARG1-of (p3 / prefer-01~e.28)
                        :manner (i / interact-01~e.23
                              :ARG0 e
                              :ARG1~e.24 (e2 / effector~e.25))
                        :manner (f / feedback~e.34)))))

# ::tok While it is difficult to eliminate this possibility , it is unlikely since , as shown in fig. S1B , the T35 mutant of K @-@ Ras , which fails to interact with downstream effectors ( fig . S1B ) undergoes comparable monobuiquitination to wild type Ras .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1 2-1.1.1.r 3-1.1 5-1.1.1 6-1.1.1.1 7-1.1.1.1.1 9-1.2.2 10-1.2.2.r 11-1.2 11-1.2.1 11-1.2.1.r 11-1.2.3.1.2.3.1 12-1.2.3 15-1.2.3.1.3 16-1.2.3.1.3.1.r 17-1.2.3.1.3.1 18-1.2.3.1.3.1.1 21-1.2.3.1.2.2.1 22-1.2.3.1.2 22-1.2.3.1.2.2 22-1.2.3.1.2.2.r 24-1.2.3.1.2.1.1 26-1.2.3.1.2.1.1 31-1.2.3.1.2.3 32-1.2.3.1.2.3.2.r 33-1.2.3.1.2.3.2.1 34-1.2.3.1.2.3.2 38-1.2.3.1.3.1.1 41-1.2.3.1.4 44-1.2.3.1.4.1.1.2 45-1.2.3.1.4.1.1.2 46-1.2.3.1.4.1.1.1.1
# ::id bio.bmtr_0001.15
# ::preferred 
(c / contrast-01~e.0
      :ARG1 (d / difficult~e.3
            :domain~e.2 (e3 / eliminate-01~e.5
                  :ARG1 (t / this~e.6
                        :mod (p / possible~e.7))))
      :ARG2 (l / likely~e.11
            :polarity~e.11 "-"~e.11
            :domain~e.10 t~e.9
            :ARG1-of (c2 / cause-01~e.12
                  :ARG0 (u / ubiquitinate-01
                        :quant "1"
                        :ARG1 (e / enzyme~e.22
                              :name (n / name :op1 "K-Ras"~e.24,26)
                              :ARG2-of~e.22 (m / mutate-01~e.22 :value "T35"~e.21)
                              :ARG0-of (i / interact-01~e.31
                                    :polarity "-"~e.11
                                    :ARG1~e.32 (e4 / effector~e.34
                                          :location (d2 / downstream~e.33))
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 (f / figure~e.17 :mod "S1B"~e.18,38))))
                        :ARG1-of (s / show-01~e.15
                              :ARG0~e.16 f)
                        :mod (c3 / comparable~e.41
                              :topic (u2 / ubiquitinate-01
                                    :ARG1 (e2 / enzyme
                                          :name (n2 / name :op1 "Ras"~e.46)
                                          :mod (w / wild-type~e.44,45))))))))

# ::tok These results , along with the crystal structure , support a model in which mono @-@ ubiquitination at a Lys residue directly involved in GDP binding either enhances nucleotide exchange on K @-@ Ras , impairs GTP hydrolysis , or both .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.1 1-1.1.1 1-1.1.1.2 1-1.1.1.2.r 6-1.1.2.1 7-1.1.2 9-1 11-1.2 14-1.2.1.1.1.1 14-1.2.1.1.1.1.r 16-1.2.1.1.1 17-1.2.1.1.1.2.r 19-1.2.1.1.1.2.1.1.1 20-1.2.1.1.1.2 21-1.2.1.1.1.2.2.2 21-1.2.1.1.1.2.2.2.r 22-1.2.1.1.1.2.2 23-1.2.1.1.1.2.2.1.r 24-1.2.1.1.1.2.2.1.1.1.1 25-1.2.1.1.1.2.2.1 27-1.2.1.1 28-1.2.1.1.2.1 29-1.2.1.1.2 30-1.2.1.1.2.2.r 31-1.2.1.1.2.2.1.1 33-1.2.1.1.2.2.1.1 35-1.2.1.2 36-1.2.1.2.2.1.1.1 37-1.2.1.2.2 39-1.2.1
# ::id bio.bmtr_0001.16
# ::preferred 
(s3 / support-01~e.9
      :ARG0 (a / and
            :op1 (t / thing~e.1
                  :mod (t2 / this~e.0)
                  :ARG2-of~e.1 (r / result-01~e.1))
            :op2 (s4 / structure~e.7
                  :poss (c / crystal~e.6)))
      :ARG1 (m / model~e.11
            :topic (o / or~e.39
                  :op1 (e2 / enhance-01~e.27
                        :ARG0 (u / ubiquitinate-01~e.16
                              :quant~e.14 "1"~e.14
                              :ARG1~e.17 (r2 / residue~e.20
                                    :mod (a2 / amino-acid
                                          :name (n4 / name :op1 "lysine"~e.19))
                                    :ARG1-of (i / involve-01~e.22
                                          :ARG2~e.23 (b / bind-01~e.25
                                                :ARG2 (s / small-molecule
                                                      :name (n / name :op1 "GDP"~e.24)))
                                          :manner~e.21 (d / direct~e.21))))
                        :ARG1 (e3 / exchange-01~e.29
                              :ARG1 (n5 / nucleotide~e.28)
                              :ARG4~e.30 (e / enzyme
                                    :name (n2 / name :op1 "K-Ras"~e.31,33))))
                  :op2 (i2 / impair-01~e.35
                        :ARG0 u
                        :ARG1 (h / hydrolyze-01~e.37
                              :ARG1 (s2 / small-molecule
                                    :name (n3 / name :op1 "GTP"~e.36))))
                  :op3 (a3 / and
                        :op1 e2
                        :op2 i2))))

# ::tok To corroborate this finding , we measure the activity of Ras by the GST @-@ RBD pull @-@ down assay .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.4 2-1.4.2.2 3-1.4.2 3-1.4.2.1 3-1.4.2.1.r 5-1.1 6-1 8-1.2 9-1.2.1.r 10-1.2.1.1.1 11-1.3.r 13-1.3.1.1.1.1 15-1.3.1.1.1.1 16-1.3.1 19-1.3
# ::id bio.bmtr_0001.17
# ::preferred 
(m / measure-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1 (a / act-02~e.8
            :ARG0~e.9 (e / enzyme
                  :name (n / name :op1 "Ras"~e.10)))
      :ARG2~e.11 (a2 / assay-00~e.19
            :manner (p / pull-00~e.16
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "GST-RBD"~e.13,15))))
      :purpose (c / corroborate-01~e.1
            :ARG0 m
            :ARG1 (t / thing~e.3
                  :ARG1-of~e.3 (f / find-01~e.3)
                  :mod (t2 / this~e.2))))

# ::tok To ensure that ubiquitinated Ras was being detected , the protein pulled down by GST @-@ RBD was subjected to a second affinity purification on a cobalt column to purify the Flag @-@ His @-@ tagged K @-@ Ras .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.3 2-1.3.2.r 3-1.3.2.1.2 4-1.3.2.1.1.1 7-1.3.2 10-1.1 10-1.2.3.2.2.1.2 11-1.1.1 13-1.1.1.1.r 14-1.1.1.1.1.1 16-1.1.1.1.1.1 18-1 21-1.2.2 21-1.2.2.1 21-1.2.2.1.r 22-1.2.4 23-1.2 23-1.2.3 23-1.2.3.r 26-1.2.5.1 27-1.2.5 29-1.2 29-1.2.3 29-1.2.3.r 31-1.2.3.2.2.1.1.1.1 35-1.2.3.2.2 36-1.2.3.2.1.1 38-1.2.3.2.1.1
# ::id bio.bmtr_0001.18
# ::preferred 
(s / subject-01~e.18
      :ARG1 (p / protein~e.10
            :ARG1-of (p2 / pull-00~e.11
                  :ARG2~e.13 (p3 / protein
                        :name (n3 / name :op1 "GST-RBD"~e.14,16))))
      :ARG2 (p4 / purify-01~e.23,29
            :ARG1 p
            :ord (o / ordinal-entity~e.21 :value~e.21 "2"~e.21)
            :purpose~e.23,29 (p5 / purify-01~e.23,29
                  :ARG0 p4
                  :ARG1 (e2 / enzyme
                        :name (n2 / name :op1 "K-Ras"~e.36,38)
                        :ARG1-of (t / tag-01~e.35
                              :ARG2 (a2 / and
                                    :op1 (p6 / protein-segment
                                          :name (n4 / name :op1 "Flag"~e.31))
                                    :op2 (p7 / protein-segment~e.10
                                          :part (a3 / amino-acid
                                                :name (n5 / name :op1 "histidine")))))))
            :mod (a / affinity~e.22)
            :location (c / column~e.27
                  :consist-of (c2 / cobalt~e.26)))
      :purpose (e3 / ensure-01~e.1
            :ARG0 s
            :ARG1~e.2 (d / detect-01~e.7
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.4)
                        :ARG3-of (u / ubiquitinate-01~e.3)))))

# ::tok As predicted , only a very small fraction of wild @-@ type K @-@ Ras was pulled down by the GST @-@ RBD ( Fig . 2C and fig. S1D ) , consistent with very little wild @-@ type K @-@ Ras being in the GTP state under these conditions ( Fig.2 , A and B ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.3 3-1.1.3.2 5-1.1.3.1.1 6-1.1.3.1 7-1.1.3 8-1.1.3.r 9-1.1.2 11-1.1.2 12-1.1.1.1 14-1.1.1.1 16-1 18-1.2.r 20-1.2.1.1 22-1.2.1.1 26-1.4.1.1.1 27-1.4.1 28-1.4.1.1 28-1.4.1.2 28-1.5.1.4.1.1 28-1.5.1.4.1.2 29-1.4.1.2.1 32-1.5 34-1.5.1.1.3.1 35-1.5.1.1.3 36-1.5.1.1.2 38-1.5.1.1.2 39-1.5.1.1.1.1 41-1.5.1.1.1.1 45-1.5.1.2.1.1 48-1.5.1.3 49-1.5.1.3.r 54-1.4.1
# ::id bio.bmtr_0001.19
# ::preferred 
(p / pull-00~e.16
      :ARG1 (e / enzyme
            :name (n / name :op1 "K-Ras"~e.12,14)
            :mod (w / wild-type~e.9,11)
            :quant~e.8 (f / fraction~e.7
                  :mod (s2 / small~e.6
                        :degree (v / very~e.5))
                  :mod (o / only~e.3)))
      :ARG2~e.18 (p2 / protein
            :name (n3 / name :op1 "GST-RBD"~e.20,22))
      :ARG1-of (p3 / predict-01~e.1)
      :ARG1-of (d / describe-01
            :ARG0 (a / and~e.27,54
                  :op1 (f2 / figure~e.28 :mod "2C"~e.26)
                  :op2 (f3 / figure~e.28 :mod "S1D"~e.29)))
      :ARG1-of (c / consistent-01~e.32
            :ARG2 (b / bind-01
                  :ARG1 (e2 / enzyme
                        :name (n4 / name :op1 "K-Ras"~e.39,41)
                        :mod (w2 / wild-type~e.36,38)
                        :quant (l / little~e.35
                              :degree (v2 / very~e.34)))
                  :ARG2 (s / small-molecule
                        :name (n2 / name :op1 "GTP"~e.45))
                  :condition~e.49 (t / this~e.48)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a2 / and
                              :op1 (f4 / figure~e.28 :mod "2A")
                              :op2 (f5 / figure~e.28 :mod "2B"))))))

# ::tok However , a much greater fraction of the ubiquitinated @-@ K @-@ Ras was pulled down by the GST @-@ RBD ( Fig . 2C and fig. S1D ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1 3-1.1.1.3.1.2 4-1.1.1.3.1 4-1.1.1.3.1.1 4-1.1.1.3.1.1.r 5-1.1.1.3 6-1.1.1.3.r 8-1.1.1.2 10-1.1.1.1.1 12-1.1.1.1.1 14-1.1 16-1.1.2.r 18-1.1.2.1.1 20-1.1.2.1.1 24-1.1.3.1.1.1 25-1.1.3.1 26-1.1.3.1.1 26-1.1.3.1.2 27-1.1.3.1.2.1
# ::id bio.bmtr_0001.20
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (p / pull-00~e.14
            :ARG1 (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.10,12)
                  :ARG3-of (u / ubiquitinate-01~e.8)
                  :quant~e.6 (f / fraction~e.5
                        :mod (g / great~e.4
                              :degree~e.4 (m / more~e.4)
                              :quant (m2 / much~e.3))))
            :ARG2~e.16 (p2 / protein
                  :name (n2 / name :op1 "GST-RBD"~e.18,20))
            :ARG1-of (d / describe-01
                  :ARG0 (a / and~e.25
                        :op1 (f2 / figure~e.26 :mod "2C"~e.24)
                        :op2 (f3 / figure~e.26 :mod "S1D"~e.27)))))

# ::tok These results are consistent with a greater fraction of ubiquitinated K @-@ Ras being in the GTP state ( Fig . 2 , A and B ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 6-1.2.1.3.1 6-1.2.1.3.1.1 6-1.2.1.3.1.1.r 7-1.2.1.3 9-1.2.1.2 10-1.2.1.1.1 12-1.2.1.1.1 16-1.2.2.1.1 24-1.3.1
# ::id bio.bmtr_0001.21
# ::preferred 
(c / consistent-01~e.3
      :ARG1 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG2 (b / bind-01
            :ARG1 (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.10,12)
                  :ARG3-of (u / ubiquitinate-01~e.9)
                  :degree (f3 / fraction~e.7
                        :mod (g / great~e.6
                              :degree~e.6 (m / more~e.6))))
            :ARG2 (s / small-molecule
                  :name (n2 / name :op1 "GTP"~e.16)))
      :ARG1-of (d / describe-01
            :ARG0 (a / and~e.24
                  :op1 (f / figure :mod "2A")
                  :op2 (f2 / figure :mod "2B"))))

# ::tok Turke et al. “ MEK inhibition leads to PI3K @/@ AKT activation by relieving a negative feedback on ERBB receptors ” ( PMC3515079 )
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.2.1.1.1 1-1.2 2-1.2.2.1 4-1.3.1.1.1.1 5-1.3.1 6-1.3 7-1.3.2.r 8-1.3.2.1.1.1 10-1.3.2.1.1.1 11-1.3.2 12-1.3.3.r 13-1.3.3 15-1.3.3.2.1 16-1.3.3.2 17-1.3.3.2.2.r 18-1.3.3.2.2.1.1 19-1.3.3.2.2 22-1.1
# ::id bio.bmtr_0002.1
# ::preferred 
(p / publication-91
      :ARG8 "PMC3515079"~e.22
      :ARG0 (a / and~e.1
            :op1 (p2 / person
                  :name (n / name :op1 "Turke"~e.0))
            :op2 (p3 / person
                  :mod (o / other~e.2)))
      :ARG1 (l / lead-03~e.6
            :ARG0 (i / inhibit-01~e.5
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "MEK"~e.4)))
            :ARG2~e.7 (a2 / activate-01~e.11
                  :ARG1 (p4 / pathway
                        :name (n3 / name :op1 "PI3K/AKT"~e.8,10)))
            :manner~e.12 (r / relieve-01~e.13
                  :ARG0 i
                  :ARG1 (f / feedback~e.16
                        :mod (n4 / negative~e.15)
                        :destination~e.17 (r2 / receptor~e.19
                              :name (n5 / name :op1 "ERBB"~e.18))))))

# ::tok We hypothesized that the MEK @/@ ERK pathway may suppress trans @-@ phosphorylation of ERBB3 by directly phosphorylating the JM domains of EGFR and HER2 , and that this could be a dominant MEK inhibitor @-@ induced feedback leading to AKT activation in these cancers .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 1-1 2-1.2.r 4-1.2.1.1.1.1.1 6-1.2.1.1.1.1.1 7-1.2.1.1.1 8-1.2.1 9-1.2.1.1 12-1.2.1.1.2 12-1.2.1.1.3 13-1.2.1.1.2.1.r 14-1.2.1.1.2.1.1.1 16-1.2.1.1.3.3 16-1.2.1.1.3.3.r 17-1.2.1.1.3 19-1.2.1.1.3.2.1.1.1 19-1.2.1.1.3.2.2.1.1 20-1.2.1.1.3.2.1.1.2 20-1.2.1.1.3.2.2.1.2 21-1.2.1.1.3.2.r 22-1.2.1.1.3.2.1.2.1.1 23-1.2.1.1.3.2 24-1.2.1.1.3.2.2.2.1.1 26-1.2 27-1.2.r 28-1.2.2.1.3.1.2.1 29-1.2.2 30-1.2.2.1.4.r 30-1.2.2.1.r 32-1.2.2.1.2 33-1.2.2.1.1.1.1.1.1.1 34-1.2.2.1.1.1 34-1.2.2.1.1.1.1 34-1.2.2.1.1.1.1.r 36-1.2.2.1.1 37-1.2.2.1 38-1.2.2.1.3 40-1.2.2.1.3.1.1.1.1 41-1.2.2.1.3.1 43-1.2.2.1.3.1.2.1 44-1.2.2.1.3.1.2
# ::id bio.bmtr_0002.2
# ::preferred 
(h / hypothesize-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2,27 (a / and~e.26
            :op1 (p / possible~e.8
                  :domain (s / suppress-01~e.9
                        :ARG0 (p2 / pathway~e.7
                              :name (n / name :op1 "MEK/ERK"~e.4,6))
                        :ARG1 (p3 / phosphorylate-01~e.12
                              :ARG1~e.13 (e / enzyme
                                    :name (n2 / name :op1 "ERBB3"~e.14)))
                        :manner (p4 / phosphorylate-01~e.12,17
                              :ARG0 p2
                              :ARG1~e.21 (a2 / and~e.23
                                    :op1 (p5 / protein-segment
                                          :name (n3 / name :op1 "JM"~e.19 :op2 "domain"~e.20)
                                          :part-of (e2 / enzyme
                                                :name (n4 / name :op1 "EGFR"~e.22)))
                                    :op2 (p6 / protein-segment
                                          :name (n5 / name :op1 "JM"~e.19 :op2 "domain"~e.20)
                                          :part-of (e3 / enzyme
                                                :name (n6 / name :op1 "HER2"~e.24))))
                              :manner~e.16 (d / direct~e.16))))
            :op2 (p7 / possible~e.29
                  :domain~e.30 (f / feedback~e.37
                        :ARG1-of (i / induce-01~e.36
                              :ARG0 (m / molecular-physical-entity~e.34
                                    :ARG0-of~e.34 (i2 / inhibit-01~e.34
                                          :ARG1 (e4 / enzyme
                                                :name (n7 / name :op1 "MEK"~e.33)))))
                        :ARG0-of (d2 / dominate-01~e.32)
                        :ARG0-of (l / lead-03~e.38
                              :ARG2 (a3 / activate-01~e.41
                                    :ARG1 (e5 / enzyme
                                          :name (n8 / name :op1 "AKT"~e.40))
                                    :location (c / cancer~e.44
                                          :mod (t / this~e.28,43))))
                        :domain~e.30 s))))

# ::tok We used tandem mass spectrometry to measure the effects of AZD6244 on phosphorylation of this JM domain threonine residue in both EGFR @-@ mutant and HER2 @- amplified cancer models .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 1-1 2-1.2.2 3-1.2.1 4-1.2 6-1.3 8-1.3.2 9-1.3.2.1.r 10-1.3.2.1.1.1 11-1.3.2.2.r 12-1.3.2.2 13-1.3.2.2.1.r 14-1.3.2.2.1.3 15-1.3.2.2.1.2.1.1 16-1.3.2.2.1.2.1.2 17-1.3.2.2.1.1.1.1 18-1.3.2.2.1 21-1.3.2.3.1.1.1.1.1.1 23-1.3.2.3.1.1.1 24-1.3.2.3 25-1.3.2.3.2.1.1.1.1.1 27-1.3.2.3.2.1.1 28-1.3.2.3.1.1 28-1.3.2.3.2.1 29-1.3.2.3.1 29-1.3.2.3.2
# ::id bio.bmtr_0002.3
# ::preferred 
(u / use-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (s / spectrometry~e.4
            :mod (m / mass~e.3)
            :mod (t / tandem~e.2))
      :ARG2 (m2 / measure-01~e.6
            :ARG0 w
            :ARG1 (a / affect-01~e.8
                  :ARG0~e.9 (s2 / small-molecule
                        :name (n / name :op1 "AZD6244"~e.10))
                  :ARG1~e.11 (p / phosphorylate-01~e.12
                        :ARG1~e.13 (r / residue~e.18
                              :mod (a2 / amino-acid
                                    :name (n2 / name :op1 "threonine"~e.17))
                              :part-of (p2 / protein-segment
                                    :name (n3 / name :op1 "JM"~e.15 :op2 "domain"~e.16))
                              :mod (t2 / this~e.14)))
                  :condition (a4 / and~e.24
                        :op1 (m3 / model~e.29
                              :topic (c / cancer~e.28
                                    :mod (m4 / mutate-01~e.23
                                          :ARG1 (e / enzyme
                                                :name (n4 / name :op1 "EGFR"~e.21)))))
                        :op2 (m5 / model~e.29
                              :topic (c3 / cancer~e.28
                                    :mod (a3 / amplify-01~e.27
                                          :ARG1 (e2 / enzyme
                                                :name (n5 / name :op1 "HER2"~e.25)))))))))

# ::tok Targeting both the phosphorylated and non @-@ phosphorylated peptide forms , we detected a 66 % average decrease in EGFR T669 phosphorylation and a 75 % decrease in HER2 T677 phosphorylation upon treatment with AZD6244 ( Figure 5B , Supplemental Figure 8 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3 3-1.3.2.2.1 5-1.3.2.2.1.1 5-1.3.2.2.1.1.r 7-1.3.2.1.1 7-1.3.2.2.1 8-1.3.2.1 8-1.3.2.2 11-1.1 12-1 14-1.2.1.2.1 15-1.2.1.2 16-1.2.1.2.2 17-1.2.1 18-1.2.1.1.r 19-1.2.1.1.1.3.1.1 21-1.2.1.1 22-1.2 24-1.2.2.2.1 25-1.2.2.2 26-1.2.2 27-1.2.2.1.r 28-1.2.2.1.1.3.1.1 30-1.2.2.1 32-1.4 33-1.4.1.r 34-1.4.1.1.1 36-1.5.1.1 37-1.5.1.1.1 39-1.5.1.2.2 40-1.5.1.2 41-1.5.1.2.1
# ::id bio.bmtr_0002.4
# ::preferred 
(d / detect-01~e.12
      :ARG0 (w / we~e.11)
      :ARG1 (a / and~e.22
            :op1 (d2 / decrease-01~e.17
                  :ARG1~e.18 (p / phosphorylate-01~e.21
                        :ARG1 (a3 / amino-acid
                              :mod "669"
                              :name (n / name :op1 "threonine")
                              :part-of (e / enzyme
                                    :name (n2 / name :op1 "EGFR"~e.19))))
                  :ARG2 (p2 / percentage-entity~e.15
                        :value "66"~e.14
                        :ARG2-of (a2 / average-01~e.16)))
            :op2 (d3 / decrease-01~e.26
                  :ARG1~e.27 (p3 / phosphorylate-01~e.30
                        :ARG1 (a4 / amino-acid
                              :mod "677"
                              :name (n3 / name :op1 "threonine")
                              :part-of (e2 / enzyme
                                    :name (n4 / name :op1 "HER2"~e.28))))
                  :ARG2 (p4 / percentage-entity~e.25 :value "75"~e.24)))
      :ARG2 (t2 / target-01~e.0
            :ARG0 w
            :ARG1 (a6 / and
                  :op1 (p5 / protein-segment~e.8
                        :ARG3-of (p7 / phosphorylate-01~e.7))
                  :op2 (p6 / protein-segment~e.8
                        :ARG3-of (p8 / phosphorylate-01~e.3,7 :polarity~e.5 "-"~e.5))))
      :condition (t / treat-04~e.32
            :ARG2~e.33 (s / small-molecule
                  :name (n5 / name :op1 "AZD6244"~e.34)))
      :ARG1-of (d4 / describe-01
            :ARG0 (a5 / and
                  :op1 (f / figure~e.36 :mod "5B"~e.37)
                  :op2 (f2 / figure~e.40
                        :mod "8"~e.41
                        :ARG2-of (s2 / supplement-01~e.39)))))

# ::tok Phospho @-@ specific antibodies confirmed that treatment with AZD6244 inhibited phosphorylation of T669 of EGFR and the analogous T677 of HER2 ( Figure 5A ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.1.1 3-1.1 4-1 5-1.2.r 6-1.2.1 7-1.2.1.1.r 8-1.2.1.1.1.1 9-1.2 10-1.1.1.1 10-1.2.2.1 10-1.2.2.2 13-1.2.2.1.1.r 13-1.2.2.r 14-1.2.2.1.1.3.1.1 15-1.2.2 17-1.2.2.2.1.3 20-1.2.2.2.1.4.1.1 22-1.3.1 23-1.3.1.1
# ::id bio.bmtr_0002.5
# ::preferred 
(c / confirm-01~e.4
      :ARG0 (a / antibody~e.3
            :mod (s / specific~e.2
                  :topic (p / phosphorylate-01~e.10)))
      :ARG1~e.5 (i / inhibit-01~e.9
            :ARG0 (t / treat-04~e.6
                  :ARG2~e.7 (s2 / small-molecule
                        :name (n / name :op1 "AZD6244"~e.8)))
            :ARG1~e.13 (a3 / and~e.15
                  :op1 (p2 / phosphorylate-01~e.10
                        :ARG1~e.13 (a2 / amino-acid
                              :mod "669"
                              :name (n2 / name :op1 "threonine")
                              :part-of (e / enzyme
                                    :name (n3 / name :op1 "EGFR"~e.14))))
                  :op2 (p3 / phosphorylate-01~e.10
                        :ARG1 (a4 / amino-acid
                              :mod "677"
                              :name (n4 / name :op1 "threonine")
                              :mod (a5 / analogous~e.17
                                    :topic a2)
                              :part-of (e2 / enzyme
                                    :name (n5 / name :op1 "HER2"~e.20))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.22 :mod "5A"~e.23)))

# ::tok Together these data indicate that loss of this inhibitory threonine phosphorylation on the JM domains of EGFR and HER2 occurs in cancer cell lines following MEK inhibition , presumably due to differential subcellular localization and @/@ or binding proteins .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2 1-1.1.1 2-1.1 3-1 4-1.2.r 5-1.2 6-1.2.1.r 7-1.2.1.3 9-1.2.1.1.1.1 10-1.2.1 13-1.2.1.1.2.1.1 14-1.2.1.1.2.1.2 16-1.2.1.1.2.2.1.1.1 18-1.2.1.1.2.2.2.1.1 20-1.2.2.r 21-1.2.2.1 22-1.2.2 22-1.2.4.1.1.1 23-1.2.2 24-1.2.3 25-1.2.3.1.1.1.1 26-1.2.1.2 26-1.2.3.1 28-1.2.4.2 29-1.2.4 30-1.2.4 31-1.2.4.1.1 31-1.2.4.1.1.2 31-1.2.4.1.1.2.r 31-1.2.4.1.2.2 34-1.2.4.1 36-1.2.1.1.2.2 36-1.2.4.1 37-1.2.4.1.2.1 38-1.2.4.1.2
# ::id bio.bmtr_0002.6
# ::preferred 
(i / indicate-01~e.3
      :ARG0 (d / data~e.2
            :mod (t / this~e.1)
            :mod (t2 / together~e.0))
      :ARG1~e.4 (l / lose-01~e.5
            :ARG1~e.6 (p / phosphorylate-01~e.10
                  :ARG1 (a / amino-acid
                        :name (n / name :op1 "threonine"~e.9)
                        :part-of (p2 / protein-segment
                              :name (n2 / name :op1 "JM"~e.13 :op2 "domain"~e.14)
                              :part-of (o / or~e.36
                                    :op1 (e / enzyme
                                          :name (n3 / name :op1 "EGFR"~e.16))
                                    :op2 (e2 / enzyme
                                          :name (n4 / name :op1 "HER2"~e.18)))))
                  :ARG0-of (i2 / inhibit-01~e.26)
                  :mod (t3 / this~e.7))
            :location~e.20 (c / cell-line~e.22,23
                  :mod (c2 / cancer~e.21))
            :ARG1-of (f / follow-01~e.24
                  :ARG2 (i3 / inhibit-01~e.26
                        :ARG1 (e3 / enzyme
                              :name (n5 / name :op1 "MEK"~e.25))))
            :ARG1-of (c3 / cause-01~e.29,30
                  :ARG0 (a2 / and-or~e.34,36
                        :op1 (l2 / location~e.31
                              :location (c4 / cell~e.22)
                              :ARG1-of~e.31 (d2 / differ-02~e.31))
                        :op2 (p4 / protein~e.38
                              :ARG1-of (b / bind-01~e.37)
                              :ARG1-of (d3 / differ-02~e.31)))
                  :ARG1-of (p3 / presume-01~e.28))))

# ::tok Mutation of T669 and T677 abrogates MEK inhibitor @-@ induced suppression of ERBB3 Activation
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 3-1.1.1 5-1 6-1.2.2.1.1.1.1.1 7-1.2.2.1 7-1.2.2.1.1 7-1.2.2.1.1.r 9-1.2.2 10-1.2 11-1.2.1.r 12-1.2.1.1.1.1 13-1.2.1
# ::id bio.bmtr_0002.7
# ::preferred 
(a / abrogate-01~e.5
      :ARG0 (m / mutate-01~e.0
            :ARG1 (a2 / and~e.3
                  :op1 (a3 / amino-acid
                        :mod "669"
                        :name (n / name :op1 "threonine"))
                  :op2 (a4 / amino-acid
                        :mod "677"
                        :name (n2 / name :op1 "threonine"))))
      :ARG1 (s / suppress-01~e.10
            :ARG1~e.11 (a5 / activate-01~e.13
                  :ARG1 (e / enzyme
                        :name (n3 / name :op1 "ERBB3"~e.12)))
            :ARG1-of (i / induce-01~e.9
                  :ARG0 (m2 / molecular-physical-entity~e.7
                        :ARG0-of~e.7 (i2 / inhibit-01~e.7
                              :ARG1 (e2 / enzyme
                                    :name (n4 / name :op1 "MEK"~e.6)))))))

# ::tok We hypothesized that MEK inhibition activates AKT by inhibiting ERK activity , which blocks an inhibitory threonine phosphorylation on the JM domains of EGFR and HER2 , thereby increasing ERBB3 phosphorylation .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1 4-1.2.1 4-1.2.3 5-1.2 6-1.2.2.1.1 8-1.2.3 8-1.2.3.3.1.2 9-1.2.3.2.1.1.1 10-1.2.3.2 13-1.2.3.3 16-1.2.3.3.1.1.1.1 17-1.2.3.3.1 20-1.2.3.3.1.1.2.1.1 21-1.2.3.3.1.1.2.1.2 23-1.2.3.3.1.1.2.2.1.1.1 25-1.2.3.3.1.1.2.2.2.1.1 27-1.2.3.r 28-1.2.3.3.2 29-1.2.3.3.2.1.1.1.1 30-1.2.3.3.2.1
# ::id bio.bmtr_0002.8
# ::preferred 
(h / hypothesize-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (a / activate-01~e.5
            :ARG0 (i / inhibit-01~e.4
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "MEK"~e.3)))
            :ARG1 (e2 / enzyme
                  :name (n2 / name :op1 "AKT"~e.6))
            :manner~e.27 (i2 / inhibit-01~e.4,8
                  :ARG0 i
                  :ARG1 (a2 / act-02~e.10
                        :ARG0 (e3 / enzyme
                              :name (n3 / name :op1 "ERK"~e.9)))
                  :ARG0-of (b / block-01~e.13
                        :ARG1 (p / phosphorylate-01~e.17
                              :ARG1 (a3 / amino-acid
                                    :name (n4 / name :op1 "threonine"~e.16)
                                    :part-of (p2 / protein-segment
                                          :name (n5 / name :op1 "JM"~e.20 :op2 "domain"~e.21)
                                          :part-of (o / or
                                                :op1 (e4 / enzyme
                                                      :name (n6 / name :op1 "EGFR"~e.23))
                                                :op2 (e5 / enzyme
                                                      :name (n7 / name :op1 "HER2"~e.25)))))
                              :ARG0-of (i3 / inhibit-01~e.8))
                        :ARG0-of (i4 / increase-01~e.28
                              :ARG1 (p3 / phosphorylate-01~e.30
                                    :ARG1 (e6 / enzyme
                                          :name (n8 / name :op1 "ERBB3"~e.29))))))))

# ::tok To test this hypothesis , we transiently transfected CHO @-@ KI cells , which do not express ERBB receptors endogenously , with wild @-@ type ERBB3 with either wild @-@ type EGFR or EGFR T669A .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.5 2-1.5.2.2 3-1.5.2 3-1.5.2.1 3-1.5.2.1.r 5-1.1 6-1.4 7-1 8-1.2.1.1.1 10-1.2.1.1.1 11-1.2 15-1.2.2.1 15-1.2.2.1.r 16-1.2.2 17-1.2.2.2.1.1 18-1.2.2.2 19-1.2.2.3 22-1.3.1.2 22-1.3.2.1.2 24-1.3.1.2 24-1.3.2.1.2 25-1.3.1.1.1 28-1.3.1.2 28-1.3.2.1.2 30-1.3.1.2 30-1.3.2.1.2 31-1.3.2.1.1.1 31-1.3.2.2.1.1 32-1.3.2 33-1.3.2.1.1.1 33-1.3.2.2.1.1 34-1.3.2.2.2.1
# ::id bio.bmtr_0002.9
# ::preferred 
(t / transfect-00~e.7
      :ARG0 (w / we~e.5)
      :ARG1 (c / cell~e.11
            :source (c2 / cell-line
                  :name (n / name :op1 "CHO-KI"~e.8,10))
            :ARG3-of (e3 / express-03~e.16
                  :polarity~e.15 "-"~e.15
                  :ARG2 (r / receptor~e.18
                        :name (n4 / name :op1 "ERBB"~e.17))
                  :mod (e4 / endogenous~e.19)))
      :ARG2 (a / and
            :op1 (e5 / enzyme
                  :name (n5 / name :op1 "ERBB3"~e.25)
                  :mod (w3 / wild-type~e.22,24,28,30))
            :op2 (o / or~e.32
                  :op1 (e / enzyme
                        :name (n2 / name :op1 "EGFR"~e.31,33)
                        :mod (w2 / wild-type~e.22,24,28,30))
                  :op2 (e2 / enzyme
                        :name (n3 / name :op1 "EGFR"~e.31,33)
                        :ARG2-of (m / mutate-01 :value "T669A"~e.34))))
      :mod (t2 / transient~e.6)
      :purpose (t3 / test-01~e.1
            :ARG0 w
            :ARG1 (t5 / thing~e.3
                  :ARG1-of~e.3 (h / hypothesize-01~e.3)
                  :mod (t4 / this~e.2))))

# ::tok In cells transfected with wild @-@ type EGFR , MEK inhibition led to feedback activation of phospho @-@ ERBB3 and phosho @-@ EGFR , recapitulating the results we had observed in our panel of cancer cell lines ( Figure 6A ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.3 2-1.3.1 3-1.3.1.1.r 4-1.3.1.1.2 6-1.3.1.1.2 7-1.3.1.1.1.1 9-1.1.1.1.1 10-1.1 11-1 12-1.2.r 13-1.2.2 14-1.2 18-1.2.1.1.1.1 19-1.2.1 22-1.2.1.2.1.1 22-1.3.1.1.1.1 24-1.4 26-1.4.1 26-1.4.1.1 26-1.4.1.1.r 27-1.4.1.2.1 29-1.4.1.2 30-1.4.1.2.2.r 31-1.4.1.2.2.2 31-1.4.1.2.2.2.r 32-1.4.1.2.2 33-1.4.1.2.2.1.r 34-1.4.1.2.2.1.1 35-1.4.1.2.2.1 36-1.4.1.2.2.1 38-1.5.1 39-1.5.1.1
# ::id bio.bmtr_0002.10
# ::preferred 
(l / lead-03~e.11
      :ARG0 (i / inhibit-01~e.10
            :ARG1 (e / enzyme
                  :name (n / name :op1 "MEK"~e.9)))
      :ARG2~e.12 (a / activate-01~e.14
            :ARG1 (a2 / and~e.19
                  :op1 (e3 / enzyme
                        :name (n3 / name :op1 "ERBB3"~e.18)
                        :ARG3-of (p / phosphorylate-01))
                  :op2 (e4 / enzyme
                        :name (n4 / name :op1 "EGFR"~e.22)
                        :ARG3-of (p2 / phosphorylate-01)))
            :subevent-of (f / feedback~e.13))
      :location (c / cell~e.1
            :ARG1-of (t / transfect-00~e.2
                  :ARG2~e.3 (e2 / enzyme
                        :name (n2 / name :op1 "EGFR"~e.7,22)
                        :mod (w / wild-type~e.4,6))))
      :ARG0-of (r / recapitulate-01~e.24
            :ARG1 (t2 / thing~e.26
                  :ARG2-of~e.26 (r2 / result-01~e.26)
                  :ARG1-of (o / observe-01~e.29
                        :ARG0 (w2 / we~e.27)
                        :location~e.30 (p3 / panel~e.32
                              :consist-of~e.33 (c2 / cell-line~e.35,36
                                    :mod (c3 / cancer~e.34))
                              :poss~e.31 w2~e.31))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.38 :mod "6A"~e.39)))

# ::tok In contrast , the EGFR T669A mutant increased both basal EGFR and ERBB3 tyrosine phosphorylation that was not augmented by MEK inhibition .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1 4-1.1.1.1.1 4-1.1.2.1.1.2.1.1 5-1.1.1.2.1 6-1.1.1 6-1.1.1.2 6-1.1.1.2.r 7-1.1 9-1.1.2.1.2 10-1.1.2.1.1.2.1.1 11-1.1.2 12-1.1.2.2.2.1.1 13-1.1.2.1.1.1.1 13-1.1.2.2.1.1.1 14-1.1.2.1 14-1.1.2.2 17-1.1.2.3.1 17-1.1.2.3.1.r 18-1.1.2.3 19-1.1.2.3.2.r 20-1.1.2.3.2.1.1.1 21-1.1.2.3.2
# ::id bio.bmtr_0002.11
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (i / increase-01~e.7
            :ARG0 (e4 / enzyme~e.6
                  :name (n4 / name :op1 "EGFR"~e.4)
                  :ARG2-of~e.6 (m / mutate-01~e.6 :value "T669A"~e.5))
            :ARG1 (a / and~e.11
                  :op1 (p2 / phosphorylate-01~e.14
                        :ARG1 (a2 / amino-acid
                              :name (n5 / name :op1 "tyrosine"~e.13)
                              :part-of (e / enzyme
                                    :name (n / name :op1 "EGFR"~e.4,10)))
                        :mod (b / basal~e.9))
                  :op2 (p3 / phosphorylate-01~e.14
                        :ARG1 (a3 / amino-acid
                              :name (n6 / name :op1 "tyrosine"~e.13))
                        :part-of (e2 / enzyme
                              :name (n2 / name :op1 "ERBB3"~e.12))
                        :mod b)
                  :ARG1-of (a4 / augment-01~e.18
                        :polarity~e.17 "-"~e.17
                        :ARG0~e.19 (i2 / inhibit-01~e.21
                              :ARG1 (e3 / enzyme
                                    :name (n3 / name :op1 "MEK"~e.20)))))))

# ::tok As a control , we treated CHO @-@ KI cells expressing EGFR T669A with HRG ligand to induce maximal ERBB3 phosphorylation ( Figure 6A ) , indicating that the lack of induction of phospho @-@ ERBB3 in EGFR T669A expressing cells following MEK inhibition was not simply due to the saturation of the system with phospho @-@ ERBB3 .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.6 4-1.1 5-1 6-1.2.1.1.1 8-1.2.1.1.1 9-1.2 10-1.2.2 11-1.2.2.1.1.1 12-1.2.2.1.2.1 13-1.3.r 14-1.3.1.1 15-1.3 17-1.4 18-1.4.2.2 19-1.4.2.1.1.1 20-1.4.2 20-1.4.3.1.2.1.1 20-1.4.3.1.3.2.2 22-1.5.1 23-1.5.1.1 26-1.4.3 27-1.4.3.1.r 29-1.4.3.1.2 30-1.4.3.1.2.1.r 31-1.4.3.1.2.1 35-1.4.3.1.3.2.1.1 36-1.4.3.1.2.1.2.r 37-1.4.3.1.2.1.2.1.1.1.1 38-1.4.3.1.2.1.2.1.1.2.1 39-1.4.3.1.2.1.2.1 40-1.4.3.1.2.1.2 41-1.4.3.1.2.1.3 42-1.4.3.1.2.1.3.1.1.1.1 43-1.4.3.1.2.1.3.1 45-1.4.3.1.1 45-1.4.3.1.1.r 46-1.4.3.1.4 47-1.4.3.1 48-1.4.3.1 50-1.4.3.1.3 51-1.4.3.1.3.1.r 53-1.4.3.1.3.1 57-1.4.2.1.1.1 57-1.4.3.1.3.2.1.1
# ::id bio.bmtr_0002.12
# ::preferred 
(t / treat-04~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (c / cell~e.9
            :source (c2 / cell-line
                  :name (n / name :op1 "CHO-KI"~e.6,8))
            :ARG3-of (e / express-03~e.10
                  :ARG2 (e2 / enzyme
                        :name (n2 / name :op1 "EGFR"~e.11)
                        :ARG2-of (m / mutate-01 :value "T669A"~e.12))))
      :ARG2~e.13 (l / ligand~e.15
            :name (n3 / name :op1 "HRG"~e.14))
      :purpose (i / induce-01~e.17
            :ARG0 w
            :ARG1 (p / phosphorylate-01~e.20
                  :ARG1 (e3 / enzyme
                        :name (n4 / name :op1 "ERBB3"~e.19,57))
                  :degree (m2 / maximum~e.18))
            :ARG0-of (i2 / indicate-01~e.26
                  :ARG1~e.27 (c3 / cause-01~e.47,48
                        :polarity~e.45 "-"~e.45
                        :ARG0 (l2 / lack-01~e.29
                              :ARG1~e.30 (i3 / induce-01~e.31
                                    :ARG1 (p3 / phosphorylate-01~e.20
                                          :ARG1 e3)
                                    :location~e.36 (c4 / cell~e.40
                                          :ARG3-of (e5 / express-03~e.39
                                                :ARG2 (e6 / enzyme
                                                      :name (n6 / name :op1 "EGFR"~e.37)
                                                      :ARG2-of (m3 / mutate-01 :value "T669A"~e.38))))
                                    :ARG2-of (f2 / follow-01~e.41
                                          :ARG1 (i4 / inhibit-01~e.43
                                                :ARG1 (e7 / enzyme
                                                      :name (n7 / name :op1 "MEK"~e.42))))))
                        :ARG1 (s / saturate-01~e.50
                              :ARG1~e.51 (s2 / system~e.53)
                              :ARG2 (e4 / enzyme
                                    :name (n5 / name :op1 "ERBB3"~e.35,57)
                                    :ARG3-of (p2 / phosphorylate-01~e.20)))
                        :mod (s3 / simple~e.46))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.22 :mod "6A"~e.23))
      :ARG2-of (c5 / control-01~e.2))

# ::tok We observed analogous results in CHO @-@ KI cells expressing wild @-@ type ERBB3 in combination with wild @-@ type or T677A mutant HER2 ( Figure 6B ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 1-1 2-1.2.2 3-1.2 3-1.2.1 3-1.2.1.r 4-1.2.1.1.r 5-1.2.1.1.1.1.1 7-1.2.1.1.1.1.1 8-1.2.1.1 9-1.2.1.1.2 10-1.2.1.1.2.1.2 10-1.2.1.1.2.1.3.1.2 12-1.2.1.1.2.1.2 12-1.2.1.1.2.1.3.1.2 13-1.2.1.1.2.1.1.1 16-1.2.1.1.2.1.3.r 17-1.2.1.1.2.1.3.1.2 19-1.2.1.1.2.1.3.1.2 20-1.2.1.1.2.1.3 21-1.2.1.1.2.1.3.2.2.1 22-1.2.1.1.2.1.3.2 22-1.2.1.1.2.1.3.2.2 22-1.2.1.1.2.1.3.2.2.r 23-1.2.1.1.2.1.3.1.1.1 23-1.2.1.1.2.1.3.2.1.1 25-1.3.1 26-1.3.1.1
# ::id bio.bmtr_0002.13
# ::preferred 
(o / observe-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (t / thing~e.3
            :ARG2-of~e.3 (r / result-01~e.3
                  :ARG1~e.4 (c / cell~e.8
                        :source (c2 / cell-line
                              :name (n / name :op1 "CHO-KI"~e.5,7))
                        :ARG3-of (e / express-03~e.9
                              :ARG2 (e2 / enzyme
                                    :name (n2 / name :op1 "ERBB3"~e.13)
                                    :mod (w2 / wild-type~e.10,12)
                                    :accompanier~e.16 (o2 / or~e.20
                                          :op1 (e3 / enzyme
                                                :name (n3 / name :op1 "HER2"~e.23)
                                                :mod (w3 / wild-type~e.10,12,17,19))
                                          :op2 (e4 / enzyme~e.22
                                                :name (n4 / name :op1 "HER2"~e.23)
                                                :ARG2-of~e.22 (m / mutate-01~e.22 :value "T677A"~e.21)))))))
            :mod (a / analogous~e.2))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.25 :mod "6B"~e.26)))

# ::tok Together these results support the hypothesis that inhibition of ERK @-@ mediated phosphorylation of a conserved JM domain threonine residue leads to feedback activation of EGFR , HER2 , and ERBB3 ( Figure 7 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2 1-1.1.3 2-1.1 2-1.1.1 2-1.1.1.r 3-1 5-1.2 6-1.2.1.r 7-1.2.1.1 8-1.2.1.1.1.r 9-1.2.1.1.1.2.1.1.1 11-1.2.1.1.1.2 12-1.2.1.1.1 13-1.2.1.1.1.1.r 15-1.2.1.1.1.1.2.2 16-1.2.1.1.1.1.2.1.1 17-1.2.1.1.1.1.2.1.2 18-1.2.1.1.1.1.1.1.1 19-1.2.1.1.1.1 20-1.2.1 21-1.2.1.2.r 22-1.2.1.2.2 23-1.2.1.2 24-1.2.1.2.1.r 25-1.2.1.2.1.1.1.1 27-1.2.1.2.1.2.1.1 29-1.2.1.2.1 30-1.2.1.2.1.3.1.1 32-1.3.1 33-1.3.1.1
# ::id bio.bmtr_0002.14
# ::preferred 
(s / support-01~e.3
      :ARG0 (t / thing~e.2
            :ARG2-of~e.2 (r / result-01~e.2)
            :mod (t2 / together~e.0)
            :mod (t3 / this~e.1))
      :ARG1 (h / hypothesize-01~e.5
            :ARG1~e.6 (l / lead-03~e.20
                  :ARG0 (i / inhibit-01~e.7
                        :ARG1~e.8 (p / phosphorylate-01~e.12
                              :ARG1~e.13 (r2 / residue~e.19
                                    :mod (a3 / amino-acid
                                          :name (n5 / name :op1 "threonine"~e.18))
                                    :part-of (p2 / protein-segment
                                          :name (n6 / name :op1 "JM"~e.16 :op2 "domain"~e.17)
                                          :ARG1-of (c / conserve-01~e.15)))
                              :ARG1-of (m / mediate-01~e.11
                                    :ARG0 (e4 / enzyme
                                          :name (n4 / name :op1 "ERK"~e.9)))))
                  :ARG2~e.21 (a / activate-01~e.23
                        :ARG1~e.24 (a2 / and~e.29
                              :op1 (e / enzyme
                                    :name (n / name :op1 "EGFR"~e.25))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "HER2"~e.27))
                              :op3 (e3 / enzyme
                                    :name (n3 / name :op1 "ERBB3"~e.30)))
                        :subevent-of (f / feedback~e.22))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.32 :mod "7"~e.33)))

# ::tok To determine if this feedback model explains the activation of PI3K signaling in EGFR @-@ mutant cancers , we used shRNA to knockdown endogenous EGFR ( which carries an exon 19 deletion ) in the HCC827 NSCLC cell line and replaced with either EGFR ( exon 19 del ) wild @-@ type at T669 , or EGFR ( exon 19 del ) carrying a T669A mutation .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1.3.2.3.2.r 4-1.3.2.2.1 5-1.3.2.2 6-1.3.2 8-1.3.2.3 9-1.3.2.3.1.r 10-1.3.2.3.1.1.1 11-1.3.2.3.1.2 13-1.3.2.3.2.1.1.1.1 15-1.3.2.3.2.1 16-1.3.2.3.2 18-1.1.1 19-1.1 20-1.1.2.1.1 23-1.1.3.2.2 24-1.1.3.2.1.1 24-1.2.3.1.1.1 27-1.2.3.1.3 29-1.1.3.2.4.1 30-1.1.3.2.4.1.1 31-1.1.3.2 31-1.1.3.2.4 31-1.1.3.2.4.r 33-1.1.3.2.3.r 35-1.1.3.2.3.1.1 36-1.1.3.2.3.1.2 37-1.1.3.2.3 38-1.1.3.2.3 39-1 40-1.2 43-1.1.3.2.1.1 43-1.2.3.1.1.1 43-1.2.3.2.1.1 45-1.1.3.2.4.1 46-1.1.3.2.4.1.1 49-1.2.3.1.2 51-1.2.3.1.2 55-1.2.3 56-1.1.3.2.1.1 56-1.2.3.1.1.1 56-1.2.3.2.1.1 58-1.1.3.2.4.1 59-1.1.3.2.4.1.1 62-1.2.3.1.3 64-1.2.3.2.3.1 65-1.2.3.2.3
# ::id bio.bmtr_0002.15
# ::preferred 
(a / and~e.39
      :op1 (u / use-01~e.19
            :ARG0 (w / we~e.18)
            :ARG1 (m / macro-molecular-complex
                  :name (n / name :op1 "shRNA"~e.20))
            :ARG2 (k / knock-02
                  :ARG0 w
                  :ARG1 (e / enzyme~e.31
                        :name (n2 / name :op1 "EGFR"~e.24,43,56)
                        :mod (e2 / endogenous~e.23)
                        :location~e.33 (c2 / cell-line~e.37,38
                              :name (n3 / name :op1 "HCC827"~e.35 :op2 "NSCLC"~e.36))
                        :ARG2-of~e.31 (d / delete-01~e.31
                              :ARG1 (e3 / exon~e.29,45,58 :mod "19"~e.30,46,59)))))
      :op2 (r / replace-01~e.40
            :ARG0 w
            :ARG1 e
            :ARG2 (o / or~e.55
                  :op1 (e4 / enzyme
                        :name (n4 / name :op1 "EGFR"~e.24,43,56)
                        :mod (w2 / wild-type~e.49,51)
                        :ARG0-of (c / carry-01~e.27,62)
                        :part (a2 / amino-acid
                              :mod "669"
                              :name (n5 / name :op1 "threonine")))
                  :op2 (e5 / enzyme
                        :name (n6 / name :op1 "EGFR"~e.43,56)
                        :ARG2-of d
                        :part (m2 / mutate-01~e.65 :value "T669A"~e.64))))
      :purpose (d2 / determine-01~e.1
            :ARG0 w
            :ARG1 (e6 / explain-01~e.6
                  :mode "interrogative"
                  :ARG0 (m3 / model~e.5
                        :mod (f / feedback~e.4))
                  :ARG1 (a4 / activate-01~e.8
                        :ARG1~e.9 (e8 / enzyme
                              :name (n7 / name :op1 "PI3K"~e.10)
                              :ARG0-of (s / signal-07~e.11))
                        :condition~e.2 (c4 / cancer~e.16
                              :mod (m4 / mutate-01~e.15
                                    :ARG1 (e7 / enzyme
                                          :name (n8 / name :op1 "EGFR"~e.13))))))))

# ::tok Of note , this is the same EGFR @-@ mutant cell line in which we observed that EGFR T669 is phosphorylated in MEK @-@ dependent manner ( Figure 5 , Supplemental Figure 8A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.1 6-1.1 7-1.1.2.1.1.1 7-1.1.2.2.1.3.1.1 9-1.1.2.1 9-1.1.2.1.2 9-1.1.2.1.2.r 10-1.1.2 11-1.1.2 14-1.1.2.2.3.1 15-1.1.2.2.3 17-1.1.2.2.1.3.1.1 20-1.1.2.2 21-1.1.2.2.2.r 22-1.1.2.2.2.1.1.1 24-1.1.2.2.2 27-1.1.3.1.1 28-1.1.3.1.1.1 30-1.1.3.1.2.2 31-1.1.3.1.2 32-1.1.3.1.2.1
# ::id bio.bmtr_0002.16
# ::preferred 
(n / note-02~e.1
      :ARG1 (s / same-01~e.6
            :ARG1 (t / this~e.3)
            :ARG2 (c / cell-line~e.10,11
                  :consist-of (e3 / enzyme~e.9
                        :name (n2 / name :op1 "EGFR"~e.7)
                        :ARG2-of~e.9 (m / mutate-01~e.9))
                  :location-of (p / phosphorylate-01~e.20
                        :ARG1 (a / amino-acid
                              :mod "669"
                              :name (n3 / name :op1 "threonine")
                              :part-of (e / enzyme
                                    :name (n4 / name :op1 "EGFR"~e.7,17)))
                        :ARG0-of~e.21 (d / depend-01~e.24
                              :ARG1 (e2 / enzyme
                                    :name (n5 / name :op1 "MEK"~e.22)))
                        :ARG1-of (o / observe-01~e.15
                              :ARG0 (w / we~e.14))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a2 / and
                        :op1 (f / figure~e.27 :mod "5"~e.28)
                        :op2 (f2 / figure~e.31
                              :mod "8A"~e.32
                              :ARG2-of (s2 / supplement-01~e.30))))))

# ::tok When endogenous EGFR was replaced with EGFR ( exon19 del ) wild @-@ type at T669 , MEK inhibition led to significant feedback activation of ERBB3/PI3K/AKT signaling ( Figure 6C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4.r 1-1.4.1.2 2-1.4.1.1.1 2-1.4.2.1.1 4-1.4 6-1.4.1.1.1 6-1.4.2.1.1 11-1.4.2.2 13-1.4.2.2 17-1.1.1.1.1 18-1.1 19-1 20-1.2.r 21-1.2.3 22-1.2.2 23-1.2 24-1.2.1.r 25-1.2.1.1.1 26-1.2.1.2 28-1.3.1 29-1.3.1.1
# ::id bio.bmtr_0002.17
# ::preferred 
(l / lead-03~e.19
      :ARG0 (i / inhibit-01~e.18
            :ARG1 (e / enzyme
                  :name (n / name :op1 "MEK"~e.17)))
      :ARG2~e.20 (a / activate-01~e.23
            :ARG1~e.24 (p / pathway
                  :name (n2 / name :op1 "ERBB3/PI3K/AKT"~e.25)
                  :ARG0-of (s / signal-07~e.26))
            :subevent-of (f / feedback~e.22)
            :ARG1-of (s2 / significant-02~e.21))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.28 :mod "6C"~e.29))
      :time~e.0 (r / replace-01~e.4
            :ARG1 (e2 / enzyme
                  :name (n3 / name :op1 "EGFR"~e.2,6)
                  :mod (e4 / endogenous~e.1))
            :ARG2 (e3 / enzyme
                  :name (n4 / name :op1 "EGFR"~e.2,6)
                  :mod (w / wild-type~e.11,13)
                  :ARG2-of (d2 / delete-01
                        :ARG1 (e5 / exon :mod "19"))
                  :part (a2 / amino-acid
                        :mod "669"
                        :name (n5 / name :op1 "threonine")))))

# ::tok However , replacement with the EGFR ( exon19 del ) T669A mutant led to increased tyrosine phosphorylation of both EGFR and ERBB3 , and activation of PI3K @/@ AKT signaling , mimicking the effect of MEK inhibition ( Figure 6C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1 3-1.1.1.r 5-1.1.1.1.1 10-1.1.1.2.1 11-1.1.1 11-1.1.1.2 11-1.1.1.2.r 12-1 13-1.2.r 14-1.2.1 15-1.2.1.1.1.1.1.1 15-1.2.1.1.2.1.1.1 16-1.2.1.1.1 16-1.2.1.1.2 19-1.2.1.1.1.1.2.1.1 20-1.2.1.1 21-1.2.1.1.2.1.2.1.1 23-1.2 24-1.2.2 25-1.2.2.1.r 26-1.2.2.1.1.1 28-1.2.2.1.1.1 29-1.2.2.1.2 31-1.2.3 33-1.2.3.1 34-1.2.3.1.1.r 35-1.2.3.1.1.1.1.1 36-1.2.3.1.1 38-1.4.1 39-1.4.1.1
# ::id bio.bmtr_0002.18
# ::preferred 
(l / lead-03~e.12
      :ARG0 (r / replace-01~e.2
            :ARG2~e.3 (e / enzyme~e.11
                  :name (n / name :op1 "EGFR"~e.5)
                  :ARG2-of~e.11 (m / mutate-01~e.11 :value "T669A"~e.10)
                  :ARG2-of (d / delete-01
                        :ARG1 (e2 / exon :mod "19"))))
      :ARG2~e.13 (a6 / and~e.23
            :op1 (i / increase-01~e.14
                  :ARG1 (a / and~e.20
                        :op1 (p / phosphorylate-01~e.16
                              :ARG1 (a2 / amino-acid
                                    :name (n2 / name :op1 "tyrosine"~e.15)
                                    :part-of (e3 / enzyme
                                          :name (n3 / name :op1 "EGFR"~e.19))))
                        :op2 (p3 / phosphorylate-01~e.16
                              :ARG1 (a3 / amino-acid
                                    :name (n4 / name :op1 "tyrosine"~e.15)
                                    :part-of (e4 / enzyme
                                          :name (n7 / name :op1 "ERBB3"~e.21))))))
            :op2 (a4 / activate-01~e.24
                  :ARG1~e.25 (p2 / pathway
                        :name (n5 / name :op1 "PI3K/AKT"~e.26,28)
                        :ARG0-of (s / signal-07~e.29)))
            :ARG1-of (m2 / mimic-01~e.31
                  :ARG0 (a5 / affect-01~e.33
                        :ARG0~e.34 (i2 / inhibit-01~e.36
                              :ARG1 (e5 / enzyme
                                    :name (n6 / name :op1 "MEK"~e.35))))))
      :ARG1-of (h / have-concession-91~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.38 :mod "6C"~e.39)))

# ::tok As expected , addition of AZD6244 failed to further augment ERBB3 and AKT phosphorylation in cells expressing the 669A mutant .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.5 3-1.2 4-1.2.1.r 5-1.2.1.1.1 8-1.4 9-1 10-1.3.1.1.1.1 11-1.3.1 12-1.3.1.2.1.1 13-1.3 14-1.3.2.r 15-1.3.2 16-1.3.2.1 19-1.3.2.1.1 19-1.3.2.1.1.2 19-1.3.2.1.1.2.r
# ::id bio.bmtr_0002.19
# ::preferred 
(a4 / augment-01~e.9
      :polarity "-"
      :ARG0 (a / add-02~e.3
            :ARG1~e.4 (s / small-molecule
                  :name (n / name :op1 "AZD6244"~e.5)))
      :ARG1 (p / phosphorylate-01~e.13
            :ARG1 (a3 / and~e.11
                  :op1 (e / enzyme
                        :name (n2 / name :op1 "ERBB3"~e.10))
                  :op2 (p2 / pathway
                        :name (n3 / name :op1 "AKT"~e.12)))
            :location~e.14 (c / cell~e.15
                  :ARG3-of (e2 / express-03~e.16
                        :ARG2 (a2 / amino-acid~e.19
                              :mod "669"
                              :ARG2-of~e.19 (m / mutate-01~e.19)))))
      :degree (f2 / further~e.8)
      :ARG1-of (e3 / expect-01~e.1))

# ::tok These results demonstrate that EGFR T669 phosphorylation is necessary for MEK @/@ ERK to suppress EGFR @-@ mediated activation of ERBB3 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 1-1.1.2 1-1.1.2.r 2-1 3-1.2.r 4-1.2.2.1.3.1.1 6-1.2.2 8-1.2 9-1.2.1.r 10-1.2.1.1.1.1 12-1.2.1.1.1.1 14-1.2.1 15-1.2.1.2.2.1.1.1 17-1.2.1.2.2 18-1.2.1.2 19-1.2.1.2.1.r 20-1.2.1.2.1.1.1
# ::id bio.bmtr_0002.20
# ::preferred 
(d / demonstrate-01~e.2
      :ARG0 (t / thing~e.1
            :mod (t2 / this~e.0)
            :ARG2-of~e.1 (r / result-01~e.1))
      :ARG1~e.3 (n / need-01~e.8
            :ARG0~e.9 (s / suppress-01~e.14
                  :ARG0 (p2 / pathway
                        :name (n4 / name :op1 "MEK/ERK"~e.10,12))
                  :ARG1 (a2 / activate-01~e.18
                        :ARG1~e.19 (e2 / enzyme
                              :name (n5 / name :op1 "ERBB3"~e.20))
                        :ARG1-of (m / mediate-01~e.17
                              :ARG0 (e3 / enzyme
                                    :name (n6 / name :op1 "EGFR"~e.15)))))
            :ARG1 (p / phosphorylate-01~e.6
                  :ARG1 (a / amino-acid
                        :mod "669"
                        :name (n2 / name :op1 "threonine")
                        :part-of (e / enzyme
                              :name (n3 / name :op1 "EGFR"~e.4))))))

# ::tok This supports the hypothesis that a dominant ERK feedback on ERBB3/PI3K/AKT is mediated though phosphorylation of T669 on EGFR ( or T677 HER2 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 3-1.2 4-1.2.1.r 6-1.2.1.2.1 7-1.2.1.2.3.1.1 8-1.2.1.2 9-1.2.1.2.2.r 10-1.2.1.2.2.1.1 12-1.2.1 14-1.2.1.1.1 14-1.2.1.1.2 17-1.2.1.1.1.1.r 18-1.2.1.1.1.1.3.1.1 20-1.2.1.1 22-1.2.1.1.2.1.3.1.1
# ::id bio.bmtr_0002.21
# ::preferred 
(s / support-01~e.1
      :ARG0 (t / this~e.0)
      :ARG1 (h / hypothesize-01~e.3
            :ARG1~e.4 (m / mediate-01~e.12
                  :ARG0 (o2 / or~e.20
                        :op1 (p2 / phosphorylate-01~e.14
                              :ARG1~e.17 (a / amino-acid
                                    :mod "669"
                                    :name (n3 / name :op1 "threonine")
                                    :part-of (e2 / enzyme
                                          :name (n4 / name :op1 "EGFR"~e.18))))
                        :op2 (p3 / phosphorylate-01~e.14
                              :ARG1 (a2 / amino-acid
                                    :mod "677"
                                    :name (n5 / name :op1 "threonine")
                                    :part-of (e3 / enzyme
                                          :name (n6 / name :op1 "HER2"~e.22)))))
                  :ARG1 (f / feedback~e.8
                        :ARG0-of (d / dominate-01~e.6)
                        :destination~e.9 (p / pathway
                              :name (n / name :op1 "ERBB3/PI3K/AKT"~e.10))
                        :mod (e / enzyme
                              :name (n2 / name :op1 "ERK"~e.7))))))

# ::tok Montero @-@ Conde et al. “ Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas.” ( PMC3651738 )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1.1 2-1.2.1.1.1 3-1.2 4-1.2.2.1 6-1.3.1 7-1.3.1.1.r 8-1.3.1.1.3 9-1.3.1.1 10-1.3.1.1.2.r 11-1.3.1.1.2.1.1.1 12-1.3.1.1.2 13-1.3.1.1.1.r 14-1.3.1.1.1.1.1.1.1.1 15-1.3.1.1.1.1.1 16-1.3.1.1.1.1.1.2.1.1 17-1.3.1.1.1 17-1.3.1.1.1.1 17-1.3.1.1.1.1.r 18-1.3 19-1.3.2.1 19-1.3.2.1.r 21-1.3.2 23-1.3.2.3.2.1.1.1.1 24-1.3.2.3.2.1.1 24-1.3.2.3.2.1.1.2 24-1.3.2.3.2.1.1.2.r 25-1.3.2.3.1 28-1.1
# ::id bio.bmtr_0003.1
# ::preferred 
(p / publication-91
      :ARG8 "PMC3651738"~e.28
      :ARG0 (a / and~e.3
            :op1 (p2 / person
                  :name (n / name :op1 "Montero-Conde"~e.0,2))
            :op2 (p3 / person
                  :mod (o / other~e.4)))
      :ARG1 (a3 / attenuate-01~e.18
            :ARG0 (r / relieve-01~e.6
                  :ARG1~e.7 (i / inhibit-01~e.9
                        :ARG0~e.13 (m / molecular-physical-entity~e.17
                              :ARG0-of~e.17 (i2 / inhibit-01~e.17
                                    :ARG1 (a2 / and~e.15
                                          :op1 (e2 / enzyme
                                                :name (n3 / name :op1 "RAF"~e.14))
                                          :op2 (e3 / enzyme
                                                :name (n4 / name :op1 "MEK"~e.16)))))
                        :ARG1~e.10 (t / transcribe-01~e.12
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "HER3"~e.11)))
                        :subevent-of (f / feedback~e.8)))
            :ARG1 (a4 / affect-01~e.21
                  :ARG0~e.19 m~e.19
                  :ARG0-of (c / counter-01
                        :ARG1 (t2 / tumor))
                  :location (c2 / carcinoma
                        :mod (t3 / thyroid~e.25)
                        :ARG1-of (e4 / encode-01
                              :ARG0 (d / DNA
                                    :part (g / gene~e.24
                                          :name (n5 / name :op1 "BRAF"~e.23)
                                          :ARG2-of~e.24 (m2 / mutate-01~e.24))))))))

# ::tok We next examined the mechanisms accounting for the increase in HER3 by MAPK pathway inhibitors in BRAF mutant thyroid cell lines .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.3 2-1 4-1.2 5-1.2.1 6-1.2.1.1.r 8-1.2.1.1 9-1.2.1.1.2.r 10-1.2.1.1.2.1.1 11-1.2.1.1.1.r 12-1.2.1.1.1.1.1.1.1 13-1.2.1.1.1.1.1 14-1.2.1.1.1 14-1.2.1.1.1.1 14-1.2.1.1.1.1.r 15-1.2.1.1.3.r 16-1.2.1.1.3.2.1.1.1.1 17-1.2.1.1.3.2.1.1 17-1.2.1.1.3.2.1.1.2 17-1.2.1.1.3.2.1.1.2.r 18-1.2.1.1.3.1 19-1.2.1.1.3 20-1.2.1.1.3
# ::id bio.bmtr_0003.2
# ::preferred 
(e / examine-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (m / mechanism~e.4
            :ARG0-of (a / account-01~e.5
                  :ARG1~e.6 (i / increase-01~e.8
                        :ARG0~e.11 (m2 / molecular-physical-entity~e.14
                              :ARG0-of~e.14 (i2 / inhibit-01~e.14
                                    :ARG1 (p / pathway~e.13
                                          :name (n2 / name :op1 "MAPK"~e.12))))
                        :ARG1~e.9 (e2 / enzyme
                              :name (n / name :op1 "HER3"~e.10))
                        :location~e.15 (c / cell-line~e.19,20
                              :source (t / thyroid~e.18)
                              :ARG1-of (e3 / encode-01
                                    :ARG0 (d / DNA
                                          :part (g / gene~e.17
                                                :name (n3 / name :op1 "BRAF"~e.16)
                                                :ARG2-of~e.17 (m3 / mutate-01~e.17))))))))
      :time (n4 / next~e.1))

# ::tok Upregulation of HER3 has been found to mediate resistance to PI3K @/@ AKT ( 26 ) or HER2 ( 27 ) inhibitors in HER2 @-@ amplified breast cancer cell lines , which is caused in part through a FoxO3A @-@ dependent induction of HER3 gene transcription .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 5-1 6-1.1.3 7-1.1 8-1.1.2 9-1.1.2.1.r 10-1.1.2.1.1.1.1.1.1 12-1.1.2.1.1.1.1.1.1 14-1.1.2.1.1.1.1.2.1.1.1 16-1.1.2.1.1.1 17-1.1.2.1.1.1.2.1.1 19-1.1.2.1.1.1.2.2.1.1 21-1.1.2.1 21-1.1.2.1.1 21-1.1.2.1.1.r 22-1.1.2.2.r 23-1.1.2.2.2.1 25-1.1.2.2.2 26-1.1.2.2.1.1 27-1.1.2.2.1 28-1.1.2.2 29-1.1.2.2 33-1.1.3 34-1.1.3.2.r 35-1.1.3.2 38-1.1.3.1.2.1.1.1 40-1.1.3.1.2 41-1.1.3.1 42-1.1.3.1.1.r 43-1.1.3.1.1.1.1.1 44-1.1.3.1.1.1 45-1.1.3.1.1
# ::id bio.bmtr_0003.3
# ::preferred 
(f / find-01~e.5
      :ARG1 (m / mediate-01~e.7
            :ARG0 (u / upregulate-01~e.0
                  :ARG1~e.1 (e / enzyme
                        :name (n / name :op1 "HER3"~e.2)))
            :ARG1 (r / resist-01~e.8
                  :ARG1~e.9 (m2 / molecular-physical-entity~e.21
                        :ARG0-of~e.21 (i / inhibit-01~e.21
                              :ARG1 (o / or~e.16
                                    :op1 (p / pathway
                                          :name (n2 / name :op1 "PI3K/AKT"~e.10,12)
                                          :ARG1-of (d / describe-01
                                                :ARG0 (p2 / publication
                                                      :ARG1-of (c / cite-01 :ARG2 "26"~e.14))))
                                    :op2 (e2 / enzyme
                                          :name (n3 / name :op1 "HER2"~e.17)
                                          :ARG1-of (d2 / describe-01
                                                :ARG1-of (c2 / cite-01 :ARG2 "27"~e.19))))))
                  :location~e.22 (c3 / cell-line~e.28,29
                        :source (c4 / cancer~e.27
                              :mod (b / breast~e.26))
                        :mod (a / amplify-01~e.25
                              :ARG0 e2~e.23)))
            :ARG1-of (c5 / cause-01~e.6,33
                  :ARG0 (i2 / induce-01~e.41
                        :ARG1~e.42 (t / transcribe-01~e.45
                              :ARG1 (g / gene~e.44
                                    :ARG0-of (e3 / encode-01
                                          :ARG1 e~e.43)))
                        :ARG0-of (d3 / depend-01~e.40
                              :ARG1 (p3 / protein
                                    :name (n4 / name :op1 "FoxO3A"~e.38))))
                  :degree~e.34 (p4 / part~e.35))))

# ::tok As shown in Fig. 5A , PLX4032 treatment increased HER3 and HER2 mRNAs in all six BRAF @-@ mutant thyroid cancer cell lines tested .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 4-1.4.1.1 6-1.1.1.1.1 7-1.1 8-1 9-1.2.1.1.1.1.1 10-1.2.1.1 11-1.2.1.1.2.1.1 12-1.2 13-1.3.r 14-1.3.3 15-1.3.1 16-1.3.2.1.1.1.1.1 18-1.3.2.1.1.1 18-1.3.2.1.1.1.2 18-1.3.2.1.1.1.2.r 19-1.3.2 20-1.3.5 21-1.3 22-1.3 23-1.3.4
# ::id bio.bmtr_0003.4
# ::preferred 
(i / increase-01~e.8
      :ARG0 (t / treat-04~e.7
            :ARG2 (s / small-molecule
                  :name (n / name :op1 "PLX4032"~e.6)))
      :ARG1 (m / mRNA~e.12
            :ARG0-of (e / encode-01
                  :ARG1 (a / and~e.10
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "HER3"~e.9))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "HER2"~e.11)))))
      :location~e.13 (c / cell-line~e.21,22
            :quant "6"~e.15
            :source (t2 / thyroid~e.19
                  :ARG1-of (e4 / encode-01
                        :ARG0 (d / DNA
                              :part (g / gene~e.18
                                    :name (n4 / name :op1 "BRAF"~e.16)
                                    :ARG2-of~e.18 (m2 / mutate-01~e.18)))))
            :mod (a2 / all~e.14)
            :ARG1-of (t3 / test-01~e.23)
            :mod (c2 / cancer~e.20))
      :ARG1-of (s2 / show-01~e.1
            :ARG0 (f / figure :mod "5A"~e.4)))

# ::tok Similar results were found following treatment with the MEK inhibitor AZD6244 ( not shown ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2 5-1.2.1 6-1.2.1.1.r 8-1.2.1.1.2.1.1.1 9-1.2.1.1 9-1.2.1.1.2 9-1.2.1.1.2.r 10-1.2.1.1.1.1 12-1.2.1.1.3.1 12-1.2.1.1.3.1.r 13-1.2.1.1.3
# ::id bio.bmtr_0003.5
# ::preferred 
(f / find-01~e.3
      :ARG1 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :ARG1-of (r2 / resemble-01~e.0))
      :ARG1-of (f2 / follow-01~e.4
            :ARG2 (t2 / treat-04~e.5
                  :ARG2~e.6 (s / small-molecule~e.9
                        :name (n / name :op1 "AZD6244"~e.10)
                        :ARG0-of~e.9 (i / inhibit-01~e.9
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "MEK"~e.8)))
                        :ARG1-of (s2 / show-01~e.13 :polarity~e.12 "-"~e.12)))))

# ::tok The effects of the MEK inhibitor on total HER2 , HER3 protein and on pHER3 were dose dependent , and inversely associated with the degree of inhibition of pERK ( Fig . 5B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1.1.1.r 4-1.1.1.1.1.1.1.1 5-1.1.1.1 5-1.1.1.1.1 5-1.1.1.1.1.r 6-1.1.1.2.r 7-1.1.1.2.1.2 8-1.1.1.2.1.1.1 10-1.1.1.2.2.1.1 10-1.1.1.2.3.1.1 12-1.1.1.2 16-1.1.2 17-1.1 19-1 20-1.2.3 21-1.2 22-1.2.2.r 24-1.2.2.1.r 26-1.2.2.1 32-1.3.1.1
# ::id bio.bmtr_0003.6
# ::preferred 
(a / and~e.19
      :op1 (d / depend-01~e.17
            :ARG0 (a2 / affect-01~e.1
                  :ARG0~e.2 (m / molecular-physical-entity~e.5
                        :ARG0-of~e.5 (i / inhibit-01~e.5
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "MEK"~e.4))))
                  :ARG1~e.6 (a3 / and~e.12
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "HER2"~e.8)
                              :mod (t / total~e.7))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "HER3"~e.10))
                        :op3 (e4 / enzyme
                              :name (n4 / name :op1 "HER3"~e.10)
                              :ARG3-of (p / phosphorylate-01))))
            :ARG1 (d2 / dose-01~e.16))
      :op2 (a4 / associate-01~e.21
            :ARG1 a2
            :ARG2~e.22 (t2 / thing
                  :degree-of~e.24 (i2 / inhibit-01~e.26
                        :ARG1 (e5 / enzyme
                              :name (n5 / name :op1 "ERK")
                              :ARG1-of p)))
            :mod (i3 / inverse~e.20))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "5B"~e.32)))

# ::tok RAF or MEK inhibitors induced luciferase activity of a HER3 promoter construct spanning ~ 1 kb upstream of the transcriptional start site in 8505C cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1.1 1-1.1 2-1.1.2.1.1.1.1 3-1.1.1 3-1.1.1.1 3-1.1.1.1.r 3-1.1.2 3-1.1.2.1 3-1.1.2.1.r 4-1 5-1.2.2 9-1.2.1.1.1.1.1 11-1.2.1 12-1.2.1.2 14-1.2.1.2.2.1.1 16-1.2.1.2.1.2 20-1.2.1.2.1.1.1 21-1.2.1.2.1.1 22-1.2.1.2.3.r 23-1.2.1.2.3.1.1 24-1.2.1.2.3
# ::id bio.bmtr_0003.7
# ::preferred 
(i / induce-01~e.4
      :ARG0 (o / or~e.1
            :op1 (m / molecular-physical-entity~e.3
                  :ARG0-of~e.3 (i2 / inhibit-01~e.3
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "RAF"~e.0))))
            :op2 (m2 / molecular-physical-entity~e.3
                  :ARG0-of~e.3 (i3 / inhibit-01~e.3
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "MEK"~e.2)))))
      :ARG1 (a / act-01
            :ARG0 (c / construct-01~e.11
                  :ARG0-of (p / promote-01
                        :ARG1 (e3 / enzyme
                              :name (n3 / name :op1 "HER3"~e.9)))
                  :ARG1-of (s / span-01~e.12
                        :location (r / relative-position
                              :op1 (s2 / site~e.21
                                    :location-of (s3 / start-01~e.20
                                          :ARG1 (t / transcribe-01)))
                              :direction (u / upstream~e.16))
                        :quant (a2 / approximately
                              :op1 (d / distance-quantity
                                    :quant "1"~e.14
                                    :unit (k / kilo-base-pair)))
                        :location~e.22 (c2 / cell~e.24
                              :name (n5 / name :op1 "8505C"~e.23))))
            :ARG1 (l / luciferase~e.5)))

# ::tok Serial deletions identified a minimal HER3 promoter retaining transcriptional response to vemurafenib and AZD6244 , which was located between -@ 401 and -@ 42 bp ( Fig . 5C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2.2 5-1.2.1.1.1.1 7-1.2.3 9-1.2.3.1 9-1.2.3.1.1 9-1.2.3.1.1.r 10-1.2.3.1.1.1.r 11-1.2.3.1.1.1.1.1.1 12-1.2.3.1.1.1 13-1.2.3.1.1.1.2.1.1 17-1.2.4.r 18-1.2.4 20-1.2.4.1.1 21-1.2.4 23-1.2.4.2.1 28-1.3.1.1
# ::id bio.bmtr_0003.8
# ::preferred 
(i / identify-01~e.2
      :ARG0 (d / delete-01~e.1
            :manner (s / serial~e.0))
      :ARG1 (m / molecular-physical-entity
            :ARG0-of (p / promote-01
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "HER3"~e.5)))
            :mod (m2 / minimal~e.4)
            :ARG0-of (r / retain-01~e.7
                  :ARG1 (t / thing~e.9
                        :ARG2-of~e.9 (r2 / respond-01~e.9
                              :ARG1~e.10 (a / and~e.12
                                    :op1 (s2 / small-molecule
                                          :name (n2 / name :op1 "vemurafenib"~e.11))
                                    :op2 (s3 / small-molecule
                                          :name (n3 / name :op1 "AZD6244"~e.13))))
                        :mod (t2 / transcribe-01)))
            :location~e.17 (b / between~e.18,21
                  :op1 (d2 / distance-quantity
                        :quant "-401"~e.20
                        :unit (b2 / base-pair))
                  :op2 (d3 / distance-quantity
                        :quant "-42"~e.23
                        :unit (b3 / base-pair))))
      :ARG1-of (d4 / describe-01
            :ARG0 (f / figure :mod "5C"~e.28)))

# ::tok This region does not contain any predicted FoxO binding sites .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2 3-1.1 3-1.1.r 4-1 5-1.3.4 6-1.3.3 7-1.3.1.1.1 8-1.3.2 9-1.3
# ::id bio.bmtr_0003.9
# ::preferred 
(c / contain-01~e.4
      :polarity~e.3 "-"~e.3
      :ARG0 (r / region~e.1
            :mod (t / this~e.0))
      :ARG1 (p3 / protein-segment~e.9
            :part-of (p / protein
                  :name (n / name :op1 "FoxO"~e.7))
            :ARG1-of (b / bind-01~e.8)
            :ARG1-of (p2 / predict-01~e.6)
            :mod (a / any~e.5)))

# ::tok Moreover , PLX4032 led to an increase in phosphorylation of FoxO1 @/@ 3A between 4–10h after addition of compound ( not shown ) , which is known to promote its dissociation from DNA , and likely discards involvement of these factors as transcriptional regulators of HER3 in response to MAPK pathway inhibition .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1 3-1.1 6-1.1.2 7-1.1.2.1.r 8-1.1.2.1 9-1.1.2.1.1.r 10-1.1.2.1.1.1.1 12-1.1.2.1.1.1.1 13-1.1.2.2.2 15-1.1.2.2 16-1.1.2.2.1 17-1.1.2.2.1.1.r 18-1.1.2.2.1.1 20-1.1.2.3.1 20-1.1.2.3.1.r 21-1.1.2.3 26-1.1.2.4.2 28-1.1.2.4 29-1.1.2.4.1.1 29-1.1.2.4.1.1.r 30-1.1.2.4.1 31-1.1.2.4.1.2.r 32-1.1.2.4.1.2 34-1.1.2.2.2 35-1.1.2.5.2 36-1.1.2.5 37-1.1.2.5.1 38-1.1.2.5.1.1.r 39-1.1.2.5.1.1.1 40-1.1.2.5.1.1 41-1.1.2.2.r 43-1.1.2.5.1.2 43-1.1.2.5.1.2.1 43-1.1.2.5.1.2.1.r 44-1.1.2.5.1.2.1.1.r 45-1.1.2.5.1.2.1.1.1.1 46-1.1.2.5.3.r 47-1.1.2.5.3 48-1.1.2.5.3.1.r 49-1.1.2.5.3.1.1.1.1 50-1.1.2.5.3.1.1 51-1.1.2.5.3.1
# ::id bio.bmtr_0003.10
# ::preferred 
(a / and
      :op2 (l / lead-03~e.3
            :ARG0 (s / small-molecule
                  :name (n / name :op1 "PLX4032"~e.2))
            :ARG1 (i / increase-01~e.6
                  :ARG1~e.7 (p / phosphorylate-01~e.8
                        :ARG1~e.9 (p2 / protein
                              :name (n2 / name :op1 "FoxO1/3A"~e.10,12)))
                  :time~e.41 (a2 / after~e.15
                        :op1 (a3 / add-02~e.16
                              :ARG1~e.17 (c / compound~e.18))
                        :quant (b / between~e.13,34
                              :op1 (t / temporal-quantity
                                    :quant "4"
                                    :unit (h / hour))
                              :op2 (t2 / temporal-quantity
                                    :quant "10"
                                    :unit (h2 / hour))))
                  :ARG1-of (s2 / show-01~e.21 :polarity~e.20 "-"~e.20)
                  :ARG0-of (p3 / promote-01~e.28
                        :ARG1 (d / dissociate-01~e.30
                              :ARG1~e.29 p2~e.29
                              :ARG2~e.31 (d2 / DNA~e.32))
                        :ARG1-of (k / know-01~e.26))
                  :ARG0-of (d3 / discard-01~e.36
                        :ARG1 (i2 / involve-01~e.37
                              :ARG1~e.38 (f / factor~e.40
                                    :mod (t3 / this~e.39))
                              :mod (m / molecular-physical-entity~e.43
                                    :ARG0-of~e.43 (r / regulate-01~e.43
                                          :ARG1~e.44 (e / enzyme
                                                :name (n3 / name :op1 "HER3"~e.45)))
                                    :mod (t4 / transcribe-01)))
                        :mod (l2 / likely~e.35)
                        :ARG2-of~e.46 (r2 / respond-01~e.47
                              :ARG1~e.48 (i3 / inhibit-01~e.51
                                    :ARG1 (p4 / pathway~e.50
                                          :name (n4 / name :op1 "MAPK"~e.49))))))))

# ::tok The minimal HER3 promoter region regulated by MAPK inhibitors overlaps with sequences previously described to be immunoprecipitated using antibodies against the ZFN217 transcription factor and CtBP1 @/@ CtBP2 corepressors ( 28–30 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.2 2-1.1.1.1.1.1.1 4-1.1 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.1.1.1 8-1.1.2.1 8-1.1.2.1.1 8-1.1.2.1.1.r 9-1 10-1.2.r 11-1.2 12-1.2.1.2.1 13-1.2.1.2 13-1.3 17-1.2.1.1 18-1.2.1.1.1 19-1.2.1.1.1.1 21-1.2.1.1.1.1.1.1.1.1.1.1 22-1.2.1.1.1.1.1.1.1 23-1.2.1.1.1.1.1.1 24-1.2.1.1.1.1.1 25-1.2.1.1.1.1.1.2.1.1.1 27-1.2.1.1.1.1.1.2.2.1.1
# ::id bio.bmtr_0003.11
# ::preferred 
(o / overlap-01~e.9
      :ARG0 (r / region~e.4
            :mod (m2 / molecular-physical-entity
                  :ARG0-of (p / promote-01
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "HER3"~e.2))
                        :mod (m / minimal~e.1)))
            :ARG1-of (r2 / regulate-01~e.5
                  :ARG0~e.6 (m3 / molecular-physical-entity~e.8
                        :ARG0-of~e.8 (i / inhibit-01~e.8
                              :ARG1 (p2 / pathway
                                    :name (n2 / name :op1 "MAPK"~e.7))))))
      :ARG1~e.10 (s / sequence~e.11
            :ARG1-of (i2 / immunoprecipitate-00
                  :ARG2-of (u / use-01~e.17
                        :ARG1 (a / antibody~e.18
                              :ARG0-of (o2 / oppose-01~e.19
                                    :ARG1 (a2 / and~e.24
                                          :op1 (f / factor~e.23
                                                :ARG0-of (t / transcribe-01~e.22
                                                      :ARG1 (e2 / enzyme
                                                            :name (n3 / name :op1 "ZFN217"~e.21))))
                                          :op2 (o3 / or
                                                :op1 (c / corepressor
                                                      :name (n4 / name :op1 "CtBP1"~e.25))
                                                :op2 (c2 / corepressor
                                                      :name (n5 / name :op1 "CtBP2"~e.27)))))))
                  :ARG1-of (d / describe-01~e.13
                        :time (p4 / previous~e.12))))
      :ARG1-of (d2 / describe-01~e.13
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (v / value-interval :op1 "28" :op2 "30")))))

# ::tok CtBPs have also been described to negatively regulate transcriptional activity of the HER3 promoter in breast carcinoma cell lines ( 30 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3 4-1 4-1.4 4-1.4.r 6-1.2.3 6-1.2.3.r 7-1.2 12-1.2.2.1.1.1.1.1 14-1.2.4.r 15-1.2.4.1.1 16-1.2.4.1 17-1.2.4 18-1.2.4 20-1.4.1.1.1
# ::id bio.bmtr_0003.12
# ::preferred 
(d / describe-01~e.4
      :ARG1 (p / protein
            :name (n / name :op1 "CtBP"))
      :ARG2 (r / regulate-01~e.7
            :ARG0 p
            :ARG1 (a2 / act-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (p2 / promote-01
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "HER3"~e.12))))
                  :ARG1 (t / transcribe-01))
            :manner~e.6 (n3 / negative~e.6)
            :location~e.14 (c / cell-line~e.17,18
                  :mod (c2 / carcinoma~e.16
                        :mod (b / breast~e.15))))
      :mod (a / also~e.2)
      :ARG1-of~e.4 (d2 / describe-01~e.4
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "30"~e.20))))

# ::tok Silencing of CtBP1 , and to a lesser extent CtBP2 , increased basal HER3 in 8505C cells , and markedly potentiated the effects of PLX4032 ( Fig . 5D and 5E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1.1 4-1.1.1.1 7-1.1.1.1.2.2 7-1.1.1.1.2.2.1 7-1.1.1.1.2.2.1.r 9-1.1.1.1.2.1.1 11-1.1 12-1.1.2.2 13-1.1.2.1.1 14-1.1.3.r 15-1.1.3.1.1 16-1.1.3 18-1 18-1.3.1 19-1.2.3 19-1.2.3.r 22-1.2.2 23-1.2.2.1.r 24-1.2.2.1.1.1 28-1.3.1.1.1 29-1.3.1 30-1.3.1.2.1
# ::id bio.bmtr_0003.13
# ::preferred 
(a / and~e.18
      :op1 (i / increase-01~e.11
            :ARG0 (s / silence-01~e.0
                  :ARG1~e.1 (a2 / and~e.4
                        :op1 (p / protein
                              :name (n / name :op1 "CtBP1"~e.2))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "CtBP2"~e.9)
                              :degree (l / less~e.7
                                    :degree~e.7 (m / more~e.7)))))
            :ARG1 (e / enzyme
                  :name (n3 / name :op1 "HER3"~e.13)
                  :mod (b / basal~e.12))
            :location~e.14 (c / cell~e.16
                  :name (n4 / name :op1 "8505C"~e.15)))
      :op2 (p3 / potentiate-00
            :ARG0 s
            :ARG1 (a3 / affect-01~e.22
                  :ARG0~e.23 (s2 / small-molecule
                        :name (n5 / name :op1 "PLX4032"~e.24)))
            :manner~e.19 (m2 / marked~e.19))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and~e.18,29
                  :op1 (f / figure :mod "5D"~e.28)
                  :op2 (f2 / figure :mod "5E"~e.30))))

# ::tok Knockdown of these factors modestly increased basal and PLX4032 @-@ induced HER2 levels , which likely contributes to the remarkable increase in pHER3 we observed ( Fig . 5D and 5E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1 3-1.1.1 4-1.3 5-1 6-1.2.1.1.2 7-1.2 8-1.2.2.1.2.1.1.1 10-1.2.2.1.2 11-1.2.1.1.1.1 11-1.2.2.1.1.1 12-1.2.1 12-1.2.2 15-1.4.2 16-1.4 19-1.4.1.2 20-1.4.1 23-1.4.1.3.1 24-1.4.1.3 28-1.5.1.1.1 29-1.5.1 30-1.5.1.2.1
# ::id bio.bmtr_0003.14
# ::preferred 
(i / increase-01~e.5
      :ARG0 (k / knock-02
            :ARG1 (f / factor~e.3
                  :mod (t / this~e.2)))
      :ARG1 (a / and~e.7
            :op1 (l2 / level~e.12
                  :mod (e / enzyme
                        :name (n / name :op1 "HER2"~e.11)
                        :mod (b / basal~e.6)))
            :op2 (l3 / level~e.12
                  :mod (e2 / enzyme
                        :name (n2 / name :op1 "HER2"~e.11)
                        :ARG1-of (i2 / induce-01~e.10
                              :ARG0 (s / small-molecule
                                    :name (n3 / name :op1 "PLX4032"~e.8))))))
      :degree (m / modest~e.4)
      :ARG0-of (c / contribute-01~e.16
            :ARG1 (i3 / increase-01~e.20
                  :ARG1 (e3 / enzyme
                        :name (n4 / name :op1 "HER3")
                        :ARG3-of (p / phosphorylate-01))
                  :mod (r / remarkable~e.19)
                  :ARG1-of (o / observe-01~e.24
                        :ARG0 (w / we~e.23)))
            :mod (l / likely~e.15))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.29
                  :op1 (f2 / figure :mod "5D"~e.28)
                  :op2 (f3 / figure :mod "5E"~e.30))))

# ::tok Finally , CtBP1 and CtBP2 chromatin immunoprecipitation assays showed decreased binding to the HER3 promoter after treatment with PLX4032 ( Fig . 5F ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.1.1.1.1.1 3-1.1.1.1 4-1.1.1.1.2.1.1 5-1.1.1.2 7-1.1 8-1 9-1.2.2 10-1.2 11-1.2.1.r 13-1.2.1.1.1.1.1 15-1.2.2.1 16-1.2.2.1.1 17-1.2.2.1.1.1.r 18-1.2.2.1.1.1.1.1 22-1.4.1.1
# ::id bio.bmtr_0003.15
# ::preferred 
(s / show-01~e.8
      :ARG0 (a / assay-00~e.7
            :ARG1 (i / immunoprecipitate-00
                  :ARG1 (a2 / and~e.3
                        :op1 (p / protein
                              :name (n / name :op1 "CtBP1"~e.2))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "CtBP2"~e.4)))
                  :mod (c / chromatin~e.5)))
      :ARG1 (b / bind-01~e.10
            :ARG2~e.11 (m / molecular-physical-entity
                  :ARG0-of (p3 / promote-01
                        :ARG1 (e / enzyme
                              :name (n3 / name :op1 "HER3"~e.13))))
            :ARG1-of (d / decrease-01~e.9
                  :time (a3 / after~e.15
                        :op1 (t / treat-04~e.16
                              :ARG2~e.17 (s2 / small-molecule
                                    :name (n4 / name :op1 "PLX4032"~e.18))))))
      :time (f / final~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "5F"~e.22)))

# ::tok These findings were confirmed in a second cell line ( Supplementary Fig. S5A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2.r 6-1.2.1 6-1.2.1.1 6-1.2.1.1.r 7-1.2 8-1.2 12-1.3.1.1
# ::id bio.bmtr_0003.16
# ::preferred 
(c / confirm-01~e.3
      :ARG0 (t / thing~e.1
            :ARG1-of~e.1 (f / find-01~e.1)
            :mod (t2 / this~e.0))
      :location~e.4 (c2 / cell-line~e.7,8
            :ord (o / ordinal-entity~e.6 :value~e.6 "2"~e.6))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure
                  :mod "S5A"~e.12
                  :ARG2-of (s / supplement-01))))

# ::tok The increase in expression of HER3 after MAPK inhibition is due to activation of gene transcription , which was associated with a reduction of binding of the transcriptional repressors CTBP1 and CTBP2 to the HER3 gene promoter .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1.2.1.r 3-1.2.1 4-1.2.1.1.r 5-1.2.1.1.1.1 6-1.2.2 7-1.2.2.1.1.1.1 8-1.2.2.1 10-1 11-1 12-1.1 14-1.1.1.1 15-1.1.1 15-1.1.2.1.1.1.3 19-1.1.2 20-1.1.2.1.r 22-1.1.2.1 23-1.1.2.1.1.r 24-1.1.2.1.1 28-1.1.2.1.1.1.1 28-1.1.2.1.1.1.1.2 28-1.1.2.1.1.1.1.2.r 29-1.1.2.1.1.1.1.1.1 30-1.1.2.1.1.1 31-1.1.2.1.1.1.2.1.1 32-1 34-1.2.1.1.1.1 35-1.1.1.1 35-1.1.2.1.1.2.1.1
# ::id bio.bmtr_0003.17
# ::preferred 
(c / cause-01~e.10,11,32
      :ARG0 (a2 / activate-01~e.12
            :ARG1 (t / transcribe-01~e.15
                  :ARG1 (g / gene~e.14,35))
            :ARG1-of (a3 / associate-01~e.19
                  :ARG2~e.20 (r / reduce-01~e.22
                        :ARG1~e.23 (b / bind-01~e.24
                              :ARG1 (a4 / and~e.30
                                    :op1 (p3 / protein~e.28
                                          :name (n3 / name :op1 "CTBP1"~e.29)
                                          :ARG0-of~e.28 (r2 / repress-01~e.28))
                                    :op2 (p4 / protein
                                          :name (n4 / name :op1 "CTBP2"~e.31)
                                          :ARG0-of r2)
                                    :ARG0-of (t2 / transcribe-01~e.15))
                              :ARG2 (m / molecular-physical-entity
                                    :ARG0-of (p2 / promote-01
                                          :ARG1 (g2 / gene~e.35
                                                :ARG0-of (e3 / encode-01
                                                      :ARG1 (e2 / enzyme
                                                            :name (n / name :op1 "HER3"~e.5,34))))))))))
      :ARG1 (i / increase-01~e.1
            :ARG1~e.2 (e / express-03~e.3
                  :ARG1~e.4 e2)
            :time (a / after~e.6
                  :op1 (i2 / inhibit-01~e.8
                        :ARG1 (p / pathway
                              :name (n2 / name :op1 "MAPK"~e.7))))))

# ::tok These corepressors have been previously linked to inhibition of HER3 transcription through promoter regions that show overlapping occupancy with ZNF217 , a transcription factor also involved in HER3 regulation ( 30 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 4-1.3 5-1 6-1.1.r 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1.1.1 10-1.1.2.1 13-1.2 15-1.2.2 16-1.2.2.1.3 19-1.2.2.1.1.1.1 22-1.2.2.1.1.2.1 23-1.2.2.1.1.2 24-1.2.2.1.1.2.2.2 25-1.2.2.1.1.2.2 26-1.2.2.1.1.2.2.1.r 27-1.2.2.1.1.2.2.1.1 28-1.2.2.1.1.2.2.1 30-1.4.1.1.1
# ::id bio.bmtr_0003.18
# ::preferred 
(l / link-01~e.5
      :ARG1~e.6 (a / and
            :op1 (c / corepressor
                  :mod (t / this~e.0))
            :op2 (i / inhibit-01~e.7
                  :ARG1~e.8 (t2 / transcribe-01~e.10
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "HER3"~e.9)))))
      :ARG2 (r / region~e.13
            :ARG0-of (p2 / promote-01)
            :ARG0-of (s / show-01~e.15
                  :ARG1 (o / occupy-01
                        :ARG0 (p3 / protein
                              :name (n2 / name :op1 "ZNF217"~e.19)
                              :mod (f / factor~e.23
                                    :ARG0-of (t3 / transcribe-01~e.22)
                                    :ARG1-of (i2 / involve-01~e.25
                                          :ARG2~e.26 (r2 / regulate-01~e.28
                                                :ARG1 e~e.27)
                                          :mod (a2 / also~e.24))))
                        :ARG1 r
                        :ARG0-of (o2 / overlap-01~e.16))))
      :time (p / previous~e.4)
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "30"~e.30))))

# ::tok Accordingly , knockdown of CTBPs acutely induced HER3 expression and phosphorylation in thyroid cancer cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 5-1.3 5-1.3.r 6-1 7-1.2.1.1.1.1 8-1.2.1 9-1.2 10-1.2.2 11-1.2.r 12-1.2.3.2 13-1.2.3.1 14-1.2.3
# ::id bio.bmtr_0003.19
# ::preferred 
(i / induce-01~e.6
      :ARG0 (k / knock-02
            :ARG1 (p / protein
                  :name (n / name :op1 "CTBP")))
      :ARG1~e.11 (a2 / and~e.9
            :op1 (e / express-03~e.8
                  :ARG1 (e2 / enzyme
                        :name (n2 / name :op1 "HER3"~e.7)))
            :op2 (p2 / phosphorylate-01~e.10
                  :ARG1 e2)
            :location (c / cell~e.14
                  :mod (c2 / cancer~e.13)
                  :source (t / thyroid~e.12)))
      :manner~e.5 (a / acute~e.5)
      :manner (a3 / accordingly~e.0))

# ::tok MAPK inhibition may dictate a chromatin redistribution of these repressors , and thus activate HER3 transcription .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 2-1 3-1.1 5-1.1.2.2 6-1.1.2 7-1.1.2.1.r 8-1.1.2.1.1 9-1.1.2.1 9-1.1.2.1.2 9-1.1.2.1.2.r 12-1.2 13-1.2.1 14-1.2.1.2.1.1.1 15-1.2.1.2
# ::id bio.bmtr_0003.20
# ::preferred 
(p / possible~e.2
      :domain (d / dictate-01~e.3
            :ARG0 (i / inhibit-01~e.1
                  :ARG1 (p2 / pathway
                        :name (n / name :op1 "MAPK"~e.0)))
            :ARG1 (r / redistribute-01~e.6
                  :ARG1~e.7 (m / molecular-physical-entity~e.9
                        :mod (t / this~e.8)
                        :ARG0-of~e.9 (r2 / repress-01~e.9))
                  :mod (c / chromatin~e.5)))
      :ARG0-of (c2 / cause-01~e.12
            :ARG1 (a2 / activate-01~e.13
                  :ARG0 i
                  :ARG1 (t2 / transcribe-01~e.15
                        :ARG1 (e / enzyme
                              :name (n2 / name :op1 "HER3"~e.14))))))

# ::tok The biochemical mechanisms involved in delocalization of CtBPs by MAPK inhibition have not been explored , but posttranslational modifications are known to regulate the repressive activity of CtBPs either by translocation to the cytoplasm or by targeting them for degradation ( 36 , 37 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1 2-1.1.2 3-1.1.2.2 9-1.1.2.2.1.1.1.1.1 10-1.1.2.2.1.1 12-1.1.1 12-1.1.1.r 14-1.1 16-1 18-1.2.1.1 20-1.2 22-1.2.1 24-1.2.1.2.2 25-1.2.1.2 29-1.2.1.3.r 30-1.2.1.3.1 31-1.2.1.3.1.2.r 33-1.2.1.3.1.2 34-1.2.1.3 36-1.2.1.3.2 38-1.2.1.3.2.2.r 39-1.2.1.3.2.2 41-1.3.1.1.1.1 43-1.3.1.1.1.2
# ::id bio.bmtr_0003.21
# ::preferred 
(c / contrast-01~e.16
      :ARG1 (e / explore-01~e.14
            :polarity~e.12 "-"~e.12
            :ARG1 (m / mechanism~e.2
                  :mod (b / biochemical~e.1)
                  :ARG1-of (i / involve-01~e.3
                        :ARG2 (d / delocalize-00
                              :ARG0 (i2 / inhibit-01~e.10
                                    :ARG1 (p / pathway
                                          :name (n / name :op1 "MAPK"~e.9)))
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "CtBP"))))))
      :ARG2 (k / know-01~e.20
            :ARG1 (r / regulate-01~e.22
                  :ARG0 (m2 / modify-01~e.18
                        :time (a3 / after
                              :op1 (t3 / translation)))
                  :ARG1 (a / act-02~e.25
                        :ARG0 p2
                        :mod (r2 / repress-01~e.24))
                  :manner~e.29 (o / or~e.34
                        :op1 (t / translocate-00~e.30
                              :ARG1 p2
                              :location~e.31 (c2 / cytoplasm~e.33))
                        :op2 (t2 / target-01~e.36
                              :ARG1 p2
                              :purpose~e.38 (d2 / degrade-01~e.39
                                    :ARG1 p2)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (a2 / and :op1 "36"~e.41 :op2 "37"~e.43)))))

# ::tok We identify four S/TP sites of B @-@ Raf phosphorylated by activated ERK and find that feedback phosphorylation of B @-@ Raf inhibits binding to activated Ras and disrupts heterodimerization with C @-@ Raf , which is dependent on the B @-@ Raf pS729 @/@ 14 @-@ 3 @-@ 3 binding site .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1 4-1.1.2 6-1.1.2.3.1.1 8-1.1.2.3.1.1 9-1.1.2.2.1 11-1.1.2.2.1.1.2 12-1.1.2.2.1.1.1.1 13-1 14-1.2 16-1.1.2.2.1.2 17-1.1.2.2.1 17-1.2.2.2.2.3.1.3 19-1.1.2.3.1.1 21-1.1.2.3.1.1 22-1.2.2.1 23-1.2.2.1.2 25-1.2.2.1.2.2.2 26-1.2.2.1.2.2.1.1 27-1.2.2 28-1.2.2.2 29-1.2.2.2.2 30-1.2.2.2.2.2.r 31-1.2.2.2.2.2.1.1 33-1.2.2.2.2.2.1.1 37-1.2.2.2.2.3 40-1.1.2.3.1.1 42-1.1.2.3.1.1 42-1.2.2.2.2.2.1.1 45-1.2.2.2.2.3.1.4.1.1.1 47-1.2.2.2.2.3.1.4.1.1.1 49-1.2.2.2.2.3.1.4.1.1.1 50-1.2.2.1.2 50-1.2.2.2.2.3.1.4 51-1.1.2
# ::id bio.mskcc_0001.1
# ::preferred 
(a / and~e.13
      :op1 (i / identify-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (p / protein-segment~e.4,51
                  :quant "4"~e.2
                  :part (a5 / amino-acid
                        :ARG3-of (p2 / phosphorylate-01~e.9,17
                              :ARG2 (e / enzyme
                                    :name (n3 / name :op1 "ERK"~e.12)
                                    :ARG1-of (a2 / activate-01~e.11))
                              :subevent-of (f2 / feedback~e.16))
                        :mod (o / or
                              :op1 (a6 / amino-acid
                                    :name (n / name :op1 "serine"))
                              :op2 (a7 / amino-acid
                                    :name (n9 / name :op1 "threonine"))))
                  :part-of (e4 / enzyme
                        :name (n2 / name :op1 "B-Raf"~e.6,8,19,21,40,42))))
      :op2 (f / find-01~e.14
            :ARG0 w
            :ARG1 (a3 / and~e.27
                  :op1 (i2 / inhibit-01~e.22
                        :ARG0 p2
                        :ARG1 (b / bind-01~e.23,50
                              :ARG1 e4
                              :ARG2 (e3 / enzyme
                                    :name (n4 / name :op1 "Ras"~e.26)
                                    :ARG1-of (a4 / activate-01~e.25))))
                  :op2 (d / disrupt-01~e.28
                        :ARG0 p2
                        :ARG1 (h / heterodimerize-00~e.29
                              :ARG1 e4
                              :ARG2~e.30 (e2 / enzyme
                                    :name (n5 / name :op1 "C-Raf"~e.31,33,42))
                              :ARG0-of (d2 / depend-01~e.37
                                    :ARG1 (a8 / amino-acid
                                          :mod "729"
                                          :name (n10 / name :op1 "serine")
                                          :ARG3-of (p4 / phosphorylate-01~e.17)
                                          :ARG1-of (b2 / bind-01~e.50
                                                :ARG2 (p3 / protein
                                                      :name (n6 / name :op1 "14-3-3"~e.45,47,49)))
                                          :part-of e4)))))))

# ::tok 14 @-@ 3 @-@ 3 dimers bind to phosphorylation sites present in both the N @- and C @-@ terminal regions and stabilize the autoinhibited state ( 22 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 4-1.1.1.1.1 5-1.1.1 6-1.1 6-1.2 8-1.1.2.1 8-1.2.2.1 9-1.1.2 9-1.2.2 9-1.3.2.1 9-1.3.2.2 14-1.1.2.2.1.1 16-1 17-1.2.2.2.1.1 19-1.1.2.2.1.1 19-1.2.2.2.1.1 21-1 22-1.3 27-1.4.1.1.1
# ::id bio.mskcc_0001.2
# ::preferred 
(a / and~e.16,21
      :op1 (b / bind-01~e.6
            :ARG1 (d / dimer~e.5
                  :name (n / name :op1 "14-3-3"~e.0,2,4))
            :ARG2 (p9 / protein-segment~e.9
                  :ARG1-of (p / phosphorylate-01~e.8)
                  :part-of (p2 / protein-segment
                        :name (n2 / name :op1 "N-terminus"~e.14,19)
                        :part-of (p5 / protein))))
      :op2 (b2 / bind-01~e.6
            :ARG1 d
            :ARG2 (p10 / protein-segment~e.9
                  :ARG1-of (p3 / phosphorylate-01~e.8)
                  :part-of (p4 / protein-segment
                        :name (n3 / name :op1 "C-terminus"~e.17,19)
                        :part-of p5)))
      :op3 (s3 / stabilize-01~e.22
            :ARG0 d
            :ARG1 (i / inhibit-01
                  :ARG0 (p6 / protein-segment~e.9
                        :part-of p5)
                  :ARG1 (p7 / protein-segment~e.9
                        :part-of p5)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p8 / publication
                  :ARG1-of (c / cite-01 :ARG2 "22"~e.27))))

# ::tok To activate the Raf proteins , autoinhibition mediated by the N terminus must be relieved and the kinase domain must adopt the active catalytic conformation
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.1 1-1.2.2 3-1.1.1.1.1 4-1.2.1.1.1 4-1.2.1.1.2 7-1.2.1.1.3 8-1.2.1.1.3.1.r 10-1.2.1.1.3.1.1.1 11-1.2.1.1.3.1.1.1 14-1.2.1 15-1.2 17-1.2.2.1.1 18-1.2.2.1 23-1.2.2.1.3
# ::id bio.mskcc_0001.3
# ::preferred 
(r / require-01
      :ARG0 (a / activate-01~e.1
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Raf"~e.3)))
      :ARG1 (a2 / and~e.15
            :op1 (r2 / relieve-01~e.14
                  :ARG1 (i / inhibit-01
                        :ARG0 (p2 / protein-segment~e.4
                              :part-of e)
                        :ARG1 (p3 / protein-segment~e.4
                              :part-of e)
                        :ARG1-of (m / mediate-01~e.7
                              :ARG0~e.8 (p5 / protein-segment
                                    :name (n2 / name :op1 "N-terminus"~e.10,11)
                                    :part-of e))))
            :op2 (a3 / activate-01~e.1
                  :ARG1 (d / domain~e.18
                        :mod (k / kinase~e.17)
                        :part-of e
                        :ARG0-of (c / catalyze-01~e.23)))))

# ::tok Under normal signaling conditions , Ras activation helps mediate these events by recruiting the Raf proteins to the plasma membrane , which induces the release of 14 @-@ 3 @-@ 3 from the N @-@ terminal binding site and facilitates phosphorylation of the Raf kinase domain ( 19 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.4 2-1.4.1 3-1.4.r 5-1.1.1.1.1 6-1.1 7-1 8-1.2 9-1.2.2.1 10-1.2.2 11-1.3.r 12-1.3 14-1.3.2.1.1 15-1.3.4.1.2 16-1.3.3.r 18-1.3.3.1 19-1.3.3 22-1.3.4 24-1.3.4.1 25-1.3.4.1.1.r 26-1.3.4.1.1.1.1 28-1.3.4.1.1.1.1 30-1.3.4.1.1.1.1 33-1.3.4.1.2.1.1.1 35-1.3.4.1.2.1.1.1 36-1.3.4.1.2.2 37-1.3.4.1.2 39-1.3.5 40-1.3.5.1 41-1.3.5.1.1.r 43-1.3.5.1.1.2 44-1.3.5.1.1.1 45-1.3.5.1.1 47-1.5.1.1.1
# ::id bio.mskcc_0001.4
# ::preferred 
(h / help-01~e.7
      :ARG0 (a / activate-01~e.6
            :ARG1 (e3 / enzyme
                  :name (n / name :op1 "Ras"~e.5)))
      :ARG1 (m / mediate-01~e.8
            :ARG0 a
            :ARG1 (e / event~e.10
                  :mod (t / this~e.9)))
      :manner~e.11 (r / recruit-01~e.12
            :ARG0 a
            :ARG1 (e2 / enzyme
                  :name (n6 / name :op1 "Raf"~e.14))
            :destination~e.16 (m2 / membrane~e.19
                  :mod (p2 / plasma~e.18))
            :ARG0-of (i / induce-01~e.22
                  :ARG1 (r2 / release-01~e.24
                        :ARG1~e.25 (p3 / protein
                              :name (n2 / name :op1 "14-3-3"~e.26,28,30))
                        :ARG2 (p8 / protein-segment~e.15,37
                              :part-of (p4 / protein-segment
                                    :name (n3 / name :op1 "N-terminus"~e.33,35))
                              :ARG1-of (b / bind-01~e.36))))
            :ARG0-of (f / facilitate-01~e.39
                  :ARG1 (p5 / phosphorylate-01~e.40
                        :ARG1~e.41 (d / domain~e.45
                              :mod (k / kinase~e.44)
                              :part-of e2~e.43))))
      :condition~e.3 (n5 / normal~e.1
            :domain (s2 / signal-07~e.2
                  :ARG0 e3))
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c / cite-01 :ARG2 "19"~e.47))))

# ::tok Once activated , either by upstream signaling or by mutational events , all Raf proteins are capable of initiating the phosphorylation cascade that results in the sequential activation of MEK and ERK .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.3 4-1.3.1.r 5-1.3.1.1.1 6-1.3.1.1 7-1.3.1 9-1.3.1.2 12-1.1.2 13-1.1.1.1 16-1 17-1.2.r 18-1.2 20-1.2.2.1 21-1.2.2 23-1.2.2.2 27-1.2.2.2.1.1 27-1.2.2.2.1.2 28-1.2.2.2.1.1.1.r 29-1.2.2.2.1.1.1.1.1 30-1.2.2.2.1 31-1.2.2.2.1.2.1.1.1
# ::id bio.mskcc_0001.5
# ::preferred 
(c / capable-01~e.16
      :ARG1 (e3 / enzyme
            :name (n / name :op1 "Raf"~e.13)
            :mod (a / all~e.12))
      :ARG2~e.17 (i / initiate-01~e.18
            :ARG0 e3
            :ARG1 (c2 / cascade~e.21
                  :subevent (p3 / phosphorylate-01~e.20)
                  :ARG1-of (r / result-01~e.23
                        :ARG2 (a3 / and~e.30
                              :op1 (a2 / activate-01~e.27
                                    :ARG1~e.28 (e / enzyme
                                          :name (n2 / name :op1 "MEK"~e.29)))
                              :op2 (a4 / activate-01~e.27
                                    :ARG1 (e2 / enzyme
                                          :name (n3 / name :op1 "ERK"~e.31))
                                    :ARG2-of (f / follow-01
                                          :ARG1 a2))))))
      :time (a6 / activate-01~e.1
            :ARG0~e.4 (o / or~e.7
                  :op1 (s / signal-07~e.6
                        :source (u / upstream~e.5))
                  :op2 (m / mutate-01~e.9))
            :ARG1 e3))

# ::tok Strikingly , the Raf proteins themselves are also substrates of activated ERK .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3 3-1.2.1.1 10-1.1.2 11-1.1.1.1
# ::id bio.mskcc_0001.6
# ::preferred 
(c / catalyze-01
      :ARG0 (e / enzyme
            :name (n / name :op1 "ERK"~e.11)
            :ARG1-of (a / activate-01~e.10))
      :ARG1 (e2 / enzyme
            :name (n2 / name :op1 "Raf"~e.3))
      :ARG1-of (s / strike-04~e.0))

# ::tok In regard to C @-@ Raf , ERK @-@ dependent feedback phosphorylation has been shown to instigate a regulatory cycle whereby phosphorylation of the feedback sites down @-@ modulates C @-@ Raf signaling , after which the hyperphosphorylated C @-@ Raf protein is dephosphorylated and returned to a signaling @-@ competent state through dephosphorylation events involving protein phosphatase 2A ( PP2A ) and the Pin1 prolyl @-@ isomerase ( 8 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.2.1.1.2.r 3-1.2.1.1.1.1.1 5-1.2.1.1.1.1.1 7-1.2.1.2.1.1.1 9-1.2.1.2 10-1.2.1.1.2 11-1.2.1 14-1 15-1.2.1.1.2.r 16-1.2 18-1.2.2.1 19-1.2.2 21-1.2.2.2.1 22-1.2.2.2.1 23-1.2.2.2.1 24-1.2.2.2.1 25-1.2.2.2.1 26-1.2.2.2.1 27-1.2.2.2.1 28-1.2.2.2.1 29-1.2.2.2.1 30-1.2.2.2.1 31-1.2.2.2.1 32-1.2.2.2.2 34-1.2.2.2.3 37-1.2.2.2.3.1.1.2 38-1.2.2.2.3.1.1.1.1 40-1.2.2.2.3.1.1.1.1 43-1.2.2.2.3.1 48-1.2.2.2.2 53-1.2.2.2.3.1 55-1.2.2.2.3.1.3 56-1.2.2.2.3.1.3.1.1.1.1 57-1.2.2.2.3.1.3.1.1.1.2 58-1.2.2.2.3.1.3.1.1.1.3 62-1.2.2.2.3.1.3.1 64-1.2.2.2.3.1.3.1.2.1.1 65-1.2.2.2.3.1.3.1.2 67-1.2.2.2.3.1.3.1.2 69-1.1.1.1
# ::id bio.mskcc_0001.7
# ::preferred 
(s / show-01~e.14
      :ARG0 (p3 / publication
            :ARG1-of (c2 / cite-01 :ARG2 "8"~e.69))
      :ARG1 (i / instigate-01~e.16
            :ARG0 (p / phosphorylate-01~e.11
                  :ARG1 (p2 / protein-segment
                        :part-of (e / enzyme
                              :name (n / name :op1 "C-Raf"~e.3,5))
                        :destination-of~e.2,15 (f / feedback~e.10))
                  :ARG0-of (d / depend-01~e.9
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "ERK"~e.7))))
            :ARG1 (c / cycle~e.19
                  :mod (r / regulate-01~e.18)
                  :subevent (d2 / downmodulate-00
                        :ARG0 p~e.21,22,23,24,25,26,27,28,29,30,31
                        :ARG1 (s2 / signal-07~e.32,48
                              :ARG0 e)
                        :op1-of (a / after~e.34
                              :time-of (d3 / dephosphorylate-01~e.43,53
                                    :ARG1 (e3 / enzyme
                                          :name (n3 / name :op1 "C-Raf"~e.38,40)
                                          :ARG3-of (h / hyperphosphorylate-00~e.37))
                                    :ARG0-of (a2 / activate-01
                                          :ARG1 s2)
                                    :ARG1-of (i2 / involve-01~e.55
                                          :ARG2 (a3 / and~e.62
                                                :op1 (e4 / enzyme
                                                      :name (n4 / name
                                                            :op1 "protein"~e.56
                                                            :op2 "phosphatase"~e.57
                                                            :op3 "2A"~e.58))
                                                :op2 (p4 / prolyl-isomerase~e.65,67
                                                      :name (n5 / name :op1 "Pin1"~e.64))))))))))

# ::tok For B @-@ Raf , two ERK @-@ dependent feedback sites , S750 and T753 , have been identified , and phosphorylation of these sites has been reported to have a negative regulatory effect
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.1.1.3.1.1 3-1.1.1.3.1.1 6-1.1.1.4.1.1.1.1 8-1.1.1.4.1 9-1.1.1.4 13-1.1.1 18-1.1 20-1 21-1.2.1.1 27-1.2 33-1.2.1
# ::id bio.mskcc_0001.8
# ::preferred 
(a / and~e.20
      :op1 (i / identify-01~e.18
            :ARG1 (a2 / and~e.13
                  :op1 (a3 / amino-acid
                        :mod "750"
                        :name (n4 / name :op1 "serine"))
                  :op2 (a4 / amino-acid
                        :mod "753"
                        :name (n3 / name :op1 "threonine"))
                  :part-of (e / enzyme
                        :name (n / name :op1 "B-Raf"~e.1,3))
                  :destination-of (f / feedback~e.9
                        :ARG0-of (d / depend-01~e.8
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "ERK"~e.6))))))
      :op2 (r / report-01~e.27
            :ARG1 (a5 / affect-01~e.33
                  :ARG0 (p / phosphorylate-01~e.21
                        :ARG1 a2)
                  :ARG1 (d2 / downregulate-01))))

# ::tok Here we find that both normal and oncogenic B @-@ Raf proteins are phosphorylated on four S/TP sites ( S151 , T401 , S750 , and T753 ) by activated ERK .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3 1-1.1 2-1 5-1.2.3.1 7-1.2.3.2 7-1.2.3.2.2 7-1.2.3.2.2.r 8-1.2.1.5.1.1 10-1.2.1.5.1.1 12-1.2.3.1.1.r 13-1.2 25-1.2.1 28-1.2.2.r 29-1.2.2.2 30-1.2.2.1.1
# ::id bio.mskcc_0001.9
# ::preferred 
(f / find-01~e.2
      :ARG0 (w / we~e.1)
      :ARG1 (p / phosphorylate-01~e.13
            :ARG1 (a / and~e.25
                  :op1 (a2 / amino-acid
                        :mod "151"
                        :name (n / name :op1 "serine"))
                  :op2 (a3 / amino-acid
                        :mod "401"
                        :name (n2 / name :op1 "threonine"))
                  :op3 (a4 / amino-acid
                        :mod "750"
                        :name (n3 / name :op1 "serine"))
                  :op4 (a5 / amino-acid
                        :mod "753"
                        :name (n4 / name :op1 "threonine"))
                  :part-of (e / enzyme
                        :name (n5 / name :op1 "B-Raf"~e.8,10)))
            :ARG2~e.28 (e2 / enzyme
                  :name (n7 / name :op1 "ERK"~e.30)
                  :ARG1-of (a6 / activate-01~e.29))
            :condition (o / or
                  :op1 (n6 / normal~e.5
                        :domain~e.12 e)
                  :op2 (c / cause-01~e.7
                        :ARG0 e
                        :ARG1~e.7 (c2 / cancer~e.7))))
      :medium (h / here~e.0))

# ::tok Previously , we found that in response to growth factor treatment , signaling from C @-@ Raf is downregulated by ERK @-@ dependent feedback phosphorylation on S/TP sites and that C @-@ Raf is subsequently dephosphorylated and returned to a signaling @-@ competent state through the activities of PP2A and the Pin1 prolyl @-@ isomerase ( 8 )
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.4 2-1.1 3-1 6-1.2.3 7-1.2.3.1.r 8-1.2.3.1.1.1.1 9-1.2.3.1.1.1.2 10-1.2.3.1 12-1.2.1.2 13-1.2.r 14-1.2.2.1.1.1 16-1.2.2.1.1.1 20-1.2.1.1.2.1.1.1 22-1.2.1.1.2 23-1.2.1.1.1.3 24-1.2.1.1 28-1.2 30-1.2.2.1.1.1 32-1.2.1.1.1.2.1.1 32-1.2.2.1.1.1 34-1.2.2.4 34-1.2.2.4.r 35-1.2.2 36-1.2 36-1.2.2.2 40-1.2.1.2 47-1.2.2.2.r 48-1.2.2.2.1.1.1 49-1.2.2.2 51-1.2.2.2.2.1.1 52-1.2.2.2.2 54-1.2.2.2.2 56-1.3.1.1.1
# ::id bio.mskcc_0001.10
# ::preferred 
(f2 / find-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.13 (a / and~e.28,36
            :op1 (d2 / downregulate-01
                  :ARG0 (p / phosphorylate-01~e.24
                        :ARG1 (a4 / amino-acid
                              :mod (o / or
                                    :op1 (a6 / amino-acid
                                          :name (n7 / name :op1 "serine"))
                                    :op2 (a7 / amino-acid
                                          :name (n8 / name :op1 "threonine")))
                              :part-of (e / enzyme
                                    :name (n / name :op1 "C-Raf"~e.32))
                              :destination-of (f / feedback~e.23))
                        :ARG0-of (d / depend-01~e.22
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "ERK"~e.20))))
                  :ARG1 (s2 / signal-07~e.12,40
                        :ARG0 e))
            :op2 (d3 / dephosphorylate-01~e.35
                  :ARG1 (e3 / enzyme
                        :name (n3 / name :op1 "C-Raf"~e.14,16,30,32))
                  :ARG2~e.47 (a3 / and~e.36,49
                        :op1 (e4 / enzyme
                              :name (n4 / name :op1 "PP2A"~e.48))
                        :op2 (p4 / prolyl-isomerase~e.52,54
                              :name (n5 / name :op1 "Pin1"~e.51)))
                  :ARG0-of (a2 / activate-01
                        :ARG1 s2)
                  :time~e.34 (a5 / after~e.34
                        :op1 d2))
            :ARG0-of (r2 / respond-01~e.6
                  :ARG1~e.7 (t / treat-04~e.10
                        :ARG2 (s / small-molecule
                              :name (n6 / name :op1 "growth"~e.8 :op2 "factor"~e.9)))))
      :ARG1-of (d4 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "8"~e.56)))
      :time (p2 / previous~e.0))

# ::tok The Pin1 prolyl @-@ isomerase binds specifically to phosphorylated S/TP ( pS/TP ) motifs ( 33 ) , and isomerization of the pS @/@ TP bond is required for PP2A to efficiently dephosphorylate certain proteins , such as cdc25C , Myc , and C @-@ Raf ( 16 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.1.1.1.1 2-1.1.1 4-1.1.1 5-1.1 6-1.1.3 7-1.1.2.r 8-1.1.2.2 9-1.1.2.1 13-1.1.2 15-1.1.4.1.1.1 24-1.1.2.1 25-1.2.2.1 27-1.2 28-1.2.1.r 29-1.2.1.2.1.1 31-1.2.1.3 32-1.2.1 33-1.2.1.1.2 34-1.2.1.1 36-1.2.1.1.1.r 37-1.2.1.1.1.r 38-1.2.1.1.1.1.1.1 40-1.2.1.1.1.2.1.1 42-1.2.1.1.1 43-1.2.1.1.1.3.1.1 45-1.2.1.1.1.3.1.1 47-1.2.3.1.1.1
# ::id bio.mskcc_0001.11
# ::preferred 
(a / and
      :op1 (b / bind-01~e.5
            :ARG1 (p7 / prolyl-isomerase~e.2,4
                  :name (n / name :op1 "Pin1"~e.1))
            :ARG2~e.7 (p / protein-segment~e.13
                  :value "S/TP"~e.9,24
                  :ARG3-of (p2 / phosphorylate-01~e.8))
            :mod (s / specific~e.6)
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c / cite-01 :ARG2 "33"~e.15))))
      :op2 (r / require-01~e.27
            :ARG0~e.28 (d2 / dephosphorylate-01~e.32
                  :ARG1 (p4 / protein~e.34
                        :example~e.36,37 (a2 / and~e.42
                              :op1 (e3 / enzyme
                                    :name (n3 / name :op1 "cdc25C"~e.38))
                              :op2 (p5 / protein
                                    :name (n4 / name :op1 "Myc"~e.40))
                              :op3 (e4 / enzyme
                                    :name (n5 / name :op1 "C-Raf"~e.43,45)))
                        :mod (c3 / certain~e.33))
                  :ARG2 (e2 / enzyme
                        :name (n2 / name :op1 "PP2A"~e.29))
                  :ARG2-of (e5 / efficient-01~e.31
                        :ARG1 e2))
            :ARG1 (i / isomerize-00
                  :ARG1 (b2 / bond~e.25
                        :part-of p))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p6 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "16"~e.47)))))

# ::tok Complex formation between B @-@ Raf and Pin1 correlated with the phosphorylation of B @-@ Raf on S/TP sites ( Fig . 1C ) and this interaction could be blocked when the MEK inhibitor U0126 was used to prevent ERK activation and the S/TP phosphorylation of B @-@ Raf ( Fig . 1D ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.1 1-1.1.1 3-1.1.1.2.1.1.1 5-1.1.1.2.1.1.1 6-1.1.1.2 7-1.1.1.2.2.1.1 8-1.1 9-1.1.2.r 11-1.1.2 12-1.1.2.1.r 13-1.1.2.1.2 14-1.1.2.1.2 15-1.1.2.1.2 17-1.1.2.1.1 18-1.1.2.1 22-1.1.3.1.1 24-1 27-1.2 28-1.2.1.r 29-1.2.1 32-1.2.2.1.2.1.1.1 33-1.2.2.1 33-1.2.2.1.2 33-1.2.2.1.2.r 34-1.2.2.1.1.1 36-1.2.2 38-1.2.2.2 39-1.2.2.2.2.1.1.1.1 40-1.2.2.2.2.1 41-1.2.2.2.2 43-1.2.2.2.2.2.1 44-1.2.2.2.2.2 46-1.1.1.2.1.1.1 48-1.1.1.2.1.1.1 52-1.2.3.1.1
# ::id bio.mskcc_0001.12
# ::preferred 
(a / and~e.24
      :op1 (c / correlate-01~e.8
            :ARG1 (f / form-01~e.1
                  :ARG1 (m / macro-molecular-complex~e.0)
                  :ARG2 (a2 / and~e.6
                        :op1 (e / enzyme
                              :name (n / name :op1 "B-Raf"~e.3,5,46,48))
                        :op2 (e2 / enzyme
                              :name (n2 / name :op1 "Pin1"~e.7))))
            :ARG2~e.9 (p / phosphorylate-01~e.11
                  :ARG1~e.12 (p2 / protein-segment~e.18
                        :value "S/TP"~e.17
                        :part-of e~e.13,14,15))
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure :mod "1C"~e.22)))
      :op2 (p3 / possible~e.27
            :domain~e.28 (b / block-01~e.29
                  :ARG1 f)
            :condition (u / use-01~e.36
                  :ARG1 (s / small-molecule~e.33
                        :name (n3 / name :op1 "U0126"~e.34)
                        :ARG0-of~e.33 (i / inhibit-01~e.33
                              :ARG1 (e3 / enzyme
                                    :name (n4 / name :op1 "MEK"~e.32))))
                  :ARG2 (p4 / prevent-01~e.38
                        :ARG0 s
                        :ARG1 (a3 / and~e.41
                              :op1 (a4 / activate-01~e.40
                                    :ARG1 (e4 / enzyme
                                          :name (n5 / name :op1 "ERK"~e.39)))
                              :op2 (p5 / phosphorylate-01~e.44
                                    :ARG1 p2~e.43))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f3 / figure :mod "1D"~e.52))))

# ::tok Together , these findings indicate that Pin1 is needed for the efficient dephosphorylation of B @-@ Raf and are consistent with the model that S/TP phosphorylation inhibits Raf signaling .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3 2-1.1.1.2 3-1.1.1 3-1.1.1.1 3-1.1.1.1.r 4-1.1 5-1.1.2.r 6-1.1.2.1.1.1 8-1.1.2 9-1.1.2.2.r 11-1.1.2.2.2 12-1.1.2.2 13-1.1.2.2.1.r 14-1.1.2.2.1.1.1 16-1.1.2.2.1.1.1 17-1 19-1.2 20-1.2.2.r 22-1.2.2 24-1.2.2.1.1.1.1 25-1.2.2.1.1 26-1.2.2.1 27-1.2.2.1.2.1.1.1 28-1.2.2.1.2
# ::id bio.mskcc_0001.13
# ::preferred 
(a / and~e.17
      :op1 (i / indicate-01~e.4
            :ARG0 (t / thing~e.3
                  :ARG1-of~e.3 (f / find-01~e.3)
                  :mod (t3 / this~e.2))
            :ARG1~e.5 (n4 / need-01~e.8
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "Pin1"~e.6))
                  :purpose~e.9 (d / dephosphorylate-01~e.12
                        :ARG1~e.13 (e2 / enzyme
                              :name (n / name :op1 "B-Raf"~e.14,16))
                        :ARG2-of (e3 / efficient-01~e.11))))
      :op2 (c / consistent-01~e.19
            :ARG1 t
            :ARG2~e.20 (m / model~e.22
                  :topic (i2 / inhibit-01~e.26
                        :ARG0 (p / phosphorylate-01~e.25
                              :ARG1 (p2 / protein-segment :value "S/TP"~e.24))
                        :ARG1 (s / signal-07~e.28
                              :ARG0 (e4 / enzyme
                                    :name (n3 / name :op1 "Raf"~e.27))))))
      :mod (t2 / together~e.0))

# ::tok Eluting in HPLC fractions 78 to 79 was a peptide phosphorylated on S750 and T753 , the previously identified ERK sites , and eluting in fractions 26 and 58 to 59 were peptides phosphorylated at S151 and T401 , respectively .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1 2-1.1.2.1 3-1.1.2 4-1.1.2.2.1 6-1.1.2.2.2 9-1.1.1 10-1.1.1.1.3 10-1.1.1.2.3 17-1.1.1.1.4.2.1 18-1.1.1.1.4.2 19-1.1.1.1.4.1.1.1 20-1.1.1.1.4 22-1 23-1.1 23-1.2 23-1.3 25-1.2.2 25-1.3.2 26-1.2.2.1 27-1.3.2.1 28-1.3.2.1.1 30-1.3.2.1.2 32-1.2.1 32-1.3.1 33-1.2.1.1.3 33-1.3.1.1.3 36-1.3.2.1
# ::id bio.mskcc_0001.14
# ::preferred 
(a / and~e.22
      :op1 (e / elute-00~e.0,23
            :ARG1 (p / peptide~e.9
                  :part (a2 / amino-acid
                        :mod "750"
                        :name (n / name :op1 "serine")
                        :ARG3-of (p2 / phosphorylate-01~e.10)
                        :part-of (p4 / protein-segment~e.20
                              :part-of (e2 / enzyme
                                    :name (n3 / name :op1 "ERK"~e.19))
                              :ARG1-of (i / identify-01~e.18
                                    :time (p5 / previous~e.17))))
                  :part (a3 / amino-acid
                        :mod "753"
                        :name (n2 / name :op1 "threonine")
                        :ARG3-of (p3 / phosphorylate-01~e.10)
                        :part-of p4))
            :ARG3 (f / fraction~e.3
                  :mod (h / HPLC~e.2)
                  :mod (b / between :op1 "78"~e.4 :op2 "79"~e.6)))
      :op2 (e3 / elute-00~e.23
            :ARG1 (p6 / peptide~e.32
                  :part (a5 / amino-acid
                        :mod "151"
                        :name (n4 / name :op1 "serine")
                        :ARG3-of (p7 / phosphorylate-01~e.33)))
            :ARG3 (f3 / fraction~e.25 :mod "26"~e.26))
      :op3 (e4 / elute-00~e.23
            :ARG1 (p9 / peptide~e.32
                  :part (a6 / amino-acid
                        :mod "401"
                        :name (n5 / name :op1 "threonine")
                        :ARG3-of (p8 / phosphorylate-01~e.33)))
            :ARG3 (f4 / fraction~e.25
                  :mod (b2 / between~e.27,36 :op1 "58"~e.28 :op2 "59"~e.30))))

# ::tok All four of these identified sites are followed by a proline residue , and their phosphorylation could be blocked by pretreating cells with the MEK inhibitor U0126 ( Fig . 2A ) , suggesting that these residues are feedback targets of the proline @-@ directed kinase , ERK .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2.2 1-1.1.2.1 3-1.1.2.3 4-1.1.2.4 5-1.1.2 7-1.1 8-1.1.1.r 10-1.1.1.1.1.1 11-1.1.1 13-1 14-1.2.1.2.1 14-1.2.1.2.1.r 15-1.2.1.2 16-1.2 17-1.2.1.r 18-1.2.1 21-1.2.1.1.1 24-1.2.1.1.2.2.1.1.1 25-1.2.1.1.2 25-1.2.1.1.2.2 25-1.2.1.1.2.2.r 26-1.2.1.1.2.1.1 30-1.2.2.1.1 33-1.3 35-1.1.2.3 36-1.1.1 38-1.3.1 39-1.3.1.1.r 42-1.3.1.1 44-1.3.1.2.2 45-1.3.1.2 47-1.3.1.2.1.1
# ::id bio.mskcc_0001.15
# ::preferred 
(a / and~e.13
      :op1 (f / follow-01~e.7
            :ARG1~e.8 (r / residue~e.11,36
                  :mod (a3 / amino-acid
                        :name (n / name :op1 "proline"~e.10)))
            :ARG2 (p / protein-segment~e.5
                  :quant "4"~e.1
                  :mod (a2 / all~e.0)
                  :mod (t / this~e.3,35)
                  :ARG1-of (i2 / identify-01~e.4)))
      :op2 (p2 / possible~e.16
            :domain~e.17 (b / block-01~e.18
                  :ARG0 (t2 / treat-04
                        :ARG1 (c / cell~e.21)
                        :ARG2 (s / small-molecule~e.25
                              :name (n2 / name :op1 "U0126"~e.26)
                              :ARG0-of~e.25 (i / inhibit-01~e.25
                                    :ARG1 (e / enzyme
                                          :name (n3 / name :op1 "MEK"~e.24))))
                        :time (b2 / before))
                  :ARG1 (p3 / phosphorylate-01~e.15
                        :ARG1~e.14 p~e.14))
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure :mod "2A"~e.30)))
      :ARG0-of (s2 / suggest-01~e.33
            :ARG1 (f3 / feedback~e.38
                  :destination~e.39 r~e.42
                  :source (k / kinase~e.45
                        :name (n4 / name :op1 "ERK"~e.47)
                        :ARG1-of (d2 / direct-01~e.44
                              :ARG2 p)))))

# ::tok Consistent with this model , we found that when purified activated ERK was incubated with kinase @-@ dead B @-@ Raf( K375M ) in vitro , ERK strongly phosphorylated B @-@ Raf on the S151 , S750 , and T753 sites , with phosphorylation of T401 also observed ( Fig . 2B ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3 1-1.3.1.r 2-1.3.1.1 3-1.3.1 5-1.1 6-1 9-1.2.3.1 10-1.2.3.1 11-1.2.3.1 13-1.2.3 14-1.2.3.2.r 15-1.2.3.2.3.2 18-1.2.3.2.1.1 21-1.2.3.2.2.1 23-1.2.3.3 24-1.2.3.3 26-1.2.1.2.1.1 27-1.2.1.3 28-1.2.1 29-1.2.3.2.1.1 31-1.2.3.2.1.1 38-1.2 38-1.2.1.1 42-1.2.r 43-1.2.2 46-1.2.2.3.1 47-1.2.2.3 51-1.2.4.1.1
# ::id bio.mskcc_0001.16
# ::preferred 
(f / find-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1~e.42 (a6 / and~e.38
            :op1 (p / phosphorylate-01~e.28
                  :ARG1 (a2 / and~e.38
                        :op1 (a3 / amino-acid
                              :mod "151"
                              :name (n4 / name :op1 "serine")
                              :part-of (e2 / enzyme
                                    :name (n2 / name :op1 "B-Raf"~e.18,29,31)
                                    :ARG2-of (m2 / mutate-01 :value "K375M"~e.21)
                                    :ARG0-of (f2 / function-01
                                          :polarity "-"
                                          :ARG1 (k / kinase~e.15))))
                        :op2 (a4 / amino-acid
                              :mod "750"
                              :name (n5 / name :op1 "serine")
                              :part-of e2)
                        :op3 (a5 / amino-acid
                              :mod "753"
                              :name (n6 / name :op1 "threonine")
                              :part-of e2))
                  :ARG2 (e / enzyme
                        :name (n / name :op1 "ERK"~e.26)
                        :ARG1-of (a / activate-01)
                        :ARG1-of (p2 / purify-01))
                  :degree (s / strong~e.27))
            :op2 (p3 / phosphorylate-01~e.43
                  :ARG1 (a7 / amino-acid
                        :mod "401"
                        :name (n7 / name :op1 "threonine")
                        :part-of e2)
                  :ARG2 e
                  :ARG1-of (o / observe-01~e.47
                        :mod (a8 / also~e.46)))
            :condition (i / incubate-01~e.13
                  :ARG1 e~e.9,10,11
                  :ARG2~e.14 e2
                  :manner (i2 / in-vitro~e.23,24))
            :ARG1-of (d / describe-01
                  :ARG0 (f3 / figure :mod "2B"~e.51)))
      :ARG1-of (c / consistent-01~e.0
            :ARG2~e.1 (m / model~e.3
                  :mod (t / this~e.2))))

# ::tok These findings are similar to what has been observed for C @-@ Raf ( 8 ) and suggest that feedback phosphorylation is a conserved mechanism used to disrupt the Ras @/@ Raf interaction .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.2 1-1.1.1.1 3-1.1 5-1.1.1 5-1.1.2 8-1.1.2.1 9-1.1.2.2.r 10-1.1.2.2.1.1 12-1.1.2.2.1.1 14-1.1.3.1.1.1 16-1 17-1.2 18-1.2.2.r 19-1.2.2.3.1 20-1.2.2.3 21-1.2.2.3.r 23-1.2.2.1 24-1.2.2 25-1.2.2.2 27-1.2.2.2.1 29-1.2.2.2.1.2.1.1.1 31-1.2.2.2.1.2.2.1.1 32-1.2.2.2.1.2
# ::id bio.mskcc_0001.17
# ::preferred 
(a / and~e.16
      :op1 (r / resemble-01~e.3
            :ARG1 (t / thing~e.5
                  :ARG1-of (f / find-01~e.1)
                  :mod (t2 / this~e.0))
            :ARG2 (t3 / thing~e.5
                  :ARG1-of (o / observe-01~e.8)
                  :topic~e.9 (e / enzyme
                        :name (n / name :op1 "C-Raf"~e.10,12)))
            :ARG1-of (d / describe-01
                  :ARG0 (p / publication
                        :ARG1-of (c / cite-01 :ARG2 "8"~e.14))))
      :op2 (s / suggest-01~e.17
            :ARG0 t
            :ARG1~e.18 (m / mechanism~e.24
                  :ARG1-of (c2 / conserve-01~e.23)
                  :ARG1-of (u / use-01~e.25
                        :ARG2 (d2 / disrupt-01~e.27
                              :ARG0 m
                              :ARG1 (i / interact-01~e.32
                                    :ARG0 (e3 / enzyme
                                          :name (n3 / name :op1 "Ras"~e.29))
                                    :ARG1 (e2 / enzyme
                                          :name (n2 / name :op1 "Raf"~e.31)))))
                  :domain~e.21 (p3 / phosphorylate-01~e.20
                        :subevent-of (f2 / feedback~e.19)))))

# ::tok Consistent with these data , we found that B @-@ Raf interacted with C @-@ Raf in an inducible and transient manner following growth factor treatment ( Fig . 3B and C ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3 1-1.3.1.r 2-1.3.1.1 3-1.3.1 5-1.1 6-1 7-1.2.r 8-1.2.1.1.1 10-1.2.1.1.1 10-1.2.2.1.1 11-1.2 12-1.2.2.r 13-1.2.2.1.1 15-1.2.1.1.1 15-1.2.2.1.1 16-1.2.3.r 18-1.2.3 20-1.2.4 22-1.2.5 23-1.2.5.1.1.1.1 24-1.2.5.1.1.1.2 25-1.2.5.1 29-1.4.1.1.1 30-1.4.1 31-1.2.2.1.1
# ::id bio.mskcc_0001.18
# ::preferred 
(f / find-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1~e.7 (i / interact-01~e.11
            :ARG0 (e / enzyme
                  :name (n / name :op1 "B-Raf"~e.8,10,15))
            :ARG1~e.12 (e2 / enzyme
                  :name (n2 / name :op1 "C-Raf"~e.10,13,15,31))
            :ARG1-of~e.16 (i2 / induce-01~e.18)
            :duration (t2 / transient~e.20)
            :ARG2-of (f4 / follow-01~e.22
                  :ARG1 (t3 / treat-04~e.25
                        :ARG2 (s / small-molecule
                              :name (n3 / name :op1 "growth"~e.23 :op2 "factor"~e.24)))))
      :ARG1-of (c / consistent-01~e.0
            :ARG2~e.1 (d / data~e.3
                  :mod (t / this~e.2)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a2 / and~e.30
                  :op1 (f2 / figure :mod "3B"~e.29)
                  :op2 (f3 / figure :mod "3C"))))

# ::tok In addition , when B @-@ Raf feedback phosphorylation was prevented , either by U0126 treatment or by mutation of all the feedback sites , an increase in the basal level of heterodimerization with C @-@ Raf was observed , and heterodimerization in response to growth factor treatment was increased and prolonged ( Fig . 3B and C ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1 0-1.1 0-1.1.r 1-1 1-1.1 1-1.1.r 4-1.1.4.2.1.1.1 6-1.1.4.2.1.1.1 7-1.1.4.2.2 8-1.1.4.2 10-1.1.4 13-1.1.4.1.r 14-1.1.4.1.1.1.1.1 15-1.1.4.1.1 16-1.1.4.1 18-1.1.4.1.2 19-1.1.4.1.2.1.r 20-1.1.4.1.2.1.3 22-1.1.4.1.2.1.2 23-1.1.4.1.2.1 26-1.1.1.1 27-1.1.1.1.1.r 29-1.1.1.1.1.1 30-1.1.1.1.1 31-1.1.1.1.1.2.r 32-1.1.1.1.1.2 33-1.1.1.1.1.2.2.r 34-1.1.1.1.1.2.2.1.1 36-1.1.1.1.1.2.2.1.1 38-1.1.1 40-1.1 40-1.1.5.1 41-1.1.2.1 42-1.1.2.1.1.r 43-1.1.2.1.1 44-1.1.2.1.1.1.r 45-1.1.2.1.1.1.1.1.1 46-1.1.2.1.1.1.1.1.2 47-1.1.2.1.1.1 49-1.1.2 50-1.1 50-1.1.5.1 51-1.1.3 55-1.1.5.1.1.1 56-1.1 56-1.1.5.1 57-1.1.1.1.1.2.2.1.1
# ::id bio.mskcc_0001.19
# ::preferred 
(a2 / and~e.0,1
      :op2~e.0,1 (a / and~e.0,1,40,50,56
            :op1 (o / observe-01~e.38
                  :ARG1 (i / increase-01~e.26
                        :ARG1~e.27 (l / level~e.30
                              :mod (b / basal~e.29)
                              :degree-of~e.31 (h / heterodimerize-00~e.32
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "B-Raf"~e.4,6))
                                    :ARG2~e.33 (e2 / enzyme
                                          :name (n3 / name :op1 "C-Raf"~e.34,36,57))))))
            :op2 (i2 / increase-01~e.49
                  :ARG1 (h2 / heterodimerize-00~e.41
                        :ARG0-of~e.42 (r / respond-01~e.43
                              :ARG1~e.44 (t2 / treat-04~e.47
                                    :ARG2 (s2 / small-molecule
                                          :name (n4 / name :op1 "growth"~e.45 :op2 "factor"~e.46))))))
            :op3 (p / prolong-01~e.51
                  :ARG1 h2)
            :condition (p2 / prevent-01~e.10
                  :ARG0~e.13 (o2 / or~e.16
                        :op1 (t / treat-04~e.15
                              :ARG2 (s / small-molecule
                                    :name (n2 / name :op1 "U0126"~e.14)))
                        :op2 (m / mutate-01~e.18
                              :ARG1~e.19 (p4 / protein-segment~e.23
                                    :part-of e
                                    :destination-of f~e.22
                                    :mod (a3 / all~e.20))))
                  :ARG1 (p3 / phosphorylate-01~e.8
                        :ARG1 e
                        :subevent-of (f / feedback~e.7)))
            :ARG1-of (d / describe-01
                  :ARG0 (a4 / and~e.40,50,56
                        :op1 (f2 / figure :mod "3B"~e.55)
                        :op2 (f3 / figure :mod "3C")))))

# ::tok These findings support a model whereby feedback phosphorylation disrupts Raf heterodimerization .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 4-1.2 6-1.2.1.1.2 7-1.2.1.1 8-1.2.1 9-1.2.1.2.1.1.1 10-1.2.1.2
# ::id bio.mskcc_0001.20
# ::preferred 
(s / support-01~e.2
      :ARG0 (t / thing~e.1
            :ARG1-of~e.1 (f / find-01~e.1)
            :mod (t2 / this~e.0))
      :ARG1 (m / model~e.4
            :topic (d / disrupt-01~e.8
                  :ARG0 (p / phosphorylate-01~e.7
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Raf"~e.9))
                        :subevent-of (f2 / feedback~e.6))
                  :ARG1 (h / heterodimerize-00~e.10
                        :ARG1 e))))

# ::tok Unlike WT B @-@ Raf , oncogenic B @-@ Raf proteins have been shown to heterodimerize constitutively with C @-@ Raf in a Ras @-@ independent manner ( 11 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.2.3.1 1-1.2.1.2 2-1.1.1.1.1 2-1.2.1.1.1 4-1.1.1.1.1 4-1.2.1.1.1 6-1.1.1 6-1.1.1.2 6-1.1.1.2.1 6-1.1.1.2.1.r 6-1.1.1.2.r 7-1.1.1.1.1 9-1.1.1.1.1 9-1.1.2.1.1 13-1.1.5 14-1.1.1 14-1.1.1.2 14-1.1.1.2.r 15-1.1 15-1.2 16-1.1.3 16-1.2.3 17-1.1.2.r 18-1.1.2.1.1 20-1.1.1.1.1 20-1.1.2.1.1 21-1.1.4.r 23-1.1.4.2.1.1 25-1.1.4 25-1.1.4.1 25-1.1.4.1.r 28-1.1.5.1.1.1
# ::id bio.mskcc_0001.21
# ::preferred 
(c5 / contrast-01
      :ARG1 (h / heterodimerize-00~e.15
            :ARG1 (e / enzyme~e.6,14
                  :name (n / name :op1 "B-Raf"~e.2,4,7,9,20)
                  :ARG0-of~e.6,14 (c / cause-01~e.6,14
                        :ARG1~e.6 (c2 / cancer~e.6)))
            :ARG2~e.17 (e2 / enzyme
                  :name (n2 / name :op1 "C-Raf"~e.9,18,20))
            :mod (c3 / constitutive~e.16)
            :ARG0-of~e.21 (d / depend-01~e.25
                  :polarity~e.25 "-"~e.25
                  :ARG1 (e4 / enzyme
                        :name (n3 / name :op1 "Ras"~e.23)))
            :ARG1-of (s / show-01~e.13
                  :ARG0 (p2 / publication
                        :ARG1-of (c4 / cite-01 :ARG2 "11"~e.28))))
      :ARG2 (h2 / heterodimerize-00~e.15
            :ARG1 (e3 / enzyme
                  :name (n4 / name :op1 "B-Raf"~e.2,4)
                  :mod (w / wild-type~e.1))
            :ARG2 e2
            :mod (c6 / constitutive~e.16 :polarity "-"~e.0)))

# ::tok When we next examined the effect of feedback phosphorylation on the ability of oncogenic B @-@ Raf to form heterodimers with C @-@ Raf , we found that the levels of endogenous C @-@ Raf associating with B @-@ Raf proteins of high ( V600E ) , intermediate ( G466A ) , and impaired ( D594G ) kinase activities all increased when the feedback sites were mutated , indicating that feedback phosphorylation also inhibits the heterodimerization of oncogenic B @-@ Raf proteins ( Fig . 3D ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.3.3.r 1-1.1 2-1.3.3 3-1.3 5-1.3.2 6-1.3.2.1.r 7-1.3.2.1.1 8-1.3.2.1 13-1.3.2.2.1.1 13-1.3.2.2.1.1.2 13-1.3.2.2.1.1.2.1 13-1.3.2.2.1.1.2.1.r 13-1.3.2.2.1.1.2.r 14-1.3.2.2.1.1.1.1 16-1.3.2.2.1.1.1.1 16-1.3.2.2.1.2.1.1 17-1.3.2.2.1.1 17-1.3.2.2.1.1.2 17-1.3.2.2.1.1.2.r 21-1.3.2.2.1.2.1.1 23-1.3.2.2.1.1.1.1 23-1.3.2.2.1.2.1.1 25-1.1 26-1 27-1.2.r 29-1.2.1.1 29-1.2.1.2 29-1.2.1.3 31-1.2.1.1.1.3 31-1.2.1.2.1.3 31-1.2.1.3.1.3 32-1.2.1.1.1.1.1 32-1.2.1.2.1.1.1 32-1.2.1.3.1.1.1 34-1.2.1.1.1.1.1 34-1.2.1.1.1.2.1.1.1 34-1.2.1.2.1.1.1 34-1.2.1.2.1.2.1.1.1 34-1.2.1.3.1.1.1 34-1.2.1.3.1.2.1.1.1 35-1.2.1.1.1.2 35-1.2.1.2.1.2 35-1.2.1.3.1.2 37-1.2.1.1.1.2.1.1.1 37-1.2.1.2.1.2.1.1.1 37-1.2.1.3.1.2.1.1.1 37-1.2.2.1.1.1.1 39-1.2.1.1.1.1.1 39-1.2.1.1.1.2.1.1.1 39-1.2.1.2.1.1.1 39-1.2.1.2.1.2.1.1.1 39-1.2.1.3.1.1.1 39-1.2.1.3.1.2.1.1.1 39-1.2.2.1.1.1.1 40-1.2.2.1 41-1.2.1.1.1.2.1.r 41-1.2.1.1.1.r 42-1.2.1.1.1.2.1.3.2 44-1.2.1.1.1.2.1.2.1 47-1.2.1.2.1.2.1.3.2 49-1.2.1.2.1.2.1.2.1 52-1.2.1 53-1.2.1.3.1.2.1.3.2 55-1.2.1.3.1.2.1.2.1 57-1.2.1.1.1.2.1.3.1 57-1.2.1.2.1.2.1.3.1 57-1.2.1.3.1.2.1.3.1 60-1.2 61-1.3.3.r 63-1.2.2.1.2 64-1.2.2.1 66-1.2.1.1.1.2.1.2 66-1.2.1.2.1.2.1.2 66-1.2.1.3.1.2.1.2 66-1.2.2 68-1.2.3 69-1.2.3.1.r 70-1.2.3.1.1 71-1.2.3.1.1 72-1.2.3.1.3 73-1.2.3.1 75-1.2.3.1.2 75-1.3.2.2.1 77-1.3.2.2.1.1 77-1.3.2.2.1.1.2 77-1.3.2.2.1.1.2.1 77-1.3.2.2.1.1.2.1.r 77-1.3.2.2.1.1.2.r 78-1.2.2.1.1.1.1 78-1.3.2.2.1.1.1.1 80-1.2.2.1.1.1.1 80-1.3.2.2.1.1.1.1 80-1.3.2.2.1.2.1.1 81-1.2.2.1 85-1.2.4.1.1
# ::id bio.mskcc_0001.22
# ::preferred 
(f / find-01~e.26
      :ARG0 (w / we~e.1,25)
      :ARG1~e.27 (i / increase-01~e.60
            :ARG1 (a / and~e.52
                  :op1 (l / level~e.29
                        :quant-of~e.41 (e / enzyme
                              :name (n / name :op1 "C-Raf"~e.32,34,39)
                              :ARG1-of (a2 / associate-01~e.35
                                    :ARG2~e.41 (e2 / enzyme
                                          :name (n2 / name :op1 "B-Raf"~e.34,37,39)
                                          :ARG2-of (m / mutate-01~e.66 :value "V600E"~e.44)
                                          :ARG0-of (a3 / act-01
                                                :ARG1 (k / kinase~e.57)
                                                :degree (h / high~e.42))))
                              :mod (e7 / endogenous~e.31)))
                  :op2 (l2 / level~e.29
                        :quant-of (e3 / enzyme
                              :name (n3 / name :op1 "C-Raf"~e.32,34,39)
                              :ARG1-of (a5 / associate-01~e.35
                                    :ARG2 (e5 / enzyme
                                          :name (n5 / name :op1 "B-Raf"~e.34,37,39)
                                          :ARG2-of (m2 / mutate-01~e.66 :value "G466A"~e.49)
                                          :ARG0-of (a4 / act-01
                                                :ARG1 (k2 / kinase~e.57)
                                                :degree (i2 / intermediate~e.47))))
                              :mod (e8 / endogenous~e.31)))
                  :op3 (l3 / level~e.29
                        :quant-of (e4 / enzyme
                              :name (n4 / name :op1 "C-Raf"~e.32,34,39)
                              :ARG1-of (a6 / associate-01~e.35
                                    :ARG2 (e6 / enzyme
                                          :name (n6 / name :op1 "B-Raf"~e.34,37,39)
                                          :ARG2-of (m3 / mutate-01~e.66 :value "D594G"~e.55)
                                          :ARG0-of (a7 / act-01
                                                :ARG1 (k3 / kinase~e.57)
                                                :ARG1-of (i3 / impair-01~e.53))))
                              :mod (e9 / endogenous~e.31))))
            :condition (m4 / mutate-01~e.66
                  :ARG1 (p / protein-segment~e.40,64,81
                        :part-of (e10 / enzyme
                              :name (n7 / name :op1 "B-Raf"~e.37,39,78,80))
                        :destination-of (f2 / feedback~e.63)))
            :ARG0-of (i4 / indicate-01~e.68
                  :ARG1~e.69 (i5 / inhibit-01~e.73
                        :ARG0 p2~e.70,71
                        :ARG1 (h3 / heterodimerize-00~e.75
                              :ARG1 (e12 / enzyme~e.13,17,77
                                    :name (n9 / name :op1 "B-Raf"~e.14,16,23,78,80)
                                    :ARG0-of~e.13,17,77 (c / cause-01~e.13,17,77
                                          :ARG1~e.13,77 (c2 / cancer~e.13,77)))
                              :ARG2 (e13 / enzyme
                                    :name (n10 / name :op1 "C-Raf"~e.16,21,23,80)))
                        :mod (a9 / also~e.72)))
            :ARG1-of (d / describe-01
                  :ARG0 (f4 / figure :mod "3D"~e.85)))
      :manner (e11 / examine-01~e.3
            :ARG0 w
            :ARG1 (a8 / affect-01~e.5
                  :ARG0~e.6 (p2 / phosphorylate-01~e.8
                        :subevent-of (f3 / feedback~e.7))
                  :ARG1 (p3 / possible
                        :domain (h2 / heterodimerize-00~e.75
                              :ARG1 e12
                              :ARG2 e13)))
            :time~e.0,61 (n8 / next~e.2)))

# ::tok Previous studies have shown that , for both normal and oncogenic B @-@ Raf proteins to heterodimerize with C @-@ Raf , the C @-@ terminal 14 @-@ 3 @-@ 3 binding site of C @-@ Raf ( S621 ) must be intact ( 11 , 27 ) ( Fig . 3E ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1 1-1.1 3-1 8-1.2.2.1.1.2 9-1.2 10-1.2.1.1.1 10-1.2.1.1.1.2 10-1.2.1.1.1.2.1 10-1.2.1.1.1.2.1.r 10-1.2.1.1.1.2.r 11-1.2.1.1.1.1.1 13-1.2.1.1.1.1.1 13-1.2.1.1.2.1.1 14-1.2.1.2.1.3 14-1.2.1.2.1.4.1 15-1.2.1.1.1 15-1.2.1.1.1.2 15-1.2.1.1.1.2.r 16-1.2.1.1 16-1.2.2.1 18-1.2.1.1.2.1.1 18-1.2.1.2.1.3.1.1 20-1.2.1.1.1.1.1 20-1.2.1.1.2.1.1 23-1.2.1.1.2.1.1 23-1.2.1.2.1.3.1.1 25-1.2.1.2.1.3.1.1 26-1.2.1.2.1.4.1.1.1 28-1.2.1.2.1.4.1.1.1 30-1.2.1.2.1.4.1.1.1 31-1.2.1.2.1.4 32-1.2.1.2.1.3 33-1.2.1.1.2.r 34-1.2.1.1.2.1.1 36-1.2.1.1.1.1.1 36-1.2.1.1.2.1.1 36-1.2.2.1.1.1.1 41-1.2.1.2.1.r 42-1.2.1.2 44-1.1.2.1.1 46-1.1.2.1.2 51-1.2.3.1.1
# ::id bio.mskcc_0001.23
# ::preferred 
(s / show-01~e.3
      :ARG0 (s2 / study~e.1
            :time (p / previous~e.0)
            :ARG1-of (c / cite-01
                  :ARG2 (a / and :op1 "11"~e.44 :op2 "27"~e.46)))
      :ARG1 (a2 / and~e.9
            :op1 (r / require-01
                  :ARG0 (h / heterodimerize-00~e.16
                        :ARG1 (e / enzyme~e.10,15
                              :name (n / name :op1 "B-Raf"~e.11,13,20,36)
                              :ARG0-of~e.10,15 (c2 / cause-01~e.10,15
                                    :ARG1~e.10 (c3 / cancer~e.10)))
                        :ARG2~e.33 (e2 / enzyme
                              :name (n2 / name :op1 "C-Raf"~e.13,18,20,23,34,36)))
                  :ARG1 (i / intact~e.42
                        :domain~e.41 (a3 / amino-acid
                              :mod "621"
                              :name (n3 / name :op1 "serine")
                              :part-of (p2 / protein-segment~e.14,32
                                    :name (n4 / name :op1 "C-terminus"~e.18,23,25)
                                    :part-of e2)
                              :ARG1-of (b / bind-01~e.31
                                    :ARG2 (p3 / protein~e.14
                                          :name (n5 / name :op1 "14-3-3"~e.26,28,30))))))
            :op2 (r2 / require-01
                  :ARG0 (h2 / heterodimerize-00~e.16
                        :ARG1 (e3 / enzyme
                              :name (n6 / name :op1 "B-Raf"~e.36)
                              :mod (n7 / normal~e.8))
                        :ARG2 e2)
                  :ARG1 i)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "3E"~e.51))))

# ::tok To determine whether binding of 14 @-@ 3 @-@ 3 to B @-@ Raf is also required for heterodimerization , B @-@ Raf proteins containing lanine substitutions in the two 14 @-@ 3 @-@ 3 binding sites , S365 and S729 ( 2 ) , were examined for their abilities to heterodimerize with C @-@ Raf in response to growth factor treatment .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.2 2-1.1.1 2-1.2.1.1 2-1.2.1.1.r 3-1.2.1.3 4-1.2.1.3.1.r 5-1.2.1.3.1 6-1.2.1.3.1 7-1.2.1.3.1 8-1.2.1.3.1 9-1.2.1.3.1 11-1.1.2.1.1.1 13-1.1.2.1.1.1 13-1.1.2.2.1.1 14-1.1.2.r 15-1.2.1.4 16-1.2.1 17-1.2.1.2.r 18-1.2.1.2 20-1.1.2.1.1.1 22-1.1.2.1.1.1 22-1.1.2.2.1.1 23-1.1.2.1.2.2.1.3.1 26-1.1.2.1.2 26-1.1.2.1.2.2 26-1.1.2.1.2.2.r 26-1.1.2.1.3 26-1.1.2.1.3.2 26-1.1.2.1.3.2.r 30-1.1.2.1.2.2.1.3.1.1.1 32-1.1.2.1.2.2.1.3.1.1.1 34-1.1.2.1.2.2.1.3.1.1.1 35-1.1.2.1.2.2.1.3 35-1.1.2.1.3.2.1.3 45-1.1.2.r 46-1 51-1.1.2 52-1.1.2.2.r 53-1.1.2.2.1.1 55-1.1.2.1.1.1 55-1.1.2.2.1.1 55-1.2.1.3.2.1.1 56-1.1.2.3.r 57-1.1.2.3 58-1.1.2.3.1.r 59-1.1.2.3.1.1.1.1 60-1.1.2.3.1.1.1.2 61-1.1.2.3.1
# ::id bio.mskcc_0001.24
# ::preferred 
(e / examine-01~e.46
      :ARG1 (p2 / possible
            :mode "interrogative"~e.2
            :domain~e.14,45 (h / heterodimerize-00~e.51
                  :ARG1 (e2 / enzyme
                        :name (n / name :op1 "B-Raf"~e.11,13,20,22,55)
                        :part (a / amino-acid~e.26
                              :name (n2 / name :op1 "alanine")
                              :ARG1-of~e.26 (s / substitute-01~e.26
                                    :ARG3 (a2 / amino-acid
                                          :mod "365"
                                          :name (n3 / name :op1 "serine")
                                          :ARG1-of (b / bind-01~e.35
                                                :ARG2 (p / protein~e.23
                                                      :name (n6 / name :op1 "14-3-3"~e.30,32,34))))))
                        :part (a3 / amino-acid~e.26
                              :name (n4 / name :op1 "alanine")
                              :ARG1-of~e.26 (s2 / substitute-01~e.26
                                    :ARG2 (a4 / amino-acid
                                          :mod "729"
                                          :name (n5 / name :op1 "serine")
                                          :ARG1-of (b2 / bind-01~e.35
                                                :ARG2 p)))))
                  :ARG2~e.52 (e3 / enzyme
                        :name (n7 / name :op1 "C-Raf"~e.13,22,53,55))
                  :ARG0-of~e.56 (r / respond-01~e.57
                        :ARG1~e.58 (t / treat-04~e.61
                              :ARG2 (s3 / small-molecule
                                    :name (n8 / name :op1 "growth"~e.59 :op2 "factor"~e.60))))))
      :purpose (d / determine-01~e.1
            :ARG1 (r2 / require-01~e.16
                  :mode~e.2 "interrogative"~e.2
                  :ARG0~e.17 (h2 / heterodimerize-00~e.18
                        :ARG1 (e4 / enzyme
                              :name (n9 / name :op1 "B-Raf"~e.55))
                        :ARG2 e3)
                  :ARG1 (b3 / bind-01~e.3
                        :ARG1~e.4 p~e.5,6,7,8,9
                        :ARG2 e4)
                  :mod (a5 / also~e.15))))

# ::tok Not surprisingly , given that mutation of the S365 14 @-@ 3 @-@ 3 binding site enhances the membrane localization of B @-@ Raf ( 2 ) , increased heterodimerization with C @-@ Raf was observed for S365A B @-@ Raf compared to WT B @-@ Raf ( Fig . 3F ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.4.1 0-1.1.4.1.r 1-1.1.4 5-1.1.1.1 5-1.1.1.1.2 5-1.1.1.1.2.r 5-1.1.3.1.1 9-1.1.3.1.1.1.3.1.1.1 11-1.1.3.1.1.1.3.1.1.1 13-1.1.3.1.1.1.3.1.1.1 14-1.1.3.1.1.1.3 16-1.1.3.1 18-1.1.3.1.2.2 21-1.1.2.1.1.1 23-1.1.1.2.1.1 25-1.1.3.1.3.1.1.1 28-1.1 29-1.1.1 29-1.1.2 31-1.1.1.2.1.1 33-1.1.1.1.1.1 33-1.1.1.2.1.1 35-1 37-1.1.1.1.2.1 38-1.1.1.1.1.1 40-1.1.1.1.1.1 41-1.1.2.r 43-1.1.2.1.2 44-1.1.1.1.1.1 44-1.1.2.1.1.1 46-1.1.1.1.1.1 46-1.1.2.1.1.1 50-1.1.5.1.1
# ::id bio.mskcc_0001.25
# ::preferred 
(o / observe-01~e.35
      :ARG1 (i / increase-01~e.28
            :ARG1 (h / heterodimerize-00~e.29
                  :ARG1 (e / enzyme~e.5
                        :name (n / name :op1 "B-Raf"~e.33,38,40,44,46)
                        :ARG2-of~e.5 (m / mutate-01~e.5 :value "S365A"~e.37))
                  :ARG2 (e2 / enzyme
                        :name (n2 / name :op1 "C-Raf"~e.23,31,33)))
            :compared-to~e.41 (h2 / heterodimerize-00~e.29
                  :ARG1 (e3 / enzyme
                        :name (n3 / name :op1 "B-Raf"~e.21,44,46)
                        :mod (w / wild-type~e.43))
                  :ARG2 e2)
            :ARG1-of (c / cause-01
                  :ARG0 (e4 / enhance-01~e.16
                        :ARG0 (m2 / mutate-01~e.5
                              :ARG1 (a / amino-acid
                                    :mod "365"
                                    :name (n4 / name :op1 "serine")
                                    :ARG1-of (b / bind-01~e.14
                                          :ARG2 (p / protein
                                                :name (n5 / name :op1 "14-3-3"~e.9,11,13)))))
                        :ARG1 (b2 / be-located-at-91
                              :ARG1 e2
                              :ARG2 (m3 / membrane~e.18))
                        :ARG1-of (d / describe-01
                              :ARG0 (p2 / publication
                                    :ARG1-of (c2 / cite-01 :ARG2 "2"~e.25)))))
            :ARG0-of (s / surprise-01~e.1 :polarity~e.0 "-"~e.0)
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "3F"~e.50))))

# ::tok In contrast , S729A B @-@ Raf failed to heterodimerize with C @-@ Raf in response to growth factor treatment , and mutation of this site disrupted the constitutive interaction of oncogenic B @-@ Raf proteins and C @-@ Raf ( Fig . 3F ) , indicating that heterodimerization with C @-@ Raf is dependent on the C @-@ terminal S729 14 @-@ 3 @-@ 3 binding site of B @-@ Raf .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1 3-1.1.1.1.1.2.1 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 6-1.1.1.1.2.1.1 7-1.1.1 9-1.1.1.1 10-1.1.1.1.2.r 11-1.1.1.1.2.1.1 13-1.1.1.1.1.1.1 13-1.1.1.1.2.1.1 14-1.1.1.1.3.r 15-1.1.1.1.3 16-1.1.1.1.3.1.r 17-1.1.1.1.3.1.1.1.1 18-1.1.1.1.3.1.1.1.2 19-1.1.1.1.3.1 22-1.1.1.1.1 22-1.1.1.1.1.2 22-1.1.1.1.1.2.r 25-1.1.4.1.2.3 26-1.1.2 28-1.1.2.2.3 29-1.1.2.2 30-1.1.2.2.1.r 31-1.1.2.2.1 31-1.1.2.2.1.2 31-1.1.2.2.1.2.1 31-1.1.2.2.1.2.1.r 31-1.1.2.2.1.2.r 32-1.1.1.1.1.1.1 32-1.1.2.2.1.1.1 32-1.1.4.1.1.1.1.1 34-1.1.1.1.1.1.1 34-1.1.1.1.2.1.1 34-1.1.2.2.1.1.1 34-1.1.4.1.1.1.1.1 35-1.1.4.1.2.3 35-1.1.4.1.2.4.1 36-1.1 37-1.1.1.1.2.1.1 37-1.1.4.1.2.3.1.1 39-1.1.1.1.1.1.1 39-1.1.1.1.2.1.1 39-1.1.2.2.1.1.1 39-1.1.4.1.1.1.1.1 43-1.1.3.1.1 46-1.1.4 48-1.1.4.1.1 50-1.1.4.1.2.3.1.1 52-1.1.4.1.1.1.1.1 54-1.1.4.1 57-1.1.4.1.2.3.1.1 59-1.1.4.1.2.3.1.1 61-1.1.4.1.2.4.1.1.1 63-1.1.4.1.2.4.1.1.1 65-1.1.4.1.2.4.1.1.1 66-1.1.4.1.2.4 67-1.1.4.1.2.3 69-1.1.1.1.1.1.1 69-1.1.2.2.1.1.1 71-1.1.1.1.1.1.1 71-1.1.1.1.2.1.1 71-1.1.2.2.1.1.1
# ::id bio.mskcc_0001.26
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (a / and~e.36
            :op1 (f / fail-01~e.7
                  :ARG1 (h / heterodimerize-00~e.9
                        :ARG1 (e / enzyme~e.22
                              :name (n / name :op1 "B-Raf"~e.4,6,13,32,34,39,69,71)
                              :ARG2-of~e.22 (m / mutate-01~e.22 :value "S729A"~e.3))
                        :ARG2~e.10 (e2 / enzyme
                              :name (n2 / name :op1 "C-Raf"~e.6,11,13,34,37,39,71))
                        :ARG0-of~e.14 (r / respond-01~e.15
                              :ARG1~e.16 (t / treat-04~e.19
                                    :ARG2 (s / small-molecule
                                          :name (n3 / name :op1 "growth"~e.17 :op2 "factor"~e.18))))))
            :op2 (d / disrupt-01~e.26
                  :ARG0 m
                  :ARG1 (i / interact-01~e.29
                        :ARG0~e.30 (e3 / enzyme~e.31
                              :name (n4 / name :op1 "B-Raf"~e.32,34,39,69,71)
                              :ARG0-of~e.31 (c2 / cause-01~e.31
                                    :ARG1~e.31 (c3 / cancer~e.31)))
                        :ARG1 e2
                        :mod (c4 / constitutive~e.28)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure :mod "3F"~e.43))
            :ARG0-of (i2 / indicate-01~e.46
                  :ARG1 (d3 / depend-01~e.54
                        :ARG0 (h2 / heterodimerize-00~e.48
                              :ARG1 (e4 / enzyme
                                    :name (n5 / name :op1 "B-Raf"~e.32,34,39,52))
                              :ARG2 e2)
                        :ARG1 (a2 / amino-acid
                              :mod "729"
                              :name (n6 / name :op1 "serine")
                              :part-of (p / protein-segment~e.25,35,67
                                    :name (n7 / name :op1 "C-terminus"~e.37,50,57,59)
                                    :part-of e4)
                              :ARG1-of (b / bind-01~e.66
                                    :ARG2 (p2 / protein~e.35
                                          :name (n8 / name :op1 "14-3-3"~e.61,63,65))))))))

# ::tok Previous studies have found that all oncogenic B @-@ Raf proteins can activate C @-@ Raf and that heterodimerization with C @-@ Raf is required for kinase @-@ impaired oncogenic B @-@ Raf proteins to mediate ERK activation in vivo ( 31 ) .
# ::amr-annotator ISI-AMR-03
# ::alignments 0-1.1.1 1-1.1 3-1 4-1.2.r 5-1.2.1.1.1.3 6-1.2.1.1.1 6-1.2.1.1.1.2 6-1.2.1.1.1.2.1 6-1.2.1.1.1.2.1.r 6-1.2.1.1.1.2.r 7-1.2.1.1.1.1.1 9-1.2.1.1.1.1.1 9-1.2.1.1.2.1.1 11-1.2.1 12-1.2.1.1 13-1.2.1.1.2.1.1 15-1.2.1.1.1.1.1 15-1.2.1.1.2.1.1 16-1.2 17-1.2.r 18-1.2.2.2 20-1.2.1.1.2.1.1 22-1.2.1.1.1.1.1 22-1.2.1.1.2.1.1 23-1.2.1.1.r 24-1.2.2 25-1.2.2.2.1.r 26-1.2.2.2.1.3.1 28-1.2.2.2.1.3.2 29-1.2.2.2.1 29-1.2.2.2.1.2 29-1.2.2.2.1.2.1 29-1.2.2.2.1.2.1.r 29-1.2.2.2.1.2.r 30-1.2.2.2.1.1.1 32-1.2.2.2.1.1.1 35-1.2.2.1 36-1.2.2.1.2.1.1.1 37-1.2.2.1.2 38-1.2.2.1.2.2 39-1.2.2.1.2.2 41-1.1.2.1
# ::id bio.mskcc_0001.27
# ::preferred 
(f / find-01~e.3
      :ARG0 (s / study~e.1
            :time (p / previous~e.0)
            :ARG1-of (c5 / cite-01 :ARG2 "31"~e.41))
      :ARG1~e.4,17 (a / and~e.16
            :op1 (p2 / possible~e.11
                  :domain~e.23 (a2 / activate-01~e.12
                        :ARG0 (e / enzyme~e.6
                              :name (n / name :op1 "B-Raf"~e.7,9,15,22)
                              :ARG0-of~e.6 (c / cause-01~e.6
                                    :ARG1~e.6 (c2 / cancer~e.6))
                              :mod (a5 / all~e.5))
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "C-Raf"~e.9,13,15,20,22))))
            :op2 (r / require-01~e.24
                  :ARG0 (m / mediate-01~e.35
                        :ARG0 (e3 / enzyme~e.29
                              :name (n3 / name :op1 "B-Raf"~e.30,32)
                              :ARG0-of~e.29 (c3 / cause-01~e.29
                                    :ARG1~e.29 (c4 / cancer~e.29))
                              :ARG0-of (a3 / act-01
                                    :ARG1 (k / kinase~e.26)
                                    :ARG1-of (i / impair-01~e.28)))
                        :ARG1 (a4 / activate-01~e.37
                              :ARG1 (e4 / enzyme
                                    :name (n4 / name :op1 "ERK"~e.36))
                              :manner (i2 / in-vivo~e.38,39)))
                  :ARG1 (h / heterodimerize-00~e.18
                        :ARG1~e.25 e3
                        :ARG2 e2))))

# ::tok Therefore , to further investigate both the impact of feedback phosphorylation and the contribution of heterodimerization to oncogenic B @-@ Raf function , we examined the transformation potential of oncogenic B @-@ Raf proteins containing mutations in either the feedback phosphorylation sites ( which exhibit increased heterodimerization ) or the S729 14 @-@ 3 @-@ 3 binding site ( which are unable to heterodimerize ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2.1.1 2-1.1.2.1.1.2 2-1.1.2.1.1.2.r 3-1.1.3.3 4-1.1.3 7-1.1.3.2.1 8-1.1.3.2.1.1.r 9-1.1.3.2.1.1.1 10-1.1.3.2.1.1 11-1.1.3.2 13-1.1.3.2.2 14-1.1.3.2.2.1.r 15-1.1.3.2.2.1 16-1.1.2.1.1 16-1.1.2.1.1.2 16-1.1.2.1.1.2.r 17-1.1.2.1.1 17-1.1.2.1.1.2 17-1.1.2.1.1.2.1 17-1.1.2.1.1.2.1.r 17-1.1.2.1.1.2.r 18-1.1.2.1.1.1.1 18-1.1.3.2.2.2.1.1.1 20-1.1.2.1.1.1.1 20-1.1.3.2.2.2.1.1.1 21-1.1.3.2.2.2 23-1.1.1 24-1.1 26-1.1.2.1 29-1.1.2.1.1 29-1.1.2.1.1.2 29-1.1.2.1.1.2.1 29-1.1.2.1.1.2.1.r 29-1.1.2.1.1.2.r 30-1.1.2.1.1.1.1 32-1.1.2.1.1.1.1 33-1.1.2.1.1.3.1.1 35-1.1.2.1.1.3 39-1.1.2.1.1.3.1.1.1.1 40-1.1.2.1.1.3.1.1.1 41-1.1.2.1.1.3.1.1 44-1.1.2.1.1.3.1.1.2 45-1.1.2.1.1.3.1.1.2.1.1 46-1.1.2.1.1.3.1.1.2.1 48-1.1.2.1.1.3.1 51-1.1.2.1.1.3.1.2.3.1.1.1 53-1.1.2.1.1.3.1.2.3.1.1.1 55-1.1.2.1.1.3.1.2.3.1.1.1 56-1.1.2.1.1.3.1.2.3 57-1.1.2.1.1.3.1.1 61-1.1.2 61-1.1.2.1.1.3.1.2.4.1 61-1.1.2.1.1.3.1.2.4.1.1 61-1.1.2.1.1.3.1.2.4.1.1.r 63-1.1.2.1.1.3.1.2 63-1.1.2.1.1.3.1.2.4 63-1.1.2.1.1.3.1.2.4.r
# ::id bio.mskcc_0001.28
# ::preferred 
(i / infer-01~e.0
      :ARG1 (e / examine-01~e.24
            :ARG0 (w / we~e.23)
            :ARG1 (p / possible~e.61
                  :domain (t / transform-01~e.26
                        :ARG0 (e2 / enzyme~e.2,16,17,29
                              :name (n / name :op1 "B-Raf"~e.18,20,30,32)
                              :ARG0-of~e.2,16,17,29 (c / cause-01~e.2,16,17,29
                                    :ARG1~e.17,29 (c2 / cancer~e.17,29))
                              :ARG2-of (m / mutate-01~e.35
                                    :ARG1 (o / or~e.48
                                          :op1 (p2 / protein-segment~e.33,41,57
                                                :ARG1-of (p3 / phosphorylate-01~e.40
                                                      :subevent-of (f / feedback~e.39))
                                                :ARG0-of (e3 / exhibit-01~e.44
                                                      :ARG1 (h / heterodimerize-00~e.46
                                                            :ARG1-of (i2 / increase-01~e.45))))
                                          :op2 (a / amino-acid~e.63
                                                :mod "729"
                                                :name (n4 / name :op1 "serine")
                                                :ARG1-of (b / bind-01~e.56
                                                      :ARG2 (p4 / protein
                                                            :name (n2 / name :op1 "14-3-3"~e.51,53,55)))
                                                :ARG0-of~e.63 (h2 / heterodimerize-00~e.63
                                                      :mod (p5 / possible~e.61 :polarity~e.61 "-"~e.61))))))))
            :purpose (i3 / investigate-01~e.4
                  :ARG0 w
                  :ARG1 (a2 / and~e.11
                        :op1 (i4 / impact-01~e.7
                              :ARG0~e.8 (p6 / phosphorylate-01~e.10
                                    :subevent-of (f3 / feedback~e.9))
                              :ARG1 (f4 / function-01~e.21
                                    :ARG0 (e4 / enzyme
                                          :name (n3 / name :op1 "B-Raf"~e.18,20)
                                          :ARG0-of c)))
                        :op2 (c4 / contribute-01~e.13
                              :ARG0~e.14 (h3 / heterodimerize-00~e.15)
                              :ARG2 f4))
                  :degree (f2 / further~e.3))))

# ::tok For these studies , FBm or S729A mutations were incorporated into a number of oncogenic B @-@ Raf proteins that exhibit various levels of kinase activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 2-1.3 5-1.1 6-1.1.2.2.1 7-1.1.1 7-1.1.1.2 7-1.1.1.2.r 7-1.1.2 7-1.1.2.2 7-1.1.2.2.r 9-1 9-1.1.1.3.1 10-1.1.1.3.2.1.r 10-1.2.r 12-1.2.3 13-1.2.3.r 14-1.2 14-1.2.2 14-1.2.2.1 14-1.2.2.1.r 14-1.2.2.r 15-1.1.1.1.1 15-1.1.2.1.1 15-1.2.1.1 17-1.1.1.1.1 17-1.1.2.1.1 17-1.2.1.1 18-1.1.1.3.2 20-1.2.4 21-1.2.4.1.1 22-1.2.4.1 24-1.2.4.1.2.1
# ::id bio.mskcc_0001.29
# ::preferred 
(i / incorporate-02~e.9
      :ARG1 (o / or~e.5
            :op1 (e3 / enzyme~e.7
                  :name (n3 / name :op1 "B-Raf"~e.15,17)
                  :ARG2-of~e.7 (m / mutate-01~e.7)
                  :ARG1-of (h / have-part-91
                        :polarity "-"~e.9
                        :ARG2 (p / protein-segment~e.18
                              :destination-of~e.10 (f / feedback))))
            :op2 (e4 / enzyme~e.7
                  :name (n4 / name :op1 "B-Raf"~e.15,17)
                  :ARG2-of~e.7 (m2 / mutate-01~e.7 :value "S729A"~e.6)))
      :ARG2~e.10 (e / enzyme~e.14
            :name (n / name :op1 "B-Raf"~e.15,17)
            :ARG0-of~e.14 (c / cause-01~e.14
                  :ARG1~e.14 (c2 / cancer~e.14))
            :quant~e.13 (n2 / number~e.12)
            :ARG0-of (e2 / exhibit-01~e.20
                  :ARG1 (l / level~e.22
                        :mod (v / various~e.21)
                        :mod (a / act-01
                              :ARG1 (k / kinase~e.24)))))
      :purpose (s / study~e.2
            :mod (t / this~e.1)))

# ::tok The proteins were then expressed in NIH 3T3 cells and examined for their abilities to alter cell morphology and induce focus formation .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 3-1.3 4-1.1 5-1.1.2.r 6-1.1.2.1.1 7-1.1.2.1.2 8-1.1.2 9-1 10-1.2 12-1.2.1.2.1.1 12-1.2.1.2.1.1.r 15-1.2.1.2.1 16-1.2.1.2.1.2.1 17-1.2.1.2.1.2 18-1.2.1.2 19-1.2.1.2.2 20-1.2.1.2.2.2.1 21-1.2.1.2.2.2
# ::id bio.mskcc_0001.30
# ::preferred 
(a / and~e.9
      :op1 (e / express-03~e.4
            :ARG2 (p / protein~e.1)
            :ARG3~e.5 (c / cell-line~e.8
                  :name (n / name :op1 "NIH"~e.6 :op2 "3T3"~e.7)))
      :op2 (e2 / examine-01~e.10
            :ARG1 (p2 / possible
                  :mode "interrogative"
                  :domain (a2 / and~e.18
                        :op1 (a3 / alter-01~e.15
                              :ARG0~e.12 p~e.12
                              :ARG1 (m / morphology~e.17
                                    :mod (c2 / cell~e.16)))
                        :op2 (i / induce-01~e.19
                              :ARG0 p
                              :ARG1 (f / form-01~e.21
                                    :ARG1 (f2 / focus~e.20))))))
      :time (t / then~e.3))

# ::tok As shown in Fig. 4A , the FBm or S729A mutation had no effect on transformation induced by the V600E or G469A B @-@ Raf protein , both of which possess high kinase activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 4-1.4.1.1 8-1.2 9-1.2.2.1 10-1.2.1 10-1.2.2 10-1.3.1.1.1 10-1.3.1.1.1.2 10-1.3.1.1.1.2.r 10-1.3.1.1.2 10-1.3.1.1.2.2 10-1.3.1.1.2.2.r 11-1.2.1.1.2 12-1.1 12-1.1.r 12-1.2.1.1.2.1 12-1.2.1.1.2.1.r 13-1 14-1.3.r 15-1.3 16-1.3.1 17-1.3.1.1.r 19-1.3.1.1.1.2.1 20-1.3.1.1 21-1.3.1.1.2.2.1 22-1.2.1.1.1.1 22-1.3.1.1.1.1.1 22-1.3.1.1.2.1.1 24-1.2.1.1.1.1 24-1.3.1.1.1.1.1 24-1.3.1.1.2.1.1 25-1.2.1.1.2.2 31-1.3.1.1.3.2 32-1.3.1.1.3.1
# ::id bio.mskcc_0001.31
# ::preferred 
(a2 / affect-01~e.13
      :polarity~e.12 "-"~e.12
      :ARG0 (o / or~e.8
            :op1 (m / mutate-01~e.10
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "B-Raf"~e.22,24)
                        :ARG1-of (h2 / have-part-91~e.11
                              :polarity~e.12 "-"~e.12
                              :ARG2 (p / protein-segment~e.25
                                    :destination-of (f2 / feedback)))))
            :op2 (m3 / mutate-01~e.10 :value "S729A"~e.9))
      :ARG1~e.14 (t / transform-01~e.15
            :ARG1-of (i / induce-01~e.16
                  :ARG0~e.17 (o2 / or~e.20
                        :op1 (e2 / enzyme~e.10
                              :name (n2 / name :op1 "B-Raf"~e.22,24)
                              :ARG2-of~e.10 (m4 / mutate-01~e.10 :value "V600E"~e.19))
                        :op2 (e3 / enzyme~e.10
                              :name (n3 / name :op1 "B-Raf"~e.22,24)
                              :ARG2-of~e.10 (m5 / mutate-01~e.10 :value "G469A"~e.21))
                        :ARG0-of (a / act-01
                              :ARG1 (k / kinase~e.32)
                              :mod (h / high~e.31)))))
      :ARG1-of (s / show-01~e.1
            :ARG0 (f / figure :mod "4A"~e.4)))

# ::tok However , mutation of the feedback sites significantly increased the transforming activities of B @-@ Raf proteins with intermediate or impaired kinase activity ( Fig . 4A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 3-1.1.1.1.r 5-1.1.1.1.1 6-1.1.1.1 7-1.1.3 8-1.1 10-1.1.2.3 13-1.1.2.1.1.1.1 13-1.1.2.2.1.1.1 15-1.1.2.1.1.1.1 15-1.1.2.2.1.1.1 16-1.1.1.1 18-1.1.2.1.3 19-1.1.2 20-1.1.2.2.3 21-1.1.2.2.2 26-1.1.4.1.1
# ::id bio.mskcc_0001.32
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (i / increase-01~e.8
            :ARG0 (m / mutate-01~e.2
                  :ARG1~e.3 (p / protein-segment~e.6,16
                        :destination-of (f / feedback~e.5)))
            :ARG1 (o / or~e.19
                  :op1 (a3 / act-01
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "B-Raf"~e.13,15))
                        :ARG1 (k / kinase~e.21)
                        :degree (i3 / intermediate~e.18))
                  :op2 (a2 / act-01
                        :ARG0 (e2 / enzyme
                              :name (n2 / name :op1 "B-Raf"~e.13,15))
                        :ARG1 k
                        :ARG1-of (i2 / impair-01~e.20))
                  :ARG0-of (t / transform-01~e.10))
            :ARG2 (s / significant-02~e.7)
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure :mod "4A"~e.26))))

# ::tok The total number of foci observed and , often , the sizes of the foci were increased , and cells within the foci exhibited a more transformed appearance .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1 2-1.1.1.1 3-1.1.1.1.1.1.r 4-1.1.1.1.1.1 5-1.1.1.1.1.1.1 6-1.1.1 8-1.1.2 11-1.1.1.2 12-1.1.1.2.1.r 14-1.1.1.2.1 16-1.1 18-1 18-1.1.1 19-1.2.1 22-1.2.1.1 23-1.2 25-1.2.2.2.1 26-1.2.2.2 27-1.2.2
# ::id bio.mskcc_0001.33
# ::preferred 
(a / and~e.18
      :op1 (i / increase-01~e.16
            :ARG1 (a3 / and~e.6,18
                  :op1 (n / number~e.2
                        :ARG2-of (t / total-01~e.1
                              :ARG1~e.3 (f / focus~e.4
                                    :ARG1-of (o / observe-01~e.5))))
                  :op2 (s / size~e.11
                        :poss~e.12 f~e.14))
            :frequency (o2 / often~e.8))
      :op3 (e / exhibit-01~e.23
            :ARG0 (c / cell~e.19
                  :location f~e.22)
            :ARG1 (a2 / appear-02~e.27
                  :ARG1 c
                  :ARG1-of (t2 / transform-01~e.26
                        :degree (m / more~e.25)))))

# ::tok In contrast , the S729A mutation reduced the transforming activities of the oncogenic proteins with intermediate or impaired kinase activity , causing a reduction in focus number and a flatter cell morphology ( Fig . 4A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 4-1.1.1.1 5-1.1.1 6-1.1 8-1.1.2.3 12-1.1.2.1.1.1 12-1.1.2.1.1.1.1 12-1.1.2.1.1.1.1.r 13-1.1.2.1.1 13-1.1.2.2.1 15-1.1.2.1.3 16-1.1.2 17-1.1.2.2.3 18-1.1.2.1.2 21-1.1.3 23-1.1.3.1.1 24-1.1.3.1.1.1.r 25-1.1.3.1.1.1.1 26-1.1.3.1.1.1 27-1.1.3.1 29-1.1.3.1.2.2 29-1.1.3.1.2.2.1 29-1.1.3.1.2.2.1.r 30-1.1.3.1.2.1 31-1.1.3.1.2 35-1.1.4.1.1
# ::id bio.mskcc_0001.34
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (r / reduce-01~e.6
            :ARG0 (m / mutate-01~e.5 :value "S729A"~e.4)
            :ARG1 (o2 / or~e.16
                  :op1 (a / act-01
                        :ARG0 (p / protein~e.13
                              :ARG0-of (c2 / cause-01~e.12
                                    :ARG1~e.12 (c3 / cancer~e.12)))
                        :ARG1 (k / kinase~e.18)
                        :degree (i / intermediate~e.15))
                  :op2 (a2 / act-01
                        :ARG0 (p2 / protein~e.13
                              :ARG0-of c2)
                        :ARG1 k
                        :ARG1-of (i2 / impair-01~e.17))
                  :ARG0-of (t / transform-01~e.8))
            :ARG0-of (c4 / cause-01~e.21
                  :ARG1 (a4 / and~e.27
                        :op1 (r2 / reduce-01~e.23
                              :ARG1~e.24 (n / number~e.26
                                    :quant-of (f / focus~e.25)))
                        :op2 (m2 / morphology~e.31
                              :mod (c5 / cell~e.30)
                              :mod (f2 / flat~e.29
                                    :degree~e.29 (m3 / more~e.29)))))
            :ARG1-of (d / describe-01
                  :ARG0 (f3 / figure :mod "4A"~e.35))))

# ::tok Examination of activated phospho @-@ MEK levels revealed that the FBm and S729 mutations had no effect on MEK activation induced by the high @-@ activity V600E B @-@ Raf protein ; however , the FBm and S729A mutations increased and decreased , respectively , the abilities of the intermediate G466A and kinase @-@ impaired D594G B @-@ Raf proteins to activate MEK ( Fig . 4B ) , indicating a correlation between the transformation potential of these proteins and their ability to activate ERK cascade signaling in vivo .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.3 5-1.1.1.1.1.1 6-1.1.1 7-1 11-1.2.1.2 13-1.2.1.2.1 13-1.2.1.2.2 14-1.2.1.2.1.1.2 15-1.2.1.1 15-1.2.1.1.r 15-1.2.1.2.1.1.2.1 15-1.2.1.2.1.1.2.1.r 16-1.2.1 17-1.2.1.3.r 18-1.2.1.3.1.1.1 19-1.2.1.3 20-1.2.1.3.2 23-1.2.1.3.2.1.3.1 25-1.2.1.3.2.1.3 26-1.2.1.3.2.1.2.1 27-1.2.1.2.1.1.1.1 27-1.2.1.3.2.1.1.1 29-1.2.1.2.1.1.1.1 29-1.2.1.3.2.1.1.1 30-1.2.1.2.1.1.2.2 32-1.2 36-1.2.2.1.1 37-1.2.2.1.1.2.1 38-1.2.1.3.2.1 38-1.2.1.3.2.1.2 38-1.2.1.3.2.1.2.r 38-1.2.2.1.1.2 38-1.2.2.1.2.1.1.1 38-1.2.2.1.2.1.1.1.2 38-1.2.2.1.2.1.1.1.2.r 38-1.2.2.1.2.1.1.2 38-1.2.2.1.2.1.1.2.2 38-1.2.2.1.2.1.1.2.2.r 39-1.2.2.1 40-1.2.2 40-1.2.2.1.1 41-1.2.2.2 43-1.2.2.3 47-1.2.2.1.2.1.1.1.2.2.r 49-1.2.2.1.2.1.1.1.2.2 50-1.2.2.1.2.1.1.1.2.1 52-1.2.2.1.2.1.1.2.3.1 54-1.2.2.1.2.1.1.2.3 55-1.2.2.1.2.1.1.2.2.1 56-1.2.1.2.1.1.1.1 56-1.2.1.3.2.1.1.1 56-1.2.2.1.2.1.1.2.1.1 58-1.2.1.2.1.1.1.1 58-1.2.1.3.2.1.1.1 58-1.2.2.1.2.1.1.1.1.1 58-1.2.2.1.2.1.1.2.1.1 59-1.2.1.2.1.1.2.2 60-1.2.1.2.1.1.2.2.1.r 60-1.2.2.r 61-1.2.2.5.1.2.1 62-1.2.1.3.1.1.1 66-1.2.2.4.1.1 69-1.2.2.5 71-1.2.2.5.1 74-1.2.2.5.1.1.1 78-1.2.1.2.1.1.2.2 83-1.2.2.1.2.1 83-1.2.2.5.1.2.1 84-1.2.2.5.1.2.1.2.1.1.1 85-1.2.2.5.1.2.1.2.3 86-1.2.2.5.1.2.1.2 87-1.2.2.5.1.2.1.2.2 88-1.2.2.5.1.2.1.2.2
# ::id bio.mskcc_0001.35
# ::preferred 
(r2 / reveal-01~e.7
      :ARG0 (e / examine-01~e.0
            :ARG1~e.1 (l / level~e.6
                  :degree-of (e2 / enzyme
                        :name (n / name :op1 "MEK"~e.5)
                        :ARG3-of (p / phosphorylate-01)
                        :ARG1-of (a / activate-01~e.2))))
      :ARG1 (c / contrast-01~e.32
            :ARG1 (a2 / affect-01~e.16
                  :polarity~e.15 "-"~e.15
                  :ARG0 (a3 / and~e.11
                        :op1 (m7 / mutate-01~e.13
                              :ARG1 (e9 / enzyme
                                    :name (n2 / name :op1 "B-Raf"~e.27,29,56,58)
                                    :ARG1-of (h2 / have-part-91~e.14
                                          :polarity~e.15 "-"~e.15
                                          :ARG2 (p5 / protein-segment~e.30,59,78
                                                :destination-of~e.60 (f2 / feedback)))))
                        :op2 (m / mutate-01~e.13
                              :ARG1 (a11 / amino-acid
                                    :mod "729"
                                    :name (n9 / name :op1 "serine"))))
                  :ARG1~e.17 (a4 / activate-01~e.19
                        :ARG1 (e3 / enzyme
                              :name (n3 / name :op1 "MEK"~e.18,62))
                        :ARG1-of (i / induce-01~e.20
                              :ARG0 (e4 / enzyme~e.38
                                    :name (n4 / name :op1 "B-Raf"~e.27,29,56,58)
                                    :ARG2-of~e.38 (m3 / mutate-01~e.38 :value "V600E"~e.26)
                                    :ARG0-of (a5 / act-02~e.25
                                          :degree (h / high~e.23))))))
            :ARG2~e.60 (a6 / and~e.40
                  :op1 (i2 / increase-01~e.39
                        :ARG0 (a7 / and~e.36,40
                              :op1 m7
                              :op2 (m4 / mutate-01~e.38 :value "S729A"~e.37))
                        :ARG1 (p2 / possible
                              :domain (a8 / activate-01~e.83
                                    :ARG0 (a9 / and
                                          :op1 (e5 / enzyme~e.38
                                                :name (n5 / name :op1 "B-Raf"~e.58)
                                                :ARG2-of~e.38 (m5 / mutate-01~e.38
                                                      :value "G466A"~e.50
                                                      :degree~e.47 (i3 / intermediate~e.49)))
                                          :op2 (e6 / enzyme~e.38
                                                :name (n6 / name :op1 "B-Raf"~e.56,58)
                                                :ARG2-of~e.38 (m6 / mutate-01~e.38 :value "D594G"~e.55)
                                                :mod (i4 / impair-01~e.54
                                                      :ARG1 (k / kinase~e.52))))
                                    :ARG1 e3)))
                  :op2 (d / decrease-01~e.41
                        :ARG0 a7)
                  :mod (r / respective~e.43)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f / figure :mod "4B"~e.66))
                  :ARG0-of (i5 / indicate-01~e.69
                        :ARG1 (c2 / correlate-01~e.71
                              :ARG1 (p3 / possible
                                    :domain (t / transform-01~e.74
                                          :ARG0 a9))
                              :ARG2 (p4 / possible
                                    :domain (a10 / activate-01~e.61,83
                                          :ARG0 a9
                                          :ARG1 (s / signal-07~e.86
                                                :ARG0 (e8 / enzyme
                                                      :name (n8 / name :op1 "ERK"~e.84))
                                                :manner (i6 / in-vivo~e.87,88)
                                                :subevent-of (c3 / cascade~e.85)))))))))

# ::tok Not unexpectedly , for all of the oncogenic B @-@ Raf proteins , the S729A mutation , which disrupts heterodimerization with C @-@ Raf , caused a >90 % decrease in C @-@ Raf activity levels ( Fig . 5B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.2.2 7-1.1.2 7-1.1.2.3 7-1.1.2.3.1 7-1.1.2.3.1.r 7-1.1.2.3.r 8-1.1.2.1.1 10-1.1.2.1.1 14-1.1.1 15-1.1 18-1.1.3 19-1.1.3.1 20-1.1.3.1.2.r 21-1.1.3.1.2.1.1 23-1.1.2.1.1 23-1.1.3.1.2.1.1 25-1 28-1.2.2.1 29-1.2 31-1.1.3.1.2.1.1 33-1.1.2.1.1 33-1.1.3.1.2.1.1 34-1.2.1.1 35-1.2.1 39-1.4.1.1
# ::id bio.mskcc_0001.36
# ::preferred 
(c / cause-01~e.25
      :ARG0 (m / mutate-01~e.15
            :value "S729A"~e.14
            :ARG2 (e / enzyme~e.7
                  :name (n / name :op1 "B-Raf"~e.8,10,23,33)
                  :mod (a / all~e.4)
                  :ARG0-of~e.7 (c2 / cause-01~e.7
                        :ARG1~e.7 (c3 / cancer~e.7)))
            :ARG0-of (d / disrupt-01~e.18
                  :ARG1 (h / heterodimerize-00~e.19
                        :ARG1 e
                        :ARG2~e.20 (e2 / enzyme
                              :name (n2 / name :op1 "C-Raf"~e.21,23,31,33)))))
      :ARG1 (d2 / decrease-01~e.29
            :ARG1 (l / level~e.35
                  :mod (a2 / act-02~e.34
                        :ARG0 e2))
            :ARG2 (m2 / more-than
                  :op1 (p / percentage-entity~e.28 :value "90")))
      :ARG1-of (e3 / expect-01)
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "5B"~e.39)))

# ::tok Together , these findings indicate a correlation between the changes in the transformation potentials of the intermediate and impaired oncogenic B @-@ Raf proteins and their abilities to heterodimerize and activate C @-@ Raf .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.2 3-1.1 3-1.1.1 3-1.1.1.r 4-1 6-1.2 9-1.2.1 12-1.2.1.1.1 14-1.2.1.1.1.1.r 16-1.2.1.1.1.1.1.2 17-1.2.1.1.1.1 18-1.2.1.1.1.1.2.2 19-1.2.1.1.1.1.1 19-1.2.1.1.1.1.1.3 19-1.2.1.1.1.1.1.3.1 19-1.2.1.1.1.1.1.3.1.r 19-1.2.1.1.1.1.1.3.r 20-1.2.1.1.1.1.1.1.1 20-1.2.1.1.1.1.2.1.1 22-1.2.1.1.1.1.1.1.1 22-1.2.1.1.1.1.2.1.1 24-1.2.1.1.1.1 25-1.2.2.1 25-1.2.2.1.r 26-1.2.2 27-1.2.2.2.r 28-1.2.2.2.1 29-1.2.2.2 30-1.2.2.2.2 31-1.2.2.2.1.2.1.1 33-1.2.2.2.1.2.1.1
# ::id bio.mskcc_0001.37
# ::preferred 
(i / indicate-01~e.4
      :ARG0 (t / thing~e.3
            :ARG1-of~e.3 (f / find-01~e.3)
            :mod (t2 / this~e.2))
      :ARG1 (c / correlate-01~e.6
            :ARG1 (c2 / change-01~e.9
                  :ARG1 (p / possible
                        :domain (t4 / transform-01~e.12
                              :ARG0~e.14 (a / and~e.17,24
                                    :op1 (e / enzyme~e.19
                                          :name (n / name :op1 "B-Raf"~e.20,22)
                                          :mod (i2 / intermediate~e.16)
                                          :ARG0-of~e.19 (c3 / cause-01~e.19
                                                :ARG1~e.19 (c4 / cancer~e.19)))
                                    :op2 (e2 / enzyme
                                          :name (n2 / name :op1 "B-Raf"~e.20,22)
                                          :ARG1-of (i3 / impair-01~e.18))))))
            :ARG2 (c5 / capable-01~e.26
                  :ARG1~e.25 a~e.25
                  :ARG2~e.27 (a2 / and~e.29
                        :op1 (h / heterodimerize-00~e.28
                              :ARG1 a
                              :ARG2 (e3 / enzyme
                                    :name (n3 / name :op1 "C-Raf"~e.31,33)))
                        :op2 (a3 / activate-01~e.30
                              :ARG0 a
                              :ARG1 e3))))
      :mod (t3 / together~e.0))

# ::tok To investigate the contributions of the various feedback sites to the overall effect of feedback phosphorylation on B @-@ Raf function , we generated a panel of mutants in which specific feedback phosphorylation sites were incorporated into either WT B @-@ Raf or the intermediate @-@ activity G466A B @-@ Raf protein .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.3.2 3-1.3.2.1 3-1.3.2.1.r 4-1.3.2.1.1.r 6-1.3.2.1.1.1 7-1.3.2.1.1.2 8-1.3.2.1.1 9-1.3.2.1.1.2.r 9-1.3.2.1.2.r 11-1.3.2.1.2.3 12-1.3.2.1.2 13-1.3.2.1.2.1.r 14-1.3.2.1.2.1 15-1.3.2.1.2.1 17-1.2.1.1.1 17-1.2.1.2.1.1.2.1.1.1 17-1.3.2.1.2.2.1.1.1 19-1.2.1.1.1 19-1.2.1.2.1.1.2.1.1.1 19-1.3.2.1.2.2.1.1.1 20-1.3.2.1.2.2 22-1.1 23-1 25-1.2 26-1.2.1.r 27-1.2.1 27-1.2.1.2 27-1.2.1.2.1.1.2.2 27-1.2.1.2.1.1.2.2.2 27-1.2.1.2.1.1.2.2.2.r 27-1.2.1.2.r 30-1.2.1.2.1.1.1.2.2 31-1.2.1.2.1.1.1.2.1 32-1.2.1.2.1.1.1.2 33-1.2.1.2.1.1.1 35-1.2.1.2.1.1 36-1.3.2.1.1.2.r 38-1.2.1.2.1.1.2.1.2 39-1.2.1.2.1.1.2.1.1.1 39-1.2.1.2.1.1.2.2.1.1 41-1.2.1.2.1.1.2.1.1.1 41-1.2.1.2.1.1.2.2.1.1 42-1.2.1.2.1.1.2 44-1.2.1.2.1.1.2.2.3.1 47-1.2.1.2.1.1.2.2.2.1 48-1.2.1.2.1.1.2.2.1.1 50-1.2.1.2.1.1.2.2.1.1 51-1.2.1.2.1.1.1
# ::id bio.mskcc_0001.38
# ::preferred 
(g / generate-01~e.23
      :ARG0 (w / we~e.22)
      :ARG1 (p / panel~e.25
            :consist-of~e.26 (e / enzyme~e.27
                  :name (n / name :op1 "B-Raf"~e.17,19)
                  :ARG2-of~e.27 (m / mutate-01~e.27
                        :ARG1-of (c2 / cause-01
                              :ARG0 (i / incorporate-02~e.35
                                    :ARG1 (p2 / protein-segment~e.33,51
                                          :part-of e
                                          :ARG1-of (p3 / phosphorylate-01~e.32
                                                :subevent-of (f / feedback~e.31)
                                                :mod (s / specific~e.30)))
                                    :ARG2 (o / or~e.42
                                          :op1 (e2 / enzyme
                                                :name (n2 / name :op1 "B-Raf"~e.17,19,39,41)
                                                :mod (w2 / wild-type~e.38))
                                          :op2 (e3 / enzyme~e.27
                                                :name (n3 / name :op1 "B-Raf"~e.39,41,48,50)
                                                :ARG2-of~e.27 (m2 / mutate-01~e.27 :value "G466A"~e.47)
                                                :ARG0-of (a / act-01
                                                      :degree (i2 / intermediate~e.44)))))))))
      :purpose (i3 / investigate-01~e.1
            :ARG0 w
            :ARG1 (t / thing~e.3
                  :ARG1-of~e.3 (c / contribute-01~e.3
                        :ARG0~e.4 (p4 / protein-segment~e.8
                              :mod (v / various~e.6)
                              :destination-of~e.9,36 f~e.7)
                        :ARG2~e.9 (a2 / affect-01~e.12
                              :ARG0~e.13 p3~e.14,15
                              :ARG1 (f2 / function-01~e.20
                                    :ARG0 (e4 / enzyme
                                          :name (n4 / name :op1 "B-Raf"~e.17,19)))
                              :mod (o2 / overall~e.11))))))

# ::tok The mutant proteins were then examined for their abilities to heterodimerize with C @-@ Raf and to bind activated Ras under conditions where feedback phosphorylation was induced ( in cycling cells for the G466A mutants and in cells treated with PDGF for 30 min for the WT B @-@ Raf mutants ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.1.1 2-1.1.2.1.1 3-1.1.2.r 4-1.2 5-1 10-1.1.2.1 11-1.1.2.1.2.r 12-1.1.2.1.2.1.1 14-1.1.2.1.2.1.1 15-1.1.2 15-1.1.2.1.1.2.1 17-1.1.2.2 18-1.1.2.2.1.2 19-1.1.2.2.1.1.1 21-1.1.2.3.r 22-1.1.2.1.1.2.1.1.3.r 22-1.1.2.1.1.2.1.2.4.r 23-1.1.2.3.1.1 24-1.1.2.3.1 26-1.1.2.3 29-1.1.2.1.1.2.1.1.3.1 30-1.1.2.1.1.2.1.1.3 33-1.1.2.1.1.2.1.1.2.1 34-1.1.2.1.1.2.1.1 34-1.1.2.1.1.2.1.1.2 34-1.1.2.1.1.2.1.1.2.r 35-1.1.2.1.1.2.1 37-1.1.2.1.1.2.1.2.4 38-1.1.2.1.1.2.1.2.4.1 39-1.1.2.1.1.2.1.2.4.1.1.r 40-1.1.2.1.1.2.1.2.4.1.1.1.1 41-1.1.2.1.1.2.1.2.4.1.2.r 42-1.1.2.1.1.2.1.2.4.1.2.1 46-1.1.2.1.1.2.1.2.3 47-1.1.2.1.1.2.1.1.1.1 47-1.1.2.1.1.2.1.2.1.1 49-1.1.2.1.1.2.1.1.1.1 49-1.1.2.1.1.2.1.2.1.1 50-1.1.2.1.1.2.1.1 50-1.1.2.1.1.2.1.1.2 50-1.1.2.1.1.2.1.1.2.r
# ::id bio.mskcc_0001.39
# ::preferred 
(e / examine-01~e.5
      :ARG1 (p2 / possible
            :mode "interrogative"
            :domain~e.3 (a / and~e.15
                  :op1 (h / heterodimerize-00~e.10
                        :ARG1 (p / protein~e.2
                              :ARG2-of (m / mutate-01~e.1)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (a3 / and~e.15,35
                                          :op1 (e4 / enzyme~e.34,50
                                                :name (n3 / name :op1 "B-Raf"~e.47,49)
                                                :ARG2-of~e.34,50 (m3 / mutate-01~e.34,50 :value "G466A"~e.33)
                                                :location~e.22 (c / cell~e.30
                                                      :mod (c2 / cycle~e.29)))
                                          :op2 (e5 / enzyme
                                                :name (n4 / name :op1 "B-Raf"~e.47,49)
                                                :ARG2-of m
                                                :mod (w / wild-type~e.46)
                                                :location~e.22 (c3 / cell~e.37
                                                      :ARG1-of (t2 / treat-04~e.38
                                                            :ARG2~e.39 (s / small-molecule
                                                                  :name (n5 / name :op1 "PDGF"~e.40))
                                                            :duration~e.41 (t3 / temporal-quantity
                                                                  :quant "30"~e.42
                                                                  :unit (m4 / minute))))))))
                        :ARG2~e.11 (e2 / enzyme
                              :name (n / name :op1 "C-Raf"~e.12,14)))
                  :op2 (b / bind-01~e.17
                        :ARG1 (e3 / enzyme
                              :name (n2 / name :op1 "Ras"~e.19)
                              :ARG1-of (a2 / activate-01~e.18)))
                  :condition~e.21 (i / induce-01~e.26
                        :ARG1 (p3 / phosphorylate-01~e.24
                              :subevent-of (f / feedback~e.23)))))
      :time (t / then~e.4))

# ::tok As shown in Fig. 6A , only mutation of the S151 feedback site , which is in close proximity to the Ras binding domain ( residues 155 to 227 ) , was found to significantly increase binding to activated Ras .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 4-1.2.1.1 6-1.1.1.2 7-1.1.1 11-1.1.1.1.3.1 12-1.1.1.1.3 16-1.1.1.1.3.2.r 17-1.1.1.1.3.2 19-1.1.1.1.3.2.1.r 21-1.1.1.1.3.2.1.1.1.1.1 22-1.1.1.1.3.2.1.1 23-1.1.1.1.3.2.1 25-1.1.1.1.3.2.1.2.1.1 25-1.1.1.1.3.2.1.2.1.2 26-1.1.1.1.3.2.1.2.1.1.1.1 27-1.1.1.1.3.2.1.2.1.2.1.r 28-1.1.1.1.3.2.1.2.1.2.1.1 32-1 34-1.1.3 35-1.1 36-1.1.2 37-1.1.2.1.r 38-1.1.2.1.2 39-1.1.2.1.1.1
# ::id bio.mskcc_0001.40
# ::preferred 
(f / find-01~e.32
      :ARG1 (i / increase-01~e.35
            :ARG0 (m / mutate-01~e.7
                  :ARG1 (a / amino-acid
                        :mod "151"
                        :name (n / name :op1 "serine")
                        :part-of (p / protein-segment~e.12
                              :destination-of (f2 / feedback~e.11)
                              :ARG1-of~e.16 (c / close-10~e.17
                                    :ARG2~e.19 (d / domain~e.23
                                          :ARG2-of (b / bind-01~e.22
                                                :ARG1 (e / enzyme
                                                      :name (n2 / name :op1 "Ras"~e.21)))
                                          :ARG1-of (m2 / mean-01
                                                :ARG2 (b2 / between
                                                      :op1 (r / residue~e.25
                                                            :mod (a3 / amino-acid :value "155"~e.26))
                                                      :op2 (r2 / residue~e.25
                                                            :mod~e.27 (a4 / amino-acid :value "227"~e.28))))))))
                  :mod (o / only~e.6))
            :ARG1 (b3 / bind-01~e.36
                  :ARG2~e.37 (e4 / enzyme
                        :name (n5 / name :op1 "Ras"~e.39)
                        :ARG1-of (a2 / activate-01~e.38)))
            :ARG2 (s / significant-02~e.34))
      :ARG1-of (s2 / show-01~e.1
            :ARG0 (f3 / figure :mod "6A"~e.4)))

# ::tok In contrast , mutation of S151A , T401A , and S750A T753A were all found to increase C @-@ Raf binding ( Fig . 6A ) , a finding consistent with peptide studies suggesting that there are multiple points of contact between heterodimerized B @- and C @-@ Raf proteins ( 27 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.1.1.1 3-1.1.1.1.2 3-1.1.1.1.3 3-1.1.1.1.4 5-1.1.1.1.1.1 7-1.1.1.1.2.1 9-1.1.1.1 10-1.1.1.1.3.1 11-1.1.1.1.4.1 14-1.1 16-1.1.1 17-1.1.1.2.1.1.1 19-1.1.1.2.1.1.1 20-1.1.1.2 24-1.1.1.3.1.1 28-1.1 29-1.1.2 30-1.1.2.1.r 31-1.1.2.1.1 32-1.1.2.1 33-1.1.2.1.2 37-1.1.2.1.2.1.3 40-1.1.2.1.2.1 43-1.1.2.1.2.1.1.1.1 46-1.1.2.1.2.1.2.1.1 48-1.1.2.1.2.1.1.1.1 48-1.1.2.1.2.1.2.1.1 51-1.1.2.1.3.1.1.1
# ::id bio.mskcc_0001.41
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (f / find-01~e.14,28
            :ARG1 (i / increase-01~e.16
                  :ARG0 (a / and~e.9
                        :op1 (m / mutate-01~e.3 :value "S151A"~e.5)
                        :op2 (m2 / mutate-01~e.3 :value "T401A"~e.7)
                        :op3 (m3 / mutate-01~e.3 :value "S750A"~e.10)
                        :op4 (m4 / mutate-01~e.3 :value "T753A"~e.11))
                  :ARG1 (b / bind-01~e.20
                        :ARG1 (e / enzyme
                              :name (n5 / name :op1 "C-Raf"~e.17,19)))
                  :ARG1-of (d / describe-01
                        :ARG0 (f2 / figure :mod "6A"~e.24)))
            :ARG1-of (c2 / consistent-01~e.29
                  :ARG2~e.30 (s / study-01~e.32
                        :ARG1 (p / peptide~e.31)
                        :ARG0-of (s2 / suggest-01~e.33
                              :ARG1 (c3 / contact-01~e.40
                                    :ARG0 (e2 / enzyme
                                          :name (n6 / name :op1 "B-Raf"~e.43,48)
                                          :ARG2-of (h / heterodimerize-00))
                                    :ARG1 (e3 / enzyme
                                          :name (n7 / name :op1 "C-Raf"~e.46,48)
                                          :ARG2-of h)
                                    :quant (m5 / multiple~e.37)))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p2 / publication
                                    :ARG1-of (c4 / cite-01 :ARG2 "27"~e.51)))))))

# ::tok Interestingly , when the S729A mutation was introduced into the FBm mutant , binding to C @-@ Raf was abolished ( Fig . 6A ) , indicating that the increased heterodimerization observed when the feedback sites are mutated is still dependent on 14 @-@ 3 @-@ 3 binding .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 0-1.4.r 2-1.3.r 4-1.3.1.1 5-1.3.1 5-1.3.2 5-1.3.2.2 5-1.3.2.2.r 7-1.3 8-1.3.2.3.2.1.r 11-1.3.1 11-1.3.2 11-1.3.2.2 11-1.3.2.2.r 13-1.1 14-1.1.1.r 15-1.1.1.1.1 17-1.1.1.1.1 17-1.3.2.1.1 19-1 23-1.2.1.1 26-1.5 27-1.5.1.r 29-1.5.1.1.1 30-1.5.1.1 31-1.5.1.1.2 32-1.5.1.1.2.1.r 34-1.3.2.3.2.1 34-1.5.1.1.2.1.1.1 35-1.3.2.3.2 35-1.5.1.1.2.1.1 37-1.5.1.1.2.1 39-1.5.1.3 40-1.5.1 41-1.5.1.2.r 42-1.5.1.2.1.1.1 44-1.5.1.2.1.1.1 46-1.5.1.2.1.1.1 47-1.5.1.2
# ::id bio.mskcc_0001.42
# ::preferred 
(a / abolish-01~e.19
      :ARG1 (b / bind-01~e.13
            :ARG2~e.14 (e / enzyme
                  :name (n / name :op1 "C-Raf"~e.15,17)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6A"~e.23))
      :time~e.2 (i / introduce-02~e.7
            :ARG1 (m / mutate-01~e.5,11 :value "S729A"~e.4)
            :ARG2 (e2 / enzyme~e.5,11
                  :name (n3 / name :op1 "B-Raf"~e.17)
                  :ARG2-of~e.5,11 (m2 / mutate-01~e.5,11)
                  :ARG1-of (h2 / have-part-91
                        :polarity "-"
                        :ARG2 (p / protein-segment~e.35
                              :destination-of~e.8 (f3 / feedback~e.34)))))
      :manner~e.0 (i2 / interesting~e.0)
      :ARG0-of (i3 / indicate-01~e.26
            :ARG1~e.27 (d2 / depend-01~e.40
                  :ARG0 (h / heterodimerize-00~e.30
                        :ARG1-of (i4 / increase-01~e.29)
                        :ARG1-of (o / observe-01~e.31
                              :time~e.32 (m3 / mutate-01~e.37
                                    :ARG1 (p2 / protein-segment~e.35
                                          :destination-of (f2 / feedback~e.34)))))
                  :ARG1~e.41 (b2 / bind-01~e.47
                        :ARG2 (p3 / protein
                              :name (n4 / name :op1 "14-3-3"~e.42,44,46)))
                  :mod (s / still~e.39))))

# ::tok Given that oncogenic B @-@ Raf proteins are targets of feedback phosphorylation , we next examined whether they might also be dephosphorylated and recycled in a manner involving the PP2A phosphatase and the Pin1 prolyl @-@ isomerase .
# ::amr-annotator ISI-AMR-01
# ::alignments 2-1.3 2-1.3.1.2 2-1.3.1.2.2 2-1.3.1.2.2.1 2-1.3.1.2.2.1.r 2-1.3.1.2.2.r 3-1.3.1.2.1.1 5-1.3.1.2.1.1 8-1.3.1 9-1.3.1.1.r 10-1.3.1.1.1 11-1.3.1.1 13-1.1 14-1.4 15-1 16-1.2.1 16-1.2.1.r 18-1.2 19-1.2.2.3 20-1.2.2.r 21-1.2.2.1 22-1.2.2 23-1.2.2.2 26-1.2.2.4.r 27-1.2.2.4 29-1.2.2.4.1.1.1.1 30-1.2.2.4.1.1 31-1.2.2.4.1 33-1.2.2.4.1.2.1.1 34-1.2.2.4.1.2 36-1.2.2.4.1.2
# ::id bio.mskcc_0001.43
# ::preferred 
(e / examine-01~e.15
      :ARG0 (w / we~e.13)
      :ARG1 (p2 / possible~e.18
            :mode~e.16 "interrogative"~e.16
            :domain~e.20 (a / and~e.22
                  :op1 (d / dephosphorylate-01~e.21
                        :ARG1 (e2 / enzyme~e.2
                              :name (n / name :op1 "B-Raf"~e.3,5)
                              :ARG0-of~e.2 (c2 / cause-01~e.2
                                    :ARG1~e.2 (c3 / cancer~e.2))))
                  :op2 (r / recycle-01~e.23
                        :ARG1 e2)
                  :mod (a2 / also~e.19)
                  :manner~e.26 (i / involve-01~e.27
                        :ARG1 (a3 / and~e.31
                              :op1 (p4 / phosphatase~e.30
                                    :name (n2 / name :op1 "PP2A"~e.29))
                              :op2 (p3 / prolyl-isomerase~e.34,36
                                    :name (n3 / name :op1 "Pin1"~e.33)))
                        :ARG2 a)))
      :ARG1-of (c / cause-01~e.2
            :ARG0 (t / target-01~e.8
                  :ARG0~e.9 (p / phosphorylate-01~e.11
                        :subevent-of (f / feedback~e.10))
                  :ARG1 e2))
      :time (n4 / next~e.14))

# ::tok As indicated in Fig. 7A , when PP2A was inhibited with okadaic acid treatment , slower @-@ migrating forms of the V600E , G466A , and D594G B @-@ Raf proteins were found to accumulate .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.2 4-1.2.1.1 7-1.1.2.1.1.1 9-1.1.2 10-1.1.2.2.r 11-1.1.2.2.1.1.1 12-1.1.2.2.1.1.2 13-1.1.2.2 15-1.1.1.4.1 15-1.1.1.4.1.1 15-1.1.1.4.1.1.r 17-1.1.1.4 21-1.1.1.1.2.1 23-1.1.1.2.2.1 25-1.1.1 26-1.1.1.3.2.1 27-1.1.1.1.1.1 27-1.1.1.2.1.1 27-1.1.1.3.1.1 29-1.1.1.1.1.1 29-1.1.1.2.1.1 29-1.1.1.3.1.1 32-1 34-1.1
# ::id bio.mskcc_0001.44
# ::preferred 
(f / find-01~e.32
      :ARG1 (a / accumulate-01~e.34
            :ARG1 (a2 / and~e.25
                  :op1 (e2 / enzyme
                        :name (n / name :op1 "B-Raf"~e.27,29)
                        :ARG2-of (m / mutate-01 :value "V600E"~e.21))
                  :op2 (e3 / enzyme
                        :name (n4 / name :op1 "B-Raf"~e.27,29)
                        :ARG2-of (m4 / mutate-01 :value "G466A"~e.23))
                  :op3 (e4 / enzyme
                        :name (n5 / name :op1 "B-Raf"~e.27,29)
                        :ARG2-of (m5 / mutate-01 :value "D594G"~e.26))
                  :ARG0-of (m2 / migrate-01~e.17
                        :manner (s / slow~e.15
                              :degree~e.15 (m3 / more~e.15))))
            :condition (i / inhibit-01~e.9
                  :ARG1 (e / enzyme
                        :name (n3 / name :op1 "PP2A"~e.7))
                  :instrument~e.10 (t / treat-04~e.13
                        :ARG2 (s2 / small-molecule
                              :name (n2 / name :op1 "okadaic"~e.11 :op2 "acid"~e.12)))))
      :ARG1-of (i2 / indicate-01~e.1
            :ARG0 (f2 / figure :mod "7A"~e.4)))

# ::tok Moreover , given their constitutive phosphorylation on S/TP sites ( Fig . 3D ) , these oncogenic B @-@ Raf mutants were found to interact constitutively with Pin1 ( Fig . 7B ) , indicating that oncogenic B @-@ Raf proteins are dephosphorylated and recycled .
# ::amr-annotator ISI-AMR-01
# ::alignments 4-1.1.1.6.1.2 5-1.1.1.6.1 6-1.1.1.6.1.1.r 7-1.1.1.6.1.1.1 8-1.1.1.6.1.1 12-1.1.1.6.1.3.1.1 15-1.1.1.1.4 16-1.1.1.1.3 16-1.1.1.1.3.1 16-1.1.1.1.3.1.r 17-1.1.1.1.1.1 19-1.1.1.1.1.1 20-1.1.1.1 20-1.1.1.1.2 20-1.1.1.1.2.r 22-1.1 23-1.1.1.6 24-1.1.1 25-1.1.1.3 26-1.1.1.2.r 27-1.1.1.2.1.1 31-1.1.1.4.1.1 34-1.1.1.5 36-1.1.1.6.1.1.2 37-1.1.1.6.1.1.2 38-1.1.1.6.1.1.2 39-1.1.1.6.1.1.2 40-1.1.1.6.1.1 42-1.1.1.5.1.1 43-1.1.1.5.1 44-1.1.1.5.1.2
# ::id bio.mskcc_0001.45
# ::preferred 
(a / and
      :op2 (f / find-01~e.22
            :ARG1 (i / interact-01~e.24
                  :ARG0 (e / enzyme~e.20
                        :name (n / name :op1 "B-Raf"~e.17,19)
                        :ARG2-of~e.20 (m / mutate-01~e.20)
                        :ARG0-of (c3 / cause-01~e.16
                              :ARG1~e.16 (c4 / cancer~e.16))
                        :mod (t / this~e.15))
                  :ARG1~e.26 (e2 / enzyme
                        :name (n2 / name :op1 "Pin1"~e.27))
                  :mod (c5 / constitutive~e.25)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f3 / figure :mod "7B"~e.31))
                  :ARG0-of (i2 / indicate-01~e.34
                        :ARG1 (a2 / and~e.43
                              :op1 (d3 / dephosphorylate-01~e.42
                                    :ARG1 e)
                              :op2 (r / recycle-01~e.44
                                    :ARG1 e)))
                  :ARG1-of (c / cause-01~e.23
                        :ARG0 (p / phosphorylate-01~e.5
                              :ARG2~e.6 (p2 / protein-segment~e.8,40
                                    :value "S/TP"~e.7
                                    :part-of e~e.36,37,38,39)
                              :mod (c2 / constitutive~e.4)
                              :ARG1-of (d / describe-01
                                    :ARG0 (f2 / figure :mod "3D"~e.12)))))))

# ::tok Consistent with the model that Pin1 influences B @-@ Raf signaling by facilitating the dephosphorylation of the feedback sites , overexpression of the Pin1 proteins had no effect on the transformation potential of G466A FBm @-@ B @-@ Raf , which lacks the sites of feedback phosphorylation .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.4 1-1.4.1.r 3-1.4.1 5-1.4.1.1.1.1.1 6-1.4.1.1 7-1.4.1.1.2.1.1.1 9-1.4.1.1.2.1.1.1 10-1.4.1.1.2 11-1.4.1.1.3.r 12-1.4.1.1.3 14-1.4.1.1.3.2 15-1.4.1.1.3.2.1.r 17-1.4.1.1.3.2.1.2 18-1.4.1.1.3.2.1 20-1.2 23-1.2.1.1.1 23-1.4.1.1.1.1.1 24-1.3.1.1.3.2 25-1.3.1.1.3 26-1.1 26-1.1.r 26-1.3.1.1.3.1 26-1.3.1.1.3.1.r 27-1 30-1.3.1 33-1.3.1.1.2.1 36-1.3.1.1.1.1 36-1.4.1.1.2.1.1.1 38-1.3.1.1.1.1 38-1.4.1.1.2.1.1.1 43-1.4.1.1.3.2.1 44-1.3.1.1.3.2.1.r 45-1.3.1.1.3.2.1.1 46-1.3.1.1.3.2.1
# ::id bio.mskcc_0001.46
# ::preferred 
(a / affect-01~e.27
      :polarity~e.26 "-"~e.26
      :ARG0 (e / express-03~e.20
            :ARG2 (e2 / enzyme
                  :name (n / name :op1 "Pin1"~e.23))
            :degree (t / too))
      :ARG1 (p / possible
            :domain (t2 / transform-01~e.30
                  :ARG0 (e3 / enzyme
                        :name (n2 / name :op1 "B-Raf"~e.36,38)
                        :ARG1-of (m / mutate-01 :value "G466A"~e.33)
                        :ARG1-of (h / have-part-91~e.25
                              :polarity~e.26 "-"~e.26
                              :ARG2 (p2 / protein-segment~e.24
                                    :ARG1-of~e.44 (p3 / phosphorylate-01~e.46
                                          :subevent (f / feedback~e.45)))))))
      :ARG1-of (c / consistent-01~e.0
            :ARG2~e.1 (m2 / model~e.3
                  :topic (i / influence-01~e.6
                        :ARG0 (e4 / enzyme
                              :name (n3 / name :op1 "Pin1"~e.5,23))
                        :ARG1 (s / signal-07~e.10
                              :ARG0 (e5 / enzyme
                                    :name (n4 / name :op1 "B-Raf"~e.7,9,36,38)))
                        :manner~e.11 (f2 / facilitate-01~e.12
                              :ARG0 e4
                              :ARG1 (d / dephosphorylate-01~e.14
                                    :ARG1~e.15 (p4 / protein-segment~e.18,43
                                          :part-of e5
                                          :destination-of (f3 / feedback~e.17))))))))

# ::tok Previous studies have found that both the C @-@ Raf and B @-@ Raf proteins are targets of ERK @-@ dependent feedback phosphorylation
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1 1-1.1 3-1 7-1.2.2.1.1.1 9-1.2.2.1.1.1 9-1.2.2.2.1.1 10-1.2.2 11-1.2.2.2.1.1 13-1.2.2.1.1.1 13-1.2.2.2.1.1 16-1.2 17-1.2.1.r 18-1.2.1.2.1.1.1 20-1.2.1.2 21-1.2.1.1 22-1.2.1
# ::id bio.mskcc_0001.47
# ::preferred 
(f / find-01~e.3
      :ARG0 (s / study~e.1
            :time (p / previous~e.0))
      :ARG1 (t / target-01~e.16
            :ARG0~e.17 (p2 / phosphorylate-01~e.22
                  :subevent-of (f2 / feedback~e.21)
                  :ARG0-of (d / depend-01~e.20
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "ERK"~e.18))))
            :ARG1 (a / and~e.10
                  :op1 (e2 / enzyme
                        :name (n2 / name :op1 "C-Raf"~e.7,9,13))
                  :op2 (e3 / enzyme
                        :name (n3 / name :op1 "B-Raf"~e.9,11,13)))))

# ::tok In the case of C @-@ Raf , six sites of feedback phosphorylation have been identified , five of which are direct targets of activated ERK ( 8 )
# ::amr-annotator ISI-AMR-01
# ::alignments 4-1.1.2.1.1 6-1.1.2.1.1 8-1.1.1 9-1.1 9-1.1.4.1 10-1.1.3.r 11-1.1.3.1 12-1.1.3 15-1 17-1.1.4.1.1 21-1.1.4.1.2.2 22-1.1.4.1.2 23-1.1.4.1.2.1.r 24-1.1.4.1.2.1.2 25-1.1.4.1.2.1.1.1 27-1.2.1.1.1
# ::id bio.mskcc_0001.48
# ::preferred 
(i / identify-01~e.15
      :ARG1 (p / protein-segment~e.9
            :quant "6"~e.8
            :part-of (e / enzyme
                  :name (n / name :op1 "C-Raf"~e.4,6))
            :ARG1-of~e.10 (p2 / phosphorylate-01~e.12
                  :subevent-of (f / feedback~e.11))
            :ARG2-of (i2 / include-91
                  :ARG1 (p3 / protein-segment~e.9
                        :quant "5"~e.17
                        :ARG1-of (t / target-01~e.22
                              :ARG0~e.23 (e2 / enzyme
                                    :name (n2 / name :op1 "ERK"~e.25)
                                    :ARG1-of (a / activate-01~e.24))
                              :manner (d / direct~e.21)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c / cite-01 :ARG2 "8"~e.27))))

# ::tok For B @-@ Raf , previous work by Brummer et al. ( 3 ) identified the C @-@ terminal S750 and T753 residues as sites phosphorylated by activated ERK .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.2.1.2.2.1.1 3-1.2.1.2.2.1.1 5-1.1.1.2 6-1.1 6-1.1.1 6-1.1.1.r 7-1.1.1.1.r 8-1.1.1.1.1.1.1 9-1.1.1.1 10-1.1.1.1.2.1 12-1.1.2.1 14-1 16-1.2.1.2.1.1 18-1.2.1.2.1.1 20-1.2 22-1.2.1 22-1.2.2 23-1.1.1.2.r 23-1.3.r 24-1.3.1 25-1.3 26-1.3.2.r 27-1.3.2.2 28-1.3.2.1.1
# ::id bio.mskcc_0001.49
# ::preferred 
(i / identify-01~e.14
      :ARG0 (p / publication~e.6
            :ARG1-of~e.6 (w / work-01~e.6
                  :ARG0~e.7 (a / and~e.9
                        :op1 (p2 / person
                              :name (n / name :op1 "Brummer"~e.8))
                        :op2 (p3 / person
                              :mod (o / other~e.10)))
                  :time~e.23 (p6 / previous~e.5))
            :ARG1-of (c / cite-01 :ARG2 "3"~e.12))
      :ARG1 (a2 / and~e.20
            :op1 (r / residue~e.22
                  :mod (a3 / amino-acid
                        :mod "750"
                        :name (n2 / name :op1 "serine"))
                  :part-of (p4 / protein-segment
                        :name (n4 / name :op1 "C-terminus"~e.16,18)
                        :part-of (e2 / enzyme
                              :name (n6 / name :op1 "B-Raf"~e.1,3))))
            :op2 (r2 / residue~e.22
                  :mod (a4 / amino-acid
                        :mod "753"
                        :name (n3 / name :op1 "threonine"))
                  :part-of p4))
      :ARG2~e.23 (p5 / phosphorylate-01~e.25
            :ARG1 a2~e.24
            :ARG2~e.26 (e / enzyme
                  :name (n5 / name :op1 "ERK"~e.28)
                  :ARG1-of (a5 / activate-01~e.27))))

# ::tok Through metabolic labeling experiments , we find here that in addition to the S750 and T753 sites , B @-@ Raf is feedback phosphorylated on two other sites , S151 and T401 .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.4.1.1 2-1.4.1 3-1.4 5-1.1 6-1 7-1.3 8-1.2.r 9-1.2.1 10-1.2.1 14-1.2.1 18-1.2.1.5.1.1 20-1.2.1.5.1.1 22-1.2.2 23-1.2 30-1.2.1
# ::id bio.mskcc_0001.50
# ::preferred 
(f / find-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1~e.8 (p / phosphorylate-01~e.23
            :ARG1 (a / and~e.9,10,14,30
                  :op1 (a2 / amino-acid
                        :mod "750"
                        :name (n / name :op1 "serine"))
                  :op2 (a3 / amino-acid
                        :mod "753"
                        :name (n2 / name :op1 "threonine"))
                  :op3 (a4 / amino-acid
                        :mod "151"
                        :name (n3 / name :op1 "serine"))
                  :op4 (a5 / amino-acid
                        :mod "401"
                        :name (n4 / name :op1 "threonine"))
                  :part-of (e2 / enzyme
                        :name (n5 / name :op1 "B-Raf"~e.18,20)))
            :subevent-of (f2 / feedback~e.22))
      :medium (h / here~e.7)
      :manner (e / experiment-01~e.3
            :ARG2 (l / label-01~e.2
                  :mod (m / metabolism~e.1))))

# ::tok These residues are phosphorylated by activated ERK in vitro ,
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1 1-1.1 3-1 4-1.2.r 5-1.2.2 6-1.2.1.1 7-1.3 8-1.3
# ::id bio.mskcc_0001.51
# ::preferred 
(p / phosphorylate-01~e.3
      :ARG1 (r / residue~e.1
            :mod (t / this~e.0))
      :ARG2~e.4 (e / enzyme
            :name (n / name :op1 "ERK"~e.6)
            :ARG1-of (a / activate-01~e.5))
      :manner (i / in-vitro~e.7,8))

# ::tok As has been observed for C @-@ Raf , we find that the hyperphosphorylated B @-@ Raf protein is subsequently dephosphorylated in a manner requiring the activities of the PP2A phosphatase and Pin1 prolyl @-@ isomerase , indicating that the feedback phosphorylation @/@ dephosphorylation cycle is a conserved regulatory mechanism for the Raf proteins .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.2.5.r 3-1.2.2.1.2 5-1.2.2.1.1.1.1 7-1.2.4.1.1.1.1.1 9-1.1 10-1 13-1.2.1.2 13-1.2.2.1.1.2 14-1.2.1.1.1 16-1.2.1.1.1 16-1.2.2.1.1.1.1 19-1.2.5 19-1.2.5.r 20-1.2 20-1.2.2.1 23-1.2.3.r 24-1.2.3 26-1.2.3.2.1 26-1.2.3.2.2 27-1.2.3.2.1.1.r 29-1.2.3.2.1.1.1.1 30-1.2.3.2.1.1 31-1.2.3.2 32-1.2.3.2.2.1.1.1 33-1.2.3.2.2.1 35-1.2.3.2.2.1 37-1.2.4 40-1.2.4.1.3.3 41-1.2.4.1.3.1 43-1.2.4.1.3.2 44-1.2.4.1.3 45-1.2.4.1.3.r 47-1.2.4.1.2 48-1.2.4.1.1 49-1.2.4.1 52-1.2.1.1.1 52-1.2.2.1.1.1.1
# ::id bio.mskcc_0001.52
# ::preferred 
(f / find-01~e.10
      :ARG0 (w / we~e.9)
      :ARG1 (d / dephosphorylate-01~e.20
            :ARG1 (e / enzyme
                  :name (n / name :op1 "B-Raf"~e.14,16,52)
                  :ARG3-of (h / hyperphosphorylate-00~e.13))
            :ARG1-of (r / resemble-01
                  :ARG2 (d2 / dephosphorylate-01~e.20
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "C-Raf"~e.5,16,52)
                              :ARG3-of (h2 / hyperphosphorylate-00~e.13))
                        :ARG1-of (o / observe-01~e.3)))
            :manner~e.23 (r2 / require-01~e.24
                  :ARG0 d
                  :ARG1 (a2 / and~e.31
                        :op1 (a / act-02~e.26
                              :ARG0~e.27 (p / phosphatase~e.30
                                    :name (n3 / name :op1 "PP2A"~e.29)))
                        :op2 (a4 / act-02~e.26
                              :ARG0 (p2 / prolyl-isomerase~e.33,35
                                    :name (n4 / name :op1 "Pin1"~e.32)))))
            :ARG0-of (i / indicate-01~e.37
                  :ARG1 (m / mechanism~e.49
                        :ARG0-of (r3 / regulate-01~e.48
                              :ARG1 (e3 / enzyme
                                    :name (n5 / name :op1 "Raf"~e.7)))
                        :ARG1-of (c / conserve-01~e.47)
                        :domain~e.45 (c2 / cycle~e.44
                              :subevent (p3 / phosphorylate-01~e.41)
                              :subevent (d3 / dephosphorylate-01~e.43)
                              :mod (f3 / feedback~e.40))))
            :time~e.0,19 (a3 / after~e.19
                  :op1 h)))

# ::tok Through mutational analysis , we find that feedback phosphorylation disrupts the abilities of B @-@ Raf to bind activated Ras and to heterodimerize with C @-@ Raf .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.2 2-1.3 4-1.1 5-1 6-1.2.r 7-1.2.1.1 8-1.2.1 9-1.2 11-1.2.2 12-1.2.2.1.r 13-1.2.2.1.1.1 15-1.2.2.1.1.1 16-1.2.2.2.r 17-1.2.2.2.1 18-1.2.2.2.1.2.2 19-1.2.2.2.1.2.1.1 20-1.2.2.2 22-1.2.2.2.2 23-1.2.2.2.2.2.r 24-1.2.2.2.2.2.1.1 26-1.2.2.1.1.1 26-1.2.2.2.2.2.1.1
# ::id bio.mskcc_0001.53
# ::preferred 
(f / find-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1~e.6 (d / disrupt-01~e.9
            :ARG0 (p / phosphorylate-01~e.8
                  :subevent-of (f2 / feedback~e.7))
            :ARG1 (c / capable-01~e.11
                  :ARG1~e.12 (e / enzyme
                        :name (n / name :op1 "B-Raf"~e.13,15,26))
                  :ARG2~e.16 (a2 / and~e.20
                        :op1 (b / bind-01~e.17
                              :ARG1 e
                              :ARG2 (e2 / enzyme
                                    :name (n2 / name :op1 "Ras"~e.19)
                                    :ARG1-of (a / activate-01~e.18)))
                        :op2 (h / heterodimerize-00~e.22
                              :ARG1 e
                              :ARG2~e.23 (e3 / enzyme
                                    :name (n3 / name :op1 "C-Raf"~e.24,26))))))
      :manner (a3 / analyze-01~e.2
            :ARG0 w
            :ARG1 (m / mutate-01~e.1)))

# ::tok Although phosphorylation of the S151 site appears to have the greatest effect on Ras binding , our results indicate that phosphorylation of all the feedback sites contributes to the inhibition of C @-@ Raf binding .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.2.1 5-1.2.1.1 6-1.3 10-1.3.1.3 10-1.3.1.3.1 10-1.3.1.3.1.r 11-1.3.1 12-1.3.1.2.r 13-1.3.1.2.1.1.1 14-1.3.1.2 16-1.1.2 16-1.1.2.r 17-1.1 17-1.1.1 17-1.1.1.r 18-1 20-1.2.1 20-1.3.1.1 22-1.2.1.1.1 24-1.2.1.1.2 25-1.2.1.1 26-1.2 27-1.2.2.r 29-1.2.2 30-1.2.2.1.r 31-1.2.2.1.1.1.1 33-1.2.2.1.1.1.1 34-1.2.2.1
# ::id bio.mskcc_0001.54
# ::preferred 
(i / indicate-01~e.18
      :ARG0 (t / thing~e.17
            :ARG2-of~e.17 (r / result-01~e.17)
            :poss~e.16 (w / we~e.16))
      :ARG1 (c / contribute-01~e.26
            :ARG0 (p / phosphorylate-01~e.1,20
                  :ARG1 (p2 / protein-segment~e.5,25
                        :mod (a / all~e.22)
                        :destination-of (f / feedback~e.24)))
            :ARG2~e.27 (i2 / inhibit-01~e.29
                  :ARG1~e.30 (b / bind-01~e.34
                        :ARG2 (e / enzyme
                              :name (n / name :op1 "C-Raf"~e.31,33)))))
      :concession~e.0 (a2 / appear-02~e.6
            :ARG1 (a3 / affect-01~e.11
                  :ARG0 (p3 / phosphorylate-01~e.20
                        :ARG1 (a4 / amino-acid
                              :mod "151"
                              :name (n2 / name :op1 "serine")))
                  :ARG1~e.12 (b2 / bind-01~e.14
                        :ARG2 (e2 / enzyme
                              :name (n3 / name :op1 "Ras"~e.13)))
                  :mod (g / great~e.10
                        :degree~e.10 (m / most~e.10)))))

# ::tok This finding is consistent with those of peptide binding studies conducted by Rushworth et al. ( 27 ) indicating that there are multiple points of contact between heterodimerized B @-@ Raf and C @-@ Raf proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 1-1.1.2 1-1.1.2.r 1-1.2 1-1.2.1 1-1.2.1.r 3-1 6-1.2.1.1.r 7-1.2.1.1.1.1 8-1.2.1.1.1 9-1.2.1.1 10-1.2.1.1.2 11-1.2.1.1.2.1.r 12-1.2.1.1.2.1.1.1.1 13-1.2.1.1.2.1 14-1.2.1.1.2.1.2.1 16-1.2.2.1.1.1 18-1.1.3 22-1.1.3.1.3 25-1.1.3.1 28-1.1.3.1.1.1.1 30-1.1.3.1.1.1.1 30-1.1.3.1.2.1.1 32-1.1.3.1.2.1.1 34-1.1.3.1.1.1.1 34-1.1.3.1.2.1.1
# ::id bio.mskcc_0001.55
# ::preferred 
(c / consistent-01~e.3
      :ARG1 (t / thing~e.1
            :mod (t2 / this~e.0)
            :ARG1-of~e.1 (f / find-01~e.1)
            :ARG0-of (i / indicate-01~e.18
                  :ARG1 (c4 / contact-01~e.25
                        :ARG0 (e / enzyme
                              :name (n2 / name :op1 "B-Raf"~e.28,30,34)
                              :ARG1-of (h / heterodimerize-00))
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "C-Raf"~e.30,32,34)
                              :ARG1-of h)
                        :quant (m / multiple~e.22))))
      :ARG2 (t3 / thing~e.1
            :ARG1-of~e.1 (f2 / find-01~e.1
                  :ARG0~e.6 (s / study-01~e.9
                        :ARG1 (b / bind-01~e.8
                              :ARG1 (p / peptide~e.7))
                        :ARG1-of (c2 / conduct-01~e.10
                              :ARG0~e.11 (a / and~e.13
                                    :op1 (p2 / person
                                          :name (n / name :op1 "Rushworth"~e.12))
                                    :op2 (p3 / person
                                          :mod (o / other~e.14))))))
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "27"~e.16)))))

# ::tok Interestingly , these peptide binding studies also indicate that homodimerized B @-@ Raf and C @-@ Raf proteins have multiple contact points ( 27 ) , suggesting that feedback phosphorylation of the Raf proteins may disrupt Raf homodimers as well
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 0-1.3.r 2-1.1.2 3-1.1.1.1 4-1.1.1 5-1.1 6-1.4 7-1 10-1.2.1.1.1.1 12-1.2.1.1.1.1 12-1.2.1.2.1.1 13-1.2.1 14-1.2.1.2.1.1 16-1.2.1.2.1.1 19-1.2.2 20-1.2 23-1.5.1.1.1 26-1.6 27-1.6.1.r 28-1.6.1.1.1.2 29-1.6.1.1.1 30-1.6.1.1.1.1.r 32-1.6.1.1.1.1.1.1 34-1.6.1 35-1.6.1.1 36-1.6.1.1.1.1.1.1 38-1.6.1.1.3 39-1.6.1.1.3
# ::id bio.mskcc_0001.56
# ::preferred 
(i / indicate-01~e.7
      :ARG0 (s / study-01~e.5
            :ARG1 (b / bind-01~e.4
                  :ARG1 (p / peptide~e.3))
            :mod (t / this~e.2))
      :ARG1 (c / contact-01~e.20
            :ARG0 (a2 / and~e.13
                  :op1 (e / enzyme
                        :name (n / name :op1 "B-Raf"~e.10,12))
                  :op2 (e2 / enzyme
                        :name (n2 / name :op1 "C-Raf"~e.12,14,16))
                  :ARG1-of (h / homodimerize-00))
            :quant (m / multiple~e.19))
      :manner~e.0 (i2 / interesting~e.0)
      :mod (a / also~e.6)
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "27"~e.23)))
      :ARG0-of (s2 / suggest-01~e.26
            :ARG1~e.27 (p3 / possible~e.34
                  :domain (d2 / disrupt-01~e.35
                        :ARG0 (p4 / phosphorylate-01~e.29
                              :ARG1~e.30 (e3 / enzyme
                                    :name (n3 / name :op1 "Raf"~e.32,36))
                              :subevent-of (f / feedback~e.28))
                        :ARG1 (h2 / homodimer
                              :part e3)
                        :mod (a3 / as-well~e.38,39)))))

# ::tok Taken together , these findings suggest a model whereby the binding of a 14 @-@ 3 @-@ 3 dimer to the C @-@ terminal pS621 site of C @-@ Raf and the C @-@ terminal pS729 site of B @-@ Raf provides the stable docking event that then allows the two proteins to make additional contacts ( Fig . 9 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.3 1-1.1.3.1 3-1.1.2 4-1.1 4-1.1.1 4-1.1.1.r 5-1 7-1.2 10-1.2.1.1.1 10-1.2.1.1.2 11-1.2.1.1.1.1.r 13-1.2.1.1.1.1.1.1 15-1.2.1.1.1.1.1.1 17-1.2.1.1.1.1.1.1 18-1.2.1.1.1.1 21-1.2.1.1.1.2.4.1.1 21-1.2.1.1.1.2.4.2.1.1 21-1.2.1.1.2.2.4.1.1 23-1.2.1.1.1.2.4.1.1 23-1.2.1.1.2.2.4.1.1 25-1.2.1.1.1.2.4 25-1.2.1.1.2.2.4 27-1.2.1.1.1.2.4.1.1 27-1.2.1.1.1.2.4.2.1.1 27-1.2.1.1.2.2.4.1.1 29-1.2.1.1.1.2.4.2.1.1 29-1.2.1.1.2.2.4.2.1.1 30-1.2.1.1 32-1.2.1.1.1.2.4.1.1 32-1.2.1.1.1.2.4.2.1.1 32-1.2.1.1.2.2.4.1.1 34-1.2.1.1.1.2.4.1.1 34-1.2.1.1.2.2.4.1.1 36-1.2.1.1.1.2.4 36-1.2.1.1.2.2.4 37-1.2.1.1.2.2.r 38-1.2.1.1.2.2.4.2.1.1 40-1.2.1.1.1.2.4.2.1.1 40-1.2.1.1.2.2.4.2.1.1 41-1.2.1 43-1.2.1.2.2 44-1.2.1.2 48-1.2.1.2.1 51-1.2.1.1.1.2.4 51-1.2.1.1.2.2.4 53-1 54-1.2.1.2.1.1.3 55-1.2.1.2.1.1
# ::id bio.mskcc_0001.57
# ::preferred 
(s / suggest-01~e.5,53
      :ARG0 (t / thing~e.4
            :ARG1-of~e.4 (f / find-01~e.4)
            :mod (t2 / this~e.3)
            :ARG1-of (t3 / take-01~e.0
                  :mod (t4 / together~e.1)))
      :ARG1 (m / model~e.7
            :topic (p / provide-01~e.41
                  :ARG0 (a / and~e.30
                        :op1 (b / bind-01~e.10
                              :ARG1~e.11 (d / dimer~e.18
                                    :name (n / name :op1 "14-3-3"~e.13,15,17))
                              :ARG2 (a2 / amino-acid
                                    :mod "621"
                                    :name (n2 / name :op1 "serine")
                                    :ARG3-of (p2 / phosphorylate-01)
                                    :part-of (p3 / protein-segment~e.25,36,51
                                          :name (n3 / name :op1 "C-terminus"~e.21,23,27,32,34)
                                          :part-of (e / enzyme
                                                :name (n4 / name :op1 "C-Raf"~e.21,27,29,32,40)))))
                        :op2 (b3 / bind-01~e.10
                              :ARG1 d
                              :ARG2~e.37 (a3 / amino-acid
                                    :mod "729"
                                    :name (n5 / name :op1 "serine")
                                    :ARG3-of (p4 / phosphorylate-01)
                                    :part-of (p5 / protein-segment~e.25,36,51
                                          :name (n6 / name :op1 "C-terminus"~e.21,23,27,32,34)
                                          :part-of (e2 / enzyme
                                                :name (n7 / name :op1 "B-Raf"~e.29,38,40))))))
                  :ARG1 (d2 / dock-01~e.44
                        :ARG0-of (a4 / allow-01~e.48
                              :ARG1 (c / contact-01~e.55
                                    :ARG0 e
                                    :ARG1 e2
                                    :mod (a5 / additional~e.54)
                                    :time (a6 / after
                                          :op1 a)))
                        :mod (s2 / stable~e.43)))))

# ::tok The most frequently mutated oncogenes in the deadliest cancers responsible for human mortality are KRAS , PIK3CA and BRAF .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.2.1.2 1-1.3.1.1 2-1.3.1 3-1.3 4-1 5-1.2.r 7-1.2.1 8-1.2 10-1.2.1.1.r 11-1.2.1.1 13-1.1.r 14-1.1.1.1.1 16-1.1.2.1.1 17-1.1 18-1.1.3.1.1
# ::id bio.ras_0001.1
# ::preferred 
(o / oncogene~e.4
      :domain~e.13 (a / and~e.17
            :op1 (g / gene
                  :name (n / name :op1 "KRAS"~e.14))
            :op2 (g2 / gene
                  :name (n2 / name :op1 "PIK3CA"~e.16))
            :op3 (g3 / gene
                  :name (n3 / name :op1 "BRAF"~e.18)))
      :location~e.5 (c / cancer~e.8
            :ARG0-of (k / kill-01~e.7
                  :ARG1~e.10 (h / human~e.11)
                  :degree (m / most~e.1)))
      :ARG1-of (m2 / mutate-01~e.3
            :frequency (f / frequent~e.2
                  :degree (m3 / most~e.1))))

# ::tok Importantly the signaling enzymes encoded by PIK3CA and BRAF are , in part , regulated by direct binding to activated forms of the Ras proteins suggesting that dysregulation of this key step in signaling is critical for tumor formation .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.4 2-1.2.1 3-1.2 4-1.2.2 5-1.2.2.1.r 6-1.2.2.1.1.1.1 7-1.2.2.1 8-1.2.2.1.2.1.1 9-1.5.1.2.r 12-1.3 14-1 16-1.1.3 17-1.1 18-1.1.2.r 19-1.1.2.1.2 20-1.5.1.1 23-1.1.2.1.1.1 25-1.5 27-1 33-1.2.1 34-1.5.1.2.r 35-1.5.1 37-1.5.1.1.1 38-1.5.1.1
# ::id bio.ras_0001.2
# ::preferred 
(r / regulate-01~e.14,27
      :ARG0 (b / bind-01~e.17
            :ARG1 (e / enzyme~e.3
                  :ARG0-of (s / signal-07~e.2,33)
                  :ARG1-of (e2 / encode-01~e.4
                        :ARG0~e.5 (a / and~e.7
                              :op1 (g / gene
                                    :name (n / name :op1 "PIK3CA"~e.6))
                              :op2 (g2 / gene
                                    :name (n2 / name :op1 "BRAF"~e.8)))))
            :ARG2~e.18 (m / macro-molecular-complex
                  :part (e3 / enzyme
                        :name (n3 / name :op1 "Ras"~e.23)
                        :ARG1-of (a2 / activate-01~e.19)))
            :manner (d / direct~e.16))
      :ARG1 e
      :degree (p / part~e.12)
      :mod (i / important~e.0)
      :ARG0-of (s2 / suggest-01~e.25
            :ARG1 (c / critical~e.35
                  :topic (f / form-01~e.20,38
                        :ARG1 (t / tumor~e.37))
                  :domain~e.9,34 (i2 / impair-01
                        :ARG1 r))))

# ::tok Ras acts as a molecular switch that is activated upon GTP loading and deactivated upon hydrolysis of GTP to GDP .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.1 4-1.4 5-1 7-1.1.r 8-1.2 10-1.2.1.2.1.1 11-1.2.1 13-1.3 15-1.3.1 16-1.3.1.1.r 17-1.3.1.1 18-1.3.1.2.r 19-1.3.1.2.1.1
# ::id bio.ras_0001.3
# ::preferred 
(s / switch~e.5
      :domain~e.7 (e / enzyme
            :name (n / name :op1 "Ras"~e.0))
      :ARG1-of (a / activate-01~e.8
            :ARG0 (l / load-01~e.11
                  :ARG1 e
                  :ARG2 (s2 / small-molecule
                        :name (n2 / name :op1 "GTP"~e.10))))
      :ARG1-of (d / deactivate-01~e.13
            :ARG0 (h / hydrolyze-01~e.15
                  :ARG1~e.16 s2~e.17
                  :ARG3~e.18 (s3 / small-molecule
                        :name (n3 / name :op1 "GDP"~e.19))))
      :mod (m / molecule~e.4))

# ::tok This switch mechanism is common to a wide variety of GTP - binding proteins and is mediated by a conserved structure called the G - domain that consists of five conserved G boxes .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.2.2 1-1.2.1 2-1.2 4-1 5-1.1.r 7-1.1.2.1 10-1.1.1.1.1.1 12-1.1.1 13-1.1 17-1.3.r 19-1.3.2 19-1.3.3.3 20-1.3 21-1.3.1.r 23-1.3.1.1 25-1.3.1.1 27-1.3.3.r 29-1.3.3.1 30-1.3.2 31-1.3.1.1 31-1.3.3.2.1 32-1.3.3.2.2
# ::id bio.ras_0001.4
# ::preferred 
(s / share-01~e.4
      :ARG0~e.5 (p / protein~e.13
            :ARG2-of (b / bind-01~e.12
                  :ARG1 (s4 / small-molecule
                        :name (n / name :op1 "GTP"~e.10)))
            :mod (v / various
                  :degree (w / wide~e.7)))
      :ARG1 (m / mechanism~e.2
            :topic (s2 / switch~e.1)
            :mod (t / this~e.0))
      :manner~e.17 (s3 / structure~e.20
            :name~e.21 (n2 / name :op1 "G-domain"~e.23,25,31)
            :ARG1-of (c2 / conserve-01~e.19,30)
            :part~e.27 (p3 / protein-segment
                  :quant "5"~e.29
                  :name (n3 / name :op1 "G"~e.31 :op2 "box"~e.32)
                  :ARG1-of (c3 / conserve-01~e.19))))

# ::tok Under physiological conditions , the rate of GDP or GTP release from the G - domain is slow .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.2 2-1.2.r 7-1.1.1.1.1.1 8-1.1.1 9-1.1.1.2.1.1 10-1.1 11-1.1.2.r 13-1.1.2.1.1 15-1.1.2.1.1 17-1
# ::id bio.ras_0001.5
# ::preferred 
(s / slow-05~e.17
      :ARG1 (r / release-01~e.10
            :ARG1 (o / or~e.8
                  :op1 (s2 / small-molecule
                        :name (n / name :op1 "GDP"~e.7))
                  :op2 (s3 / small-molecule
                        :name (n2 / name :op1 "GTP"~e.9)))
            :ARG2~e.11 (p3 / protein-segment
                  :name (n3 / name :op1 "G-domain"~e.13,15)))
      :condition~e.2 (p2 / physiology~e.1))

# ::tok As a consequence the GDP produced by GTP hydrolysis on Ras is trapped and the bulk of cellular Ras accumulates in the GDP - bound ‘off’ state , despite the high GTP / GDP ratio in the cytosol ( 1 – 3 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1 1-1 2-1 4-1.1.1.1.1.1 7-1.1.1.1.2.1.1.1 8-1.1.1.1.2 10-1.1.1.1.2.1.2.1.1.1 12-1.1.1 13-1.1 15-1.1.2.1.2.2 17-1.1.2.1.2.1.2 18-1.1.2.1.1.1 18-1.1.2.1.2.1.1.1 19-1.1.2 22-1.1.1.1.1.1 24-1.1.1.1.2.1 24-1.1.1.1.2.1.2 24-1.1.1.1.2.1.2.r 24-1.1.2.1 24-1.1.2.1.4 24-1.1.2.1.4.r 28-1.1.2.2.r 30-1.1.2.2 31-1.1.2.2.1.2 32-1.1.2.2.1.2 33-1.1.2.2.1.2 34-1.1.2.2.1 35-1.1.2.2.1.3.r 37-1.1.2.2.1.3 39-1.2.1.1.1.1 41-1.2.1.1.1.2
# ::id bio.ras_0001.6
# ::preferred 
(c / cause-01~e.0,1,2
      :ARG1 (a / and~e.13
            :op1 (t / trap-01~e.12
                  :ARG1 (s / small-molecule
                        :name (n / name :op1 "GDP"~e.4,22)
                        :ARG3-of (h / hydrolyze-01~e.8
                              :ARG1 (s2 / small-molecule~e.24
                                    :name (n2 / name :op1 "GTP"~e.7)
                                    :ARG1-of~e.24 (b3 / bind-01~e.24
                                          :ARG2 (e / enzyme
                                                :name (n3 / name :op1 "Ras"~e.10)))))))
            :op2 (a2 / accumulate-01~e.19
                  :ARG1 (e3 / enzyme~e.24
                        :name (n4 / name :op1 "Ras"~e.18)
                        :ARG1-of (i / include-91
                              :ARG2 (e2 / enzyme
                                    :name (n5 / name :op1 "Ras"~e.18)
                                    :location (c5 / cell~e.17))
                              :ARG3 (b / bulk~e.15))
                        :ARG1-of (d / deactivate-01)
                        :ARG2-of~e.24 (b2 / bind-01~e.24
                              :ARG1 s))
                  :concession~e.28 (h2 / high~e.30
                        :domain (r / ratio-of~e.34
                              :op1 s2
                              :op2 s~e.31,32,33
                              :location~e.35 (c6 / cytosol~e.37)))))
      :ARG1-of (a3 / attest-01
            :ARG0 (p4 / publication
                  :ARG1-of (c7 / cite-01
                        :ARG2 (v / value-interval :op1 "1"~e.39 :op2 "3"~e.41)))))

# ::tok Growth factors can turn on Ras by activating Guanine nucleotide Exchange Factors ( GEFs ) or by inhibiting the GTPase Activating Proteins ( GAPs ) or by both mechanisms .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 2-1 3-1.1 4-1.1 5-1.1.2.1.1 6-1.1.3.r 7-1.1.3.1 8-1.1.3.1.2.1.1 9-1.1.3.1.2.1.2 10-1.1.3.1.2.1.3 11-1.1.3.1.2.1.4 15-1.1.3 17-1.1.3.2 19-1.1.3.2.2.1.1.1.1 20-1.1.3.1 20-1.1.3.2.2.1 21-1.1.3.2.2 25-1.1.3
# ::id bio.ras_0001.7
# ::preferred 
(p5 / possible~e.2
      :domain (t / turn-on-13~e.3,4
            :ARG0 (s / small-molecule
                  :name (n4 / name :op1 "growth"~e.0 :op2 "factor"~e.1))
            :ARG1 (e2 / enzyme
                  :name (n / name :op1 "Ras"~e.5))
            :manner~e.6 (o / or~e.15,25
                  :op1 (a / activate-01~e.7,20
                        :ARG0 s
                        :ARG1 (p2 / protein
                              :name (n2 / name
                                    :op1 "guanine"~e.8
                                    :op2 "nucleotide"~e.9
                                    :op3 "exchange"~e.10
                                    :op4 "factor"~e.11)))
                  :op2 (i / inhibit-01~e.17
                        :ARG0 s
                        :ARG1 (p3 / protein~e.21
                              :ARG0-of (a2 / activate-01~e.20
                                    :ARG1 (e / enzyme
                                          :name (n3 / name :op1 "GTPase"~e.19)))))
                  :op3 (a3 / and
                        :op1 a
                        :op2 i))))

# ::tok RasGEFs bind to Ras and lower the transition energy for the nucleotide exchange of the bound GDP for the more abundant cytosolic GTP , whereas RasGAPs bind to Ras and catalyze GTP hydrolysis .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 2-1.1.1.2.r 3-1.1.1.2.1.1.1 4-1.1 5-1.1.2 7-1.1.2.2.1 8-1.1.2.2 12-1.1.2.2.2 15-1.1.2.2.2.1 15-1.1.2.2.2.1.2 15-1.1.2.2.2.1.2.r 16-1.1.2.2.2.1.1.1 17-1.1.2.2.2.2.r 19-1.1.2.2.2.2.2.1 20-1.1.2.2.2.2.2 21-1.1.2.2.2.2.3 22-1.1.2.2.2.2.1.1 24-1 26-1.1.2.2.2.1 26-1.1.2.2.2.1.2 26-1.1.2.2.2.1.2.r 26-1.2.1 28-1.1.1.2.1.1.1 28-1.2.1.2.1.1.1 29-1.2 30-1.2.2 31-1.2.2.2.1 32-1.2.2.2
# ::id bio.ras_0001.8
# ::preferred 
(c / contrast-01~e.24
      :ARG1 (a / and~e.4
            :op1 (b / bind-01~e.1
                  :ARG1 (p / protein
                        :name (n / name :op1 "RasGEF"~e.0))
                  :ARG2~e.2 (m2 / macro-molecular-complex
                        :part (e3 / enzyme
                              :name (n2 / name :op1 "Ras"~e.3,28))))
            :op2 (l / lower-05~e.5
                  :ARG0 p
                  :ARG1 (e / energy~e.8
                        :mod (t / transition-01~e.7)
                        :poss (e2 / exchange-01~e.12
                              :ARG1 (s2 / small-molecule~e.15,26
                                    :name (n4 / name :op1 "GDP"~e.16)
                                    :ARG1-of~e.15,26 (b2 / bind-01~e.15,26
                                          :ARG2 e3))
                              :ARG3~e.17 (s / small-molecule
                                    :name (n5 / name :op1 "GTP"~e.22)
                                    :mod (a2 / abundant~e.20
                                          :degree (m / more~e.19)
                                          :compared-to s2)
                                    :location (c3 / cytosol~e.21))))))
      :ARG2 (a3 / and~e.29
            :op1 (b3 / bind-01~e.26
                  :ARG1 (p5 / protein
                        :name (n3 / name :op1 "RasGAP"))
                  :ARG2 (m3 / macro-molecular-complex
                        :part (e4 / enzyme
                              :name (n6 / name :op1 "Ras"~e.28))))
            :op2 (c2 / catalyze-01~e.30
                  :ARG0 p5
                  :ARG1 (h / hydrolyze-01~e.32
                        :ARG1 s~e.31))))

# ::tok The most prevalent oncogenic mutations in Ras ( Gly12 and Gly13 in the G1 box , and Gln61 in the G3 box ) preserve the GTP bound state by inhibiting intrinsic GTPase activity and by interfering with the ability of GAPs .
# ::amr-annotator ISI-AMR-01
# ::alignments 1-1.1.1.1 2-1.1.1 3-1.1.2 3-1.1.2.1 3-1.1.2.1.r 4-1.1 5-1.1.1.2.r 6-1.1.1.2.1.1 8-1.1.3.1.1.1 9-1.1.3 10-1.1.3.2.1.1 13-1.1.3.1.2.1.1 14-1.1.3.1.2.1.2 17-1.1.3.3.1.1 20-1.1.3.3.2.1.1 21-1.1.3.3.2.1.2 23-1 25-1.2.1.1.1 26-1.2 28-1.3.r 29-1.3.1 30-1.3.1.2.2 31-1.3.1.2.1.1.1 32-1.3.1.2 33-1.3 35-1.3.2 36-1.3.2.2.r 38-1.3.2.2 39-1.3.2.2.1.r 40-1.3.2.2.1.1.1
# ::id bio.ras_0001.9
# ::preferred 
(p / preserve-01~e.23
      :ARG0 (m / mutation~e.4
            :ARG1-of (p2 / prevail-02~e.2
                  :degree (m2 / most~e.1)
                  :compared-to~e.5 (e / enzyme
                        :name (n / name :op1 "Ras"~e.6)))
            :ARG0-of (c / cause-01~e.3
                  :ARG1~e.3 (c2 / cancer~e.3))
            :location (a / and~e.9
                  :op1 (p4 / protein-segment
                        :name (n2 / name :op1 "Gly12"~e.8)
                        :location (p7 / protein-segment
                              :name (n5 / name :op1 "G1"~e.13 :op2 "box"~e.14)
                              :location e))
                  :op2 (p5 / protein-segment
                        :name (n3 / name :op1 "Gly13"~e.10)
                        :location p7)
                  :op3 (p6 / protein-segment
                        :name (n4 / name :op1 "Gln61"~e.17)
                        :location (p8 / protein-segment
                              :name (n6 / name :op1 "G3"~e.20 :op2 "box"~e.21)
                              :location e))))
      :ARG1 (b / bind-01~e.26
            :ARG1 (s / small-molecule
                  :name (n7 / name :op1 "GTP"~e.25))
            :ARG2 e)
      :manner~e.28 (a2 / and~e.33
            :op1 (i / inhibit-01~e.29
                  :ARG0 m
                  :ARG1 (a3 / act-02~e.32
                        :ARG0 (e2 / enzyme
                              :name (n8 / name :op1 "GTPase"~e.31))
                        :mod (i3 / intrinsic~e.30)))
            :op2 (i2 / interfere-01~e.35
                  :ARG0 m
                  :ARG1~e.36 (c4 / capable-01~e.38
                        :ARG1~e.39 (p10 / protein
                              :name (n9 / name :op1 "GAP"~e.40))))))

# ::tok Other less frequently observed mutations , such as those found in the G4 and G5 boxes , increase the rate of nucleotide exchange , thereby mimicking the GEFs and increasing the GTP - bound state ( 1 – 7 ) .
# ::amr-annotator ISI-AMR-01
# ::alignments 0-1.1.2 1-1.1.1.1.1 2-1.1.1.1 3-1.1.1 4-1.1 4-1.1.3 6-1.1.3.r 7-1.1.3.r 10-1.1.3.1.r 12-1.1.3.1.1.1.1 14-1.1.3.1.2.1.1 15-1.1.3.1.1.1.2 15-1.1.3.1.2.1.2 17-1 17-1.4.1 19-1.2 20-1.2.1.r 21-1.2.1.1 22-1.2.1 24-1.3.r 25-1.3 27-1.3.2.1.1 29-1 29-1.4.1 31-1.4.1.1.1.2.1.1.1 33-1.4.1.1.1 33-1.4.1.1.1.2 33-1.4.1.1.1.2.r 36-1.5.1.1.1.1 38-1.5.1.1.1.2
# ::id bio.ras_0001.10
# ::preferred 
(i / increase-01~e.17,29
      :ARG0 (m / mutation~e.4
            :ARG1-of (o / observe-01~e.3
                  :frequency (f / frequent~e.2
                        :degree (l / less~e.1)))
            :mod (o2 / other~e.0)
            :example~e.6,7 (m2 / mutation~e.4
                  :location~e.10 (o3 / or
                        :op1 (p / protein-segment
                              :name (n / name :op1 "G4"~e.12 :op2 "box"~e.15))
                        :op2 (p2 / protein-segment
                              :name (n2 / name :op1 "G5"~e.14 :op2 "box"~e.15)))))
      :ARG1 (r / rate~e.19
            :degree-of~e.20 (e / exchange-01~e.22
                  :ARG1 (n3 / nucleotide~e.21)))
      :manner-of~e.24 (m3 / mimic-01~e.25
            :ARG0 m
            :ARG1 (p3 / protein
                  :name (n4 / name :op1 "GEF"~e.27)))
      :ARG0-of (c / cause-01
            :ARG1 (i2 / increase-01~e.17,29
                  :ARG1 (n7 / number
                        :quant-of (e2 / enzyme~e.33
                              :name (n5 / name :op1 "Ras")
                              :ARG2-of~e.33 (b / bind-01~e.33
                                    :ARG1 (s / small-molecule
                                          :name (n6 / name :op1 "GTP"~e.31)))))))
      :ARG1-of (a / attest-01
            :ARG0 (p6 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (v / value-interval :op1 "1"~e.36 :op2 "7"~e.38)))))

# ::tok Activated Ras controls diverse signaling pathways that ultimately determine Ras - induced cellular responses such as cell proliferation , survival , differentiation and motility .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.1.1 2-1 3-1.2.1 4-1.2.2 5-1.2 7-1.2.3.2 8-1.2.3 9-1.2.3.1.3.1 11-1.2.3.1.3 12-1.2.3.1.1 13-1.2.3.1 15-1.2.3.1.2.r 15-1.2.3.2.r 16-1.2.3.1.2.1.1 17-1.2.3.1.2.1 19-1.2.3.1.2.2 21-1.2.3.1.2.3 22-1.2.3.1.2 23-1.2.3.1.2.4
# ::id bio.ras_0002.1
# ::preferred 
(c / control-01~e.2
      :ARG0 (e / enzyme
            :name (n / name :op1 "Ras"~e.1)
            :ARG1-of (a / activate-01~e.0))
      :ARG1 (p / pathway~e.5
            :mod (d / diverse~e.3)
            :ARG0-of (s / signal-07~e.4)
            :ARG0-of (d2 / determine-01~e.8
                  :ARG1 (r / respond-01~e.13
                        :ARG0 (c2 / cell~e.12)
                        :ARG2~e.15 (a2 / and~e.22
                              :op1 (p2 / proliferate-01~e.17
                                    :ARG0 c2~e.16)
                              :op2 (s2 / survive-01~e.19
                                    :ARG0 c2)
                              :op3 (d3 / differentiate-01~e.21
                                    :ARG1 c2)
                              :op4 (m / motility~e.23
                                    :mod c2))
                        :ARG1-of (i / induce-01~e.11
                              :ARG0 e~e.9))
                  :time~e.15 (u / ultimate~e.7))))

# ::tok These multiple Ras functions depend on its binding to a range of functionally diverse effector molecules such as Raf , PI3K , AF6 and RASSFs ( 1 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.1 2-1.1.3.1.1.1 3-1.1 3-1.1.3 3-1.1.3.r 4-1 5-1.2.r 6-1.2.1 6-1.2.1.r 7-1.2 8-1.2.2.r 10-1.2.2.3 11-1.2.2.3.r 12-1.2.2.4 13-1.2.2.4.1 14-1.2.2.1 15-1.2.2 16-1.2.2.2.r 17-1.2.2.2.r 18-1.2.2.2.1.1.1 20-1.2.2.2.2.1.1 22-1.2.2.2.3.1.1 23-1.2.2.2 26-1.3.1.1.1
# ::id bio.ras_0002.2
# ::preferred 
(d / depend-01~e.4
      :ARG0 (t3 / thing~e.3
            :quant (m / multiple~e.1)
            :mod (t / this~e.0)
            :ARG1-of~e.3 (f / function-01~e.3
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "Ras"~e.2))))
      :ARG1~e.5 (b / bind-01~e.7
            :ARG1~e.6 e~e.6
            :ARG2~e.8 (m2 / molecule~e.15
                  :mod (e3 / effector~e.14)
                  :example~e.16,17 (a / and~e.23
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "Raf"~e.18))
                        :op2 (e4 / enzyme
                              :name (n3 / name :op1 "PI3K"~e.20))
                        :op3 (e5 / enzyme
                              :name (n4 / name :op1 "AF6"~e.22))
                        :op4 (p / protein
                              :name (n5 / name :op1 "RASSF")))
                  :quant~e.11 (r / range~e.10)
                  :ARG0-of (f2 / function-01~e.12
                        :mod (d2 / diverse~e.13))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c / cite-01 :ARG2 "1"~e.26))))

# ::tok The enhancement of specific effector pathways plays a critical role in maintaining an appropriate biological response ( 8 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.2 4-1.1.1.1 5-1.1.1 6-1 8-1.2.1 9-1.2 10-1.2.2.r 11-1.2.2 13-1.2.2.2.3 14-1.2.2.2.2 15-1.2.2.2 15-1.2.2.2.1 15-1.2.2.2.1.r 17-1.3.1.1.1
# ::id bio.ras_0002.3
# ::preferred 
(p / play-02~e.6
      :ARG0 (e / enhance-01~e.1
            :ARG1~e.2 (p2 / pathway~e.5
                  :mod (e2 / effector~e.4)
                  :mod (s / specific~e.3)))
      :ARG1 (r / role~e.9
            :mod (c / critical~e.8)
            :topic~e.10 (m / maintain-01~e.11
                  :ARG0 e
                  :ARG1 (t / thing~e.15
                        :ARG2-of~e.15 (r2 / respond-01~e.15)
                        :mod (b / biology~e.14)
                        :mod (a / appropriate~e.13))))
      :ARG1-of (d / describe-01
            :ARG2 (p3 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "8"~e.17))))

# ::tok The specificity in Ras - induced signaling is primarily determined by the balance between Ras affinity for each of its effectors and the local concentrations of those effectors .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1.2.1.r 3-1.2.1.1.1 5-1.2.1.1 6-1.2.1 8-1.3 9-1 10-1.1.r 12-1.1 14-1.1.1.1.1.1 15-1.1.1 16-1.1.1.2.r 17-1.1.1.2.1 19-1.1.1.2.2 19-1.1.1.2.2.r 20-1.1.1.2 23-1.1.2.2 24-1.1.2 27-1.1.2.1
# ::id bio.ras_0002.4
# ::preferred 
(d / determine-01~e.9
      :ARG0~e.10 (b / balance-01~e.12
            :ARG1 (a / affinity~e.15
                  :poss (e / enzyme
                        :name (n / name :op1 "Ras"~e.14))
                  :topic~e.16 (e2 / effector~e.20
                        :mod (e3 / each~e.17)
                        :poss~e.19 e~e.19))
            :ARG2 (c / concentrate-02~e.24
                  :ARG1 e2~e.27
                  :mod (l / local~e.23)))
      :ARG1 (s / specificity~e.1
            :mod~e.2 (s2 / signal-07~e.6
                  :ARG1-of (i / induce-01~e.5
                        :ARG0 e~e.3)))
      :mod (p / primary~e.8))

# ::tok In addition , scaffold proteins have been shown to guide activation of specific effector pathway( s ) . For example , SHOC2 / Sur @-@ 8 bridges Ras and Raf to specifically enhance the Raf / MEK / ERK pathway without enhancing PI3K / AKT signaling ( 9 , 10 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1 3-1.1.1.1.1.1 4-1.1.1.1.1 7-1.1.1 9-1.1.1.1 10-1.1.1.1.2 12-1.2.1.4.3 13-1.1.1.1.2.1.1 18-1.2 19-1.2 21-1.2.1.1.1.1.1 23-1.2.1.1.2.1.1 25-1.2.1.1.2.1.1 26-1.2.1 27-1.2.1.2.1.1 28-1.2.1.6.1.1.1 29-1.2.1.3.1.1 31-1.1.1.1.2.1.2 31-1.2.1.4.3 32-1.2.1.4 34-1.2.1.4.2.1.1 36-1.2.1.4.2.1.1 38-1.2.1.4.2.1.1 39-1.1.1.1.2.1 40-1.2.1.5.1 40-1.2.1.5.1.r 41-1.2.1.5 42-1.2.1.5.3.1.1.1 44-1.2.1.5.3.1.1.1 45-1.2.1.5.3 47-1.2.1.6.1.1.1.1 49-1.2.1.6.1.1.1.2
# ::id bio.ras_0002.5
# ::preferred 
(m / multi-sentence
      :snt1 (a4 / and~e.0,1
            :op2 (s / show-01~e.7
                  :ARG1 (g / guide-01~e.9
                        :ARG0 (p / protein~e.4
                              :mod (s5 / scaffold~e.3))
                        :ARG1 (a / activate-01~e.10
                              :ARG1 (p2 / pathway~e.39
                                    :mod (e5 / effector~e.13)
                                    :mod (s2 / specific~e.31))))))
      :snt2 (e8 / exemplify-01~e.18,19
            :ARG0 (b / bridge-01~e.26
                  :ARG0 (m2 / macro-molecular-complex
                        :part (e3 / enzyme
                              :name (n3 / name :op1 "SHOC2"~e.21))
                        :part (e4 / enzyme
                              :name (n4 / name :op1 "Sur-8"~e.23,25)))
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.27))
                  :ARG2 (e2 / enzyme
                        :name (n2 / name :op1 "Raf"~e.29))
                  :purpose (e6 / enhance-01~e.32
                        :ARG0 m2
                        :ARG1 (p4 / pathway
                              :name (n7 / name :op1 "Raf/MEK/ERK"~e.34,36,38))
                        :mod (s3 / specific~e.12,31))
                  :manner (e7 / enhance-01~e.41
                        :polarity~e.40 "-"~e.40
                        :ARG0 m2
                        :ARG1 (s4 / signal-07~e.45
                              :ARG0 (p5 / pathway
                                    :name (n8 / name :op1 "PI3K/AKT"~e.42,44))))
                  :ARG1-of (d / describe-01
                        :ARG0 (p6 / publication
                              :ARG1-of (c / cite-01
                                    :ARG2 (a3 / and~e.28 :op1 "9"~e.47 :op2 "10"~e.49)))))))

# ::tok We utilized an unbiased mass spectrometry - based approach to identify ubiquitination sites of Ras .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 3-1.2.1 3-1.2.1.1 3-1.2.1.1.r 4-1.2.2.1.1 5-1.2.2.1 7-1.2.2 8-1.2 10-1.3 11-1.3.2.2 12-1.3.2 13-1.3.2.1.r 14-1.3.2.1.1.1
# ::id bio.ras_0003.1
# ::preferred 
(u / utilize-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (a / approach-02~e.8
            :ARG1-of (b / bias-01~e.3 :polarity~e.3 "-"~e.3)
            :ARG1-of (b2 / base-02~e.7
                  :ARG2 (s / spectrometry~e.5
                        :mod (m / mass~e.4))))
      :purpose (i / identify-01~e.10
            :ARG0 w
            :ARG1 (p / protein-segment~e.12
                  :part-of~e.13 (e / enzyme
                        :name (n / name :op1 "Ras"~e.14))
                  :ARG1-of (u2 / ubiquitinate-01~e.11))))

# ::tok His - tagged ubiquitin and Flag - tagged K @-@ Ras4B ( K @-@ Ras hereafter ) were expressed in HEK293T cells at levels similar to endogenous K @-@ Ras ( Fig. 1B ) and subjected to sequential affinity chromatography .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.2 2-1.1.1.2.3 3-1.1.1.1.1.1 5-1.1.1.2.3.1.1.1 7-1.1.1.2.3 8-1.1.1.2.1.1 8-1.1.1.2.2.1 10-1.1.1.2.1.1 12-1.1.1.2.1.1 12-1.1.1.2.2.1 14-1.1.1.2.2.1 18-1.1 18-1.1.3.1.1.1 19-1.1.2.r 20-1.1.2.1.1 21-1.1.2 22-1.1.3.r 23-1.1.3 23-1.1.3.1.1 24-1.1.3.1 25-1.1.3.1.1.1.1.r 26-1.1.3.1.1.1.1.2 27-1.1.1.2.1.1 27-1.1.1.2.2.1 27-1.1.3.1.1.1.1.1.1 29-1.1.1.2.2.1 29-1.1.3.1.1.1.1.1.1 32-1.1.4.1.1 34-1 35-1.2 36-1.2.2.r 37-1.2.2.2 38-1.2.2.1 39-1.2.2
# ::id bio.ras_0003.2
# ::preferred 
(a3 / and~e.34
      :op1 (e2 / express-03~e.18
            :ARG2 (a / and
                  :op1 (p / protein
                        :name (n / name :op1 "ubiquitin"~e.3)
                        :ARG1-of (t / tag-01~e.2
                              :ARG2 (a2 / amino-acid
                                    :name (n3 / name :op1 "histidine"))))
                  :op2 (e / enzyme
                        :name (n2 / name :op1 "K-Ras4B"~e.8,10,12,27)
                        :name (n7 / name :op1 "K-Ras"~e.8,12,14,27,29)
                        :ARG1-of (t2 / tag-01~e.2,7
                              :ARG2 (p2 / protein-segment
                                    :name (n4 / name :op1 "Flag"~e.5)))))
            :ARG3~e.19 (c / cell-line~e.21
                  :name (n5 / name :op1 "HEK293T"~e.20))
            :degree~e.22 (l / level~e.23
                  :ARG1-of (r / resemble-01~e.24
                        :ARG2 (l2 / level~e.23
                              :degree-of (e4 / express-03~e.18
                                    :ARG2~e.25 (e3 / enzyme
                                          :name (n6 / name :op1 "K-Ras"~e.27,29)
                                          :mod (e5 / endogenous~e.26))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "1B"~e.32)))
      :op2 (s / subject-01~e.35
            :ARG1 a
            :ARG2~e.36 (c2 / chromatography~e.39
                  :mod (a4 / affinity~e.38)
                  :mod (s2 / sequence~e.37))))

# ::tok His - ubiquitinated proteins were purified by Co2+ metal affinity chromatography in 8M urea denaturing conditions .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1 3-1.1 5-1 6-1.2.r 7-1.2.1.1.1.1 8-1.2.1.1 9-1.2.1 10-1.2 13-1.2.2.2.1.1 14-1.2.2 15-1.2.2.r
# ::id bio.ras_0003.3
# ::preferred 
(p / purify-01~e.5
      :ARG1 (p2 / protein~e.3
            :ARG3-of (u / ubiquitinate-01~e.2
                  :mod (a / amino-acid
                        :name (n / name :op1 "histidine"))))
      :manner~e.6 (c / chromatography~e.10
            :mod (a2 / affinity~e.9
                  :topic (m2 / metal~e.8
                        :name (n2 / name :op1 "Co2+"~e.7)))
            :condition~e.15 (d2 / denature-00~e.14
                  :ARG1 p2
                  :instrument (s / small-molecule
                        :name (n3 / name :op1 "urea"~e.13)
                        :mod (c2 / concentration-quantity
                              :quant "8"
                              :unit (m / molar))))))

# ::tok His - ubiquitinated K @-@ Ras was subsequently purified with anti - Flag resin .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.2 3-1.1.1.1 5-1.1.1.1 7-1.2 7-1.2.r 8-1 9-1.3.r 10-1.3.1 12-1.3.1.1.1.1 13-1.3
# ::id bio.ras_0003.4
# ::preferred 
(p / purify-01~e.8
      :ARG1 (e / enzyme
            :name (n / name :op1 "K-Ras"~e.3,5)
            :ARG3-of (u / ubiquitinate-01~e.2
                  :mod (a / amino-acid
                        :name (n2 / name :op1 "histidine"))))
      :time~e.7 (s / subsequent~e.7)
      :instrument~e.9 (r / resin~e.13
            :ARG0-of (c / counter-01~e.10
                  :ARG1 (p2 / protein-segment
                        :name (n3 / name :op1 "Flag"~e.12)))))

# ::tok Following purification , mono @- and di @- ubiquitinated K @-@ Ras appeared to be the major ubiquitination forms , which is consistent with the endogenous K @-@ Ras ubiquitination pattern ( Fig. 1 , A and B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1.2.1 3-1.2.1.1 4-1.2.1.1 5-1.2.1.1 6-1.2.1.1 7-1.2.1.1 8-1.2.1.1 9-1.2.1.1 10-1.2.1.1 11-1.2.1.1 12-1 13-1.1.r 14-1.1.3.r 16-1.1.2 17-1.1.1 17-1.1.3.2 18-1.1 21-1.1.3.r 22-1.3 23-1.3.1.r 25-1.3.1.1.1.2 26-1.3.1.1.1.1.1 28-1.3.1.1.1.1.1 29-1.3.1.1 30-1.3.1 33-1.1.3.2.1.1 36-1.4.1
# ::id bio.ras_0003.5
# ::preferred 
(a / appear-02~e.12
      :ARG1~e.13 (f2 / form~e.18
            :mod (u2 / ubiquitinate-01~e.17)
            :mod (m / major~e.16)
            :domain~e.14,21 (e / enzyme
                  :name (n / name :op1 "K-Ras")
                  :ARG3-of (u / ubiquitinate-01~e.17
                        :quant (o / or :op1 "1"~e.33 :op2 "2"))))
      :ARG1-of (f / follow-01~e.0
            :ARG2 (p / purify-01~e.1
                  :ARG1 e~e.3,4,5,6,7,8,9,10,11))
      :ARG1-of (c / consistent-01~e.22
            :ARG2~e.23 (p2 / pattern~e.30
                  :topic (u3 / ubiquitinate-01~e.29
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "K-Ras"~e.26,28)
                              :mod (e3 / endogenous~e.25)))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.36
                  :op1 (f3 / figure :mod "1A")
                  :op2 (f4 / figure :mod "1B"))))

# ::tok H @-@ Ras ubiquitination sites were also determined by the same approach .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.1 2-1.1.2.1.1 3-1.1.1 4-1.1 6-1.2 7-1 8-1.3.r 10-1.3.1 11-1.3
# ::id bio.ras_0003.6
# ::preferred 
(d / determine-01~e.7
      :ARG1 (p / protein-segment~e.4
            :ARG1-of (u / ubiquitinate-01~e.3)
            :part-of (e / enzyme
                  :name (n / name :op1 "H-Ras"~e.0,2)))
      :mod (a / also~e.6)
      :manner~e.8 (a2 / approach-02~e.11
            :ARG1-of (s / same-01~e.10)))

# ::tok Tandem mass spectrometric analysis of tryptic fragments from the bands migrating at the positions expected for mono @- and di @- ubiquitinated Ras revealed ubiquitination at Lys residues 104 and 147 of K @-@ Ras , and Lys residues 117 , 147 and 170 for H @-@ Ras ( fig. S1C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.2 1-1.1.2.1 2-1.1.2 3-1.1 4-1.1.1.r 5-1.1.1.2.1.1 6-1.1.1 7-1.1.1.1.r 9-1.1.1.1 10-1.1.1.1.1 11-1.1.1.1.1.1.1 13-1.1.1.1.1.1 14-1.1.1.1.1.1.1.2 16-1.1.1.1.1.1.1.1.2.1.1 16-1.1.1.1.1.1.1.1.2.1.r 19-1.1.1.1.1.1.1.1.2.1.2 19-1.1.1.1.1.1.1.1.2.1.r 21-1.1.1.1.1.1.1.1.2 21-1.2 22-1.1.1.1.1.1.1.1.1.1 23-1 24-1.1.1.1.1.1.1.1.2 24-1.2 25-1.1.1.1.1.1.1 25-1.2.1.r 26-1.2.1.1.1.1.2.1 26-1.2.1.1.2.1.2.1 26-1.2.1.2.1.1.2.1 26-1.2.1.2.2.1.2.1 27-1.2.1.1.1 27-1.2.1.1.2 27-1.2.1.2.1 27-1.2.1.2.2 28-1.2.1.1.1.1.1 29-1.2.1.1 30-1.2.1.1.2.1.1 32-1.2.1.1.3.1.1 34-1.2.1.1.3.1.1 36-1.2.1 36-1.2.1.1 36-1.2.1.1.r 36-1.2.1.2 37-1.2.1.1.2.1.2.1 37-1.2.1.2.1.1.2.1 37-1.2.1.2.2.1.2.1 37-1.2.1.2.3.1.2.1 38-1.2.1.1.2 38-1.2.1.2.1 38-1.2.1.2.2 38-1.2.1.2.3 39-1.2.1.2.1.1.1 41-1.2.1.2.2.1.1 43-1.2.1.2.3.1.1 44-1.2.1.2.r 45-1.2.1.2.4.1.1 47-1.2.1.2.4.1.1 49-1.3.1 50-1.3.1.1
# ::id bio.ras_0003.7
# ::preferred 
(r / reveal-01~e.23
      :ARG0 (a / analyze-01~e.3
            :ARG1~e.4 (f / fragment~e.6
                  :source~e.7 (b / band~e.9
                        :ARG0-of (m / migrate-01~e.10
                              :ARG1 (p / position~e.13
                                    :ARG2-of (b2 / be-located-at-91~e.11,25
                                          :ARG1 (e / enzyme
                                                :name (n / name :op1 "Ras"~e.22)
                                                :ARG3-of (u / ubiquitinate-01~e.21,24
                                                      :quant~e.16,19 (o / or :op1 "1"~e.16 :op2 "2"~e.19)))
                                          :ARG1-of (e4 / expect-01~e.14)))))
                  :mod (e5 / enzyme
                        :name (n9 / name :op1 "trypsin"~e.5)))
            :manner (s / spectrometry~e.2
                  :mod (m2 / mass~e.1)
                  :mod (t2 / tandem~e.0)))
      :ARG1 (u2 / ubiquitinate-01~e.21,24
            :ARG1~e.25 (a2 / and~e.36
                  :op1~e.36 (a3 / and~e.29,36
                        :op1 (r2 / residue~e.27
                              :mod (a4 / amino-acid
                                    :mod "104"~e.28
                                    :name (n4 / name :op1 "lysine"~e.26)))
                        :op2 (r3 / residue~e.27,38
                              :mod (a5 / amino-acid
                                    :mod "147"~e.30
                                    :name (n5 / name :op1 "lysine"~e.26,37)))
                        :part-of (e2 / enzyme
                              :name (n2 / name :op1 "K-Ras"~e.32,34)))
                  :op2~e.44 (a6 / and~e.36
                        :op1 (r4 / residue~e.27,38
                              :mod (a7 / amino-acid
                                    :mod "117"~e.39
                                    :name (n6 / name :op1 "lysine"~e.26,37)))
                        :op2 (r5 / residue~e.27,38
                              :mod (a8 / amino-acid
                                    :mod "147"~e.41
                                    :name (n7 / name :op1 "lysine"~e.26,37)))
                        :op3 (r6 / residue~e.38
                              :mod (a9 / amino-acid
                                    :mod "170"~e.43
                                    :name (n8 / name :op1 "lysine"~e.37)))
                        :part-of (e3 / enzyme
                              :name (n3 / name :op1 "H-Ras"~e.45,47)))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.49 :mod "S1C"~e.50)))

# ::tok The tryptic peptide with ubiquitination at Lys147 ( K147 ) was the most frequently observed peptide for both K @-@ Ras and H @-@ Ras , while Lys117 appeared as a secondary major ubiquitination site in H @-@ Ras .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.1.1.1 2-1.2.1 4-1.1.2.2 4-1.1.2.2.3 4-1.1.2.2.3.r 4-1.2.1.1 10-1.1.2.r 10-1.2.1.5.r 12-1.1.1.1.1 13-1.1.1.1 14-1.1 15-1.1.1 15-1.1.2 18-1.1.1.2.1.1.1 20-1.1.1.2.1.1.1 20-1.1.1.2.2.1.1 21-1.1.1.2 22-1.1.1.2.2.1.1 22-1.2.1.2.1.1 24-1.1.1.2.2.1.1 24-1.2.1.2.1.1 26-1 28-1.2 31-1.2.1.4 32-1.2.1.3 33-1.2.1.1 34-1.2.1 36-1.1.1.2.2.1.1 36-1.2.1.2.1.1 38-1.1.1.2.2.1.1 38-1.2.1.2.1.1
# ::id bio.ras_0003.8
# ::preferred 
(c / contrast-01~e.26
      :ARG1 (o / observe-01~e.14
            :ARG1 (p / peptide~e.15
                  :frequency (f / frequent~e.13
                        :degree (m / most~e.12))
                  :part-of (a / and~e.21
                        :op1 (e / enzyme
                              :name (n / name :op1 "K-Ras"~e.18,20))
                        :op2 (e2 / enzyme
                              :name (n2 / name :op1 "H-Ras"~e.20,22,24,36,38))))
            :domain~e.10 (p2 / peptide~e.15
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e3 / enzyme
                              :name (n3 / name :op1 "trypsin"~e.1)))
                  :part (a2 / amino-acid~e.4
                        :mod "147"
                        :name (n4 / name :op1 "lysine")
                        :ARG1-of~e.4 (u / ubiquitinate-01~e.4))))
      :ARG2 (a3 / appear-01~e.28
            :ARG1 (p3 / protein-segment~e.2,34
                  :ARG1-of (u2 / ubiquitinate-01~e.4,33)
                  :part-of (e4 / enzyme
                        :name (n6 / name :op1 "H-Ras"~e.22,24,36,38))
                  :mod (m2 / major~e.32)
                  :mod (s / secondary~e.31)
                  :domain~e.10 (a4 / amino-acid
                        :mod "117"
                        :name (n5 / name :op1 "lysine")))))

# ::tok Site @-@ Specific Monoubiquitination Activates Ras by Impeding GTPase Activating Protein ( PMC3537887 )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.2.1 2-1.2.1.2 4-1.2 5-1.2.2.1.1 6-1.2.3.r 7-1.2.3 8-1.2.3.2.1.1 9-1.2.3.2.1.2 10-1.2.3.2.1.3 12-1.1
# ::id bio.bmtr_0004.1
# ::preferred 
(p / publication-91
      :ARG8 "PMC3537887"~e.12
      :ARG1 (a / activate-01~e.4
            :ARG0 (u / ubiquitinate-01
                  :quant "1"
                  :mod (s / specific~e.2
                        :prep-to (p3 / protein-segment~e.0)))
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Ras"~e.5))
            :manner~e.6 (i / impede-01~e.7
                  :ARG0 u
                  :ARG1 (p2 / protein
                        :name (n2 / name
                              :op1 "GTPase"~e.8
                              :op2 "Activating"~e.9
                              :op3 "Protein"~e.10)))))

# ::tok Passage 1 @-@ 1 ( Results )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1 3-1.1 5-1.2 5-1.2.1 5-1.2.1.r
# ::id bio.bmtr_0004.2
# ::preferred 
(p / passage~e.0
      :mod "1-1"~e.1,3
      :topic (t / thing~e.5
            :ARG2-of~e.5 (r / result-01~e.5)))

# ::tok We next considered the effect of Ras monoubiquitination on GAP @-@ mediated hydrolysis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.3 2-1 4-1.2 6-1.2.1.2.1.1 8-1.2.2.r 9-1.2.2.1.1.1.1 11-1.2.2.1 12-1.2.2
# ::id bio.bmtr_0004.3
# ::preferred 
(c / consider-02~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (a / affect-01~e.4
            :ARG0 (u / ubiquitinate-01
                  :quant "1"
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.6)))
            :ARG1~e.8 (h / hydrolyze-01~e.12
                  :ARG1-of (m / mediate-01~e.11
                        :ARG0 (p / protein
                              :name (n2 / name :op1 "GAP"~e.9)))))
      :time (n3 / next~e.1))

# ::tok To this end we compared the rate of GTP hydrolysis for Ras and mUbRas in the presence of the catalytic domains of two GAPs , NF1 ( NF1 @-@ 333 ) and p120GAP( GAP @-@ 334 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 3-1.1 4-1 6-1.2 6-1.3 8-1.2.1.1.1.1 8-1.3.1.1.1.1 9-1.2.1 9-1.3.1 11-1.2.1.1.2.1.1.1 11-1.3.1.1.2.1.1.1 12-1.2.1.2 17-1.2.1.2.r 19-1.2.1.2.3 20-1.2.1.2.1 20-1.2.1.2.2 23-1.2.1.2.1.2.2.1.1.1 25-1.2.1.2.1.2.1.1 27-1.2.1.2.1.2.1.1 29-1.2.1.2.1.1.1 31-1.2.1.2 33-1.2.1.2.2.1.1 35-1.2.1.2.2.1.1
# ::id bio.bmtr_0004.4
# ::preferred 
(c / compare-01~e.4
      :ARG0 (w / we~e.3)
      :ARG1 (r / rate~e.6
            :degree-of (h / hydrolyze-01~e.9
                  :ARG1 (s / small-molecule
                        :name (n / name :op1 "GTP"~e.8)
                        :ARG1-of (b / bind-01
                              :ARG2 (e / enzyme
                                    :name (n2 / name :op1 "Ras"~e.11))))
                  :condition~e.17 (a / and~e.12,31
                        :op1 (d2 / domain~e.20
                              :name (n10 / name :op1 "NF1-333"~e.29)
                              :part-of (p4 / protein
                                    :name (n12 / name :op1 "NF1"~e.25,27)
                                    :ARG1-of (i / include-91
                                          :ARG2 (p6 / protein
                                                :name (n13 / name :op1 "GAP"~e.23)))))
                        :op2 (d3 / domain~e.20
                              :name (n11 / name :op1 "GAP-334"~e.33,35)
                              :part-of (p7 / protein
                                    :name (n14 / name :op1 "p120GAP")
                                    :ARG1-of (i2 / include-91
                                          :ARG2 p6)))
                        :ARG0-of (c2 / catalyze-01~e.19))))
      :ARG2 (r2 / rate~e.6
            :degree-of (h2 / hydrolyze-01~e.9
                  :ARG1 (s2 / small-molecule
                        :name (n9 / name :op1 "GTP"~e.8)
                        :ARG1-of (b2 / bind-01
                              :ARG2 (e2 / enzyme
                                    :name (n3 / name :op1 "Ras"~e.11)
                                    :ARG3-of (u / ubiquitinate-01 :quant "1"))))
                  :condition a))
      :purpose (t / this~e.1))

# ::tok At a GAP @-@ to @-@ Ras ratio of 1 @:@ 500 , we observed an order of magnitude increase in the rate of GTP hydrolysis for unmodified Ras relative to the intrinsic rate of GTP hydrolysis .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.3.2.1.1.1 6-1.2.3.2.2.1.1 7-1.2.3.2 8-1.2.3.2 9-1.2.3.1 11-1.2.3.1 13-1.1 14-1 17-1.2.2 19-1.2 22-1.2.1 22-1.2.2.2 23-1.2.1.1.r 23-1.2.2 24-1.2.1.1.1.1.1 25-1.2.1.1 27-1.2.1.1.1.2.1.2 27-1.2.1.1.1.2.1.2.1 27-1.2.1.1.1.2.1.2.1.r 28-1.2.1.1.1.2.1.1.1 32-1.2.2.2.1 33-1.2.2.2 34-1.2.2.2.2.r 35-1.2.2.2.2.1.1.1 36-1.2.2.2.2
# ::id bio.bmtr_0004.5
# ::preferred 
(o / observe-01~e.14
      :ARG0 (w / we~e.13)
      :ARG1 (i / increase-01~e.19
            :ARG1 (r / rate~e.22
                  :degree-of~e.23 (h / hydrolyze-01~e.25
                        :ARG1 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.24)
                              :ARG1-of (b / bind-01
                                    :ARG2 (e / enzyme
                                          :name (n2 / name :op1 "Ras"~e.28)
                                          :ARG1-of (m2 / modify-01~e.27 :polarity~e.27 "-"~e.27))))))
            :ARG4 (p2 / product-of~e.17,23
                  :op1 (a / about :op1 "10")
                  :op2 (r3 / rate~e.22,33
                        :mod (i2 / intrinsic~e.32)
                        :degree-of~e.34 (h2 / hydrolyze-01~e.36
                              :ARG1 (s2 / small-molecule
                                    :name (n5 / name :op1 "GTP"~e.35)))))
            :condition (e3 / equal-01
                  :ARG2 "1/500"~e.9,11
                  :ARG1 (r4 / ratio-of~e.7,8
                        :op1 (p / protein
                              :name (n3 / name :op1 "GAP"~e.2))
                        :op2 (e2 / enzyme
                              :name (n4 / name :op1 "Ras"~e.6))))))

# ::tok No increase in the rate of GTP hydrolysis was observed for mUbRas in the presence of the same GAP @-@ to Ras ratio ( Fig . 5b ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1 2-1.1.2.r 4-1.1.2 5-1.1.2.1.r 6-1.1.2.1.1.1.1 7-1.1.2.1 9-1 15-1.1.3 17-1.1.3.3 18-1.1.3.1.1.1 21-1.1.2.1.1.2.1.1.1 21-1.1.3.2.1.1 22-1.1.3 26-1.2.1.1
# ::id bio.bmtr_0004.6
# ::preferred 
(o / observe-01~e.9
      :ARG1 (i / increase-01~e.1
            :polarity~e.0 "-"~e.0
            :ARG1~e.2 (r / rate~e.4
                  :degree-of~e.5 (h / hydrolyze-01~e.7
                        :ARG1 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.6)
                              :ARG1-of (b / bind-01
                                    :ARG2 (e / enzyme
                                          :name (n4 / name :op1 "Ras"~e.21)
                                          :ARG3-of (u / ubiquitinate-01 :quant "1"))))))
            :condition (r2 / ratio-of~e.15,22
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "GAP"~e.18))
                  :op2 (e2 / enzyme
                        :name (n3 / name :op1 "Ras"~e.21))
                  :ARG1-of (s2 / same-01~e.17)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5b"~e.26)))

# ::tok Therefore , mUbRas is insensitive to GAP @-@ mediated regulation , similar to an oncogenic Ras @-@ G12V mutation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 4-1.1 4-1.1.1 4-1.1.1.r 5-1.1.3.r 6-1.1.3.2.1.1.1 8-1.1.3.2 9-1.1.3 11-1.1.4 12-1.1.4.1.3 14-1.1.4.1.3 14-1.1.4.1.3.1 14-1.1.4.1.3.1.r 15-1.1.2.1.1 15-1.1.4.1.2.1.1 17-1.1.4.1.1 18-1.1.4.1
# ::id bio.bmtr_0004.7
# ::preferred 
(c / cause-01~e.0
      :ARG1 (s / sensitive-03~e.4
            :polarity~e.4 "-"~e.4
            :ARG0 (e / enzyme
                  :name (n / name :op1 "Ras"~e.15)
                  :ARG3-of (u / ubiquitinate-01 :quant "1"))
            :ARG1~e.5 (r / regulate-01~e.9
                  :ARG1 e
                  :ARG1-of (m / mediate-01~e.8
                        :ARG0 (p / protein
                              :name (n2 / name :op1 "GAP"~e.6))))
            :ARG1-of (r2 / resemble-01~e.11
                  :ARG2 (m2 / mutate-01~e.18
                        :value "G12V"~e.17
                        :ARG2 (e2 / enzyme
                              :name (n3 / name :op1 "Ras"~e.15))
                        :ARG0-of (c2 / cause-01~e.12,14
                              :ARG1~e.14 (c3 / cancer~e.14))))))

# ::tok We obtained similar results using K @-@ Ras ( Supplementary Figure 6 ) , indicating that the effects of monoubiquitination on Ras are not isoform @-@ specific .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.2 3-1.2 3-1.2.1 3-1.2.1.r 4-1.3 5-1.3.2.1.1 7-1.3.2.1.1 10-1.2.3.1 11-1.2.3.1.1 14-1.2.4 15-1.2.4.1.r 17-1.2.4.1.2 20-1.2.4.1.2.2.r 21-1.2.4.1.2.2.1.1 22-1.2.4.1.2.r 23-1.2.4.1.1 23-1.2.4.1.1.r 24-1.2.4.1.3 26-1.2.4.1
# ::id bio.bmtr_0004.8
# ::preferred 
(o / obtain-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (t / thing~e.3
            :ARG2-of~e.3 (r / result-01~e.3)
            :ARG1-of (r2 / resemble-01~e.2)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure~e.10
                        :mod "6"~e.11
                        :ARG2-of (s / supplement-01)))
            :ARG0-of (i / indicate-01~e.14
                  :ARG1~e.15 (s2 / specific~e.26
                        :polarity~e.23 "-"~e.23
                        :domain~e.22 (a / affect-01~e.17
                              :ARG0 (u2 / ubiquitinate-01 :quant "1")
                              :ARG1~e.20 (e2 / enzyme
                                    :name (n2 / name :op1 "Ras"~e.21)))
                        :topic (i2 / isoform~e.24))))
      :manner (u / use-01~e.4
            :ARG0 w
            :ARG1 (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.5,7))))

# ::tok To verify that the differences between the enzymatic and chemical ubiquitination linkers ( seven bonds and five bonds , respectively ) do not alter GAP @-@ responsiveness , we placed an additional cysteine at the c @-@ terminus of Ubiquitin ( Ubiquitin @-@ C77 ) , thereby creating a linker one bond longer than the native linker .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.6.1 2-1.6.1.2.r 4-1.6.1.2.2 7-1.5.1 7-1.5.1.1.2 7-1.6.1.2.2.1 7-1.6.1.2.2.1.3.1 7-1.6.1.2.2.2 9-1.6.1.2.2.2.1.1 10-1.6.1.2.2.1.3 10-1.6.1.2.2.2.1 13-1.6.1.2.2.1.1.1 14-1.6.1.2.2.1.1 16-1.6.1.2.2.2.2.1 17-1.6.1.2.2.2.2 22-1.6.1.2.1 22-1.6.1.2.1.r 23-1.6.1.2 24-1.6.1.2.3.1.1.1 28-1.1 29-1 31-1.2.2 32-1.2.1.1 32-1.4.2.2.1 37-1.3.1.1 39-1.3.2.1.1 41-1.3.2.1.1 46-1.4.r 47-1.5 50-1.5.1.1.1.1.1 51-1.5.1.1.1.1 52-1.5.1.1 52-1.5.1.1.1 52-1.5.1.1.1.r 53-1.5.1.1.2.r 55-1.5.1.1.2.1
# ::id bio.bmtr_0004.9
# ::preferred 
(p / place-01~e.29
      :ARG0 (w / we~e.28)
      :ARG1 (a / amino-acid
            :name (n / name :op1 "cysteine"~e.32)
            :mod (a2 / additional~e.31))
      :ARG2 (p2 / protein-segment
            :name (n2 / name :op1 "C-terminus"~e.37)
            :part-of (p3 / protein
                  :name (n3 / name :op1 "ubiquitin"~e.39,41)))
      :manner-of~e.46 (b4 / become-01
            :ARG1 a
            :ARG2 (a5 / amino-acid
                  :mod "77"
                  :name (n4 / name :op1 "cysteine"~e.32)
                  :part-of p3))
      :ARG0-of (c / create-01~e.47
            :ARG1 (p6 / protein-segment~e.7
                  :mod (l / long~e.52
                        :degree~e.52 (m2 / more~e.52
                              :quant (b / bond~e.51 :quant "1"~e.50))
                        :compared-to~e.53 (p7 / protein-segment~e.7
                              :mod (n7 / native~e.55)
                              :ARG0-of (l3 / link-01)))
                  :ARG0-of (l2 / link-01)))
      :ARG1-of (h / have-purpose-91
            :ARG2 (v / verify-01~e.1
                  :ARG0 w
                  :ARG1~e.2 (a4 / alter-01~e.23
                        :polarity~e.22 "-"~e.22
                        :ARG0 (d / differ-02~e.4
                              :ARG1 (p8 / protein-segment~e.7
                                    :consist-of (b2 / bond~e.14 :quant "7"~e.13)
                                    :ARG0-of (l4 / link-01)
                                    :location-of (u2 / ubiquitinate-01~e.10
                                          :mod (e / enzyme~e.7)))
                              :ARG2 (p9 / protein-segment~e.7
                                    :location-of (u / ubiquitinate-01~e.10
                                          :mod (c2 / chemical~e.9))
                                    :consist-of (b3 / bond~e.17 :quant "5"~e.16)
                                    :ARG0-of (l5 / link-01)))
                        :ARG1 (r / respond-01
                              :ARG0 (p5 / protein
                                    :name (n5 / name :op1 "GAP"~e.24)))))))

# ::tok We measured the rate of GAP @-@ mediated GTP hydrolysis and observed that the response of Ras ligated to Ubiquitin @-@ C77 was identical to Ras ligated to Ubiquitin @-@ G76C ( Fig . 5b ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1.1.2 4-1.1.2.1.r 5-1.1.2.1.2.1.1.1 7-1.1.2.1.2 8-1.1.2.1.1.1.1 9-1.1.2.1 10-1 11-1.2 12-1.2.2.r 14-1.2.2.1 14-1.2.2.1.1 14-1.2.2.1.1.r 14-1.2.2.2 14-1.2.2.2.1 14-1.2.2.2.1.r 16-1.2.2.1.1.1.1.1 16-1.2.2.2.1.1.1.1 17-1.2.2.1.1.1.2 17-1.2.2.2.1.1.2 19-1.2.2.1.1.1.2.1.3.1.1 19-1.2.2.2.1.1.2.1.3.1.1 23-1.2.2 25-1.2.2.1.1.1.1.1 25-1.2.2.2.1.1.1.1 26-1.2.2.1.1.1.2 26-1.2.2.2.1.1.2 28-1.2.2.1.1.1.2.1.3.1.1 28-1.2.2.2.1.1.2.1.3.1.1 30-1.2.2.2.1.1.2.1.3.2.1 34-1.2.2.3.1.1
# ::id bio.bmtr_0004.10
# ::preferred 
(a / and~e.10
      :op1 (m / measure-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (r / rate~e.3
                  :degree-of~e.4 (h / hydrolyze-01~e.9
                        :ARG1 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.8))
                        :ARG1-of (m2 / mediate-01~e.7
                              :ARG0 (p / protein
                                    :name (n2 / name :op1 "GAP"~e.5))))))
      :op2 (o / observe-01~e.11
            :ARG0 w
            :ARG1~e.12 (i / identical-01~e.23
                  :ARG1 (t / thing~e.14
                        :ARG2-of~e.14 (r2 / respond-01~e.14
                              :ARG0 (e / enzyme
                                    :name (n5 / name :op1 "Ras"~e.16,25)
                                    :ARG1-of (l / ligate-01~e.17,26
                                          :ARG3 (a2 / amino-acid
                                                :mod "77"
                                                :name (n7 / name :op1 "cysteine")
                                                :part-of (p4 / protein
                                                      :name (n8 / name :op1 "ubiquitin"~e.19,28)))))))
                  :ARG2 (t2 / thing~e.14
                        :ARG2-of~e.14 (r3 / respond-01~e.14
                              :ARG0 (e2 / enzyme
                                    :name (n4 / name :op1 "Ras"~e.16,25)
                                    :ARG1-of (l2 / ligate-01~e.17,26
                                          :ARG3 (a3 / amino-acid
                                                :mod "76"
                                                :name (n3 / name :op1 "cysteine")
                                                :part-of (p2 / protein
                                                      :name (n9 / name :op1 "ubiquitin"~e.19,28)
                                                      :ARG3-of (m3 / mutate-01 :value "G76C"~e.30)))))))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure :mod "5b"~e.34)))))

# ::tok These results indicate that variations in the linker length on this scale ( 1 @-@ 2 bonds ) do not influence the sensitivity of mUbRas to GAP downregulation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.r 4-1.2.2 8-1.2.2.3 10-1.1.2 13-1.2.2.2.1.1 13-1.2.3.1.2.1 15-1.2.2.2.2.1 16-1.2.2.2.1 16-1.2.2.2.2 19-1.2.1 19-1.2.1.r 20-1.2 22-1.2.3 25-1.2.3.2.r 26-1.2.3.2.2.1.1 27-1.2.3.2
# ::id bio.bmtr_0004.11
# ::preferred 
(i / indicate-01~e.2
      :ARG0 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0,10))
      :ARG1~e.3 (i2 / influence-01~e.20
            :polarity~e.19 "-"~e.19
            :ARG0 (v2 / vary-01~e.4
                  :ARG1 (p2 / protein-segment
                        :ARG0-of (l2 / link-01))
                  :ARG2 (o / or
                        :op1 (b / bond~e.16 :quant "1"~e.13)
                        :op2 (b2 / bond~e.16 :quant "2"~e.15))
                  :ARG5 (l / length~e.8))
            :ARG1 (s / sensitive-03~e.22
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "Ras")
                        :ARG3-of (u / ubiquitinate-01 :quant "1"~e.13))
                  :ARG1~e.25 (d / downregulate-01~e.27
                        :ARG1 e
                        :ARG2 (p / protein
                              :name (n2 / name :op1 "GAP"~e.26))))))

# ::tok To validate the use of an in vitro system to dissect the mechanism of Ras regulation , we measured the sensitivity of mUbRas to GAP @-@ mediated hydrolysis in a cellular reconstitution system .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 3-1.3 3-1.3.1.2 4-1.3.1.2.2.r 6-1.3.1.2.2.1 7-1.3.1.2.2.1 8-1.3.1.2.2 10-1.3.1.2.3 14-1.2.1.1.1 14-1.3.1.2.3.2.1.1.1 15-1.3.1.2.3.2 17-1.1 18-1 20-1.2 23-1.2.2.r 24-1.2.2.1.1.1.1 26-1.2.2.1 27-1.2.2 28-1.3.1.2.2.1 30-1.2.3.1.1 32-1.2.3 32-1.3.1.2.2
# ::id bio.bmtr_0004.12
# ::preferred 
(m / measure-01~e.18
      :ARG0 (w / we~e.17)
      :ARG1 (s / sensitive-03~e.20
            :ARG0 (e / enzyme
                  :name (n / name :op1 "Ras"~e.14)
                  :ARG3-of (u / ubiquitinate-01 :quant "1"))
            :ARG1~e.23 (h / hydrolyze-01~e.27
                  :ARG1-of (m2 / mediate-01~e.26
                        :ARG0 (p / protein
                              :name (n2 / name :op1 "GAP"~e.24))))
            :location (s2 / system~e.32
                  :ARG0-of (r / reconstitute-01
                        :ARG1 (c / cell~e.30))))
      :ARG1-of (h2 / have-purpose-91~e.3
            :ARG2 (v / validate-01~e.1
                  :ARG0 w
                  :ARG1 (u2 / use-01~e.3
                        :ARG0 w
                        :ARG1~e.4 (s3 / system~e.8,32
                              :mod (i / in-vitro~e.6,7,28))
                        :ARG2 (d / dissect-01~e.10
                              :ARG0 w
                              :ARG1 (r2 / regulate-01~e.15
                                    :ARG1 (e2 / enzyme
                                          :name (n3 / name :op1 "Ras"~e.14))))))))

# ::tok We immunoprecipitated Ras from HEK293T cells and compared the sensitivity of the monoubiquitinated and unmodified fractions of Ras to regulation by GAP .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 2-1.1.2.1.1 4-1.1.3.1.1 5-1.1.3 6-1 7-1.2 9-1.2.2 9-1.2.3 14-1.2.3.1.2 14-1.2.3.1.2.1 14-1.2.3.1.2.1.r 15-1.2.2.1 15-1.2.3.1 17-1.1.2.1.1 19-1.2.2.2 19-1.2.3.2 20-1.2.2.2.1.r 21-1.2.2.2.1.1.1
# ::id bio.bmtr_0004.13
# ::preferred 
(a / and~e.6
      :op1 (i / immunoprecipitate-00
            :ARG0 (w / we~e.0)
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Ras"~e.2,17))
            :ARG2 (c / cell-line~e.5
                  :name (n2 / name :op1 "HEK293T"~e.4)))
      :op2 (c2 / compare-01~e.7
            :ARG0 w
            :ARG1 (s / sensitive-03~e.9
                  :ARG0 (f / fraction~e.15
                        :part-of e
                        :ARG1-of (u / ubiquitinate-01 :quant "1"))
                  :ARG1 (r / regulate-01~e.19
                        :ARG0~e.20 (p / protein
                              :name (n3 / name :op1 "GAP"~e.21))
                        :ARG1 f))
            :ARG2 (s2 / sensitive-03~e.9
                  :ARG0 (f2 / fraction~e.15
                        :part-of e
                        :ARG1-of (m / modify-01~e.14 :polarity~e.14 "-"~e.14))
                  :ARG1 (r2 / regulate-01~e.19
                        :ARG0 p
                        :ARG1 f2))))

# ::tok As seen in Figure 5c , monoubiquitinated K @-@ Ras is less sensitive than the unmodified protein to GAP @-@ mediated GTP hydrolysis .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.5 2-1.5.1.r 3-1.5.1 4-1.5.1.1 7-1.1.1.1 7-1.4.1.1 9-1.1.1.1 9-1.4.1.1 11-1.3 12-1 13-1.4.r 15-1.4.2 15-1.4.2.1 15-1.4.2.1.r 16-1.2.2.1 18-1.2.2.1.1.1 20-1.2.2 21-1.2.1.1.1 22-1.2
# ::id bio.bmtr_0004.14
# ::preferred 
(s / sensitive-03~e.12
      :ARG0 (e / enzyme
            :name (n / name :op1 "K-Ras"~e.7,9)
            :ARG1-of (u / ubiquitinate-01 :quant "1"))
      :ARG1 (h / hydrolyze-01~e.22
            :ARG1 (s2 / small-molecule
                  :name (n2 / name :op1 "GTP"~e.21))
            :ARG1-of (m2 / mediate-01~e.20
                  :ARG0 (p2 / protein~e.16
                        :name (n3 / name :op1 "GAP"~e.18))))
      :degree (l / less~e.11)
      :compared-to~e.13 (e2 / enzyme
            :name (n4 / name :op1 "K-Ras"~e.7,9)
            :ARG1-of (m / modify-01~e.15 :polarity~e.15 "-"~e.15))
      :ARG1-of (s3 / see-01~e.1
            :medium~e.2 (f / figure~e.3 :mod "5c"~e.4)))

# ::tok These data support our in vitro findings that monoubiquitination increases the population of active , GTP @-@ bound Ras through a defect in sensitivity to GAP @-@ mediated regulation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.1 3-1.2.1.r 4-1.2.3 5-1.2.3 6-1.2 9-1.2.2 11-1.2.2.2 15-1.2.2.2.1.3.1.1.1 17-1.2.2.2.1 17-1.2.2.2.1.3 17-1.2.2.2.1.3.r 18-1.2.2.2.1.1.1 21-1.2.2.3 22-1.2.2.3.1.r 22-1.2.3 23-1.2.2.3.1 24-1.2.2.3.1.1.r 25-1.2.2.3.1.1.1.1.1.1 27-1.2.2.3.1.1.1 28-1.2.2.3.1.1
# ::id bio.bmtr_0004.15
# ::preferred 
(s / support-01~e.2
      :ARG0 (d / data~e.1
            :mod (t / this~e.0))
      :ARG1 (f / find-01~e.6
            :ARG0~e.3 (w / we~e.3)
            :ARG1 (i / increase-01~e.9
                  :ARG0 (u / ubiquitinate-01 :quant "1")
                  :ARG1 (p / population~e.11
                        :consist-of (e / enzyme~e.17
                              :name (n / name :op1 "Ras"~e.18)
                              :ARG1-of (a / activate-01)
                              :ARG2-of~e.17 (b / bind-01~e.17
                                    :ARG1 (s2 / small-molecule
                                          :name (n2 / name :op1 "GTP"~e.15)))))
                  :manner (d2 / defect~e.21
                        :topic~e.22 (s3 / sensitive-03~e.23
                              :ARG1~e.24 (r / regulate-01~e.28
                                    :ARG1-of (m / mediate-01~e.27
                                          :ARG0 (p2 / protein
                                                :name (n3 / name :op1 "GAP"~e.25)))))))
            :manner (i2 / in-vitro~e.4,5,22)))

# ::tok Passage 1 @-@ 2 ( Discussion/Conclusion )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1 3-1.1
# ::id bio.bmtr_0004.16
# ::preferred 
(p / passage~e.0
      :mod "1-2"~e.1,3
      :topic (s / slash
            :op1 (t / thing
                  :ARG1-of (d / discuss-01))
            :op2 (t2 / thing
                  :ARG1-of (c / conclude-01))))

# ::tok It was established recently that monoubiquitination increases the proportion of Ras that is in the activated ( GTP @-@ bound ) state , that monoubiquitination enhances association with the downstream effectors Raf and PI3 @-@ Kinase , and that mutation of the primary site of monoubiquitination impairs oncogenic Ras @-@ mediated tumorigenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 3-1.2 6-1.1.1 8-1.1.1.2 9-1.1.1.2.1.r 10-1.1.1.2.1.1.1 13-1.1.1.2.2.r 15-1.1.1.2.2 17-1.1.1.2.3.1.1.1 19-1.1.1.2.3 25-1.1.2 26-1.1.2.2 27-1.1.2.2.1.r 29-1.1.2.2.1.1.2 30-1.1.2.2.1.1 30-1.1.2.2.1.2 31-1.1.2.2.1.1.1.1 32-1.1.2.2.1 33-1.1.2.2.1.2.1.1 35-1.1.2.2.1.2.1.1 37-1.1.2.2.1 38-1.1.r 39-1.1.3.1 40-1.1.3.1.1.r 42-1.1.3.1.1.1 43-1.1.3.1.1 46-1.1.3 47-1.1.3.2.2.1 47-1.1.3.2.2.1.2 47-1.1.3.2.2.1.2.1 47-1.1.3.2.2.1.2.1.r 47-1.1.3.2.2.1.2.r 48-1.1.3.2.2.1.1.1 50-1.1.3.2.2
# ::id bio.bmtr_0004.17
# ::preferred 
(e / establish-01~e.2
      :ARG1~e.38 (a / and
            :op1 (i / increase-01~e.6
                  :ARG0 (u / ubiquitinate-01 :quant "1")
                  :ARG1 (p / proportion~e.8
                        :quant-of~e.9 (e2 / enzyme
                              :name (n / name :op1 "Ras"~e.10))
                        :ARG1-of~e.13 (a2 / activate-01~e.15)
                        :ARG1-of (b / bind-01~e.19
                              :ARG2 (s / small-molecule
                                    :name (n2 / name :op1 "GTP"~e.17)))))
            :op2 (e3 / enhance-01~e.25
                  :ARG0 u
                  :ARG1 (a3 / associate-01~e.26
                        :ARG2~e.27 (a4 / and~e.32,37
                              :op1 (e4 / effector~e.30
                                    :name (n3 / name :op1 "Raf"~e.31)
                                    :mod (d / downstream~e.29))
                              :op2 (e5 / effector~e.30
                                    :name (n4 / name :op1 "PI3-Kinase"~e.33,35)))))
            :op3 (i2 / impair-01~e.46
                  :ARG0 (m2 / mutate-01~e.39
                        :ARG1~e.40 (p3 / protein-segment~e.43
                              :mod (p2 / primary~e.42)
                              :part-of u))
                  :ARG1 (c3 / create-01
                        :ARG1 (t / tumor)
                        :ARG1-of (m3 / mediate-01~e.50
                              :ARG0 (e6 / enzyme~e.47
                                    :name (n5 / name :op1 "Ras"~e.48)
                                    :ARG0-of~e.47 (c / cause-01~e.47
                                          :ARG1~e.47 (c2 / cancer~e.47)))))))
      :time (r / recent~e.3))

# ::tok Here we show that monoubiquitination decreases the sensitivity of Ras to GAP @-@ mediated hydrolysis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.1 2-1 5-1.2 7-1.2.2 8-1.2.2.1.r 9-1.2.2.1.1.1 10-1.2.2.2.r 11-1.2.2.2.1.1.1.1 13-1.2.2.2.1 14-1.2.2.2
# ::id bio.bmtr_0004.18
# ::preferred 
(s / show-01~e.2
      :ARG0 (w / we~e.1)
      :ARG1 (d / decrease-01~e.5
            :ARG0 (u / ubiquitinate-01 :quant "1")
            :ARG1 (s2 / sensitive-03~e.7
                  :ARG0~e.8 (e / enzyme
                        :name (n / name :op1 "Ras"~e.9))
                  :ARG1~e.10 (h / hydrolyze-01~e.14
                        :ARG1-of (m / mediate-01~e.13
                              :ARG0 (p / protein
                                    :name (n2 / name :op1 "GAP"~e.11))))))
      :location (h2 / here~e.0))

# ::tok A major advance was our ability to easily generate mUbRas , modified at a single site , in a form suitable for detailed biophysical studies .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1 3-1.2.r 4-1.2.1 4-1.2.1.r 5-1.2 6-1.2.3.r 7-1.2.3 8-1.2.2 11-1.2.2.2.3 12-1.2.2.2.3.1.r 14-1.2.2.2.3.1.1 15-1.2.2.2.3.1 17-1.2.2.3.r 19-1.2.2.3 20-1.2.2.3.1 21-1.2.2.3.1.1.r 22-1.2.2.3.1.1.2 23-1.2.2.3.1.1.1 24-1.2.2.3.1.1
# ::id bio.bmtr_0004.19
# ::preferred 
(a / advance~e.2
      :mod (m / major~e.1)
      :domain~e.3 (c / capable-01~e.5
            :ARG1~e.4 (w / we~e.4)
            :ARG2 (g / generate-01~e.8
                  :ARG0 w
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras")
                        :ARG3-of (u / ubiquitinate-01 :quant "1")
                        :ARG1-of (m2 / modify-01~e.11
                              :location~e.12 (p / protein-segment~e.15
                                    :mod (s2 / single~e.14))))
                  :ARG4~e.17 (f / form~e.19
                        :ARG1-of (s / suitable-04~e.20
                              :ARG2~e.21 (s4 / study-01~e.24
                                    :ARG1 (b / biophysical~e.23)
                                    :ARG1-of (d / detail-01~e.22)))))
            :manner~e.6 (e2 / easy~e.7)))

# ::tok This chemical ligation strategy will likely be useful for the study of other monoubiquitinated proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1.1.1 3-1.1.1 5-1 6-1.1.1.r 6-1.1.r 7-1.1 8-1.1.2.r 10-1.1.2 11-1.1.2.1.r 12-1.1.2.1.2 14-1.1.2.1
# ::id bio.bmtr_0004.20
# ::preferred 
(l / likely~e.5
      :domain~e.6 (u / useful~e.7
            :domain~e.6 (s / strategy~e.3
                  :mod (l2 / ligate-01
                        :mod (c / chemical~e.1))
                  :mod (t / this~e.0))
            :purpose~e.8 (s2 / study-01~e.10
                  :ARG1~e.11 (p / protein~e.14
                        :ARG1-of (u2 / ubiquitinate-01 :quant "1")
                        :mod (o / other~e.12)))))

# ::tok Surprisingly , monoubiquitination did not alter the intrinsic activity of Ras , despite the size of the modification .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 4-1.1.1 4-1.1.1.r 5-1.1 7-1.1.3.2 8-1.1.3 9-1.1.3.1.r 10-1.1.3.1.1.1 12-1.2.r 14-1.2 14-1.2.1 14-1.2.1.r 15-1.2.1.1.r 17-1.2.1.1
# ::id bio.bmtr_0004.21
# ::preferred 
(s / surprise-01~e.0
      :ARG0 (a / alter-01~e.5
            :polarity~e.4 "-"~e.4
            :ARG0 (u / ubiquitinate-01 :quant "1")
            :ARG1 (a2 / act-02~e.8
                  :ARG0~e.9 (e / enzyme
                        :name (n / name :op1 "Ras"~e.10))
                  :mod (i / intrinsic~e.7)))
      :concession~e.12 (t / thing~e.14
            :ARG2-of~e.14 (s2 / size-01~e.14
                  :ARG1~e.15 (m / modify-01~e.17))))

# ::tok Our modeling and NMR analyses indicated that Ubiquitin dynamically samples a broad surface area of Ras that alters switch region dynamics .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.1.1.1.r 1-1.1.1 2-1.1 3-1.1.2.2 4-1.1.2 5-1 6-1.2.r 7-1.2.1.1.1 8-1.2.3 9-1.2 11-1.2.2.1.1 12-1.2.2.1 13-1.2.2 14-1.2.2.2.r 15-1.2.2.2.1.1 17-1.2.4 18-1.2.4.1.1.1 19-1.2.4.1.1 20-1.2.4.1
# ::id bio.bmtr_0004.22
# ::preferred 
(i / indicate-01~e.5
      :ARG0 (a / and~e.2
            :op1 (m / model-01~e.1
                  :ARG0~e.0 (w / we~e.0))
            :op2 (a2 / analyze-01~e.4
                  :ARG0 w
                  :instrument (n / NMR~e.3)))
      :ARG1~e.6 (s / sample-01~e.9
            :ARG0 (p / protein
                  :name (n2 / name :op1 "ubiquitin"~e.7))
            :ARG1 (a3 / area~e.13
                  :mod (s2 / surface~e.12
                        :mod (b / broad~e.11))
                  :part-of~e.14 (e / enzyme
                        :name (n3 / name :op1 "Ras"~e.15)))
            :manner (d / dynamic~e.8)
            :ARG0-of (a4 / alter-01~e.17
                  :ARG1 (d2 / dynamic~e.20
                        :location (r / region~e.19
                              :mod (s3 / switch-01~e.18))))))

# ::tok These results led us to examine the effect of monoubiquitination on the interaction of Ras with its cognate GEF and GAPs , which also target the switch domains .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2 5-1.3 7-1.3.2 10-1.3.2.2.r 12-1.3.2.2 13-1.3.2.2.1.r 14-1.3.2.2.1.1.1 15-1.3.2.2.2.3.1.r 16-1.3.2.2.2.3.1 17-1.3.2.2.2.3 18-1.3.2.2.2.1.1.1 19-1.3.2.2.2 20-1.3.2.2.2.2.1.1 23-1.3.2.2.2.4.2 24-1.3.2.2.2.4 26-1.3.2.2.2.4.1.1 27-1.3.2.2.2.4.1
# ::id bio.bmtr_0004.23
# ::preferred 
(l / lead-03~e.2
      :ARG0 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG1 (w / we~e.3)
      :ARG2 (e / examine-01~e.5
            :ARG0 w
            :ARG1 (a / affect-01~e.7
                  :ARG0 (u / ubiquitinate-01 :quant "1")
                  :ARG1~e.10 (i / interact-01~e.12
                        :ARG0~e.13 (e2 / enzyme
                              :name (n / name :op1 "Ras"~e.14))
                        :ARG1 (a2 / and~e.19
                              :op1 (p / protein
                                    :name (n2 / name :op1 "GEF"~e.18))
                              :op2 (p2 / protein
                                    :name (n3 / name :op1 "GAP"~e.20))
                              :mod (c / cognate~e.17
                                    :prep-with~e.15 e2~e.16)
                              :ARG0-of (t3 / target-01~e.24
                                    :ARG1 (d / domain~e.27
                                          :mod (s / switch-01~e.26))
                                    :mod (a3 / also~e.23)))))))

# ::tok The analysis revealed that monoubiquitination abrogates GAP @-@ mediated GTP hydrolysis .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1 5-1.2 6-1.2.2.2.1.1.1 8-1.2.2.2 9-1.2.2.1.1.1 10-1.2.2
# ::id bio.bmtr_0004.24
# ::preferred 
(r / reveal-01~e.2
      :ARG0 (a / analyze-01~e.1)
      :ARG1 (a2 / abrogate-01~e.5
            :ARG0 (u / ubiquitinate-01 :quant "1")
            :ARG1 (h / hydrolyze-01~e.10
                  :ARG1 (s / small-molecule
                        :name (n / name :op1 "GTP"~e.9))
                  :ARG1-of (m / mediate-01~e.8
                        :ARG0 (p / protein
                              :name (n2 / name :op1 "GAP"~e.6))))))

# ::tok All other activities , including the ability to bind regulators , were largely preserved and our kinetic modeling suggests that the GAP defect will dominate .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1.1.1 4-1.1.1.3 8-1.1.1.3.1.1 9-1.1.1.3.1.1.1 9-1.1.1.3.1.1.1.1 9-1.1.1.3.1.1.1.1.r 11-1.1.1.3.1.1.r 12-1.1.2 13-1.1 14-1 15-1.2.1.1 15-1.2.1.1.r 16-1.2.1.2 17-1.2.1 18-1.2 19-1.2.2.r 21-1.2.2.1.1.1.1 22-1.2.2.1 24-1.2.2
# ::id bio.bmtr_0004.25
# ::preferred 
(a3 / and~e.14
      :op1 (p / preserve-01~e.13
            :ARG1 (a / act-02~e.2
                  :mod (a2 / all~e.0)
                  :mod (o / other~e.1)
                  :ARG2-of (i / include-01~e.4
                        :ARG1 (p2 / possible
                              :domain~e.11 (b / bind-01~e.8
                                    :ARG1 (m2 / molecular-physical-entity~e.9
                                          :ARG0-of~e.9 (r / regulate-01~e.9))))))
            :mod (l / large~e.12))
      :op2 (s / suggest-01~e.18
            :ARG0 (m / model-01~e.17
                  :ARG0~e.15 (w / we~e.15)
                  :mod (k / kinetic~e.16))
            :ARG1~e.19 (d / dominate-01~e.24
                  :ARG1 (d2 / defect~e.22
                        :mod (p3 / protein
                              :name (n / name :op1 "GAP"~e.21))))))

# ::tok Furthermore , this outcome was specific to monoubiquitination at position 147 .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.2.1 3-1.1.2 4-1.1.2.r 5-1.1 6-1.1.1.r 10-1.1.1.2.1
# ::id bio.bmtr_0004.26
# ::preferred 
(a / and
      :op2 (s / specific~e.5
            :prep-to~e.6 (u / ubiquitinate-01
                  :quant "1"
                  :ARG1 (a2 / amino-acid :mod "147"~e.10))
            :domain~e.4 (o / outcome~e.3
                  :mod (t / this~e.2))))

# ::tok Thus our work establishes an entirely new mode of Ras activation in which signaling is sustained even in the absence of hormone stimulus or oncogene mutation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.3.2.1.2.1 1-1.1.1 1-1.1.1.r 2-1.1 3-1 5-1.2.1.1 6-1.2.1 7-1.2 8-1.2.2.r 9-1.2.2.1.1.1 10-1.2.2 13-1.2.3.1 15-1.2.3 21-1.2.3.2.1.1.1 22-1.2.3.2.1.1 23-1.2.3.2.1 25-1.2.3.2.1.2
# ::id bio.bmtr_0004.27
# ::preferred 
(e / establish-01~e.3
      :ARG0 (w / work-01~e.2
            :ARG0~e.1 (w2 / we~e.1))
      :ARG1 (m / mode~e.7
            :mod (n / new~e.6
                  :degree (e2 / entire~e.5))
            :mod~e.8 (a / activate-01~e.10
                  :ARG1 (e3 / enzyme
                        :name (n2 / name :op1 "Ras"~e.9)))
            :ARG0-of (s / sustain-01~e.15
                  :ARG1 (s2 / signal-07~e.13)
                  :concession (l / lack-01
                        :ARG1 (o / or~e.23
                              :op1 (s3 / stimulus~e.22
                                    :mod (h / hormone~e.21))
                              :op2 (m2 / mutate-01~e.25
                                    :ARG0-of (c / cause-01~e.0
                                          :ARG1 (c2 / cancer))))))))

# ::tok Phosphorylation of ASPP2 by RAS @/@ MAPK Pathway Is Critical for Its Full Pro @-@ Apoptotic Function ( PMC3847091 )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2.1.1.r 2-1.2.1.1.1.1 3-1.2.1.2.r 4-1.2.1.2.1.1 6-1.2.1.2.1.1 7-1.2.1.2 8-1.2.1.r 9-1.2 10-1.2.2.r 11-1.2.2.1 11-1.2.2.1.r 12-1.2.2.3 13-1.2.2.2.1 15-1.2.2.2 16-1.2.2 18-1.1
# ::id bio.bmtr_0005.1
# ::preferred 
(p5 / publication-91
      :ARG8 "PMC3847091"~e.18
      :ARG1 (c / critical~e.9
            :domain~e.8 (p / phosphorylate-01~e.0
                  :ARG1~e.1 (p2 / protein
                        :name (n / name :op1 "ASPP2"~e.2))
                  :ARG2~e.3 (p3 / pathway~e.7
                        :name (n2 / name :op1 "RAS/MAPK"~e.4,6)))
            :prep-for~e.10 (f / function-01~e.16
                  :ARG0~e.11 p2~e.11
                  :ARG1 (a / apoptosis~e.15
                        :ARG1-of (f3 / favor-01~e.13))
                  :mod (f2 / full~e.12))))

# ::tok Passage 1 @-@ 1 ( Results )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1 3-1.1 5-1.2 5-1.2.1 5-1.2.1.r
# ::id bio.bmtr_0005.2
# ::preferred 
(p / passage~e.0
      :mod "1-1"~e.1,3
      :topic (t / thing~e.5
            :ARG2-of~e.5 (r / result-01~e.5)))

# ::tok It has recently been shown that oncogenic RAS can enhance the apoptotic function of p53 via ASPP1 and ASPP2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2 3-1.1.1.r 4-1 5-1.1.r 6-1.1.1.1 6-1.1.1.1.2 6-1.1.1.1.2.1 6-1.1.1.1.2.1.r 6-1.1.1.1.2.r 7-1.1.1.1.1.1 8-1.1 9-1.1.1 11-1.1.1.2.2 12-1.1.1.2 13-1.1.1.2.1.r 14-1.1.1.2.1.1.1 16-1.1.1.3.1.1.1 17-1.1.1.3 18-1.1.1.3.2.1.1
# ::id bio.bmtr_0005.3
# ::preferred 
(s / show-01~e.4
      :ARG1~e.5 (p / possible~e.8
            :domain~e.3 (e / enhance-01~e.9
                  :ARG0 (e2 / enzyme~e.6
                        :name (n / name :op1 "Ras"~e.7)
                        :ARG0-of~e.6 (c / cause-01~e.6
                              :ARG1~e.6 (c2 / cancer~e.6)))
                  :ARG1 (f / function-01~e.12
                        :ARG0~e.13 (p2 / protein
                              :name (n2 / name :op1 "p53"~e.14))
                        :ARG1 (a / apoptosis~e.11))
                  :instrument (a2 / and~e.17
                        :op1 (p3 / protein
                              :name (n3 / name :op1 "ASPP1"~e.16))
                        :op2 (p4 / protein
                              :name (n4 / name :op1 "ASPP2"~e.18)))))
      :time (r / recent~e.2))

# ::tok Mechanistically ASPP1 and ASPP2 bind RAS @-@ GTP and potentiates RAS signalling to enhance p53 mediated apoptosis [2].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.1.1.1.1 2-1.1 3-1.1.2.1.1 4-1 5-1.2.1.1.1 7-1.2.2.1.1 8-1.1 9-1.4 10-1.4.1.1 11-1.4.1 13-1.4.2 14-1.4.2.1.1.1.1.1 15-1.4.2.1.1 16-1.4.2.1
# ::id bio.bmtr_0005.4
# ::preferred 
(b / bind-01~e.4
      :ARG1 (a2 / and~e.2,8
            :op1 (p / protein
                  :name (n / name :op1 "ASPP1"~e.1))
            :op2 (p2 / protein
                  :name (n2 / name :op1 "ASPP2"~e.3)))
      :ARG2 (m3 / macro-molecular-complex
            :part (e / enzyme
                  :name (n3 / name :op1 "Ras"~e.5))
            :part (s / small-molecule
                  :name (n4 / name :op1 "GTP"~e.7)))
      :manner (m / mechanistic~e.0)
      :ARG0-of (p3 / potentiate-00~e.9
            :ARG1 (s2 / signal-07~e.11
                  :ARG0 e~e.10)
            :purpose (e2 / enhance-01~e.13
                  :ARG1 (a / apoptosis~e.16
                        :ARG1-of (m2 / mediate-01~e.15
                              :ARG0 (p4 / protein
                                    :name (n5 / name :op1 "p53"~e.14))))))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c / cite-01 :ARG2 "2"))))

# ::tok As RAS is upstream of several signalling cascades [13], we queried whether the activity of ASPP2 is regulated by the activation of a RAS @-@ mediated signalling pathway .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1.1.1 2-1.3.1 3-1.3.1.2.2 5-1.3.1.2.1.2 6-1.3.1.2.1.1 7-1.3.1.2.1 9-1.1 10-1 13-1.2.2 14-1.2.2.1.r 15-1.2.2.1.1.1 17-1.2 18-1.2.1.r 20-1.2.1 21-1.2.1.1.r 23-1.2.1.1.1.1.1 25-1.2.1.1.1.1 26-1.2.1.1.1 27-1.2.1.1
# ::id bio.bmtr_0005.5
# ::preferred 
(q / query-01~e.10
      :ARG0 (w / we~e.9)
      :ARG2 (r / regulate-01~e.17
            :ARG0~e.18 (a / activate-01~e.20
                  :ARG0~e.21 (p / pathway~e.27
                        :ARG0-of (s / signal-07~e.26
                              :ARG1-of (m / mediate-01~e.25
                                    :ARG0 e~e.23))))
            :ARG1 (a2 / act-02~e.13
                  :ARG0~e.14 (p2 / protein
                        :name (n2 / name :op1 "ASPP2"~e.15))))
      :ARG1-of (c / cause-01
            :ARG0 (b / be-located-at-91~e.2
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.1))
                  :ARG2 (r2 / relative-position
                        :op1 (c2 / cascade~e.7
                              :subevent (s2 / signal-07~e.6)
                              :quant (s3 / several~e.5))
                        :direction (u / upstream~e.3))
                  :ARG1-of (d / describe-01
                        :ARG0 (p3 / publication
                              :ARG0-of (c3 / cite-01 :ARG2 "13"))))))

# ::tok One of the most studied downstream pathways of RAS signalling is the Raf @-@ MAPK pathway .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.2.1.1 4-1.2.1 5-1.2.2 6-1.2 8-1.2.3.1.1.1 9-1.2.3 12-1.1.1.1 14-1.1.1.1 15-1.2
# ::id bio.bmtr_0005.6
# ::preferred 
(i / include-91
      :ARG1 (p / pathway
            :name (n / name :op1 "Raf-MAPK"~e.12,14))
      :ARG2 (p2 / pathway~e.6,15
            :ARG1-of (s / study-01~e.4
                  :degree (m / most~e.3))
            :mod (d / downstream~e.5)
            :location-of (s2 / signal-07~e.9
                  :ARG0 (e / enzyme
                        :name (n2 / name :op1 "Ras"~e.8)))))

# ::tok Interestingly , we observed two conserved putative MAPK phosphorylation sites in ASPP1 and ASPP2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 3-1 4-1.2.1.1 5-1.2.1.2 6-1.2.1.3.2 7-1.2.1.3.1.1.1 8-1.2.1.3 9-1.2.1 10-1.2.1.4.r 11-1.2.1.4.1.1.1 12-1.2.1.4 13-1.2.1.4.2.1.1
# ::id bio.bmtr_0005.7
# ::preferred 
(o / observe-01~e.3
      :ARG0 (w2 / we~e.2)
      :ARG1 (a / and
            :op1 (p3 / protein-segment~e.9
                  :quant "2"~e.4
                  :ARG1-of (c / conserve-01~e.5)
                  :ARG1-of (p2 / phosphorylate-01~e.8
                        :ARG0 (p4 / pathway
                              :name (n / name :op1 "MAPK"~e.7))
                        :ARG2-of (t / think-01~e.6))
                  :part-of~e.10 (a2 / and~e.12
                        :op1 (p5 / protein
                              :name (n2 / name :op1 "ASPP1"~e.11))
                        :op2 (p6 / protein
                              :name (n3 / name :op1 "ASPP2"~e.13)))))
      :ARG2-of (i / interest-01
            :ARG1 w2))

# ::tok The ASPP1 sites are at residues 671 and 746 , and the ASPP2 sites are at residues 698 and 827 ( Figure 1A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1.1 2-1.1.1 3-1.1 4-1.1 5-1.1.2.1 5-1.1.2.2 5-1.2.2.2 6-1.1.2.1.1.1 7-1.1.2 8-1.1.2.2.1.1 10-1.1.2 12-1.2.1.1.1.1 13-1.1.1 13-1.2.1 14-1.1 14-1.2 15-1.1 16-1.2.2.1 17-1.2.2.1.1.1 18-1.2.2 19-1.2.2.2.1.1 21-1.3.1 22-1.3.1.1
# ::id bio.bmtr_0005.8
# ::preferred 
(a4 / and
      :op1 (b / be-located-at-91~e.3,4,14,15
            :ARG1 (p / protein-segment~e.2,13
                  :part-of (p2 / protein
                        :name (n / name :op1 "ASPP1"~e.1)))
            :ARG2 (a2 / and~e.7,10
                  :op1 (r / residue~e.5
                        :mod (a / amino-acid :mod "671"~e.6))
                  :op2 (r2 / residue~e.5
                        :mod (a3 / amino-acid :mod "746"~e.8))))
      :op2 (b2 / be-located-at-91~e.14
            :ARG1 (p3 / protein-segment~e.13
                  :part-of (p4 / protein
                        :name (n2 / name :op1 "ASPP2"~e.12)))
            :ARG2 (a5 / and~e.18
                  :op1 (r3 / residue~e.16
                        :mod (a6 / amino-acid :mod "698"~e.17))
                  :op2 (r4 / residue~e.5
                        :mod (a7 / amino-acid :mod "827"~e.19))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.21 :mod "1A"~e.22)))

# ::tok We thus tested whether RAS activation may regulate ASPP2 phosphorylation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1 3-1.1.2.1 3-1.1.2.1.r 4-1.1.2.2.1.1.1.1 5-1.1.2.2.1 6-1.1.2 7-1.1.2.2 8-1.1.2.2.2.1.1.1 9-1.1.2.2.2
# ::id bio.bmtr_0005.9
# ::preferred 
(c / cause-01~e.1
      :ARG1 (t / test-01~e.2
            :ARG0 (w / we~e.0)
            :ARG1 (p / possible~e.6
                  :mode~e.3 "interrogative"~e.3
                  :domain (r / regulate-01~e.7
                        :ARG0 (a / activate-01~e.5
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "RAS"~e.4)))
                        :ARG1 (p2 / phosphorylate-01~e.9
                              :ARG1 (p3 / protein
                                    :name (n2 / name :op1 "ASPP2"~e.8)))))))

# ::tok An in vitro phophorylation assay was performed with a purified C @-@ terminus fragment of ASPP2 ( 693 @-@ 1128 ) containing both MAPK putative phosphorylation sites .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1.2 4-1 9-1.1.1.2 10-1.1.1.1.1.1 12-1.1.1.1.1.1 15-1.1.1.1.2.1.1 17-1.1.1.3.1.1 19-1.1.1.3.2.1 21-1.1.1.4 22-1.1.1.4.1.2 23-1.1.1.4.1.1.1.1.1 24-1.1.1.4.1.1.2 25-1.1 25-1.1.1.4.1.1 26-1.1.1 26-1.1.1.4.1
# ::id bio.bmtr_0005.10
# ::preferred 
(a / assay-00~e.4
      :ARG1 (p / phosphorylate-01~e.25
            :ARG1 (p2 / protein-segment~e.26
                  :part-of (p3 / protein-segment
                        :name (n / name :op1 "C-terminus"~e.10,12)
                        :part-of (p4 / protein
                              :name (n2 / name :op1 "ASPP2"~e.15)))
                  :ARG1-of (p5 / purify-01~e.9)
                  :mod (b / between
                        :op1 (a2 / amino-acid :mod "693"~e.17)
                        :op2 (a3 / amino-acid :mod "1128"~e.19))
                  :ARG0-of (c / contain-01~e.21
                        :ARG1 (p6 / protein-segment~e.26
                              :ARG1-of (p7 / phosphorylate-01~e.25
                                    :ARG2 (e / enzyme
                                          :name (n4 / name :op1 "MAPK"~e.23))
                                    :ARG1-of (t / think-01~e.24))
                              :mod (b2 / both~e.22))))
            :manner (i / in-vitro~e.1,2)))

# ::tok When compared to p38 SAPK , MAPK1 was clearly able to phosphorylate the ASPP2 fragment in vitro ( Figure 1B , left and middle panels ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.r 3-1.3.1.2.1.1 4-1.3.1.2.1.2 6-1.2.2.1.1 7-1.2.r 7-1.3.1.r 8-1.1 9-1 9-1.3 11-1.2 11-1.3.1 13-1.2.1.1.1.1 15-1.2.3 16-1.2.3 18-1.4.1.3 19-1.4.1.3.1 21-1.4.1.1.1 22-1.4.1 23-1.4.1.2.1 24-1.4.1.1 24-1.4.1.2
# ::id bio.bmtr_0005.11
# ::preferred 
(p / possible~e.9
      :mod (c / clear~e.8)
      :domain~e.7 (p2 / phosphorylate-01~e.11
            :ARG1 (p3 / protein-segment
                  :part-of (p4 / protein
                        :name (n2 / name :op1 "ASPP2"~e.13)))
            :ARG2 (e / enzyme
                  :name (n / name :op1 "MAPK1"~e.6))
            :manner (i / in-vitro~e.15,16))
      :compared-to~e.1 (p5 / possible~e.9
            :domain~e.7 (p6 / phosphorylate-01~e.11
                  :ARG1 p3
                  :ARG2 (e2 / enzyme
                        :name (n3 / name :op1 "p38"~e.3 :op2 "SAPK"~e.4))))
      :ARG1-of (d / describe-01
            :ARG0 (a / and~e.22
                  :op1 (p7 / panel~e.24
                        :location (l / left~e.21))
                  :op2 (p8 / panel~e.24
                        :location (m / middle~e.23))
                  :part-of (f / figure~e.18 :mod "1B"~e.19))))

# ::tok As shown in Figure S1 , histone 2B phosphorylated by p38 SAPK had high levels of incorporated 32P , suggesting that p38 SAPK was active ; while under the same conditions , ASPP2 ( 693 @-@ 1128 ) fragment phosphorylated by p38 SAPK had very low levels of incorporated 32P , indicating that p38 SAPK is not an efficient kinase for ASPP2 phosphorylation .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 2-1.1.r 3-1.1 4-1.1.1 6-1.2.1.1.1.1 7-1.2.1.1.1.2 8-1.2.1.1.2 8-1.2.2.3.1.3 10-1.2.1.1.2.1.1.1 11-1.2.1.1.2.1.1.2 12-1.2.1 13-1.2.1.2.2.1 14-1.2.1.2.2 16-1.2.1.2.3 19-1.2.1.3 21-1.2.1.3.1.1 22-1.2.1.3.1.1 26-1.2 29-1.2.2.4 29-1.2.2.4.1 29-1.2.2.4.1.r 30-1.2.2.4.1.1.1.r 30-1.2.2.4.r 32-1.2.2.1.2.1.1 34-1.2.2.1.1.1.1 36-1.2.2.1.1.2.1 39-1.2.1.1.2 39-1.2.2.1.3 41-1.2.1.1.2.1.1.1 42-1.2.1.1.2.1.1.2 43-1.2.2 44-1.2.2.2.2.1.1 45-1.2.2.2.2.1 46-1.2.2.2.2 48-1.2.2.2.3 51-1.2.2.3 52-1.2.2.3.1.r 53-1.2.2.3.1.2 54-1.2.2.3.1.2 56-1.2.2.3.1.1 56-1.2.2.3.1.1.r 58-1.2.2.3.1 61-1.2.2.1.2.1.1 62-1.2.1.1.2 62-1.2.2.1.3
# ::id bio.bmtr_0005.12
# ::preferred 
(s / show-01~e.1
      :ARG0~e.2 (f / figure~e.3 :mod "S1"~e.4)
      :ARG1 (c / contrast-01~e.26
            :ARG1 (h / have-part-91~e.12
                  :ARG1 (p8 / protein
                        :name (n / name :op1 "Histone"~e.6 :op2 "2B"~e.7)
                        :ARG3-of (p2 / phosphorylate-01~e.8,39,62
                              :ARG2 (e / enzyme
                                    :name (n2 / name :op1 "p38"~e.10,41 :op2 "SAPK"~e.11,42))))
                  :ARG2 (p / phosphorus
                        :mod (m / molecular-mass :value "32")
                        :quant (l / level~e.14
                              :mod (h3 / high~e.13))
                        :ARG1-of (i / incorporate-02~e.16
                              :ARG2 p8))
                  :ARG0-of (s2 / suggest-01~e.19
                        :ARG1 (a / activate-01
                              :ARG1 e~e.21,22)))
            :ARG2 (h4 / have-part-91~e.43
                  :ARG1 (p3 / protein-segment
                        :mod (b / between
                              :op1 (a2 / amino-acid :mod "693"~e.34)
                              :op2 (a3 / amino-acid :mod "1128"~e.36))
                        :part (p5 / protein
                              :name (n3 / name :op1 "ASPP2"~e.32,61))
                        :ARG3-of (p6 / phosphorylate-01~e.39,62
                              :ARG2 e))
                  :ARG2 (p4 / phosphorus
                        :mod (m2 / molecular-mass :value "32")
                        :quant (l2 / level~e.46
                              :ARG1-of (l3 / low-04~e.45
                                    :degree (v / very~e.44)))
                        :ARG1-of (i2 / incorporate-02~e.48
                              :ARG2 p3))
                  :ARG0-of (i3 / indicate-01~e.51
                        :ARG1~e.52 (e2 / efficient-01~e.58
                              :polarity~e.56 "-"~e.56
                              :ARG1 e~e.53,54
                              :ARG2 (p7 / phosphorylate-01~e.8
                                    :ARG1 p5
                                    :ARG2 e)))
                  :condition~e.30 (t / thing~e.29
                        :ARG1-of~e.29 (s3 / same-01~e.29
                              :ARG2 (t2 / thing
                                    :condition-of~e.30 h))))))

# ::tok The phosphorylated ASPP2 fragment by MAPK1 was digested by trypsin and fractioned on a high performance liquid chromatography ( HPLC ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.2 2-1.1.2.1.1.1 4-1.1.2.2.1.r 5-1.1.2.2.1.1.1 7-1.1 8-1.1.1.r 9-1.1.1.1.1 10-1 11-1.2 12-1.2.2.r 14-1.2.2.1.1.1 15-1.2.2.1.1 16-1.2.2.1 17-1.2.2
# ::id bio.bmtr_0005.13
# ::preferred 
(a / and~e.10
      :op1 (d / digest-01~e.7
            :ARG0~e.8 (e / enzyme
                  :name (n / name :op1 "trypsin"~e.9))
            :ARG1 (p / protein-segment
                  :part-of (p2 / protein
                        :name (n2 / name :op1 "ASPP2"~e.2))
                  :ARG3-of (p3 / phosphorylate-01~e.1
                        :ARG2~e.4 (e2 / enzyme
                              :name (n3 / name :op1 "MAPK1"~e.5)))))
      :op2 (f / fraction-01~e.11
            :ARG1 p
            :manner~e.12 (c / chromatography~e.17
                  :mod (l / liquid~e.16
                        :ARG0-of (p4 / perform-01~e.15
                              :degree (h / high~e.14))))))

# ::tok Each eluted fraction was measured for its radioactivity content ( Figure 1B , right panel ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.1 2-1.1 4-1 7-1.2.1 8-1.2 8-1.2.2 8-1.2.2.r 10-1.3.1.2 11-1.3.1.2.1 13-1.3.1.1 14-1.3.1
# ::id bio.bmtr_0005.14
# ::preferred 
(m / measure-01~e.4
      :ARG1 (f / fraction~e.2
            :ARG3-of (e / elute-00~e.1)
            :mod (e2 / each~e.0))
      :purpose (t / thing~e.8
            :mod (r2 / radioactive~e.7)
            :ARG1-of~e.8 (c / contain-01~e.8
                  :ARG0 f))
      :ARG1-of (d / describe-01
            :ARG0 (p / panel~e.14
                  :location (r / right~e.13)
                  :part-of (f2 / figure~e.10 :mod "1B"~e.11))))

# ::tok The fractions representing these radioactive peaks were analysed by mass spectrometry .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1 3-1.1.1.1.2 4-1.1.1.1.1 5-1.1.1.1 9-1.2.1 10-1.2
# ::id bio.bmtr_0005.15
# ::preferred 
(a / analyze-01
      :ARG1 (f / fraction~e.1
            :ARG0-of (r / represent-01~e.2
                  :ARG1 (p / peak~e.5
                        :mod (r2 / radioactive~e.4)
                        :mod (t / this~e.3))))
      :manner (s / spectrometry~e.10
            :mod (m / mass~e.9)))

# ::tok Of the two radioactive peaks , one represented the linker region between the GST and our ASPP2 fragment and the other corresponded to a fragment of the same mass as that containing the second putative phosphorylation site , serine 827 .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1.1 3-1.1.1.1.1.2 4-1.1.1 4-1.1.1.1.1 4-1.2.1 7-1.1 10-1.1.2 13-1.1.2.1.1.1.1.1 15-1.1.2.1.1.2.2 15-1.1.2.1.1.2.2.r 16-1.1.2.1.1.2.1.1.1 18-1 18-1.1.2.1.1 20-1.2.1.1 21-1.2 28-1.2.2.1 33-1.2.2.1.1.2 33-1.2.2.1.1.2.1 33-1.2.2.1.1.2.1.r 34-1.2.2.1.1.3.2 35-1.2.2.1.1.1 36-1.1.2.1.1.2 36-1.2.2 36-1.2.2.1.1 38-1.2.2.1.1.3.1.2.1 39-1.2.2.1.1.3.1.1
# ::id bio.bmtr_0005.16
# ::preferred 
(a / and~e.18
      :op1 (r / represent-01~e.7
            :ARG0 (p / peak~e.4
                  :ARG1-of (i / include-91
                        :ARG2 (p2 / peak~e.4
                              :quant "2"~e.2
                              :mod (r2 / radioactive~e.3))))
            :ARG1 (r4 / region~e.10
                  :ARG0-of (l / link-01
                        :ARG1 (a2 / and~e.18
                              :op1 (e / enzyme
                                    :name (n / name :op1 "GST"~e.13))
                              :op2 (p3 / protein-segment~e.36
                                    :part-of (p4 / protein
                                          :name (n2 / name :op1 "ASPP2"~e.16))
                                    :poss~e.15 (w / we~e.15))))))
      :op2 (c / correspond-02~e.21
            :ARG1 (p5 / peak~e.4
                  :mod (o / other~e.20)
                  :ARG1-of (i2 / include-91
                        :ARG2 p2))
            :ARG2 (p6 / protein-segment~e.36
                  :mod (m / mass~e.28
                        :domain (p7 / protein-segment~e.36
                              :ARG1-of (p8 / phosphorylate-01~e.35)
                              :ord (o2 / ordinal-entity~e.33 :value~e.33 "2"~e.33)
                              :ARG1-of (e2 / equal-01
                                    :ARG2 (a3 / amino-acid
                                          :mod "827"~e.39
                                          :name (n3 / name :op1 "serine"~e.38))
                                    :ARG1-of (t / think-01~e.34)))))))

# ::tok Hence ASPP2 can be phosphorylated at serine 827 by MAPK1 in vitro .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.1.3.1.1 2-1.1 3-1.1.1.r 4-1.1.1 6-1.1.1.1.2.1 7-1.1.1.1.1 8-1.1.1.2.r 9-1.1.1.2.1.1 10-1.1.1.3 11-1.1.1.3
# ::id bio.bmtr_0005.17
# ::preferred 
(c / cause-01~e.0
      :ARG1 (p / possible~e.2
            :domain~e.3 (p2 / phosphorylate-01~e.4
                  :ARG1 (a / amino-acid
                        :mod "827"~e.7
                        :name (n / name :op1 "serine"~e.6)
                        :part-of (p3 / protein
                              :name (n2 / name :op1 "ASPP2"~e.1)))
                  :ARG2~e.8 (e / enzyme
                        :name (n3 / name :op1 "MAPK1"~e.9))
                  :manner (i / in-vitro~e.10,11))))

# ::tok Passage 1 @-@ 2 ( Discussion/Conclusion )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1 3-1.1
# ::id bio.bmtr_0005.18
# ::preferred 
(p / passage~e.0
      :mod "1-2"~e.1,3
      :topic (s / slash
            :op1 (t2 / thing
                  :ARG1-of (d / discuss-01))
            :op2 (t / thing
                  :ARG1-of (c / conclude-01))))

# ::tok We and others have recently shown that ASPP2 can potentiate RAS signaling by binding directly via the ASPP2 N @-@ terminus [2,6].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1 4-1.3 5-1 6-1.2.r 7-1.2.1.1.1.1 8-1.2 9-1.2.1 10-1.2.1.2.1.1.1 11-1.2.1.2 12-1.2.1.3.r 13-1.2.1.3 14-1.2.1.3.3 14-1.2.1.3.3.r 17-1.2.1.3.2.2 18-1.2.1.3.2.1.1 20-1.2.1.3.2.1.1
# ::id bio.bmtr_0005.19
# ::preferred 
(s / show-01~e.5
      :ARG0 (a / and~e.1
            :op1 (w / we~e.0)
            :op2 (p / person
                  :mod (o / other~e.2)))
      :ARG1~e.6 (p2 / possible~e.8
            :domain (p3 / potentiate-00~e.9
                  :ARG0 (p4 / protein
                        :name (n / name :op1 "ASPP2"~e.7))
                  :ARG1 (s2 / signal-07~e.11
                        :ARG0 (e / enzyme
                              :name (n2 / name :op1 "RAS"~e.10)))
                  :manner~e.12 (b / bind-01~e.13
                        :ARG1 e
                        :ARG2 (p5 / protein-segment
                              :name (n3 / name :op1 "N-terminus"~e.18,20)
                              :part-of p4~e.17)
                        :manner~e.14 (d / direct~e.14))))
      :time (r / recent~e.4)
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (v / value-interval :op1 "2" :op2 "6")))))

# ::tok Moreover , the RAS @-@ ASPP interaction enhances the transcription function of p53 in cancer cells [2].
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1.1.1 5-1.1.1.2.1.1 6-1.1.1 7-1.1 9-1.1.2.2 10-1.1.2 11-1.1.2.1.r 12-1.1.2.1.1.1 13-1.1.2.3.r 14-1.1.2.3.1 15-1.1.2.3
# ::id bio.bmtr_0005.20
# ::preferred 
(a / and
      :op2 (e / enhance-01~e.7
            :ARG0 (i / interact-01~e.6
                  :ARG0 (e2 / enzyme
                        :name (n / name :op1 "RAS"~e.3))
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "ASPP"~e.5)))
            :ARG1 (f / function-01~e.10
                  :ARG0~e.11 (p2 / protein
                        :name (n3 / name :op1 "p53"~e.12))
                  :ARG1 (t / transcribe-01~e.9)
                  :location~e.13 (c2 / cell~e.15
                        :mod (c3 / cancer~e.14)))
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c4 / cite-01 :ARG2 "2")))))

# ::tok Until now , it has been unclear how RAS could affect ASPP2 to enhance p53 function .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3.1 5-1.2.r 6-1 6-1.1 6-1.1.r 7-1.2.1.r 8-1.2.1.1.1.1.1 9-1.2.1 10-1.2.1.1 11-1.2.1.1.2.1.1 12-1.2.1.1.3 13-1.2.1.1.3.1 14-1.2.1.1.3.1.1.1.1.1 15-1.2.1.1.3.1.1
# ::id bio.bmtr_0005.21
# ::preferred 
(c / clear~e.6
      :polarity~e.6 "-"~e.6
      :domain~e.5 (t / thing
            :manner-of~e.7 (p / possible~e.9
                  :domain (a / affect-01~e.10
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "RAS"~e.8))
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "ASPP2"~e.11))
                        :ARG0-of (c2 / cause-01~e.12
                              :ARG1 (e2 / enhance-01~e.13
                                    :ARG1 (f / function-01~e.15
                                          :ARG0 (p3 / protein
                                                :name (n4 / name :op1 "p53"~e.14))))))))
      :time (u / until~e.0
            :op1 (n2 / now~e.1)))

# ::tok We show here that ASPP2 is phosphorylated by the RAS/Raf/MAPK pathway and that this phosphorylation leads to its increased translocation to the cytosol @/@ nucleus and increased binding to p53 , providing an explanation of how RAS can activate p53 pro @-@ apoptotic functions ( Figure 5 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.3 3-1.2.r 4-1.2.1.1.1 6-1.2 9-1.2.2.1.1 10-1.2.2 14-1.2 15-1.2.3 18-1.2.3.1.1 19-1.2.3.1.1.1 22-1.2.3.1.1.1.2.1 24-1.2.3.1.1.1.2.2 25-1.2.3.1 26-1.2.3.1.1 26-1.2.3.1.2 27-1.2.3.1.2.1 28-1.2.3.1.2.1.2.r 29-1.2.3.1.2.1.2.1.1 33-1.2.4 36-1.2.4.1.1.1.1.1 37-1.2.4.1 38-1.2.4.1.1 39-1.2.4.1.1.2.1 40-1.2.4.1.1.2.2.1 42-1.2.4.1.1.2.2 43-1.2.4.1.1.2 45-1.2.5.1 46-1.2.5.1.1
# ::id bio.bmtr_0005.22
# ::preferred 
(s / show-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.3 (p / phosphorylate-01~e.6,14
            :ARG1 (p3 / protein
                  :name (n2 / name :op1 "ASPP2"~e.4))
            :ARG2 (p2 / pathway~e.10
                  :name (n / name :op1 "RAS/Raf/MAPK"~e.9))
            :ARG0-of (l / lead-03~e.15
                  :ARG2 (a / and~e.25
                        :op1 (i / increase-01~e.18,26
                              :ARG1 (t / translocate-00~e.19
                                    :ARG1 p3
                                    :ARG2 (s2 / slash
                                          :op1 (c / cytosol~e.22)
                                          :op2 (n3 / nucleus~e.24))))
                        :op2 (i2 / increase-01~e.26
                              :ARG1 (b / bind-01~e.27
                                    :ARG1 p3
                                    :ARG2~e.28 (p4 / protein
                                          :name (n4 / name :op1 "p53"~e.29))))))
            :ARG0-of (e2 / explain-01~e.33
                  :ARG1 (p5 / possible~e.37
                        :domain (a2 / activate-01~e.38
                              :ARG0 (e / enzyme
                                    :name (n5 / name :op1 "RAS"~e.36))
                              :ARG1 (f / function-01~e.43
                                    :ARG0 p4~e.39
                                    :ARG1 (a3 / apoptosis~e.42
                                          :ARG1-of (f2 / favor-01~e.40))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f3 / figure~e.45 :mod "5"~e.46)))
      :location (h / here~e.2))

# ::tok Additionally , RAS/Raf/MAPK pathway activation stabilizes ASPP2 protein , although the underlying mechanism remains to be investigated .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1.1 3-1.1.1.1 4-1.1.1 5-1.1 6-1.1.2.1.1 7-1.1.2 9-1.1.3.r 11-1.1.3.1.1 12-1.1.3.1 13-1.1.3 16-1.1.3.2
# ::id bio.bmtr_0005.23
# ::preferred 
(a / and
      :op2 (s / stabilize-01~e.5
            :ARG0 (a2 / activate-01~e.4
                  :ARG1 (p / pathway~e.3
                        :name (n / name :op1 "RAS/Raf/MAPK"~e.2)))
            :ARG1 (p2 / protein~e.7
                  :name (n2 / name :op1 "ASPP2"~e.6))
            :concession~e.9 (r / remain-01~e.13
                  :ARG1 (m / mechanism~e.12
                        :ARG0-of (u / underlie-01~e.11
                              :ARG1 s))
                  :ARG3 (i / investigate-01~e.16
                        :ARG1 m))))

